WO2017220989A1 - Anti-pd-l1 and il-2 cytokines - Google Patents

Anti-pd-l1 and il-2 cytokines Download PDF

Info

Publication number
WO2017220989A1
WO2017220989A1 PCT/GB2017/051795 GB2017051795W WO2017220989A1 WO 2017220989 A1 WO2017220989 A1 WO 2017220989A1 GB 2017051795 W GB2017051795 W GB 2017051795W WO 2017220989 A1 WO2017220989 A1 WO 2017220989A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
amino acid
acid sequence
concept
dependent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2017/051795
Other languages
English (en)
French (fr)
Other versions
WO2017220989A8 (en
Inventor
Jamie Campbell
Nikole SANDY
Cassandra VAN KRINKS
Stephen John ARKINSTALL
Volker Germaschewski
Ian Kirby
Miha Kosmac
Thomas Gallagher
Cecilia DEANTONIO
Stephen Douglas GILLIES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kymab Ltd
Original Assignee
Kymab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/211,504 external-priority patent/US9567399B1/en
Priority claimed from GBGB1615224.1A external-priority patent/GB201615224D0/en
Priority claimed from GBGB1615335.5A external-priority patent/GB201615335D0/en
Priority claimed from GBGB1620414.1A external-priority patent/GB201620414D0/en
Priority claimed from GBGB1621782.0A external-priority patent/GB201621782D0/en
Priority claimed from GBGB1702338.3A external-priority patent/GB201702338D0/en
Priority claimed from GBGB1702339.1A external-priority patent/GB201702339D0/en
Priority claimed from GBGB1703071.9A external-priority patent/GB201703071D0/en
Priority to RU2018147423A priority Critical patent/RU2769282C2/ru
Priority to CA3026474A priority patent/CA3026474A1/en
Priority to KR1020197001344A priority patent/KR102531889B1/ko
Priority to US16/311,434 priority patent/US11965026B2/en
Priority to BR112018076281-4A priority patent/BR112018076281A2/pt
Application filed by Kymab Ltd filed Critical Kymab Ltd
Priority to EP17734405.8A priority patent/EP3471753A1/en
Priority to CN201780045595.4A priority patent/CN109475602B/zh
Priority to JP2019518159A priority patent/JP7461741B2/ja
Priority to US16/323,980 priority patent/US11858996B2/en
Priority to CA3032897A priority patent/CA3032897A1/en
Priority to CN202310636091.7A priority patent/CN116640214A/zh
Priority to RU2019104980A priority patent/RU2764548C2/ru
Priority to PCT/GB2017/052352 priority patent/WO2018029474A2/en
Priority to BR112019002529-4A priority patent/BR112019002529A2/pt
Priority to CN202310348318.8A priority patent/CN117736325A/zh
Priority to KR1020197006706A priority patent/KR102604433B1/ko
Priority to JP2019529699A priority patent/JP7198752B2/ja
Priority to KR1020237009918A priority patent/KR20230044038A/ko
Priority to EP17752162.2A priority patent/EP3497128A2/en
Priority to TW106126908A priority patent/TWI760352B/zh
Priority to CN201780045638.9A priority patent/CN109689688B/zh
Priority to US15/698,600 priority patent/US9957323B2/en
Priority to JP2019533195A priority patent/JP7290568B2/ja
Priority to EP17840565.0A priority patent/EP3559041A1/en
Priority to US16/471,161 priority patent/US20200190191A1/en
Priority to PCT/GB2017/053826 priority patent/WO2018115859A1/en
Publication of WO2017220989A1 publication Critical patent/WO2017220989A1/en
Anticipated expiration legal-status Critical
Publication of WO2017220989A8 publication Critical patent/WO2017220989A8/en
Priority to US17/727,288 priority patent/US20220380467A1/en
Priority to US17/727,309 priority patent/US20220403029A1/en
Priority to JP2022089801A priority patent/JP7448586B2/ja
Priority to JP2022143907A priority patent/JP2022180438A/ja
Priority to JP2023016174A priority patent/JP7750887B2/ja
Priority to US18/499,431 priority patent/US20240158502A1/en
Priority to JP2023205810A priority patent/JP7781129B2/ja
Priority to US18/592,425 priority patent/US20240360218A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Definitions

  • Antibodies and methods of using the antibodies are described. In particular, antibodies that specifically bind human PD-L1 antigen and their use in treating various diseases are described.
  • Immunocvtokines (antibody-cytokine fusion proteins) were first reported in the literature in the early 1990s and consisted of whole antibody fusions with cytokines such as lymphotoxin (TNF-a) or interleukin 2 (IL-2). Subsequent studies in GD2-expressing tumour models in mice indicated that the chl4.18 antibody and chl4.18-IL2 immunocytokine both had anti-tumour activity but that the immunocytokine was far more potent than the antibody, even when combined with free IL-2, (see Sabzevari H etal., Proc. Natl. Acad. Sci. USA, 1994, 91:9626-30; Pancook JD, etal., Cancer Immunol.
  • IL-2 IL-2-tumour vaccine effect that is not possible with the antibody, either alone or together with the free cytokine.
  • a related humanized immunocytokine, hu 14.18-IL2 achieved clinical proof of concept in relapsed non-bulky neuroblastoma as monotherapy where it induced a significant number of complete responses in patients with no other treatment options (see Shusterman etal, Journal of Clinical Oncology, 2010, 28(33), 4969-4975).
  • a number of publications describe the ability of this molecule to activate several components of the immune system to kill tumour cells (particularly NK cells and CD8 + T-cells), and develop T-cell memory in order to resist subsequent tumour challenge (Yamane et al. 2009; Expert Opi, Investig. Drugs, 18(7): 991-1000; Neal et al., 2004, Clin. Cancer Res., 1010, 4839-1847).
  • IL-2 based immunocvtokines can have significant side effects, recent efforts have focused on the reduction of toxicity whilst maintaining efficacy.
  • One example is Selectikine (EMD 521873), which has a substitution of aspartic acid for threonine at position 20 of IL-2, a key residue in the binding of IL-2R (Gillies etal, Clinical Cancer Research, 2011, 17(11), 3673-3685).
  • Selectikine which binds necrotic tissue, has been shown to have good anti-tumour activity, despite its selectivity for the high affinity IL-2R, over the intermediate IL-2R and good tolerability in Phase I studies (Laurent et al, Journal of Translational Medicine, 2013, 11(1), 5.
  • WO2012/178137 (Gillies) and an associated journal article (Gilles, Protein Engineering, Design and Selection, 2013, 26(10), 561-569) describe light chain immunocytokine fusions with tumour targeting antibodies, and modulation of IL-2 activity by the introduction of truncations in the N- terminal part of the cytokine, which decreases signalling through IL-2RPy.
  • IL-2 fusion proteins that specifically target IL-2RJ3y have been shown to have increased toxicity compared with wild-type (Vasquez-Lombardi eta/. Nat Comm, 2017, DOI: 10.1038/ncommsl5373), supporting the notion that decreasing IL-2RPy binding may be beneficial in terms of side effects.
  • T-cell activation involves activation, selection, and clonal proliferation of two major classes of lymphocytes termed T-cells and B-cells. After encountering an antigen, T-cells proliferate and differentiate into antigen-specific effector cells, while B-cells proliferate and differentiate into antibody-secreting cells.
  • T-cell activation is a multi-step process requiring several signalling events between the T-cell and an antigen-presenting cell (APC).
  • APC antigen-presenting cell
  • T-cell activation two types of signals must be delivered to a resting T-cell. The first type is mediated by the antigen-specific T-cell receptor (TcR), and confers specificity to the immune response.
  • TcR antigen-specific T-cell receptor
  • the second signal a costimulatory type signal, regulates the magnitude of the response and is delivered through accessory receptors on the T-cell.
  • a primary costimulatory signal is delivered through the activating CD28 receptor upon engagement of its ligands B7-1 or B7-2.
  • engagement of the inhibitory CTLA-4 receptor by the same B7-1 or B7-2 ligands results in attenuation of a T-cell response.
  • CTLA-4 signals antagonize costimulation mediated by CD28.
  • CD28 costimulation overrides the CTLA-4 inhibitory effect.
  • Temporal regulation of the CD28 and CTLA-4 expression maintains a balance between activating and inhibitory signals and ensures the development of an effective immune response, while safeguarding against the development of autoimmunity.
  • PD-1 is a 50-55 kDa type I transmembrane receptor that is a member of the CD28 family. PD-1 is involved in the regulation of T-cell activation and is expressed on T-cells, B cells, and myeloid cells. Two ligands for PD-1, PD ligand 1 (PD-L1) and ligand 2 (PD-L2) have been identified and have co-stimulatory features.
  • Programmed cell death 1 ligand 1 also known as cluster of differentiation (CD274) or B7 homolog 1 (B7-H1), is a member of the B7 family that modulates activation or inhibition of the PD-1 receptor.
  • the open reading frame of PD-L1 encodes a putative type 1 transmembrane protein of 290 amino acids, which includes two extracellular Ig domains (a N-terminal V-like domain and a Ig C-like domain), a hydrophobic transmembrane domain and a cytoplasmic tail of 30 amino acids.
  • the 30 amino acid intracellular (cytoplasmic) domain contains no obvious signalling motifs, but does have a potential site for protein kinase C phosphorylation.
  • NPJD54862.1 (SEQ ID NO: 1), which refers to many journal articles, including, for example, Dong, H., et al. (1999), "PD-L1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion," Nat. Med. 5 (12), 1365-1369.
  • the PD-Ll gene is conserved in chimpanzee, Rhesus monkey, dog, cow, mouse, rat, chicken, and zebrafish.
  • the murine form of PD-Ll bears 69% amino acid identity with the human form of PD-Ll, and also shares a conserved structure.
  • PD-Ll is expressed on a number of immune cell types including activated and anergic/exhausted T-cells, on naive and activated B-cells, as well as on myeloid dendritic cells (DC), monocytes and mast cells. It is also expressed on non-immune cells including islets of the pancreas, Kupffer cells of the liver, vascular endothelium and selected epithelia, for example airway epithelia and renal tubule epithelia, where its expression is enhanced during inflammatory episodes.
  • immune cell types including activated and anergic/exhausted T-cells, on naive and activated B-cells, as well as on myeloid dendritic cells (DC), monocytes and mast cells. It is also expressed on non-immune cells including islets of the pancreas, Kupffer cells of the liver, vascular endothelium and selected epithelia, for example airway epithelia and renal tubule epithelia, where its expression is enhanced during
  • PD-Ll expression is also found at increased levels on a number of tumours including, but not limited to breast (including but not limited to triple negative breast cancer and inflammatory breast cancer), ovarian, cervical, colon, colorectal, lung, including non-small cell lung cancer, renal, including renal cell carcinoma, gastric, oesophageal, bladder, hepatocellular cancer, squamous cell carcinoma of the head and neck (SCCHN) and pancreatic cancer, melanoma and uveal melanoma.
  • breast including but not limited to triple negative breast cancer and inflammatory breast cancer
  • ovarian including, cervical, colon, colorectal
  • lung including non-small cell lung cancer
  • renal including renal cell carcinoma, gastric, oesophageal, bladder, hepatocellular cancer, squamous cell carcinoma of the head and neck (SCCHN) and pancreatic cancer, melanoma and uveal melanoma.
  • SCCHN squamous cell carcinoma of the
  • PD-1/PD-L1 signalling is believed to serve a critical non-redundant function within the immune system by negatively regulating T-cell responses. This regulation is involved in T-cell development in the thymus, in regulation of chronic inflammatory responses and in maintenance of both peripheral tolerance and immune privilege. It appears that upregulation of PD-Ll may allow cancers to evade the host immune system and, in many cancers, the expression of PD-Ll is associated with reduced survival and an unfavourable prognosis. Therapeutic monoclonal antibodies that are able to block the PD-1/PD-L1 pathway may enhance anti-tumoural immune responses in patients with cancer.
  • PD-Ll expression in tumours or tumour-infiltrating leukocytes is a candidate molecular marker for use in selecting patients for immunotherapy, for example, immunotherapy using anti-PD-Ll antibodies.
  • Patient enrichment based on surface expression of PD-Ll may significantly enhance the clinical success of treatment with drugs targeting the PD-1/PD-L1 pathway.
  • an on-going immune response such as the tumour infiltrating CD8 + T-cells, or the presence of signature of cytokine activation, such as IFNy.
  • Atezolizumab is the most advanced, and recent data from Phase II trials shows therapeutic effects in metastatic urothelial carcinoma and NSCLC, particularly in patients with PD-L1 + immune cells in the tumour microenvironment (see Fehrenbacher et al., 2016, The Lancet, http://doi.org/10.1016/S0140-6736(16)00587-0; Rosenberg et al., 2016, The Lancet, http://doi.org/10.1016/S0140-6736(16)00561-4).
  • antibodies and antigen binding fragments thereof that specifically bind to PD-L1.
  • the antibody or antigen binding fragment thereof specifically binds to surface expressed PD-L1.
  • an antibody or a fragment thereof that specifically binds to hPD-Ll as defined by Seq ID No: l, and competes for binding to said hPD-Ll with the antibody 1D05, wherein the antibody or fragment comprises a VH domain which comprises a CDRH3 comprising the motif X1GSGX2YGX3X4FD, wherein Xi, X2 and X3 are independently any amino acid, and X4 is either present or absent, and if present, may be any amino acid.
  • an antibody or a fragment thereof which specifically binds to hPD-Ll, and competes for binding to said hPD-Ll with the antibody 1D05, wherein the antibody or fragment comprises a VH domain which comprises the CDRH3 sequence of SEQ ID NO: 29 or 32, or the CDRH3 sequence of SEQ ID NO: 29 or 32 comprising 6 or fewer amino acid substitutions.
  • an antibody or fragment thereof which specifically binds to an epitope that is identical to an epitope to which the antibody 1D05 specifically binds.
  • an antibody or fragment thereof which competes for binding to hPD-Ll with the antibody 1D05.
  • a bispecific antibody or fusion protein comprising an antibody or fragment thereof as defined in any other configuration, embodiment or concept.
  • an antibody or fragment as defined in any other configuration, embodiment or concept for use in treating or preventing a hPD-Ll-mediated disease or condition is provided.
  • a seventh configuration there is provided the use of an antibody or fragment as defined in any other configuration, embodiment or concept in the manufacture of a medicament for administration to a human for treating or preventing a hPD-Ll mediated disease or condition in the human.
  • a method of treating or preventing a hPD-Ll mediated disease or condition in a human comprising administering to said human a therapeutically effective amount of an antibody or fragment as defined in any other configuration, embodiment or concept, wherein the hPD-Ll mediated disease or condition is thereby treated or prevented.
  • a pharmaceutical composition comprising an antibody of fragment as defined in any other configuration, embodiment or concept and a pharmaceutically acceptable excipient, diluent or carrier.
  • kits comprising a pharmaceutical composition comprising an antibody of fragment as defined in any other configuration, embodiment or concept and a pharmaceutically acceptable excipient, diluent or carrier.
  • a method of modulating PD-1/PD-L1 interaction in a patient comprising administering an effective amount of an antibody or fragment as defined in any other configuration, embodiment or concept to said patient.
  • a method of inhibiting PD-Ll activity in a patient comprising administering an effective amount of an antibody or fragment as defined in any other configuration, embodiment or concept to said patient.
  • a method of treating a proliferative disease in an animal comprising administering an effective amount of an antibody or fragment as defined in any other configuration, embodiment or concept to said patient.
  • a fourteenth configuration there is provided a method of detecting PD-Ll expression in a sample, comprising contacting the sample with an antibody or fragment as defined in any other configuration, embodiment or concept.
  • a method comprising contacting a biological sample with an antibody or fragment as defined in any other configuration, embodiment or concept to form a complex with PD-Ll present in the sample and measuring the presence, absence or level of the complex in the biological sample.
  • a method of detecting PD-Ll expression in a sample comprising contacting the sample with an antibody or fragment as defined in any other configuration, embodiment or concept.
  • a method comprising contacting a biological sample with an antibody or fragment as defined in any other configuration, embodiment or concept to form a complex with PD-Ll present in the sample and measuring the presence, absence or level of the complex in the biological sample.
  • a method for identifying binding partners for PD-Ll comprising immunoprecipitating an intact protein complex comprising PD-Ll using an antibody or fragment as defined in any other configuration, embodiment or concept.
  • a method of diagnosing a disease in a human subject associated with altered PD-Ll expression comprising the steps of contacting a biological sample from the human subject with an antibody as defined in other configuration, embodiment or concept to form a complex between the antibody and PD-Ll present in the sample; and detecting the amount of the complex.
  • nucleic acid that encodes the CDRH3 of an antibody or fragment as defined in any other configuration, embodiment or concept.
  • nucleic acid that encodes a VH domain and/or a VL domain of an antibody or fragment as defined in any other configuration, embodiment or concept.
  • a vector comprising the nucleic acid of any other configuration, embodiment or concept; optionally wherein the vector is a CHO or HEK293 vector.
  • a host comprising the nucleic acid of any other configuration, embodiment or concept or the vector of any other configuration, embodiment or concept.
  • an immunocytokine comprising an immunoglobulin heavy chain and an immunoglobulin light chain, wherein the heavy chain comprises in N- to C-terminal direction:
  • VH domain comprising CDRH1, CDRH2 and CDRH3;
  • VL domain comprising CDRL1, CDRL2 and CDRL3;
  • VH domain and VL domain are comprised by an antigen-binding site that specifically binds to hPD-Ll as defined by Seq ID No: l, and competes for binding to said hPD-Ll with the antibody 1D05; and
  • the immunocytokine comprises a VH domain which comprises a CDRH3 comprising the motif X1GSGX2YGX3X4FD, wherein Xi, X2 and X3 are independently any amino acid, and X 4 is either present or absent, and if present, may be any amino acid.
  • an immunocytokine comprising an immunoglobulin heavy chain and an immunoglobulin light chain, wherein the heavy chain comprises in N- to C-terminal direction :
  • VH domain comprising CDRH 1, CDRH2 and CDRH3;
  • VH domain and VL domain are comprised by an antigen-binding site that specifically binds to hPD-Ll, and competes for binding to said hPD-Ll with the antibody 1D05, wherein the antibody or fragment comprises a VH domain which comprises the CDRH3 sequence of SEQ ID NO: 29 or 32, or the CDRH3 sequence of SEQ ID NO: 29 or 32 comprising 6 or fewer amino acid substitutions.
  • an immunocytokine comprising an immunoglobulin heavy chain and an immunoglobulin light chain, wherein the heavy chain comprises in N- to C-terminal direction:
  • VH domain comprising CDRH1, CDRH2 and CDRH3;
  • VL domain comprising CDRL1, CDRL2 and CDRL3;
  • VH domain and VL domain are comprised by an antigen-binding site that specifically binds to hPD-Ll; and wherein the VH domain comprises a CDRH3 of from 12 to 20 amino acids and which is derived from the recombination of a human VH gene segment, a human D gene segment and a human JH gene segment, wherein the human JH gene segment is IGHJ5 (e.g. IGHJ5*02).
  • an immunocytokine comprising an immunoglobulin heavy chain and an immunoglobulin light chain, wherein the heavy chain comprises in N- to C-terminal direction:
  • VH domain comprising CDRH1, CDRH2 and CDRH3;
  • VL domain comprising CDRL1, CDRL2 and CDRL3;
  • VH domain and Vi_ domain are comprised by an antigen-binding site that specifically binds to an epitope that is identical to an epitope to which the antibody 1D05 specifically binds.
  • an immunocytokine comprising an immunoglobulin heavy chain and an immunoglobulin light chain, wherein the heavy chain comprises in N- to C-terminal direction:
  • VH domain comprising CD H1, CDRH2 and CDRH3;
  • VL domain comprising CDRL1, CDRL2 and CDRL3;
  • VH domain and VL domain are comprised by an antigen-binding site which competes for binding to hPD-Ll with the antibody 1D05.
  • an immunocytokine as defined in any other configuration, embodiment or aspect for use in treating or preventing a hPD-Ll-mediated disease or condition.
  • an immunocytokine as defined in any other configuration, embodiment or aspect in the manufacture of a medicament for administration to a human for treating or preventing a hPD-Ll mediated disease or condition in the human.
  • a method of treating or preventing a hPD-Ll mediated disease or condition in a human comprising administering to said human a therapeutically effective amount of an immunocytokine as defined in any other configuration, embodiment or aspect, wherein the hPD-Ll mediated disease or condition is thereby treated or prevented.
  • a pharmaceutical composition comprising an immunocytokine as defined in any other configuration, embodiment or aspect, and a pharmaceutically acceptable excipient, diluent or carrier.
  • kits comprising a pharmaceutical composition comprising an immunocytokine as defined in any other configuration, embodiment or aspect, and a pharmaceutically acceptable excipient, diluent or carrier.
  • nucleic acid that encodes a heavy chain and/or a light chain of an immunocytokine as defined in any other configuration, embodiment or aspect.
  • a vector comprising the nucleic acid that encodes a heavy chain and/or a light chain of an immunocytokine as defined in any other configuration, embodiment or aspect.
  • a host comprising the nucleic acid of any other configuration, embodiment or aspect or the vector as defined in any other configuration, embodiment or aspect.
  • a multispecific antibody e.g. bispecific antibody or a dual-binding antibody
  • ICOS e.g. human ICOS
  • composition comprising a multispecific, bispecific or dual-binding antibody as described herein and a pharmaceutically acceptable excipient, diluent or carrier.
  • a multispecific, bispecific or dual-binding antibody as described herein for use in treating or preventing a disease or condition, selected from neurological disease, neoplastic or non-neoplastic disease, chronic viral infections, and malignant tumours; such as melanoma, Merkel cell carcinoma, non-small cell lung cancer (squamous and non-squamous), renal cell cancer, bladder cancer, head and neck squamous cell carcinoma, mesothelioma, virally induced cancers (such as cervical cancer and nasopharyngeal cancer), soft tissue sarcomas, haematological malignancies such as Hodgkin's and non-Hodgkin's disease and diffuse large B-cell lymphoma (for example melanoma, Merkel cell carcinoma, non-small cell lung cancer (squamous and non-squamous), renal cell cancer, bladder cancer, head and neck squamous cell carcinoma and mesothelioma or for example viral
  • a disease or condition selected
  • a multispecific, bispecific or dual-binding antibody as described herein in the manufacture of a medicament for administration to a human for treating or preventing a disease or condition in the human selected from neurological disease, neoplastic or non-neoplastic disease, chronic viral infections, and malignant tumours, such as melanoma, Merkel cell carcinoma, non-small cell lung cancer (squamous and non-squamous), renal cell cancer, bladder cancer, head and neck squamous cell carcinoma, mesothelioma, virally induced cancers (such as cervical cancer and nasopharyngeal cancer), soft tissue sarcomas, haematological malignancies such as Hodgkin's and non-Hodgkin's disease and diffuse large B-cell lymphoma (for example melanoma, Merkel cell carcinoma, non-small cell lung cancer (squamous and non-squamous), renal cell cancer, bladder cancer, head and neck squa
  • a disease or condition in the human selected from
  • a disease or condition selected from neurological disease, neoplastic or non-neoplastic disease, chronic viral infections, and malignant tumours, such as melanoma, Merkel cell carcinoma, non-small cell lung cancer (squamous and non-squamous), renal cell cancer, bladder cancer, head and neck squamous cell carcinoma, mesothelioma, virally induced cancers (such as cervical cancer and nasopharyngeal cancer), soft tissue sarcomas, haematological malignancies such as Hodgkin's and non-Hodgkin's disease and diffuse large B-cell lymphoma (for example melanoma, Merkel cell carcinoma, non-small cell lung cancer (squamous and non-squamous), renal cell cancer, bladder cancer, head and neck squamous cell carcinoma and mesothelioma or for example virally induced cancers (such as cervical cancer and nasophary
  • a disease or condition selected from neurological disease, neo
  • nucleic acid that encodes a heavy chain and/or a light chain of a multispecific antibody as described herein.
  • a vector comprising the nucleic acid that encodes a heavy chain and/or a light chain of a multispecific antibody as described herein.
  • FIG. 1 Analysis of selected antibodies in a dendritic cell— T-cell mixed lymphocyte reaction. Monocytes were cultured with GM-CSF and IL-4 for seven days, before addition of allogeneic purified CD3 + T-cells and titrations of antibodies. Supernatants were taken at day 5 for analysis of IFNy production. Data is shown from one experiment. Note that for 84G09, there is a single point per concentration, as one replicate failed
  • FIG. 2 PD-L1 direct neutralisation ELISA with PD-1 receptor. Neutralisation profiles of 1D05 and 84G09 compared to a benchmark anti-PD-Ll antibody and isotype control. Data representative of three independent experiments
  • Figure 3 Human PD-L1 CHO-S FACS neutralisation with PD-1 receptor. Neutralisation profiles of 1D05 and 84G09 compared to a benchmark anti-PD-Ll antibody and isotype control. Data representative of three independent experiments
  • Figure 4 Human PD-L1 CHO FACS neutralisation with CD80 receptor. Neutralisation profiles of the 1D05 and 84G09 compared to the benchmark anti-PD-Ll antibody and isotype control. Data representative of three independent experiments
  • Figure 5 Binding of lead antibodies to PD-L1 but not PD-L2.
  • Lead antibodies bind to plate bound PD-L1 ( Figure 5a) but not PD-L2 ( Figure 5b).
  • An anti-PD-L2 antibody was used as a control.
  • Data are expressed as time resolved fluorescence units at 615 nm. Data representative of two independent experiments
  • FIG. 6 Lead antibodies induce IFNy production in a Dendritic Cell-T-cell mixed lymphocyte reaction. Immature dendritic cells were co-cultured with allogeneic CD4 + T-cells in the presence of antibodies for 5 days. IFNy was measured in supernatants by ELISA. Data are representative of three independent experiments. Bl refers to a benchmark antibody
  • Figure 7 Lead antibodies bind to natively expressed PD-L1 on dendritic cells. Dendritic cells were generated from monocyte precursors with GM-CSF and IL-4 and stained with lead antibodies (a) 1D05 and (b) 84G09, and isotype control directly labelled with AlexaFluor647. Data shown is from one blood donor, representative of four donors
  • Figure 8a PD-L1 direct neutralisation ELISA with PD-1 receptor. Neutralisation profiles of
  • Figure 8b PD-L1 direct neutralisation ELISA with PD-1 receptor. Neutralisation profiles of KM122 lead candidate molecules compared to the benchmark anti-PD-Ll antibody. Data is from a single experiment
  • Figure 8c PD-L1 direct neutralisation ELISA with PD-1 receptor. Neutralisation profile of KM122 lead candidate molecule 416E01 compared to the benchmark anti-PD-Ll antibody. Data is from a single experiment
  • Figure 9a PD-L1 direct neutralisation ELISA with CD80 receptor. Neutralisation profiles of KM121 hits compared to a benchmark anti-PD-Ll antibody and isotype control. Data representative of three independent experiments
  • Figure 9b PD-L1 direct neutralisation ELISA with CD80 receptor. Neutralisation profiles of KM122 lead candidate molecules compared to the benchmark anti-PD-Ll antibody. Data is from a single experiment
  • Figure 9c PD-L1 direct neutralisation ELISA with CD80 receptor. Neutralisation profiles of
  • Figure 12(a) Ability of immunocytokine constructs to induce proliferation in IL-2RaPy expressing TF-1 cells, compared with equimolar concentrations of free IL-2. Data shown is from a single experiment, representative of three experiments
  • Figure 12(b) Ability of immunocytokine constructs to induce proliferation in IL-2R y expressing TF-1 cells, compared with equimolar concentrations of free IL-2. Data shown is from a single experiment, representative of four experiments
  • Figure 14 Mean group and individual animal growth curves for the NOD/SCID: Xenograft in vivo efficacy study
  • the shaded area shows the area where the last reading is being used
  • A375 tumour cell were co-injected with CD4 + /8 + T-cells at a 6: 1 ratio;
  • Isotype Control antibody at 10 mg/kg and
  • anti-PD-Ll antibody 1D05 at 10 mg/kg. Dosing was at 1-hour post tumour/T-cell implantation and on days 3, 6, 8 and 10, shown on the graph by the dotted lines
  • Treatment with 10 mg/kg of the anti-PD-Ll antibody 1D05 significantly increased the time on study when compared to the isotype control group. Dosing was 1-hour post injection of the T-cells/tumour cells and on days 3, 6, 8 and 10, show on the graph by the dotted lines
  • Figure 16 Expanding of lymphocytes in response to dosing with immunocytokines. Fasting blood samples were taken into EDTA treated tubes pre-treatment (0), and 2, 5 and 7 days post- treatment. Cell counts were measured by the Bayer Advia 120. Results are expressed as fold change in lymphocyte count
  • Figure 17 Analysis of standard haematological parameters in response to dosing with immunocytokines. Fasting blood samples were taken into EDTA treated tubes pre-treatment and 7 days post-treatment. Analysis of haemoglobin, haematocrit, red blood cell counts and platelet counts were performed using the Bayer Advia 120. Results are expressed as the percentage change in parameter 7 days post-dosing
  • FIG 18 Cytokine levels in plasma of cynomolgus monkeys dosed with immunocytokine molecules. Plasma samples were obtained pre-treatment (PT) and 3 days after dosing (D3) and analysed by MSD for levels of a) TNF-a; b) IL-8; c) IL-6; d) IFNy; e) G-CSF and f) IL-2. Where no bar is included, cytokine levels were below the limit of quantification of the assay. IL4, IL-5 and IL- ⁇ were not detectable in any sample at either timepoint and so are not included in the graphs Figure 19: Levels of soluble CD25 in plasma of cynomolgus monkeys dosed with immunocytokine molecules. Plasma samples were obtained pre-treatment (PT) and 3 days after dosing (D3) and analysed using a commercial ELISA kit. * indicates levels above limit of quantification (20,000 pg/mL)
  • FIG. 20 Flow cytometric analysis of PBMC subsets. Whole blood was stained for markers of a) T-cells and b) B-cells, NK cells, neutrophils and monocytes, prior to red blood cell lysis and fixation. Data is expressed as the fold change in cell number 5 days after dosing. Data for 1D05 LC D9-7 ICK is missing due to unusable sample
  • FIG. 21 Pharmacokinetic (PK) analysis of immunocytokines. Serum was prepared from blood samples taken at various time points over 96 hours. In panels a) and b), serum was incubated on plates coated with PD-Ll and immunocytokines detected with a biotinylated anti-human Fc detection antibody, and streptavidin-labelled Europium. In panels c) and d), serum was incubated on plates coated with PD-Ll and immunocytokines detected with a biotinylated anti-human IL-2 antibody, and streptavidin-labelled Europium. Results are expressed as ng/mL
  • Figure 22a Induction of IFNy production in a monocyte-T-cell co-culture assay by anti-PD-
  • Figure 22b Induction of IFNy production in a monocyte-T-cell co-culture assay by an anti- PD-L1 antibody in human IgG4(PE) format. Each data point represents the mean fold induction from two independent experiments, ⁇ standard deviation
  • Human PD-Ll transfected LK35.2 cells were loaded with ovalbumin peptide and co-cultured overnight with DO-11-10 T-cell hybridoma cells in the presence of anti-PD-Ll antibodies or controls, prior to collection of supernatants and analysis of IL-2 release.
  • Each data point indicates background-corrected mean IL-2 release from three independent experiments ⁇ standard deviation
  • Figure 23(b) Induction of IL-2 in a murine T-cell hybridoma assay.
  • Human PD-Ll transfected LK35.2 cells were loaded with ovalbumin peptide and co-cultured overnight with DO-11-10 T-cell hybridoma cells in the presence of ICOS/PD-Ll bi-specific molecules, or individual antibodies, prior to collection of supernatants and analysis of IL-2 release.
  • Each data point indicates background-corrected mean IL-2 release from three independent experiments ⁇ standard deviation
  • FIG. 24(a) Induction of IFNy in a DC-T-cell MLR assay.
  • Monocyte derived dendritic cells DC were activated with E co//LPS and co-cultured with allogeneic CD3 + T-cells at a 1: 1 ratio.
  • IFNy was measured by DELFIA assay after 5 days of co-culture. Data is from a single experiment
  • Figure 24(b) Induction of IL-2 in a DC-T-cell MLR assay.
  • Monocyte derived dendritic cells DC were activated with E coli LPS and co-cultured with allogeneic CD3 + T-cells at a 1: 1 ratio.
  • IL-2 was measured by DELFIA assay after 3 days of co-culture. Data is from a single experiment
  • Figure 25 Titration of FIT-Ig molecules, parental monospecific antibodies, and control antibodies in PD-L1/TIGIT AlphaScreen ® Binding Assay using method one.
  • Antibodies were incubated with PD-Ll and TIGIT proteins for an hour before the addition of AlphaScreen ® acceptor beads for an hour followed by the addition of AlphaScreen ® donor beads for another hour prior to the detection of fluorescence.
  • Figure 26 Titration of FIT-Ig molecules, parental monospecific antibodies, and control antibodies in PD-L1/TIGIT AlphaScreen ® Binding Assay using method two.
  • AlphaScreen ® donor and acceptor beads were coated for an hour with PD-Ll and TIGIT proteins respectively before the addition of antibodies for an hour followed by the detection of fluorescence.
  • Figure 27 Titration of FIT-Ig molecules, and control antibody in a PD-L1/TIGIT cell recruitment assay by flow cytometry.
  • CHO human PD-Ll and HEK human TIGIT were stained with CellTraceTM Far Red and CellTraceTM Violet respectively and co-cultured in presence of antibodies for an hour prior to the detection of fluorescence and identification of double positive population. Data shown are representative of one unique experiment
  • Figure 28 Expansion of lymphocytes in response to dosing with immunocytokines. Fasting blood samples were taken into EDTA treated tubes pre-treatment (0), and 2, 5 and 7, 10, 14 and 23 days post-treatment. Cell counts were measured by the Bayer Advia 120. Results are expressed as fold change in lymphocyte count
  • FIG. 29 Levels of soluble CD25 in plasma of cynomolgus monkeys dosed with immunocytokine molecules. Plasma samples were obtained pre-treatment (0) and 3, 7 and 10 days after dosing and analysed using a commercial ELISA kit
  • Figure 30 Analysis of standard haematological parameters in response to dosing with immunocytokines. Fasting blood samples were taken into EDTA treated tubes pre-treatment (0) and 2, 5, 7, 10, 14 and 23 days post-treatment. Analysis of A) haemoglobin, B) haematocrit, C) red blood cell counts and D) platelet counts were performed using the Bayer Advia 120. Results are expressed as the fold change in parameter at each timepoint
  • FIG. 31 Cytokine levels in plasma of cynomolgus monkeys dosed with immunocytokine molecules. Plasma samples were obtained pre-treatment (0) and 1, 3, 7, 10, 14 and 23 days after dosing and analysed by MSD for levels of a) TNF-a; b) IL-8; c) IL-6; d) IFNy; e) G-CSF, f) IL-2, g) IL- 4 and h) IL-5. Where no bar is included, cytokine levels were below the limit of quantification of the assay. IL- ⁇ was not detectable in any samples and so is not included in the graphs
  • FIG 32 Pharmacokinetic (PK) analysis of immunocytokines. Serum was prepared from blood samples taken at various time points over 96 hours. Serum was incubated on plates coated with PD-Ll and immunocytokines detected with a biotinylated anti-human Fc detection antibody, and streptavidin-labelled Europium. Results are expressed as % peak concentration
  • Figure 33 .Expansion of specific T-cell subsets by ICK molecules. Whole blood was incubated with antibodies for staining, before red blood cell lysis, fixation and analysis by flow cytometry. Results are expressed as fold change in absolute (a) CD4 + T-cell and (b) CD8 + T-cell numbers at each timepoint.
  • Figure 34 Effector function of lead antibodies in a reporter cell assay.
  • PD-L1 expressing target cells ES2
  • Jurkat cells engineered to express NFAT-induced luciferase and FcyRIIIa, in the presence of PD-L1 antibodies.
  • Each data point indicates mean fold induction of relative light units ⁇ standard deviation. Data is from one representative experiment, of three independent experiments
  • Figure 35 Binding of lead antibodies to cell-expressed cynomolgus PD-L1. Antibodies were titrated on CHO cells expressing cynomolgus PD-L1, and bound antibody detected with an anti-human IgG AlexaFluor 647. Data is from a single experiment
  • Figure 37 Induction of IFNy production in a monocyte-T-cell co-culture assay by anti-PD- LI antibodies in human IgGl format. Each data point represents the mean fold induction of IFNy from at least three independent experiments, ⁇ standard error of the mean
  • the term "about” is used to modify, for example, the quantity of an ingredient in a composition, concentration, volume, process temperature, process time, yield, flow rate, pressure, and like values, and ranges thereof, employed in describing the embodiments of the disclosure.
  • the term “about” refers to variation in the numerical quantity that can occur, for example, through typical measuring and handling procedures used for making compounds, compositions, concentrates or use formulations; through inadvertent error in these procedures; through differences in the manufacture, source, or purity of starting materials or ingredients used to carry out the methods, and like proximate considerations.
  • administer refers to the act of injecting or otherwise physically delivering a substance as it exists outside the body (e.g., an anti-hPD-Ll antibody provided herein) into a patient, such as by mucosal, intradermal, intravenous, intramuscular delivery and/or any other method of physical delivery described herein or known in the art.
  • a disease, or a symptom thereof is being treated, administration of the substance typically occurs after the onset of the disease or symptoms thereof.
  • administration of the substance typically occurs before the onset of the disease or symptoms thereof.
  • antibody means an immunoglobulin molecule that recognizes and specifically binds to a target, such as a protein, polypeptide, peptide, carbohydrate, polynucleotide, lipid, or combinations of the foregoing through at least one antigen recognition site within the variable region of the immunoglobulin molecule.
  • antibody encompasses intact polyclonal antibodies, intact monoclonal antibodies, antibody fragments (such as Fab, Fab', F(ab') 2 , and Fv fragments), single chain Fv (scFv) mutants, multispecific antibodies such as bispecific antibodies (including dual binding antibodies), chimeric antibodies, humanized antibodies, human antibodies, fusion proteins comprising an antigen determination portion of an antibody, and any other modified immunoglobulin molecule comprising an antigen recognition site so long as the antibodies exhibit the desired biological activity.
  • antibody can also refer to a Y-shaped glycoprotein with a molecular weight of approximately 150 kDa that is made up of four polypeptide chains: two light (L) chains and two heavy (H) chains.
  • L light
  • H heavy
  • the type of heavy chain defines the class of antibody, i.e., IgA, IgD, IgE, IgG, and IgM, respectively.
  • the ⁇ and a classes are further divided into subclasses on the basis of differences in the constant domain sequence and function, e.g., IgGl, hIgG2, mIgG2A, mIgG2B, IgG3, IgG4, IgAl and IgA2.
  • immunoglobulin light chains there are two types of immunoglobulin light chains, ⁇ and ⁇ .
  • the "variable region” or “variable domain” of an antibody refers to the amino-terminal domains of the heavy or light chain of the antibody.
  • the variable domains of the heavy chain and light chain may be referred to as "VH" and "VL", respectively.
  • the antibodies described herein may be oligoclonal, polyclonal, monoclonal (including full- length monoclonal antibodies), camelised, chimeric, CDR-grafted, multi-specific, bi-specific (including dual-binding antibodies), catalytic, chimeric, humanized, fully human, anti-idiotypic, including antibodies that can be labelled in soluble or bound form as well as fragments, variants or derivatives thereof, either alone or in combination with other amino acid sequences provided by known techniques.
  • An antibody may be from any species.
  • Antibodies described herein can be naked or conjugated to other molecules such as toxins, radioisotopes, etc.
  • antigen binding domain refers to that portion of an antibody which comprises the amino acid residues that interact with an antigen and confer on the binding agent its specificity and affinity for the antigen (e.g. the complementarity determining regions (CDRs)).
  • the antigen binding region can be derived from any animal species, such as rodents (e.g. rabbit, rat or hamster) and humans. Preferably, the antigen binding region will be of human origin.
  • Antigen binding fragments described herein can include single-chain Fvs (scFv), single- chain antibodies, single domain antibodies, domain antibodies, Fv fragments, Fab fragments, F(ab') fragments, F(ab') 2 fragments, antibody fragments that exhibit the desired biological activity, disulfide- stabilised variable region (dsFv), dimeric variable region (diabody), anti-idiotypic (anti-Id) antibodies (including, e.g. anti-Id antibodies to antibodies), intrabodies, linear antibodies, single-chain antibody molecules and multispecific antibodies formed from antibody fragments and epitope-binding fragments of any of the above.
  • scFv single-chain Fvs
  • dsFv disulfide- stabilised variable region
  • dimeric variable region dimeric variable region
  • anti-Id anti-idiotypic antibodies
  • antibodies and antibody fragments described herein can include immunoglobulin molecules and immunologically active fragments of immunoglobulin molecules, i.e., molecules that contain an antigen-binding site. Digestion of antibodies with the enzyme, papain, results in two identical antigen-binding fragments, known also as "Fab” fragments, and a "Fc” fragment, having no antigen-binding activity but having the ability to crystallize.
  • Fab when used herein refers to a fragment of an antibody that includes one constant and one variable domain of each of the heavy and light chains.
  • Fc region herein is used to define a C- terminal region of an immunoglobulin heavy chain, including native- sequence Fc regions and variant Fc regions.
  • the "Fc fragment” refers to the carboxy-terminal portions of both H chains held together by disulfides.
  • the effector functions of antibodies are determined by sequences in the Fc region, the region which is also recognized by Fc receptors (FcR) found on certain types of cells. Digestion of antibodies with the enzyme, pepsin, results in a F(ab') 2 fragment in which the two arms of the antibody molecule remain linked and comprise two-antigen binding sites.
  • the F(ab') 2 fragment has the ability to crosslink antigen.
  • Fv when used herein refers to the minimum fragment of an antibody that retains both antigen-recognition and antigen-binding sites. This region consists of a dimer of one heavy and one light chain variable domain in tight, non-covalent or covalent association. It is in this configuration that the three CDRs of each variable domain interact to define an antigen-binding site on the surface of the VH-VL dimer. Collectively, the six CDRs confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.
  • monoclonal antibody refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e. the individual antibodies comprising the population are identical except for possible naturally occurring mutations and/or post-translation modifications (e.g. isomerizations, amidations) that may be present in minor amounts.
  • Monoclonal antibodies are highly specific, and are directed against a single antigentic determinant or epitope.
  • polyclonal antibody preparations typically include different antibodies directed against different antigenic determinants (or epitopes).
  • monoclonal antibody encompasses both intact and full-length monoclonal antibodies as well as antibody fragments (such as Fab, Fab', F(ab') 2 , Fv), single chain (scFv) mutants, fusion proteins comprising an antibody portion, and any other modified immunoglobulin molecule comprising an antigen recognition site.
  • monoclonal antibody refers to such antibodies made in any number of ways including, but not limited to, hybridoma, phage selection, recombinant expression, and transgenic animals.
  • the monoclonal antibodies herein can include "chimeric" antibodies (immunoglobulins) in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is(are) identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies that exhibit the desired biological activity.
  • chimeric antibodies immunoglobulins in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is(are) identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies that exhibit the desired biological activity.
  • humanized antibody refers to a subset of chimeric antibodies in which a "hypervariable region" from a non-human immunoglobulin (the donor antibody) replaces residues from a hypervariable region in a human immunoglobulin (recipient antibody).
  • a humanized antibody will include substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin sequence, and all or substantially all of the framework regions are those of a human immunoglobulin sequence, although the framework regions may include one or more substitutions that improve antibody performance, such as binding affinity, isomerization, immunogenicity, etc.
  • bispecific antibody means an antibody which comprises specificity for two target molecules, and includes, but is not limited to, formats such as DVD-Ig (see DiGiammarino et al., "Design and generation of DVD-IgTM molecules for dual-specific targeting", Meth. Mo.
  • mAb 2 see WO2008/003103, the description of the mAb 2 format is incorporated herein by reference
  • FIT-Ig see WO2015/ 103072, the description of the FIT-Ig scaffold is incorporated herein by reference
  • mAb-dAb see WO2015/ 103072, the description of the FIT-Ig scaffold is incorporated herein by reference
  • mAb-dAb dock and lock
  • Fab-arm exchange see Fab-arm exchange
  • SEEDbody Triomab, LUZ-Y, Fcab, ⁇ - body, orthogonal Fab, scDiabody-Fc, diabody-Fc, tandem scFv-Fc, Fab-scFv-Fc, Fab-scFv, intrabody, BiTE, diabody, DART, TandAb, scDiabody, scDiabody-CH3, Diabody-CH3, Triple body, Miniantibody, minibody, TriBi minibody, scFv-CH
  • the bispecific molecule comprises an antibody which is fused to another non-Ig format, for example a T-cell receptor binding domain; an immunoglobulin superfamily domain; an agnathan variable lymphocyte receptor; a fibronectin domain (e.g. an AdnectinTM); an antibody constant domain (e.g.
  • a CH 3 domain e.g., a CH2 and/or CH 3 of an FcabTM
  • the constant domain is not a functional CHi domain; an scFv; an (scFv) 2 ; an sc-diabody; an scFab; a centyrin and an epitope binding domain derived from a scaffold selected from CTLA-4 (EvibodyTM); a lipocalin domain; Protein A such as Z-domain of Protein A (e.g. an AffibodyTM or SpA); an A-domain (e.g. an AvimerTM or MaxibodyTM); a heat shock protein (such as and epitope binding domain derived from GroEI and GroES); a transferrin domain (e.g.
  • trans-body a trans-body
  • ankyrin repeat protein e.g. a DARPinTM
  • peptide aptamer e.g. TetranectinTM
  • C-type lectin domain e.g. TetranectinTM
  • human ⁇ - crystallin or human ubiquitin an affilin
  • PDZ domain e.g. scorpion toxin
  • kunitz type domain of a human protease inhibitor e.g. a trans-body
  • ankyrin repeat protein e.g. a DARPinTM
  • peptide aptamer e.g. TetranectinTM
  • human ⁇ - crystallin or human ubiquitin an affilin
  • PDZ domain e.g. PDZ domain
  • scorpion toxin e.g., scorpion toxin
  • kunitz type domain of a human protease inhibitor e.g. a kunitz type domain of a
  • the bispecific antibody is a mAb 2 .
  • a mAb 2 comprises a VH and VL domain from an intact antibody, fused to a modified constant region, which has been engineered to form an antigen-binding site, known as an "Fcab".
  • the technology behind the Fcab/mAb 2 format is described in more detail in WO2008/003103, and the description of the mAb 2 format is incorporated herein by reference.
  • a "bispecific antibody” does not include a FIT-Ig format. In one embodiment, a “bispecific antibody” does not include a mAb 2 format. In one embodiment, a "bispecific antibody” does not include either a FIT-Ig format or a mAb 2 format.
  • the bispecific antibody is a "dual binding antibody”.
  • the term “dual binding antibody” is a bispecific antibody wherein both antigen-binding domains are formed by a VH/VL pair, and includes FIT-Ig (see WO2015/103072, incorporated herein by reference), mAb-dAb, dock and lock, Fab-arm exchange, SEEDbody, Triomab, LUZ-Y, Fcab, ⁇ -body, orthogonal Fab, scDiabody-Fc, diabody-Fc, tandem scFv-Fc, Fab-scFv-Fc, Fab-scFv, intrabody, BiTE, diabody, DART, TandAb, scDiabody, scDiabody-CH3, Diabody-CH3, Triple body, Miniantibody, minibody, scFv- CH3 KIH, scFv-CH-CL-scFv, F(ab')2-sc
  • CDR region refers to the regions of an antibody variable domain which are hypervariable in sequence and/or form structurally defined loops.
  • antigen binding sites of an antibody include six hypervariable regions: three in the VH (CDRHl, CDRH2, CDRH3), and three in the VL (CDRLl, CDRL2, CDRL3). These regions of the heavy and light chains of an antibody confer antigen-binding specificity to the antibody.
  • CDRs may be defined according to the Kabat system (see Kabat, E. A. et a/., 1991, "Sequences of Proteins of Immunological Interest", 5 th edit., NIH Publication no. 91-3242, U.S.
  • CDRs which as the system devised by Chothia et a/ (see Chothia, C. & Lesk, A. M., 1987, "Canonical structures for the hypervariable regions of immunoglobulins", J. Mol. Biol., 196, 901-917) and the IMGT system (see Lefranc, M. P., 1997, "Unique database numbering system for immunogenetic analysis", Immunol. Today, 18, 50).
  • An antibody typically contains 3 heavy chain CDRs and 3 light chain CDRs.
  • the term CDR or CDRs is used here to indicate one or several of these regions. A person skilled in the art is able to readily compare the different systems of nomenclature and determine whether a particular sequence may be defined as a CDR.
  • a "human antibody” is an antibody that possesses an amino-acid sequence corresponding to that of an antibody produced by a human and/or has been made using any of the techniques for making human antibodies and specifically excludes a humanized antibody comprising non- human antigen-binding residues.
  • the term "specifically binds to” refers to measurable and reproducible interactions such as binding between a target and an antibody, which is determinative of the presence of the target in the presence of a heterogeneous population of molecules including biological molecules.
  • an antibody that specifically binds to a target (which can be an epitope) is an antibody that binds this target with greater affinity, avidity, more readily, and/or with greater duration than it binds to other targets.
  • the extent of binding of an antibody to an unrelated target is less than about 10% of the binding of the antibody to the target as measured, e.g. by a radioimmunoassay (RIA).
  • An antibody or a fragment thereof that specifically binds to a hPD-Ll antigen may be cross- reactive with related antigens.
  • an antibody or a fragment thereof that specifically binds to a hPD-Ll antigen does not cross-react with other antigens (but may optionally cross-react with PD-L1 of a different species, e.g. rhesus, or murine).
  • An antibody or a fragment thereof that specifically binds to a hPD-Ll antigen can be identified, for example, by immunoassays, BIAcoreTM, or other techniques known to those of skill in the art.
  • an antibody or a fragment thereof binds specifically to a PD-L1 antigen when it binds to a hPD-Ll antigen with higher affinity than to any cross-reactive antigen as determined using experimental techniques, such as radioimmunoassays (RIA) and enzyme-linked immunosorbent assays (ELISAs).
  • a specific or selective reaction will be at least twice background signal or noise and more typically more than 10 times (such as more than 15 times, more than 20 times, more than 50 times or more than 100 times) background. See, e.g. Paul, ed., 1989, Fundamental Immunology Second Edition, Raven Press, New York at pages 332-336 for a discussion regarding antibody specificity.
  • aliphatic amino acid means that the amino acid R groups are nonpolar and hydrophobic. Hydrophobicity increases with increasing number of C atoms in the hydrocarbon chain. Glycine, Alanine, Valine, Leucine and Isoleucine are aliphatic amino acids.
  • aromatic amino acid means that the amino acid R groups contain an aromatic ring system. Phenylalanine, Tyrosine and Tryptophan are aromatic amino acids.
  • hydroxyl-containing amino acid means that the amino acid R groups contain a hydroxyl group, and are hydrophilic. Serine, Cysteine, Threonine and Methionine are hydroxyl- containing amino acids.
  • basic amino acid means that the amino acid R groups are nitrogen containing and are basic at neutral pH. Histidine, Lysine and Arginine are basic amino acids.
  • cyclic amino acid means that the amino acid R groups have an aliphatic cyclic structure.
  • Proline is the only cyclic aliphatic amino acid.
  • amino acid means that the amino acid R groups are polar and are negatively charged at physiological pH. Aspartate and Glutamate are acidic amino acids.
  • amide amino acid means that the amino acid R groups contain an amide group. Asparagine and Glutamine are amide amino acids.
  • authorization number or "marketing authorization number” refers to a number issued by a regulatory agency upon that agency determining that a particular medical product and/or composition may be marketed and/or offered for sale in the area under the agency's jurisdiction.
  • regulatory agency refers to one of the agencies responsible for evaluating, e.g. the safety and efficacy of a medical product and/or composition and controlling the sales/marketing of such products and/or compositions in a given area.
  • the Food and Drug Administration (FDA) in the US and the European Medicines Agency (EPA) in Europe are but two examples of such regulatory agencies.
  • Other non-limiting examples can include SDA, MPA, MHPRA, IMA, AN MAT, Hong Kong Department of Health-Drug Office, CDSCO, Medsafe, and KFDA.
  • biomarker refers to a gene that is differentially expressed in individuals having a disease of interest, for example, a gene that is differentially expressed in individuals having cancer.
  • PD-L1 is a biomarker whose expression in tumours may be indicative as to whether or not a patient would respond to a particular type of treatment, in particular, whether a patient would response to treatment targeting PD-L1, for example, immunotherapy using anti-PD-Ll antibodies.
  • PD-L1 is a biomarker whose expression in tumours may be indicative as to whether or not a patient would respond to a particular type of treatment, in particular, whether a patient would response to treatment targeting PD-1, for example, immunotherapy using anti-PD-1 antibodies.
  • PD-L1 may be free or membrane bound. In another embodiment, PD-L1 may be fixed or unfixed.
  • a "buffer” refers to a chemical agent that is able to absorb a certain quantity of acid or base without undergoing a strong variation in pH.
  • carrier refers to a diluent, adjuvant (e.g., Freund's adjuvant (complete and incomplete)), excipient, or vehicle with which the therapeutic is administered.
  • adjuvant e.g., Freund's adjuvant (complete and incomplete)
  • excipient or vehicle with which the therapeutic is administered.
  • Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously.
  • Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
  • chemotherapeutic agent refers to a therapeutic agent whose primary purpose is to destroy cancer cells, typically by interfering with the tumour cell's ability to grow or multiply.
  • chemotherapeutic agents can be classified based on how they work. Alkylating drugs kill cancer cells by directly attacking DNA, the genetic material of the genes. Cyclophosphamide is an alkylating drug.
  • Antimetabolites interfere with the production of DNA and keep cells from growing and multiplying.
  • An example of an antimetabolite is 5-fluorouracil (5-FU).
  • Anti-tumour antibiotics are made from natural substances such as fungi in the soil.
  • DDR DNA damage response
  • chemotherapeutic agents include Adriamycin, Doxorubicin, 5-Fluorouracil,
  • Cytosine arabinoside (Ara-C), Cyclophosphamide, Thiotepa, Taxotere (docetaxel), Busulfan, Cytoxin, Taxol, Methotrexate, Cisplatin, Melphalan, Vinblastine, Bleomycin, Etoposide, Ifosfamide, Mitomycin C, Mitoxantrone, Vincreistine, Vinorelbine, Carboplatin, Teniposide, Daunomycin, Carminomycin, Aminopterin, Dactinomycin, Mitomycins, Esperamicins (see, U.S. Patent No. 4,675,187), Melphalan, and other related nitrogen mustards.
  • Suitable toxins and chemotherapeutic agents are described in Remington's Pharmaceutical Sciences, 19th Ed. (Mack Publishing Co. 1995), and in Goodman and Gilman's The Pharmacological Basis of Therapeutics, 7 th Ed. (MacMillan Publishing Co. 1985).
  • Another example of chemotherapeutic agents is the class of antibody-conjugated toxins, including, but not limited to pyrrolobenzodiazepiness, maytansanoids, calicheamicin, etc.
  • Other suitable toxins and/or chemotherapeutic agents are known to those of skill in the art.
  • composition is intended to encompass a product containing the specified ingredients (e.g. an antibody of the invention) in, optionally, the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in, optionally, the specified amounts.
  • specified ingredients e.g. an antibody of the invention
  • the term “consisting essentially of” refers to those elements required for a given embodiment. The term permits the presence of elements that do not materially affect the basic and novel or functional characteristic(s) of that embodiment.
  • derivative refers to a polypeptide that comprises an amino acid sequence of a hPD-Ll polypeptide, a fragment of a hPD-Ll polypeptide, or an antibody that specifically binds to a hPD-Ll polypeptide which has been altered by the introduction of amino acid residue substitutions, deletions or additions.
  • derivative also refers to a hPD-Ll polypeptide, a fragment of a hPD-Ll polypeptide, or an antibody that specifically binds to a hPD-Ll polypeptide which has been chemically modified, e.g.
  • a hPD-Ll polypeptide, a fragment of a hPD-Ll polypeptide, or a hPD-Ll antibody may be chemically modified, e.g. by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc.
  • the derivatives are modified in a manner that is different from naturally occurring or starting peptide or polypeptides, either in the type or location of the molecules attached.
  • Derivatives further include deletion of one or more chemical groups which are naturally present on the peptide or polypeptide.
  • a derivative of a hPD-Ll polypeptide, a fragment of a hPD-Ll polypeptide, or a hPD-Ll antibody may be chemically modified by chemical modifications using techniques known to those of skill in the art, including, but not limited to specific chemical cleavage, acetylation, formulation, metabolic synthesis of tunicamycin, etc.
  • a derivative of a hPD-Ll polypeptide, a fragment of a hPD-Ll polypeptide, or a hPD-Ll antibody may contain one or more non-classical amino acids.
  • a polypeptide derivative possesses a similar or identical function as a hPD-Ll polypeptide, a fragment of a hPD-Ll polypeptide, or a hPD-Ll antibody described herein.
  • effector function refers to one or more of antibody dependant cell mediated cytotoxic activity (ADCC), complement-dependant cytotoxic activity (CDC) mediated responses, Fc-mediated phagocytosis or antibody dependant cellular phagocytosis (ADCP) and antibody recycling via the Fc n receptor.
  • An “effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired effect, including a therapeutic or prophylactic result.
  • a “therapeutically effective amount” refers to the minimum concentration required to effect a measurable improvement or prevention of a particular disorder.
  • a therapeutically effective amount herein may vary according to factors such as the disease state, age, sex, and weight of the patient, and the ability of the antibody to elicit a desired response in the individual.
  • a therapeutically effective amount is also one in which toxic or detrimental effects of the antibody are outweighed by the therapeutically beneficial effects.
  • a “prophylactically effective amount” refers to an amount effective, at the dosages and for periods of time necessary, to achieve the desired prophylactic result.
  • the effective amount of an antibody of the invention is from about 0.1 mg/kg (mg of antibody per kg weight of the subject) to about 100 mg/kg.
  • an effective amount of an antibody provided therein is about 0.1 mg/kg, about 0.5 mg/kg, about 1 mg/kg, 3 mg/kg, 5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg, about 60 mg/kg, about 70 mg/kg, about 80 mg/kg about 90 mg/kg or about 100 mg/kg (or a range therein).
  • "effective amount” as used herein also refers to the amount of an antibody of the invention to achieve a specified result (e.g. inhibition of a hPD-Ll biological activity of a cell).
  • epitope refers to a localized region on the surface of an antigen, such as hPD-Ll polypeptide or hPD-Ll polypeptide fragment, that is capable of being bound to one or more antigen binding regions of an antibody, and that has antigenic or immunogenic activity in an animal, preferably a mammal, and most preferably in a human, that is capable of eliciting an immune response.
  • An epitope having immunogenic activity is a portion of a polypeptide that elicits an antibody response in an animal.
  • An epitope having antigenic activity is a portion of a polypeptide to which an antibody specifically binds as determined by any method well known in the art, for example, by the immunoassays described herein.
  • Antigenic epitopes need not necessarily be immunogenic. Epitopes usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and have specific three dimensional structural characteristics as well as specific charge characteristics. A region of a polypeptide contributing to an epitope may be contiguous amino acids of the polypeptide or the epitope may come together from two or more non-contiguous regions of the polypeptide. The epitope may or may not be a three-dimensional surface feature of the antigen. In certain embodiments, a hPD-Ll epitope is a three-dimensional surface feature of a hPD-Ll polypeptide (e.g. in a trimeric form of a hPD-Ll polypeptide).
  • a hPD-Ll epitope is linear feature of a hPD-Ll polypeptide (e.g. in a trimeric form or monomeric form of the hPD-Ll polypeptide).
  • Antibodies provided herein may specifically bind to an epitope of the monomeric (denatured) form of hPD-Ll, an epitope of the trimeric (native) form of hPD-Ll, or both the monomeric (denatured) form and the trimeric (native) form of hPD-Ll.
  • the antibodies provided herein specifically bind to an epitope of the trimeric form of hPD-Ll but do not specifically bind the monomeric form of hPD-Ll.
  • excipients refers to inert substances which are commonly used as a diluent, vehicle, preservatives, binders, or stabilizing agent for drugs and includes, but not limited to, proteins (e.g. serum albumin, etc.), amino acids (e.g. aspartic acid, glutamic acid, lysine, arginine, glycine, histidine, etc.), fatty acids and phospholipids (e.g. alkyl sulfonates, caprylate, etc.), surfactants (e.g. SDS, polysorbate, nonionic surfactant, etc.), saccharides (e.g.
  • proteins e.g. serum albumin, etc.
  • amino acids e.g. aspartic acid, glutamic acid, lysine, arginine, glycine, histidine, etc.
  • fatty acids and phospholipids e.g. alkyl sulfonates, caprylate, etc.
  • surfactants
  • sucrose, maltose, trehalose, etc. sucrose, maltose, trehalose, etc.
  • polyols e.g. mannitol, sorbitol, etc.
  • fixation refers to a chemical process by which biological tissues are preserved from decay, to prevent autolysis or putrefaction. In general, fixation involves exposing the tissue to chemical compounds such as alcohols or aldehydes such as formaldehyde to terminate ongoing biochemical reactions. In some instances, fixation may also increase the mechanical strength or stability of the treated tissues.
  • unfixed refers to a tissue that has not been subjected to a chemical process to prevent tissue decay.
  • surface expressed means that the protein is embedded in or spans a cell membrane or is associated with a protein that is embedded in or spans a cell membrane (i.e. a membrane associated protein).
  • a surface expressed protein includes one or more transmembrane domains.
  • the protein is associated with the exterior or interior surface of a cell membrane indirectly via association with another membrane spanning protein (i.e. the surface expressed protein is not spanning the cell membrane itself).
  • the surface expressed protein is not spanning the cell membrane itself.
  • surface expressed proteins that are integrated into a cell membrane or expressed endogenously within a cell are more likely to fold in the correct conformation than recombinantly produced free forms of the same protein.
  • fragment refers to a peptide or polypeptide that comprises less than the full length amino acid sequence. Such a fragment may arise, for example, from a truncation at the amino terminus, a truncation at the carboxy terminus, and/or an internal deletion of a residue(s) from the amino acid sequence. Fragments may, for example, result from alternative RNA splicing or from in vivo protease activity.
  • PD-L1 fragments include polypeptides comprising an amino acid sequence of at least 5 contiguous amino acid residues, at least 10 contiguous amino acid residues, at least 15 contiguous amino acid residues, at least 20 contiguous amino acid residues, at least 25 contiguous amino acid residues, at least 40 contiguous amino acid residues, at least 50 contiguous amino acid residues, at least 60 contiguous amino residues, at least 70 contiguous amino acid residues, at least 80 contiguous amino acid residues, at least 90 contiguous amino acid residues, at least contiguous 100 amino acid residues, at least 125 contiguous amino acid residues, at least 150 contiguous amino acid residues, at least 175 contiguous amino acid residues, at least 200 contiguous amino acid residues, or at least 250 contiguous amino acid residues of the amino acid sequence of a hPD-Ll polypeptide or an antibody that specifically binds to a hPD-Ll polypeptide.
  • polypeptides comprising an
  • free refers to a polypeptide, for example, PD-L1 or fragments and variants thereof, that is combined with a buffer, wherein the polypeptide is not associated with a cell surface or cell membrane.
  • the term “free” can refer to a polypeptide that is capable of surface expression (i.e. includes one or more transmembrane domains or membrane association domains), but that is not, in its present state, expressed on the surface of a cell or bound to a protein that is expressed on the surface of a cell.
  • a free polypeptide can also refer to a free recombinant or native or unbound polypeptide.
  • a free antigen in solution (referred to herein as a “soluble selection”) or adsorbed to a surface, for example, adsorbed to the surface of a 96-well plate (referred to herein as “biopanning selection”).
  • fusion protein refers to a polypeptide that comprises an amino acid sequence of an antibody and an amino acid sequence of a heterologous polypeptide or protein (i.e. a polypeptide or protein not normally a part of the antibody (e.g. a non-anti-hPD-Ll antigen antibody)).
  • fusion when used in relation to hPD-Ll or to an anti-hPD-Ll antibody refers to the joining of a peptide or polypeptide, or fragment, variant and/or derivative thereof, with a heterologous peptide or polypeptide.
  • the fusion protein retains the biological activity of the hPD-Ll or anti-hPD- Ll antibody.
  • the fusion protein comprises a hPD-Ll antibody VH domain, VL domain, VH CDR (one, two or three VH CDRs), and/or VL CDR (one, two or three VL CDRs), wherein the fusion protein specifically binds to a hPD-Ll epitope.
  • heavy chain when used with reference to an antibody refers to five distinct types, called alpha (a), delta ( ⁇ ), epsilon ( ⁇ ), gamma (y) and mu ( ⁇ ), based on the amino acid sequence of the heavy chain constant domain.
  • These distinct types of heavy chains are well known and give rise to five classes of antibodies, IgA, IgD, IgE, IgG and IgM, respectively, including four subclasses of IgG, namely IgGl, IgG2, IgG3 and IgG4.
  • the heavy chain is a human heavy chain. In the human population, multiple heavy chain constant region alleles, of each immunoglobulin or immunoglobulin subclass, exist.
  • the antibodies and antibody fragments disclosed herein comprise a heavy chain encoded by a IgGl constant region allele, which includes, but is not limited to, human IGHG1*01 (Seq ID Nos:340, 341 & 537), IGHG1*02 (Seq ID Nos:340, 341 8637), IGHG1*03 (Seq ID Nos:523 & 524), IGHG1*04 (Seq ID Nos:525 & 526) and IGHG1*05 (Seq ID Nos:340, 341 & 537).
  • the antibodies and antibody fragments disclosed herein comprise a protein encoded by a IgG2 constant region allele, which includes, but is not limited to, human IGHG2*01 (Seq ID Nos:527 & 528), IGHG2*02 (Seq ID Nos:529 & 530), IGHG2*03 (Seq ID Nos:527 & 528), IGHG2*04 (Seq ID Nos:531 & 532), IGHG2*05 (Seq ID Nos:527 & 528) and IGHG2*06 (Seq ID Nos:533 & 534).
  • a IgG2 constant region allele which includes, but is not limited to, human IGHG2*01 (Seq ID Nos:527 & 528), IGHG2*02 (Seq ID Nos:529 & 530), IGHG2*03 (Seq ID Nos:527 & 528), IGHG2*04
  • the antibodies or antibody fragments disclosed herein comprise a protein encoded by a IgG3 constant region allele, which includes but is not limited to human IGHG3*01, IGHG3*02, IGHG3*03, IGHG3*04, IGHG3*05, IGHG3*06, IGHG3*07, IGHG3*08, IGHG3*09, IGHG3*10, IGHG3*11, IGHG3*12, IGHG3*13, IGHG3*14, IGHG3*15, IGHG3*16, IGHG3*17, IGHG3*18 and IGHG3*19.
  • a IgG3 constant region allele which includes but is not limited to human IGHG3*01, IGHG3*02, IGHG3*03, IGHG3*04, IGHG3*05, IGHG3*06, IGHG3*07, IGHG3*08, IGHG3*09, IGHG
  • the antibodies or antibody fragments disclosed herein comprise a protein encoded by a IgG4 constant region allele, which includes but is not limited to human IGHG4*01 (Seq ID Nos: 192 & 193), IGHG4*02 (Seq ID Nos:194 & 195), IGHG4*03 (Seq ID Nos:196 & 197) and IGHG4*04 (Seq ID Nos: 192 & 193).
  • the heavy chain is a disabled IgG isotype, e.g. a disabled IgG4.
  • the antibodies of the invention comprise a human gamma 4 constant region.
  • the heavy chain constant region does not bind Fc- ⁇ receptors, and e.g. comprises a Leu235Glu mutation.
  • the heavy chain constant region comprises a Ser228Pro mutation to increase stability.
  • the heavy chain constant region is IgG4-PE (SEQ ID No: 199.
  • the antibodies and antibody fragments disclosed herein comprise a heavy chain constant region encoded by a murine IgGl constant region allele, which includes but is not limited to mouse IGHG1*01 or IGHG1*02.
  • the antibodies and antibody fragments disclosed herein comprise a heavy chain constant region encoded by a murine IgG2 constant region allele, which includes, but is not limited to, mouse IGHG2A*01, IGHG2A*02, IGHG2B*01, IGHG2B*02, IGHG2C*01, IGHG2C*02 or IGHG2C*03.
  • the antibodies or antibody fragments disclosed herein comprise a protein encoded by a murine IgG3 constant region allele, which includes but is not limited to mouse IGHG3*01.
  • host refers to an animal, preferably a mammal, and most preferably a human.
  • host cell refers to the particular subject cell transfected with a nucleic acid molecule and the progeny or potential progeny of such a cell. Progeny of such a cell may not be identical to the parent cell transfected with the nucleic acid molecule due to mutations or environmental influences that may occur in succeeding generations or integration of the nucleic acid molecule into the host cell genome.
  • an IL-2 cytokine refers to a cytokine-like molecule which has a similar activity to a wild-type IL-2. It may have activity at the high ( ⁇ ) affinity IL-2 receptor and/or the intermediate affinity ( ⁇ ) IL-2 receptor.
  • the cytokine may be a variant IL-2 cytokine having one or more amino acid deletions, substitutions or additions. Variant cytokines are described in more detail hereinbelow.
  • immunomodulatory agent and variations thereof including, but not limited to, immunomodulatory agents, as used herein refer to an agent that modulates a host's immune system.
  • an immunomodulatory agent is an immunosuppressant agent.
  • an immunomodulatory agent is an immunostimulatory agent.
  • an immunomodulatory agent used in the combination therapies of the invention does not include an anti-hPD-Ll antibody or antigen-binding fragment.
  • Immunomodulatory agents include, but are not limited to, small molecules, peptides, polypeptides, proteins, fusion proteins, antibodies, inorganic molecules, mimetic agents, and organic molecules.
  • the antibodies of the invention can be administered in combination with one or more therapies (e.g. therapies that are not the antibodies of the invention that are currently administered to prevent, treat, manage, and/or ameliorate a hPD-Ll-mediated disease.
  • therapies e.g. therapies that are not the antibodies of the invention that are currently administered to prevent, treat, manage, and/or ameliorate a hPD-Ll-mediated disease.
  • Non-limiting examples of therapies that can be administered in combination with an antibody of the invention include analgesic agents, anaesthetic agents, antibiotics, or immunomodulatory agents or any other agent listed in the U.S. Pharmacopoeia and/or Physician's Desk Reference.
  • immunocytokine refers to an antibody format which is fused to a cytokine molecule.
  • the antibody format may be any of those described herein, and the cytokine may be fused directly, or by means of a linker or chemical conjugation to either the N- or C-terminus of the heavy or the light chain of the antibody format.
  • an injection device refers to a device that is designed for carrying out injections, an injection including the steps of temporarily fluidically coupling the injection device to a person's tissue, typically the subcutaneous tissue. An injection further includes administering an amount of liquid drug into the tissue and decoupling or removing the injection device from the tissue.
  • an injection device can be an intravenous device or IV device, which is a type of injection device used when the target tissue is the blood within the circulatory system, e.g. the blood in a vein.
  • a common, but non-limiting example of an injection device is a needle and syringe.
  • instructions refers to a display of written, printed or graphic matter on the immediate container of an article, for example the written material displayed on a vial containing a pharmaceutically active agent, or details on the composition and use of a product of interest included in a kit containing a composition of interest. Instructions set forth the method of the treatment as contemplated to be administered or performed.
  • an “isolated” or “purified” antibody or protein is one that has been identified, separated and/or recovered from a component of its production environment (e.g. natural or recombinant).
  • the antibody or protein is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the antibody is derived, or substantially free of chemical precursors or other chemicals when chemically synthesized.
  • substantially free of cellular material includes preparations of an antibody in which the antibody is separated from cellular components of the cells from which it is isolated or recombinantly produced.
  • an antibody that is substantially free of cellular material includes preparations of antibody having less than about 30%, 20%, 10%, or 5% (by dry weight) of heterologous protein (also referred to herein as a "contaminating protein").
  • heterologous protein also referred to herein as a "contaminating protein”
  • the antibody is recombinantly produced, it is also preferably substantially free of culture medium, i.e. culture medium represents less than about 20%, 10%, or 5% of the volume of the protein preparation.
  • culture medium represents less than about 20%, 10%, or 5% of the volume of the protein preparation.
  • the antibody is produced by chemical synthesis, it is preferably substantially free of chemical precursors or other chemicals, i.e., it is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. Accordingly, such preparations of the antibody have less than about 30%, 20%, 10%, 5% (by dry weight) of chemical precursors or compounds other than the antibody of interest.
  • antibodies of the invention are isolated or purified.
  • Kabat numbering and like terms are recognized in the art and refer to a system of numbering amino acid residues which are more variable (i.e. hypervariable) than other amino acid residues in the heavy chain variable regions of an antibody, or an antigen binding portion thereof (Kabat etal., (1971) Ann. NY Acad. Sci., 190:382-391 and, Kabat eta/. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242).
  • the hypervariable region typically ranges from amino acid positions 31 to 35 for CDR1, amino acid positions 50 to 65 for CDR2, and amino acid positions 95 to 102 for CDR3.
  • Label refers to the addition of a detectable moiety to a polypeptide, for example, a radiolabel, fluorescent label, enzymatic label, chemiluminescent label or a biotinyl group or gold.
  • Radioisotopes or radionuclides may include 3 H, 14 C, 15 N, 35 S, 90 Y, "Tc, 115 In, 125 I, 131 I, fluorescent labels may include rhodamine, lanthanide phosphors or FITC and enzymatic labels may include horseradish peroxidase, ⁇ -galactosidase, luciferase, alkaline phosphatase.
  • Additional labels include, by way of illustration and not limitation: enzymes, such as glucose-6- phosphate dehydrogenase (“G6PDH”), alpha-D-galactosidase, glucose oxydase, glucose amylase, carbonic anhydrase, acetylcholinesterase, lysozyme, malate dehydrogenase and peroxidase; dyes (e.g. cyanine dyes, e.g. Cy5TM, Cy5.5TM. or Cy7TM); additional fluorescent labels or fluorescers include, such as fluorescein and its derivatives, fluorochrome, GFP (GFP for "Green Fluorescent Protein”), other fluorescent proteins (e.g.
  • fluorophores such as lanthanide cryptates and chelates e.g.
  • chemoluminescent labels or chemiluminescers such as isoluminol, luminol and the dioxetanes; sensitisers; coenzymes; enzyme substrates; particles, such as latex or carbon particles; metal sol; crystallite; liposomes; cells, etc., which may be further labelled with a dye, catalyst or other detectable group; molecules such as biotin, digoxygenin or 5-bromodeoxyuridine; toxin moieties, such as for example a toxin moiety selected from a group of Pseudomonas exotoxin (PE or a cytotoxic fragment or mutant thereof), Diptheria toxin or a cytotoxic fragment or mutant thereof, a botulinum toxin A, B, C, D, E or F, ricin or a cytotoxic fragment thereof e.g. ricin A, abrin or a cytotoxic fragment thereof, sap
  • light chain when used in reference to an antibody refers to the immunoglobulin light chains, of which there are two types in mammals, lambda ( ⁇ ) and kappa ( ⁇ ).
  • the light chain is a human light chain.
  • the light chain constant region is a human constant region. In the human population, multiple light chain constant region alleles exist.
  • the nucleotide and amino acid sequences of these allelic variants are accessible on publicly available databases such as IMGT, ENSEMBL, Swiss-Prot and Uniprot.
  • the antibodies or antibody fragments disclosed herein comprise a protein encoded by a human ⁇ constant region allele, which includes, but is not limited to, IGKC*01 (Seq ID Nos:206 & 207), IGKC*02 (Seq ID Nos:208 & 209), IGKC*03 (Seq ID Nos:210 & 211), IGKC*04 (Seq ID Nos:212 & 213) and IGKC*05 (Seq ID Nos:214 & 215).
  • IGKC*01 Seq ID Nos:206 & 207
  • IGKC*02 Seq ID Nos:208 & 209
  • IGKC*03 Seq ID Nos:210 & 211
  • IGKC*04 Seq ID Nos:212 & 213
  • IGKC*05 Seq ID Nos:214 & 215.
  • the antibodies or antibody fragments disclosed herein comprise a protein encoded by a human ⁇ constant region allele, which includes but is not limited to IGLC1*01 (Seq ID Nos:216 & 217), IGLC1*02 (Seq ID Nos:218, 219 & 220), IGLC2*01 (Seq ID Nos:221, 222 & 538), IGLC2*02 (Seq ID Nos:224 & 225), IGLC2*03 (Seq ID Nos:224 & 225), IGLC3*01 (Seq ID Nos:226 & 227), IGLC3*02 (Seq ID Nos:228 & 229), IGLC3*03 (Seq ID Nos:230 & 231), IGLC3*04 (Seq ID Nos:232 & 233), IGLC6*01 (Seq ID Nos:234 & 235), IGLC7*01 (Seq ID No
  • the antibodies and antibody fragments disclosed herein comprise a light chain constant region encoded by a mouse ⁇ constant region allele, which includes, but is not limited to, IGKC*01, IGKC*03 or IGKC*03.
  • the antibodies and antibody fragments disclosed herein comprise a light chain constant region encoded by a mouse ⁇ constant region allele, which includes, but is not limited to, IGLC1*01, IGLC2*01 or IGLC3*01.
  • Percent (%) amino acid sequence identity and “homology” with respect to a peptide, polypeptide or antibody sequence are defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the specific peptide or polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or MEG ALIGNTM (DNASTAR) software. In one embodiment, the % homology is about 70%.
  • the % homology is about 75%. In one embodiment, the % homology is about 80%. In one embodiment, the % homology is about 85%. In one embodiment, the % homology is about 90%. In one embodiment, the % homology is about 92%. In one embodiment, the % homology is about 95%. In one embodiment, the % homology is about 97%. In one embodiment, the % homology is about 98%. In one embodiment, the % homology is about 99%. In one embodiment, the % homology is 100%.
  • Naturally occurring or “native” when used in connection with biological materials such as nucleic acid molecules, polypeptides, host cells, and the like, refers to those which are found in nature and not manipulated by a human being.
  • Packaging refers to how the components are organized and/or restrained into a unit fit for distribution and/or use.
  • Packaging can include, e.g. boxes, bags, syringes, ampoules, vials, tubes, clamshell packaging, barriers and/or containers to maintain sterility, labelling, etc.
  • pharmaceutically acceptable means being approved by a regulatory agency of the Federal or a state government, or listed in the U.S. Pharmacopeia, European Pharmacopeia or other generally recognized Pharmacopeia for use in animals, and more particularly in humans.
  • nucleic acid nucleic acid molecule
  • polynucleotide As used herein, the term “polynucleotide,” “nucleotide,” nucleic acid” “nucleic acid molecule” and other similar terms are used interchangeable and include DNA, RNA, mRNA and the like.
  • the terms “prevent”, “preventing”, and “prevention” refer to the total or partial inhibition of the development, recurrence, onset or spread of a hPD-Ll-mediated disease and/or symptom related thereto, resulting from the administration of a therapy or combination of therapies provided herein (e.g. a combination of prophylactic or therapeutic agents, such as an antibody of the invention).
  • soluble refers to a polypeptide, such as PD-L1 and variants or fragments thereof, that is lacking one or more transmembrane or cytoplasmic domains found in the native or membrane- associated form.
  • the "soluble" form of PD-L1 lacks both the transmembrane domain and the cytoplasmic domain.
  • subject or “patient” refers to any animal, including, but not limited to, mammals.
  • mammal refers to any vertebrate animal that suckle their young and either give birth to living young (eutharian or placental mammals) or are egg-laying (metatharian or nonplacental mammals).
  • mammalian species include, but are not limited to, humans and other primates, including non-human primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, sheep, pigs, goats and horses; domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats (including cotton rats) and guinea pigs; birds, including domestic, wild and game birds such as chickens, turkeys and other gallinaceous birds, ducks, geese, and the like.
  • substantially all refers to refers to at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or about 100%.
  • substantially free of surfactant refers to a formulation of an antibody that specifically binds to a hPD-Ll antigen, said formulation containing less than 0.0005%, less than 0.0003%, or less than 0.0001% of surfactants and/or less than 0.0005%, less than 0.0003%, or less than 0.0001% of surfactants.
  • substantially free of salt refers to a formulation of an antibody that specifically binds to a hPD-Ll antigen, said formulation containing less than 0.0005%, less than 0.0003%, or less than 0.0001% of inorganic salts.
  • surfactant refers to organic substances having amphipathic structures; namely, they are composed of groups of opposing solubility tendencies, typically an oil- soluble hydrocarbon chain and a water-soluble ionic group. Surfactants can be classified, depending on the charge of the surface-active moiety, into anionic, cationic, and non-ionic surfactants. Surfactants are often used as wetting, emulsifying, solubilizing, and dispersing agents for various pharmaceutical compositions and preparations of biological materials.
  • the term "tag” refers to any type of moiety that is attached to, e.g. a polypeptide and/or a polynucleotide that encodes a hPD-Ll or hPD-Ll antibody or antigen binding fragment thereof.
  • a polynucleotide that encodes a hPD-Ll, hPD-Ll antibody or antigen binding fragment thereof can contain one or more additional tag-encoding nucleotide sequences that encode e.g. a detectable moiety or a moiety that aids in affinity purification.
  • the tag and the antibody can be in the form of a fusion protein.
  • detectable or “detection” with reference to a tag refers to any tag that is capable of being visualized or wherein the presence of the tag is otherwise able to be determined and/or measured (e.g. by quantitation).
  • a non-limiting example of a detectable tag is a fluorescent tag.
  • the term “therapeutic agent” refers to any agent that can be used in the treatment, management or amelioration of a hPD-Ll-mediated disease and/or a symptom related thereto.
  • the term “therapeutic agent” refers to an antibody of the invention.
  • the term “therapeutic agent” refers to an agent other than an antibody of the invention.
  • a therapeutic agent is an agent which is known to be useful for, or has been or is currently being used for the treatment, management or amelioration of a hPD-Ll-mediated disease or one or more symptoms related thereto.
  • the therapeutic agent is a fully human anti-hPD-Ll antibody, such as a fully human anti-hPD-Ll monoclonal antibody.
  • the term “therapy” refers to any protocol, method and/or agent that can be used in the prevention, management, treatment and/or amelioration of a hPD-Ll-mediated disease (e.g. cancer).
  • the terms “therapies” and “therapy” refer to a biological therapy, supportive therapy, and/or other therapies useful in the prevention, management, treatment and/or amelioration of a hPD-Ll-mediated disease known to one of skill in the art such as medical personnel.
  • treat refers to the reduction or amelioration of the progression, severity, and/or duration of a hPD-Ll-mediated disease (e.g. cancer) resulting from the administration of one or more therapies (including, but not limited to, the administration of one or more prophylactic or therapeutic agents, such as an antibody of the invention).
  • therapies including, but not limited to, the administration of one or more prophylactic or therapeutic agents, such as an antibody of the invention.
  • such terms refer to the reduction or inhibition of the binding of hPD-Ll to PD-1, the reduction or inhibition of the binding of hPD-Ll to CD80, and/or the inhibition or reduction of one or more symptoms associated with a hPD-Ll-mediated disease, such as cancer.
  • such terms refer to the reduction or inhibition of the binding of hPD-Ll to PD-1 and/or CD80, and/or the inhibition or reduction of one or more symptoms associated with a hPD-Ll-mediated disease, such as cancer.
  • the cell is a human cell.
  • a prophylactic agent is a fully human anti-hPD-Ll antibody, such as a fully human anti-hPD-Ll monoclonal antibody.
  • variable region refers to a portion of the light and heavy chains, typically about the amino-terminal 120 to 130 amino acids in the heavy chain and about 100 to 110 amino acids in the light chain, which differ extensively in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen.
  • the variability in sequence is concentrated in those regions called complimentarily determining regions (CDRs) while the more highly conserved regions in the variable domain are called framework regions (FR).
  • CDRs of the PD-L1 and heavy chains are primarily responsible for the interaction of the antibody with antigen. Numbering of amino acid positions used herein is according to the EU Index, as in Kabat et al. (1991) Sequences of proteins of immunological interest. (U.S. Department of Health and Human Services, Washington, D.C.) 5 th ed. ("Kabat eta/.”).
  • the variable region is a human variable region.
  • tumour cells express surface molecules that are specific to cancer that can serve as diagnostic and/or therapeutic antibody targets.
  • cell surface proteins expressed by tumour molecules that can be useful as biomarkers include, for example, members of the B7 family of proteins, major histocompatibility complex molecules (MHC), cytokine and growth factor receptors such as the receptor for eipdermal growth factor (EGFR).
  • MHC major histocompatibility complex molecules
  • cytokine cytokine
  • growth factor receptors such as the receptor for eipdermal growth factor (EGFR).
  • EGFR epidermal growth factor
  • the B7 family is a group of proteins that are members of the immunoglobulin (Ig) superfamily of cell-surface proteins that bind to receptors on lymphocytes to regulate immune responses.
  • Ig immunoglobulin
  • the family includes transmembrane or glycosylphosphatidylinositol (GPI)-linked proteins characterized by extracellular Ig-like domains (IgV and IgC domains related to the variable and constant domains of immunoglobulins). All members have short cytoplasmic domains.
  • NP_054862.1 (SEQ ID No: l), which refers to many journal articles, including, for example, Dong, H. ( et al. (1999), "PD-L1, a third member of the B7 family, co-stimulates T- cell proliferation and interleukin-10 secretion," Nat. Med. 5 (12), 1365-1369, the disclosure of which is hereby incorporated by reference herein in its entirety.
  • the amino acid sequence of PD-L1 includes a 30 amino acid long cytoplasmic domain that is unique to PD-L1, which shows little homology to other molecules, including other B7 family members.
  • the antibody is a polyclonal antibody.
  • Methods for generating polyclonal antibodies include, for example, inoculating a suitable mammal with an antigen to induce the immune system of the animal to produce immunoglobulins (IgGs) that specifically bind the injected antigen.
  • suitable mammals include, for example, mouse, guinea pig, hamster, rat, rabbit sheep or goat.
  • the polyclonal IgG is then typically purified from the mammal's serum.
  • the antibody is a polyclonal antibody that binds to a surface expressed protein.
  • the antibody is a polyclonal antibody that specifically binds to a member of the B7 family of proteins.
  • the antibody is a polyclonal antibody that specifically binds PD-L1.
  • the antibody is a polyclonal antibody that specifically binds surface expressed PD-LI.
  • the polyclonal antibody or antigen binding fragment thereof specifically binds human PD-LI.
  • the antibody is a polyclonal antibody that specifically binds soluble PD-Ll.
  • the term "soluble" also refers to a protein, such as PD-Ll that is lacking one or more transmembrane domain or cytoplasmic domains.
  • the "soluble" form of PD-Ll lacks both the transmembrane domain and the cytoplasmic domain.
  • the antibody is a polyclonal antibody that binds "free" PD-Ll (i.e. PD-Ll that is not associated with a cell membrane or surface, either directly or indirectly).
  • the antibody can be a monoclonal antibody.
  • Methods of making monoclonal antibodies are known and include, for example, fusing myeloma cells with the cells from an animal that was immunized with the desired antigen.
  • the monoclonal antibodies may be generated using recombinant DNA technology.
  • the antibody is a monoclonal antibody that specifically binds a surface expressed protein.
  • the antibody is a fully human monoclonal antibody.
  • the antibody is a monoclonal antibody that specifically binds to a member of the B7 family of proteins.
  • the antibody is a monoclonal antibody that specifically binds PD-Ll.
  • the antibody is a monoclonal antibody that specifically binds surface expressed PD-Ll. In a more particular embodiment, the monoclonal antibody or antigen binding fragment thereof specifically binds human PD-Ll. In another embodiment, the antibody is a monoclonal antibody that specifically binds soluble PD-Ll. In one embodiment, the antibody is a monoclonal antibody that specifically binds soluble PD-Ll that is lacking one or more transmembrane domain or cytoplasmic domains. In one embodiment, the antibody is a monoclonal antibody that specifically binds soluble PD-Ll that is lacking both the transmembrane domain and the cytoplasmic domain. In one embodiment, the antibody is a monoclonal antibody that binds "free" PD-Ll (i.e. PD-Ll that is not associated with a cell membrane or surface, either directly or indirectly).
  • PD-Ll i.e. PD-Ll that is not associated with a cell membrane or surface, either
  • the binding site(s) of the antibody or fragment are selected from a plurality (e.g. library) of binding sites.
  • the plurality of binding sites comprises or consists of a plurality of 4-chain antibodies or fragments thereof, e.g. dAbs, Fabs or scFvs.
  • Suitable methods for producing pluralities of binding sites for screening include phage display (producing a phage display library of antibody binding sites), ribosome display (producing a ribosome display library of antibody binding sites), yeast display (producing a yeast display library of antibody binding sites), or immunisation of a non-human vertebrate (e.g. a rodent, e.g. a mouse or rat, e.g.
  • a VelocimouseTM KymouseTM, XenomouseTM, Aliva MouseTM, HuMab MouseTM, OmnimouseTM, OmniratTM or MeMo MouseTM
  • hPD-Ll or a hPD-Ll epitope and isolation of a repertoire of antibody-producing cells (e.g. a B-cell, plasma cell or plasmablast repertoire) and/or a repertoire of isolated antibodies, fragments or binding sites.
  • PD-Ll binding ability, specificity and affinity can be determined by any routine method in the art, e.g. by surface plasmon resonance (SPR).
  • SPR surface plasmon resonance
  • Kd or “KD”, as used herein, is intended to refer to the equilibrium dissociation constant of a particular antibody-antigen interaction.
  • binding measurements can be made using a variety of binding assays known in the art, e.g. using surface plasmon resonance (SPR), such as by BiacoreTM or using the ProteOn XPR36TM (Bio-Rad ® ), using KinExA ® (Sapidyne Instruments, Inc), or using ForteBio Octet (Pall ForteBio Corp.).
  • the surface plasmon resonance (SPR) is carried out at 25 °C. In another embodiment, the SPR is carried out at 37 °C.
  • the SPR is carried out at physiological pH, such as about pH7 or at pH7.6 (e.g. using Hepes buffered saline at pH 7.6 (also referred to as HBS-EP)).
  • physiological pH such as about pH7 or at pH7.6
  • HBS-EP Hepes buffered saline at pH 7.6
  • the SPR is carried out at a physiological salt level, e.g. 150 mM NaCI.
  • the SPR is carried out at a detergent level of no greater than 0.05% by volume, e.g. in the presence of P20 (polysorbate 20; e.g. Tween 20TM) at 0.05% and EDTA at 3 mM.
  • P20 polysorbate 20; e.g. Tween 20TM
  • EDTA 3 mM
  • the SPR is carried out at 25 °C or 37 °C in a buffer at pH 7.6, 150 mM NaCI, 0.05% detergent (e.g. P20) and 3mM EDTA.
  • the buffer can contain 10 mM Hepes.
  • the SPR is carried out at 25 °C or 37 °C in HBS-EP.
  • HBS-EP is available from Teknova Inc. (California; catalogue number H8022).
  • the affinity of the antibody or fragment is determined using SPR by:
  • IgG anti-mouse (or other relevant human, rat or non-human vertebrate antibody constant region species-matched) IgG (e.g. BiacoreTM BR- 1008-38) to a biosensor chip (e.g. GLM chip) such as by primary amine coupling;
  • a biosensor chip e.g. GLM chip
  • SPR surface plasmon resonance
  • surface plasmon resonance e.g. under an SPR condition discussed above (e.g. at 25 °C in physiological buffer).
  • SPR can be carried out using any standard SPR apparatus, such as by BiacoreTM or using the ProteOn XPR36TM (Bio-Rad ® ).
  • Regeneration of the capture surface can be carried out with 10 mM glycine at pH 1.7. This removes the captured antibody and allows the surface to be used for another interaction.
  • the binding data can be fitted to 1:1 model inherent using standard techniques, e.g. using a model inherent to the ProteOn XPR36TM analysis software.
  • the present inventors have identified a number of antibodies having specificity for hPD-Ll, which have a number of potential utilities and benefits over existing antibodies.
  • the antibodies described herein may have one or more of the following properties:
  • VH heavy chain variable region amino acid sequence of Seq ID No:33, comprising the CDRHl amino acid sequence of Seq ID No:27 (IMGT) or Seq ID No:30 (Kabat), the CDRH2 amino acid sequence of Seq ID No:28 (IMGT) or Seq ID No:31 (Kabat), and the CDRH3 amino acid sequence of Seq ID No:29 (IMGT) or Seq ID No:32 (Kabat).
  • the heavy chain nucleic acid sequence of the VH domain is Seq ID No:34.
  • VL light chain variable region
  • the light chain nucleic acid sequence of the VL domain is Seq ID No:44.
  • the VH domain may be combined with any of the heavy chain constant region sequences described herein, e.g.
  • the VL domain may be combined with any of the light chain constant region sequences described herein, e.g. Seq ID Nos:207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536 and 538.
  • a full length heavy chain amino acid sequence is Seq ID No:35 (heavy chain nucleic acid sequence Seq ID No:36).
  • a full length light chain amino acid sequence is Seq ID No:45 (light chain nucleic acid sequence Seq ID No:46).
  • VH heavy chain variable region amino acid sequence of Seq ID No: 13, comprising the CDRHl amino acid sequence of Seq ID No:7 (IMGT) or Seq ID No: 10 (Kabat), the CDRH2 amino acid sequence of Seq ID No:8 (IMGT) or Seq ID No:ll (Kabat), and the CDRH3 amino acid sequence of Seq ID No:9 (IMGT) or Seq ID No: 12 (Kabat).
  • the heavy chain nucleic acid sequence of the VH domain is Seq ID No: 14.
  • VL light chain variable region
  • the light chain nucleic acid sequence of the VL domain is Seq ID No: 24.
  • the VH domain may be combined with any of the heavy chain constant region sequences described herein, e.g.
  • the VL domain may be combined with any of the light chain constant region sequences described herein, e.g. Seq ID Nos:207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536 and 538.
  • a full length heavy chain amino acid sequence is Seq ID No: 15 (heavy chain nucleic acid sequence Seq ID No: 16).
  • a full length light chain amino acid sequence is Seq ID No:25 (light chain nucleic acid sequence Seq ID No:26).
  • VH heavy chain variable region amino acid sequence of Seq ID No:47, comprising the CDRH1 amino acid sequence of Seq ID No:27 (IMGT) or Seq ID No:30 (Kabat), the CDRH2 amino acid sequence of Seq ID No:28 (IMGT) or Seq ID No:31 (Kabat), and the CDRH3 amino acid sequence of Seq ID No:29 (IMGT) or Seq ID No:32 (Kabat).
  • 1D05 HC mutant 1 has a light chain variable region (VL) amino acid sequence of Seq ID No:43, comprising the CDRL1 amino acid sequence of Seq ID No:37 (IMGT) or Seq ID No:40 (Kabat), the CDRL2 amino acid sequence of Seq ID No:38 (IMGT) or Seq ID No:41 (Kabat), and the CDRL3 amino acid sequence of Seq ID No:39 (IMGT) or Seq ID No:42 (Kabat).
  • the light chain nucleic acid sequence of the VL domain is Seq ID No:44.
  • the VH domain may be combined with any of the heavy chain constant region sequences described herein, e.g.
  • the VL domain may be combined with any of the light chain constant region sequences described herein, e.g. Seq ID Nos:207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536 and 538.
  • a full length light chain amino acid sequence is Seq ID No:45 (light chain nucleic acid sequence Seq ID No:46).
  • VH heavy chain variable region amino acid sequence of Seq ID No:48, comprising the CDRH1 amino acid sequence of Seq ID No:27 (IMGT) or Seq ID No:30 (Kabat), the CDRH2 amino acid sequence of Seq ID No:28 (IMGT) or Seq ID No:31 (Kabat), and the CDRH3 amino acid sequence of Seq ID No:29 (IMGT) or Seq ID No:32 (Kabat).
  • 1D05 HC mutant 2 has a light chain variable region (VL) amino acid sequence of Seq ID No:43, comprising the CDRL1 amino acid sequence of Seq ID No:37 (IMGT) or Seq ID No:40 (Kabat), the CDRL2 amino acid sequence of Seq ID No:38 (IMGT) or Seq ID No:41 (Kabat), and the CDRL3 amino acid sequence of Seq ID No:39 (IMGT) or Seq ID No:42 (Kabat).
  • the light chain nucleic acid sequence of the VL domain is Seq ID No:44.
  • the VH domain may be combined with any of the heavy chain constant region sequences described herein, e.g.
  • the VL domain may be combined with any of the light chain constant region sequences described herein, e.g. Seq ID Nos:207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536 and 538.
  • a full length light chain amino acid sequence is Seq ID No:45 (light chain nucleic acid sequence Seq ID No:46).
  • 1D05 HC mutant 3 has a heavy chain variable (VH) region amino acid sequence of Seq ID No:49, comprising the CDRH1 amino acid sequence of Seq ID No:27 (IMGT) or Seq ID No:30 (Kabat), the CDRH2 amino acid sequence of Seq ID No:28 (IMGT) or Seq ID No:31 (Kabat), and the CDRH3 amino acid sequence of Seq ID No:29 (IMGT) or Seq ID No:32 (Kabat).
  • VH heavy chain variable
  • 1D05 HC mutant 3 has a light chain variable region (VL) amino acid sequence of Seq ID No:43, comprising the CDRL1 amino acid sequence of Seq ID No:37 (IMGT) or Seq ID No:40 (Kabat), the CDRL2 amino acid sequence of Seq ID No:38 (IMGT) or Seq ID No:41 (Kabat), and the CDRL3 amino acid sequence of Seq ID No:39 (IMGT) or Seq ID No:42 (Kabat).
  • the light chain nucleic acid sequence of the VL domain is Seq ID No:44.
  • the VH domain may be combined with any of the heavy chain constant region sequences described herein, e.g.
  • the VL domain may be combined with any of the light chain constant region sequences described herein, e.g. Seq ID Nos:207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536 and 538.
  • a full length light chain amino acid sequence is Seq ID No:45 (light chain nucleic acid sequence Seq ID No:46).
  • 1D05 HC mutant 4 has a heavy chain variable (VH) region amino acid sequence of Seq ID No:342, comprising the CDRH1 amino acid sequence of Seq ID No:27 (IMGT) or Seq ID No:30 (Kabat), the CDRH2 amino acid sequence of Seq ID No:28 (IMGT) or Seq ID No:31 (Kabat), and the CDRH3 amino acid sequence of Seq ID No:29 (IMGT) or Seq ID No:32 (Kabat).
  • VH heavy chain variable
  • 1D05 HC mutant 4 has a light chain variable region (VL) amino acid sequence of Seq ID No:43, comprising the CDRL1 amino acid sequence of Seq ID No:37 (IMGT) or Seq ID No:40 (Kabat), the CDRL2 amino acid sequence of Seq ID No:38 (IMGT) or Seq ID No:41 (Kabat), and the CDRL3 amino acid sequence of Seq ID No:39 (IMGT) or Seq ID No:42 (Kabat).
  • the light chain nucleic acid sequence of the VL domain is Seq ID No:44.
  • the VH domain may be combined with any of the heavy chain constant region sequences described herein, e.g.
  • the VL domain may be combined with any of the light chain constant region sequences described herein, e.g. Seq ID Nos:207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536 and 538.
  • a full length light chain amino acid sequence is Seq ID No:45 (light chain nucleic acid sequence Seq ID No:46).
  • 1D05 LC mutant 1 has a heavy chain variable (VH) region amino acid sequence of Seq ID No:33, comprising the CDRH1 amino acid sequence of Seq ID No:27 (IMGT) or Seq ID No:30 (Kabat), the CDRH2 amino acid sequence of Seq ID No:28 (IMGT) or Seq ID No:31 (Kabat), and the CDRH3 amino acid sequence of Seq ID No:29 (IMGT) or Seq ID No:32 (Kabat).
  • the heavy chain nucleic acid sequence of the VH domain is Seq ID No:34.
  • 1D05 LC mutant l has a light chain variable region (VL) amino acid sequence of Seq ID No: 50, comprising the CDRL1 amino acid sequence of Seq ID No: 37 (IMGT) or Seq ID No:40 (Kabat), and the CDRL3 amino acid sequence of Seq ID No:39 (IMGT) or Seq ID No:42 (Kabat).
  • VL light chain variable region
  • the CDRL2 sequence of 1D05 LC Mutant 1 is as defined by the Kabat or IMGT systems from the VL sequence of Seq ID No: 50.
  • the VH domain may be combined with any of the heavy chain constant region sequences described herein, e.g.
  • the VL domain may be combined with any of the light chain constant region sequences described herein, e.g. Seq ID Nos:207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536 and 538.
  • a full length heavy chain amino acid sequence is Seq ID No:35 (heavy chain nucleic acid sequence Seq ID No:36).
  • 1D05 LC mutant 2 has a heavy chain variable (VH) region amino acid sequence of Seq ID No:33, comprising the CDRH1 amino acid sequence of Seq ID No:27 (IMGT) or Seq ID No:30 (Kabat), the CDRH2 amino acid sequence of Seq ID No:28 (IMGT) or Seq ID No:31 (Kabat), and the CDRH3 amino acid sequence of Seq ID No:29 (IMGT) or Seq ID No:32 (Kabat).
  • the heavy chain nucleic acid sequence of the VH domain is Seq ID No: 34.
  • VL light chain variable region
  • the VH domain may be combined with any of the heavy chain constant region sequences described herein, e.g.
  • the VL domain may be combined with any of the light chain constant region sequences described herein, e.g. Seq ID Nos:207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536 and 538.
  • a full length heavy chain amino acid sequence is Seq ID No:35 (heavy chain nucleic acid sequence Seq ID No:36).
  • 1D05 LC mutant 3 has a heavy chain variable (VH) region amino acid sequence of Seq ID No:33, comprising the CDRH1 amino acid sequence of Seq ID No:27 (IMGT) or Seq ID No:30 (Kabat), the CDRH2 amino acid sequence of Seq ID No:28 (IMGT) or Seq ID No:31 (Kabat), and the CDRH3 amino acid sequence of Seq ID No:29 (IMGT) or Seq ID No:32 (Kabat).
  • the heavy chain nucleic acid sequence of the VH domain is Seq ID No: 34.
  • 1D05 LC mutant 3 has a light chain variable region (VL) amino acid sequence of Seq ID No: 298, comprising the CDRL1 amino acid sequence of Seq ID No: 37 (IMGT) or Seq ID No:40 (Kabat), and the CDRL3 amino acid sequence of Seq ID No:39 (IMGT) or Seq ID No:42 (Kabat).
  • the CDRL2 sequence of 1D05 LC Mutant 3 is as defined by the Kabat or IMGT systems from the VL sequence of Seq ID No:298.
  • the light chain nucleic acid sequence of the VL domain is Seq ID No:44.
  • the VH domain may be combined with any of the heavy chain constant region sequences described herein, e.g.
  • the VL domain may be combined with any of the light chain constant region sequences described herein, e.g. Seq ID Nos:207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536 and 538.
  • a full length heavy chain amino acid sequence is Seq ID No:35 (heavy chain nucleic acid sequence Seq ID No:36).
  • a full length light chain amino acid sequence is Seq ID No:45 (light chain nucleic acid sequence Seq ID No:46).
  • 411B08 has a heavy chain variable (VH) region amino acid sequence of Seq ID No:58, comprising the CDRH1 amino acid sequence of Seq ID No: 52 (IMGT) or Seq ID No: 55 (Kabat), the CDRH2 amino acid sequence of Seq ID No: 53 (IMGT) or Seq ID No: 56 (Kabat), and the CDRH3 amino acid sequence of Seq ID No: 54 (IMGT) or Seq ID No: 57 (Kabat).
  • VH heavy chain variable
  • the heavy chain nucleic acid sequence of the VH domain is Seq ID No: 59.
  • 411B08 has a light chain variable region (VL) amino acid sequence of Seq ID No: 68, comprising the CDRL1 amino acid sequence of Seq ID No:62 (IMGT) or Seq ID No:65 (Kabat), the CDRL2 amino acid sequence of Seq ID No:63 (IMGT) or Seq ID No:66 (Kabat), and the CDRL3 amino acid sequence of Seq ID No:64 (IMGT) or Seq ID No:67 (Kabat).
  • the light chain nucleic acid sequence of the VL domain is Seq ID No:69.
  • the VH domain may be combined with any of the heavy chain constant region sequences described herein, e.g.
  • the VL domain may be combined with any of the light chain constant region sequences described herein, e.g . Seq ID Nos:207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536 and 538.
  • a full length heavy chain amino acid sequence is Seq ID No:60 (heavy chain nucleic acid sequence Seq ID No:61).
  • a full length light chain amino acid sequence is Seq ID No:70 (light chain nucleic acid sequence Seq ID No:71).
  • VH heavy chain variable region amino acid sequence of Seq ID No:78, comprising the CDRH1 amino acid sequence of Seq ID No: 72 (IMGT) or Seq ID No:75 (Kabat), the CDRH2 amino acid sequence of Seq ID No:73 (IMGT) or Seq ID No:76 (Kabat), and the CDRH3 amino acid sequence of Seq ID No:74 (IMGT) or Seq ID No: 77 (Kabat).
  • the heavy chain nucleic acid sequence of the VH domain is Seq ID No:79.
  • VL light chain variable region
  • the light chain nucleic acid sequence of the VL domain is Seq ID No:89.
  • the VH domain may be combined with any of the heavy chain constant region sequences described herein, e.g.
  • the VL domain may be combined with any of the light chain constant region sequences described herein, e.g . Seq ID Nos:207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536 and 538.
  • a full length heavy chain amino acid sequence is Seq ID No:80 (heavy chain nucleic acid sequence Seq ID No:81).
  • a full length light chain amino acid sequence is Seq ID No:90 (light chain nucleic acid sequence Seq ID No:91).
  • VH heavy chain variable region amino acid sequence of Seq ID No:98, comprising the CDRH1 amino acid sequence of Seq ID No:92 (IMGT) or Seq ID No:95 (Kabat), the CDRH2 amino acid sequence of Seq ID No:93 (IMGT) or Seq ID No:96 (Kabat), and the CDRH3 amino acid sequence of Seq ID No:94 (IMGT) or Seq ID No:97 (Kabat).
  • the heavy chain nucleic acid sequence of the VH domain is Seq ID No:99.
  • VL light chain variable region
  • the light chain nucleic acid sequence of the VL domain is Seq ID No: 109.
  • the VH domain may be combined with any of the heavy chain constant region sequences described herein, e.g.
  • the VL domain may be combined with any of the light chain constant region sequences described herein, e.g. Seq ID Nos:207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536 and 538.
  • a full length heavy chain amino acid sequence is Seq ID No: 100 (heavy chain nucleic acid sequence Seq ID No: 101).
  • a full length light chain amino acid sequence is Seq ID No: 110 (light chain nucleic acid sequence Seq ID No: 111).
  • VH heavy chain variable
  • Seq ID No: 118 comprising the CDRH1 amino acid sequence of Seq ID No:112 (IMGT) or Seq ID No: 115 (Kabat), the CDRH2 amino acid sequence of Seq ID No: 113 (IMGT) or Seq ID No: 116 (Kabat), and the CDRH3 amino acid sequence of Seq ID No: 114 (IMGT) or Seq ID No: 117 (Kabat).
  • the heavy chain nucleic acid sequence of the VH domain is Seq ID No: 119.
  • VL light chain variable region
  • the light chain nucleic acid sequence of the VL domain is Seq ID No: 129.
  • the VH domain may be combined with any of the heavy chain constant region sequences described herein, e.g.
  • the VL domain may be combined with any of the light chain constant region sequences described herein, e.g. Seq ID Nos:207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536 and 538.
  • a full length heavy chain amino acid sequence is Seq ID No: 120 (heavy chain nucleic acid sequence Seq ID No: 121).
  • a full length light chain amino acid sequence is Seq ID No: 130 (light chain nucleic acid sequence Seq ID No: 131).
  • VH heavy chain variable
  • Seq ID No: 158 comprising the CDRH1 amino acid sequence of Seq ID No:152 (IMGT) or Seq ID No: 155 (Kabat), the CDRH2 amino acid sequence of Seq ID No: 153 (IMGT) or Seq ID No: 156 (Kabat), and the CDRH3 amino acid sequence of Seq ID No: 154 (IMGT) or Seq ID No: 157 (Kabat).
  • the heavy chain nucleic acid sequence of the VH domain is Seq ID No: 159.
  • VL light chain variable region
  • the light chain nucleic acid sequence of the VL domain is Seq ID No: 169.
  • the VH domain may be combined with any of the heavy chain constant region sequences described herein, e.g.
  • the VL domain may be combined with any of the light chain constant region sequences described herein, e.g. Seq ID Nos:207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536 and 538.
  • a full length heavy chain amino acid sequence is Seq ID No: 160 (heavy chain nucleic acid sequence Seq ID No: 161).
  • a full length light chain amino acid sequence is Seq ID No: 170 (light chain nucleic acid sequence Seq ID No: 171).
  • VH heavy chain variable
  • Seq ID No: 178 comprising the CDRH1 amino acid sequence of Seq ID No:172 (IMGT) or Seq ID No: 175 (Kabat), the CDRH2 amino acid sequence of Seq ID No: 173 (IMGT) or Seq ID No: 176 (Kabat), and the CDRH3 amino acid sequence of Seq ID No: 174 (IMGT) or Seq ID No: 177 (Kabat).
  • the heavy chain nucleic acid sequence of the VH domain is Seq ID No: 179.
  • VL light chain variable region
  • the light chain nucleic acid sequence of the VL domain is Seq ID No: 189.
  • the VH domain may be combined with any of the heavy chain constant region sequences described herein, e.g.
  • the VL domain may be combined with any of the light chain constant region sequences described herein, e.g. Seq ID Nos:207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536 and 538.
  • a full length heavy chain amino acid sequence is Seq ID No: 180 (heavy chain nucleic acid sequence Seq ID No: 181).
  • a full length light chain amino acid sequence is Seq ID No: 190 (light chain nucleic acid sequence Seq ID No: 191).
  • VH heavy chain variable
  • Seq ID No: 138 comprising the CDRH1 amino acid sequence of Seq ID No: 132 (IMGT) or Seq ID No: 135 (Kabat), the CDRH2 amino acid sequence of Seq ID No: 133 (IMGT) or Seq ID No:136 (Kabat), and the CDRH3 amino acid sequence of Seq ID No: 134 (IMGT) or Seq ID No: 137 (Kabat).
  • the heavy chain nucleic acid sequence of the VH domain is Seq ID No: 139.
  • VL light chain variable region
  • the light chain nucleic acid sequence of the VL domain is Seq ID No: 149.
  • the VH domain may be combined with any of the heavy chain constant region sequences described herein, e.g.
  • the VL domain may be combined with any of the light chain constant region sequences described herein, e.g. Seq ID Nos:207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536 and 538.
  • a full length heavy chain amino acid sequence is Seq ID No: 140 (heavy chain nucleic acid sequence Seq ID No: 141).
  • a full length light chain amino acid sequence is Seq ID No: 150 (light chain nucleic acid sequence Seq ID No: 151).
  • VH heavy chain variable region amino acid sequence of Seq ID No:244, comprising the CDRH1 amino acid sequence of Seq ID No:238 (IMGT) or Seq ID No:241 (Kabat), the CDRH2 amino acid sequence of Seq ID No:239 (IMGT) or Seq ID No:242 (Kabat), and the CDRH3 amino acid sequence of Seq ID No:240 (IMGT) or Seq ID No:243 (Kabat).
  • the heavy chain nucleic acid sequence of the VH domain is Seq ID No:245.
  • VL light chain variable region
  • IMGT CDRL1 amino acid sequence of Seq ID No:248 (IMGT) or Seq ID No:251 (Kabat)
  • the light chain nucleic acid sequence of the VL domain is Seq ID No:255.
  • the VH domain may be combined with any of the heavy chain constant region sequences described herein, e.g.
  • the VL domain may be combined with any of the light chain constant region sequences described herein, e.g. Seq ID Nos:207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536 and 538.
  • a full length heavy chain amino acid sequence is Seq ID No:246 (heavy chain nucleic acid sequence Seq ID No:247).
  • a full length light chain amino acid sequence is Seq ID No:256 (light chain nucleic acid sequence Seq ID No:257 ).
  • VH heavy chain variable region amino acid sequence of Seq ID No:264, comprising the CDRH1 amino acid sequence of Seq ID No:258 (IMGT) or Seq ID No:261 (Kabat), the CDRH2 amino acid sequence of Seq ID No:259 (IMGT) or Seq ID No:262 (Kabat), and the CDRH3 amino acid sequence of Seq ID No:260 (IMGT) or Seq ID No:263 (Kabat).
  • the heavy chain nucleic acid sequence of the VH domain is Seq ID No: 265.
  • VL light chain variable region
  • IMGT CDRL1 amino acid sequence of Seq ID No:268 (IMGT) or Seq ID No:271 (Kabat)
  • the light chain nucleic acid sequence of the VL domain is Seq ID No:275.
  • the VH domain may be combined with any of the heavy chain constant region sequences described herein, e.g.
  • the VL domain may be combined with any of the light chain constant region sequences described herein, e.g. Seq ID Nos:207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536 and 538.
  • a full length heavy chain amino acid sequence is Seq ID No:266 (heavy chain nucleic acid sequence Seq ID No:267).
  • a full length light chain amino acid sequence is Seq ID No:276 (light chain nucleic acid sequence Seq ID No:277).
  • VH heavy chain variable region amino acid sequence of Seq ID No:284, comprising the CDRH1 amino acid sequence of Seq ID No:278 (IMGT) or Seq ID No:281 (Kabat), the CDRH2 amino acid sequence of Seq ID No:279 (IMGT) or Seq ID No:282 (Kabat), and the CDRH3 amino acid sequence of Seq ID No:280 (IMGT) or Seq ID No:283 (Kabat).
  • the heavy chain nucleic acid sequence of the VH domain is Seq ID No:285.
  • VL light chain variable region
  • IMGT CDRL1 amino acid sequence of Seq ID No:288 (IMGT) or Seq ID No:291(Kabat)
  • the light chain nucleic acid sequence of the VL domain is Seq ID No:295.
  • the VH domain may be combined with any of the heavy chain constant region sequences described herein, e.g.
  • the VL domain may be combined with any of the light chain constant region sequences described herein, e.g. Seq ID Nos:207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536 and 538.
  • a full length heavy chain amino acid sequence is Seq ID No:286 (heavy chain nucleic acid sequence Seq ID No:287).
  • a full length light chain amino acid sequence is Seq ID No:296 (light chain nucleic acid sequence Seq ID No:297).
  • VH heavy chain variable region amino acid sequence of Seq ID No:349, comprising the CDRH1 amino acid sequence of Seq ID No:343 (IMGT) or Seq ID No:346 (Kabat), the CDRH2 amino acid sequence of Seq ID No:344 (IMGT) or Seq ID No:347 (Kabat), and the CDRH3 amino acid sequence of Seq ID No:345 (IMGT) or Seq ID No:348 (Kabat).
  • the heavy chain nucleic acid sequence of the VH domain is Seq ID No:350.
  • VL light chain variable region
  • IMGT CDRL1 amino acid sequence of Seq ID No:353
  • IMGT CDRL2 amino acid sequence of Seq ID No:354
  • Seq ID No:357 CDRL3 amino acid sequence of Seq ID No:355 (IMGT) or Seq ID No:358 (Kabat).
  • the light chain nucleic acid sequence of the VL domain is Seq ID No:360.
  • the VH domain may be combined with any of the heavy chain constant region sequences described herein, e.g.
  • the VL domain may be combined with any of the light chain constant region sequences described herein, e.g. Seq ID Nos:207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 536 and 538.
  • a full length heavy chain amino acid sequence is Seq ID No:351 (heavy chain nucleic acid sequence Seq ID No:352).
  • a full length light chain amino acid sequence is Seq ID No:361 (light chain nucleic acid sequence Seq ID No:362).
  • An antibody or a fragment thereof which specifically binds to hPD-Ll as defined by Seq ID No: l, and competes for binding to said hPD-Ll with the antibody 1D05, wherein the antibody or fragment comprises a VH domain which comprises a CDRH3 comprising the motif X1GSGX2YGX3X4FD, wherein Xi, X2 and X3 are independently any amino acid, and X4 is either present or absent, and if present, may be any amino acid.
  • antibodies or fragments may include or may not include bispecific antibodies.
  • antibodies or fragments includes bispecific antibodies.
  • a bispecific antibody does not include a FIT-Ig format.
  • a bispecific antibody does not include a mAb 2 format.
  • a bispecific antibody does not include either a FIT-Ig format or a mAb 2 format.
  • the antibody or fragment in these concepts includes a bispecific antibody, but does not include a bispecific antibody having a FIT-Ig format.
  • the antibody or fragment in these concepts includes a bispecific antibody, but does not include a bispecific antibody having a mAb 2 format.
  • the antibody or fragment in these concepts includes a bispecific antibody, but does not include a bispecific antibody having a FIT-Ig format or a mAb 2 format.
  • the antibody or fragment in these concepts includes a bispecific antibody, but does not include a bispecific antibody having a FIT-Ig format or a mAb 2 format.
  • antibodies or fragments include dual binding
  • an antibody or a fragment thereof that specifically binds to a hPD-Ll antigen does not cross-react with other antigens (but may optionally cross-react with PD-L1 of a different species, e.g., rhesus, cynomolgus, or murine).
  • An antibody or a fragment thereof that specifically binds to a hPD-Ll antigen can be identified, for example, by immunoassays, BIAcoreTM, or other techniques known to those of skill in the art.
  • an antibody or a fragment thereof binds specifically to a hPD-Ll antigen when it binds to a hPD-Ll antigen with higher affinity than to any cross- reactive antigen as determined using experimental techniques, such as radioimmunoassays (RIA) and enzyme-linked immunosorbent assays (ELISAs).
  • RIA radioimmunoassays
  • ELISAs enzyme-linked immunosorbent assays
  • a specific or selective reaction will be at least twice background signal or noise and more typically more than 10 times background. See, e.g. Paul, ed., 1989, Fundamental Immunology Second Edition, Raven Press, New York at pages 332-336 for a discussion regarding antibody specificity.
  • the antibody or fragment is a human antibody. In one embodiment, the antibody or fragment is a human antibody or fragment. In one embodiment, the antibody or fragment is a fully human antibody or fragment. In one embodiment, the antibody or fragment is a fully human monoclonal antibody or fragment.
  • concept la An antibody or a fragment thereof, that specifically binds to hPD-Ll as defined by Seq ID No: l, and competes for binding to said hPD-Ll with the antibody 411B08, wherein the antibody or fragment comprises a VH domain which comprises a CDRH3 comprising the motif ARX1RX2X3SDX4X5D, wherein Xi, X2, X3, X and Xs are independently any amino acid.
  • concept lb An antibody or a fragment thereof, that specifically binds to hPD-Ll as defined by Seq ID No: l, and competes for binding to said hPD-Ll with the antibody 411B08, wherein the antibody or fragment comprises a VH domain which comprises a CDRH3 comprising the motif XiRDGSGSY, wherein Xi is any amino acid.
  • an anti-PD-Ll antibody or immunocytokine may bind to PD-L1, e.g. human PD-L1 with a KD of less than 50 nM, less than 40 nM, less than 30 nM as determined by surface plasmon resonance.
  • anti-PD-Ll antibody or immunocytokine may bind to PD-L1, e.g. human PD-L1 with a KD of less than 20 nM, less than 15 nM, less than 10 nM as determined by surface plasmon resonance.
  • anti-PD-Ll antibody or immunocytokine may bind to PD-L1, e.g.
  • human PD-L1 with a KD of less than 8 nM, less than 5 nM, less than 4 nM, less than 3 nM, less than 2 nM or less than 1 nM as determined by surface plasmon resonance.
  • the KD may be 0.9 nM or less, 0.8 nM or less, 0.7 nM or less, 0.6 nM or less, 0.5 nM or less, 0.4 nM or less, 0.3 nM or less, 0.2 nM or less, or 0.1 nM or less.
  • the KD is within a range of 0.01 to 1 nM, or a range of 0.05 to 2 nM, or a range of 0.05 to InM.
  • the KD may be with regard to hPD-Ll, cynoPD-Ll and/or mouse PD-L1.
  • the anti-PD-Ll antibodies described herein have a KON rate (e.g. as measured by SPR, e.g. at 25 °C or at 37 °C) of approximately 0.5 to 10 ⁇ , for example approximately 1 to 8 ⁇ or approximately 1 to 7 ⁇ .
  • the KON rate is approximately 1 to 5 ⁇ , e.g. approximately 1 ⁇ , approximately 1.5 ⁇ , approximately 2 ⁇ , approximately 2.5 ⁇ or approximately 3 ⁇ .
  • the KON rate is approximately 3.5 ⁇ , approximately 4 ⁇ , approximately 4.5 ⁇ , approximately 5 ⁇ or approximately 5.5 ⁇ .
  • the anti-PD-Ll antibodies described herein have a KOFF rate (e.g. as measured by SPR, e.g. at 25 °C or at 37 °C) of approximately 0.01 to 100 mM, for example approximately 0.1 to 50 mM or approximately 0.5 to 50 mM.
  • the KOFF rate is approximately 0.5 to 10 mM, or approximately 0.5 to 10 mM, e.g. approximately 1 mM, approximately 2 mM, approximately 3 mM, approximately 4 mM or approximately 5 mM.
  • the KOFF rate is approximately 0.6 mM, approximately 0.7 mM, approximately 0.8 mM or approximately 0.9 mM.
  • the anti-PD-Ll antibodies (and immunocytokines) described in the concepts and aspects herein provide improved transient expression levels over other anti-PD-Ll antibodies and immunocytokines.
  • the anti-PD-Ll antibody (or immunocytokine) is expressed in a HEK293 cell, e.g. a HEK293T cell, at an expression level of approximately 100 pg/mL, or in a range of approximately 100 to 350 pg/mL. In another embodiment, the expression level is above approximately 350 pg/mL.
  • the anti-PD-Ll antibody (or immunocytokine) is expressed in a CHO cell, e.g. an Expi-CHO cell, at an expression level of approximately 100 pg/mL, or in a range of approximately 100 to 350 pg/mL. In another embodiment, the expression level is above approximately 350 pg/mL.
  • the anti-PD-Ll antibody (or immunocytokine) is expressed in a CHO cell, e.g. an Expi-CHO cell or a CHO-E7 EBNA cell, at an expression level of approximately 100 pg/mL, or in a range of approximately 100 to 350 pg/mL In another embodiment, the expression level is above approximately 350 pg/mL.
  • the antibody described herein as 1D05, formatted as a human IgGl (Seq ID No:340, at 2L volume in CHO-E7 EBNA cells has an expression level of approximately 115 pg/mL.
  • the antibody described herein as 416E01, formatted as a human IgGl (Seq ID No:340), at 2L volume in CHO-E7 EBNA cells has an expression level of approximately 160 pg/mL.
  • the antibody described herein as 1414B06, formatted as a human IgGl (Seq ID No:340), at 2L volume in CHO-E7 EBNA cells has an expression level of approximately 783 pg/mL.
  • the antibody described herein as 413G05, formatted as a human IgGl (Seq ID No: 340), at 2L volume in CHO-E7 EBNA cells has an expression level of approximately 383 pg/mL.
  • the expression is carried out of a scale of between approximately 0.5 mL and 3 mL, for example between approximately 0.5 mL and 2 mL.
  • the anti-PD-Ll antibody (or immunocytokine) may be expressed from a pTT5 vector.
  • the anti-PD-Ll antibody (or immunocytokine) may be expressed in conjunction with a lipid transfection reagent, and may optionally be expressed in a CHO cell, e.g. an Expi-CHO cell.
  • the anti-PD-Ll antibody may be expressed in conjunction with a PEI transfection reagent, and may optionally be expressed in a CHO cell, e.g. an CHO-E7 EBNA cell.
  • the anti- PD-Ll antibody may be expressed in conjunction with a helper plasmid (e.g. an AKT helper plasmid), and may optionally be expressed in a CHO cell, e.g. an CHO-E7 EBNA cell.
  • the expression level is between approximately 100 pg/mL and approximately 1500 pg/mL, for example between approximately 100 pg/mL and approximately 1000 pg/mL, or between approximately 200 pg/mL and approximately 1000 pg/mL, or between approximately 350 pg/mL and approximately 1000 pg/mL.
  • the lower limit of expression may be approximately 100 pg/mL, approximately 200 pg/mL, approximately 300 pg/mL, or approximately 400 pg/mL. In another embodiment, the lower limit of expression may be approximately 500 pg/mL, approximately 600 pg/mL, approximately 700 pg/mL, or approximately 800 pg/mL.
  • the upper limit of expression may be approximately 2000 pg/mL, approximately 1800 pg/mL, approximately 1600 pg/mL, or approximately 1500 pg/mL. In another embodiment, the upper limit of expression may be approximately 1250 pg/mL, approximately 1000 pg/mL, approximately 900 pg/mL, or approximately 800 pg/mL.
  • the expression system is a Lonza expression system, e.g. Lonza X- Ceed ® system.
  • the expression may be carried out at a scale of approximately 30 mL to 2 L, for example 50 mL to 1 L, or 1 L tp 2 L.
  • the anti-PD-Ll antibody (or immunocytokine) may be expressed in conjunction with electroporation, and optionally without any helper plasmids.
  • the anti-PD-Ll antibody (or immunocytokine) may be expressed at a level of approximately 1 g/L, or approximately 900 mg/L, or approximately 800 mg/L, or approximately 700 mg/L.
  • the anti-PD-Ll antibody may be expressed at a level of approximately 600 mg/L or approximately 500 mg/L or approximately 400 mg/L. In the Lonza expression system, the anti-PD-Ll antibody (or immunocytokine) may be expressed at a level of between approximately 400 mg/L and approximately 2 g/L, for example between approximately 500 mg/L and approximately 1.5 g/L, or between approximately 500 mg/L and approximately 1 g/L. In another embodiment, the expression level is above 1 g/L. In another embodiment, the anti-PD-Ll antibodies described in the concepts provide improved half-life over other anti-PD-Ll antibodies as further described in Aspect 1 hereinbelow.
  • the hydroxyl-containing amino acid is Serine. In one embodiment, the hydroxyl-containing amino acid is Cysteine. In one embodiment, the hydroxyl-containing amino acid is Threonine. In one embodiment, the hydroxyl-containing amino acid is Methionine. In one embodiment, the hydroxyl-containing amino acid is Serine or Cysteine. In one embodiment, the hydroxyl-containing amino acid is Serine or Threonine. In one embodiment, the hydroxyl-containing amino acid is Serine or Methionine. In one embodiment, the hydroxyl-containing amino acid is Cysteine or Threonine. In one embodiment, the hydroxyl-containing amino acid is Cysteine or Methionine. In one embodiment, the hydroxyl-containing amino acid is Threonine or Methionine. In one embodiment, the hydroxyl-containing amino acid is Threonine or Methionine.
  • the hydroxyl-containing amino acid is selected from serine, cysteine, threonine and methionine.
  • Xi is selected from Asparagine (N) and valine (V). In one embodiment, Xi is valine. In one embodiment, Xi is asparagine.
  • Xi is an aliphatic amino acid.
  • Xi is selected from alanine (A) or valine (V).
  • Xi is valine.
  • Xi is alanine.
  • the hydroxyl-containing amino acid is Histidine. In one embodiment, the hydroxyl-containing amino acid is Lysine. In one embodiment, the hydroxyl-containing amino acid is Arginine. In one embodiment, the hydroxyl-containing amino acid is Histidine or Lysine. In one embodiment, the hydroxyl-containing amino acid is Histidine or Arginine. In one embodiment, the hydroxyl-containing amino acid is Lysine or Arginine.
  • the hydroxyl-containing amino acid is selected from Histidine, Lysine and
  • X2 is selected from leucine (L), isoleucine (I), Valine (V), Asparagine (N) and glutamine (Q). In one embodiment, X2 is selected from leucine (L), isoleucine (I) and Valine (V). In one embodiment, X2 is selected from Asparagine (N) and glutamine (Q)In one embodiment, X 2 is selected from leucine (L) and glutamine (Q). In one embodiment, X2 is leucine (L). In one embodiment, X2 is glutamine (Q).
  • the hydroxyl-containing amino acid is Serine. In one embodiment, the hydroxyl-containing amino acid is Cysteine. In one embodiment, the hydroxyl-containing amino acid is Threonine. In one embodiment, the hydroxyl-containing amino acid is Methionine. In one embodiment, the hydroxyl-containing amino acid is Serine or Cysteine. In one embodiment, the hydroxyl-containing amino acid is Serine or Threonine. In one embodiment, the hydroxyl-containing amino acid is Serine or Methionine. In one embodiment, the hydroxyl-containing amino acid is Cysteine or Threonine. In one embodiment, the hydroxyl-containing amino acid is Cysteine or Methionine. In one embodiment, the hydroxyl-containing amino acid is Threonine or Methionine. In one embodiment, the hydroxyl-containing amino acid is Threonine or Methionine.
  • the hydroxyl-containing amino acid is selected from serine, cysteine, threonine and methionine.
  • X3 is selected from Phenylalanine (F), Tyrosine (Y) and Tryptophan (W). In one embodiment, X3 is selected from Tyrosine (Y) and Tryptophan (W). In one embodiment, X3 is Tyrosine (Y). In one embodiment, X3 is Tryptophan (W).
  • Concept 5 The antibody or fragment according to any one of concepts 1 to 4, wherein X3 is an aromatic amino acid, optionally W.
  • the hydroxyl-containing amino acid is Phenylalanine. In one embodiment, the hydroxyl-containing amino acid is Tyrosine. In one embodiment, the hydroxyl-containing amino acid is Tryptophan. In one embodiment, the hydroxyl-containing amino acid is Phenylalanine or Tyrosine. In one embodiment, the hydroxyl-containing amino acid is Phenylalanine or Tryptophan. In one embodiment, the hydroxyl-containing amino acid is Tyrosine or Tryptophan.
  • the hydroxyl-containing amino acid is selected from Phenylalanine, Tyrosine and Tryptophan.
  • X 4 is selected from Phenylalanine (F), Tyrosine (Y) and Tryptophan (W). In one embodiment, X4 is selected from Tyrosine (Y) and Phenylalanine (F). In one embodiment, X4 is Tyrosine (Y). In one embodiment, X4 is Phenylalanine (F).
  • Concept 6 The antibody or fragment according to any one of concepts 1 to 5, wherein X4 is absent.
  • X5 is selected from leucine (L), isoleucine (I), Valine (V), Serine (S), Cysteine (C) and Threonine (T). In one embodiment, X5 is selected from leucine (L), isoleucine (I) and Valine (V). In one embodiment, X5 is selected from Serine (S), Cysteine (C) and Threonine (T). In one embodiment, X5 is selected from leucine (L) and Serine (S). In one embodiment, X5 is Serine (S). In one embodiment, X5 is leucine (L).
  • the hydroxyl-containing amino acid is selected from Glycine, Alanine, Valine, Leucine and Isoleucine.
  • the hydroxyl-containing amino acid is selected from Glycine and Alanine. In one embodiment, the hydroxyl-containing amino acid is selected from Glycine and Valine. In one embodiment, the hydroxyl-containing amino acid is selected from Glycine and Leucine. In one embodiment, the hydroxyl-containing amino acid is selected from Glycine and Isoleucine. In one embodiment, the hydroxyl-containing amino acid is selected from Alanine and Valine. In one embodiment, the hydroxyl-containing amino acid is selected from Alanine and Leucine. In one embodiment, the hydroxyl-containing amino acid is selected from Alanine and Isoleucine. In one embodiment, the hydroxyl-containing amino acid is selected from Valine and Leucine. In one embodiment, the hydroxyl-containing amino acid is selected from Valine and Isoleucine. In one embodiment, the hydroxyl-containing amino acid is selected from, Leucine and Isoleucine. In one embodiment, the hydroxyl-containing amino acid is selected from, Leucine and Isoleucine.
  • the hydroxyl-containing amino acid selected from three of each of Glycine, Alanine, Valine, Leucine and Isoleucine. In one embodiment, the hydroxyl-containing amino acid selected from four of each of Glycine, Alanine, Valine, Leucine and Isoleucine.
  • Concept 9 An antibody or a fragment thereof, optionally according to any one of concepts 1 to 8, which specifically binds to hPD-Ll, and competes for binding to said hPD-Ll with the antibody 1D05, wherein the antibody or fragment comprises a VH domain which comprises the CDRH3 sequence of SEQ ID NO:29 or 32, or the CDRH3 sequence of SEQ ID NO:29 or 32 comprising 6 or fewer amino acid substitutions.
  • Concept 9a An antibody or a fragment thereof, optionally according to any one of concepts 1 to 8, which specifically binds to hPD-Ll, and competes for binding to said hPD-Ll with the antibody 84G09, wherein the antibody or fragment comprises a VH domain which comprises the CDRH3 sequence of SEQ ID NO:9 or 12, or the CDRH3 sequence of SEQ ID NO:9 or 12 comprising 6 or fewer amino acid substitutions.
  • Concept 9b An antibody or a fragment thereof, optionally according to any one of concepts 1 to 8, which specifically binds to hPD-Ll, and competes for binding to said hPD-Ll with the antibody 411B08, wherein the antibody or fragment comprises a VH domain which comprises the CDRH3 sequence of SEQ ID NO:54 or 57, or the CDRH3 sequence of SEQ ID NO:54 or 57 comprising 6 or fewer amino acid substitutions.
  • Concept 9c An antibody or a fragment thereof, optionally according to any one of concepts 1 to 8, which specifically binds to hPD-Ll, and competes for binding to said hPD-Ll with the antibody 411C04, wherein the antibody or fragment comprises a VH domain which comprises the CDRH3 sequence of SEQ ID No:74 or 77, or the CDRH3 sequence of SEQ ID NO:74 or 77 comprising 6 or fewer amino acid substitutions.
  • Concept 9d An antibody or a fragment thereof, optionally according to any one of concepts 1 to 8, which specifically binds to hPD-Ll, and competes for binding to said hPD-Ll with the antibody 411D07, wherein the antibody or fragment comprises a VH domain which comprises the CDRH3 sequence of SEQ ID NO:94 or 97, or the CDRH3 sequence of SEQ ID NO:94 or 97 comprising 3 or fewer amino acid substitutions.
  • Concept 9e An antibody or a fragment thereof, optionally according to any one of concepts 1 to 8, which specifically binds to hPD-Ll, and competes for binding to said hPD-Ll with the antibody 385F01, wherein the antibody or fragment comprises a VH domain which comprises the CDRH3 sequence of SEQ ID NO: 114 or 117, or the CDRH3 sequence of SEQ ID NO: 114 or 117 comprising 6 or fewer amino acid substitutions.
  • Concept 9f An antibody or a fragment thereof, optionally according to any one of concepts 1 to 8, which specifically binds to hPD-Ll, and competes for binding to said hPD-Ll with the antibody 386H03, wherein the antibody or fragment comprises a VH domain which comprises the CDRH3 sequence of SEQ ID NO: 144 or 147, or the CDRH3 sequence of SEQ ID NO: 144 or 147 comprising 3 or fewer amino acid substitutions.
  • Concept 9g An antibody or a fragment thereof, optionally according to any one of concepts 1 to 8, which specifically binds to hPD-Ll, and competes for binding to said hPD-Ll with the antibody 389A03, wherein the antibody or fragment comprises a VH domain which comprises the CDRH3 sequence of SEQ ID NO: 174 or 177, or the CDRH3 sequence of SEQ ID NO: 174 or 177 comprising 6 or fewer amino acid substitutions.
  • Concept 9h An antibody or a fragment thereof, optionally according to any one of concepts 1 to 8, which specifically binds to hPD-Ll, and competes for binding to said hPD-Ll with the antibody 413D08, wherein the antibody or fragment comprises a VH domain which comprises the CDRH3 sequence of SEQ ID NO: 134 or 137, or the CDRH3 sequence of SEQ ID NO: 134 or 137 comprising 5 or fewer amino acid substitutions.
  • Concept 9i An antibody or a fragment thereof, optionally according to any one of concepts 1 to 8, which specifically binds to hPD-Ll, and competes for binding to said hPD-Ll with the antibody 413G05, wherein the antibody or fragment comprises a VH domain which comprises the CDRH3 sequence of SEQ ID NO:240 or 243, or the CDRH3 sequence of SEQ ID NO:240 or 243 comprising 6 or fewer amino acid substitutions.
  • Concept 9j An antibody or a fragment thereof, optionally according to any one of concepts 1 to 8, which specifically binds to hPD-Ll, and competes for binding to said hPD-Ll with the antibody 413F09, wherein the antibody or fragment comprises a VH domain which comprises the CDRH3 sequence of SEQ ID NO:260 or 263, or the CDRH3 sequence of SEQ ID NO:260 or 263 comprising 6 or fewer amino acid substitutions.
  • Concept 9k An antibody or a fragment thereof, optionally according to any one of concepts 1 to 8, which specifically binds to hPD-Ll, and competes for binding to said hPD-Ll with the antibody 414B06, wherein the antibody or fragment comprises a VH domain which comprises the CDRH3 sequence of SEQ ID NO:280 or 283, or the CDRH3 sequence of SEQ ID NO:280 or 283 comprising 6 or fewer amino acid substitutions.
  • Concept 91 An antibody or a fragment thereof, optionally according to any one of concepts 1 to 8, which specifically binds to hPD-Ll, and competes for binding to said hPD-Ll with the antibody 416E01, wherein the antibody or fragment comprises a VH domain which comprises the CDRH3 sequence of SEQ ID No: 345 or 348, or the CDRH3 sequence of SEQ ID No: 345 or 348 comprising 6 or fewer amino acid substitutions.
  • the CDR comprises one amino acid substitution, which may be a conservative amino acid substitution.
  • the CDR comprises two amino acid substitutions, which may be conservative amino acid substitutions.
  • the CDR comprises three amino acid substitutions, which may be conservative amino acid substitutions.
  • the CDR comprises four amino acid substitutions, which may be conservative amino acid substitutions.
  • the CDR comprises five amino acid substitutions, which may be conservative amino acid substitutions.
  • the CDR comprises six amino acid substitutions, which may be conservative amino acid substitutions.
  • Amino acid substitutions include alterations in which an amino acid is replaced with a different naturally-occurring amino acid residue. Such substitutions may be classified as “conservative", in which case an amino acid residue contained in a polypeptide is replaced with another naturally occurring amino acid of similar character either in relation to polarity, side chain functionality or size. Such conservative substitutions are well known in the art. Substitutions encompassed by the present invention may also be "non-conservative", in which an amino acid residue which is present in a peptide is substituted with an amino acid having different properties, such as naturally-occurring amino acid from a different group (e.g. substituting a charged or hydrophobic amino; acid with alanine), or alternatively, in which a naturally-occurring amino acid is substituted with a non-conventional amino acid.
  • the conservative amino acid substitutions are as described herein.
  • the substitution may be of Y with F, T with S or K, P with A, E with D or Q, N with D or G, R with K, G with N or A, T with S or K, D with N or E, I with L or V, F with Y, S with T or A, R with K, G with N or A, K with R, A with S, K or P.
  • the conservative amino acid substitutions may be wherein Y is substituted with F, T with A or S, I with L or V, W with Y, M with L, N with D, G with A, T with A or S, D with N, I with L or V, F with Y or L, S with A or T and A with S, G, T or V.
  • the CDRH3 is from 14 to 17 amino acids and the human JH gene segment is IGHJ5 (e.g. IGHJ5*02).
  • concept 10a an antibody or fragment which specifically binds to hPD-Ll and comprises a VH domain comprising a CDRH3 of from 8 to 16 amino acids and which is derived from the recombination of a human VH gene segment, a human D gene segment and a human JH gene segment, wherein the human JH gene segment is selected from IGHJ4 (e.g. IGHJ4*02), IGHJ5 (e.g. IGHJ5*02) and IGHJ6 (e.g. IGHJ6*02).
  • IGHJ4 e.g. IGHJ4*02
  • IGHJ5 e.g. IGHJ5*02
  • IGHJ6 e.g. IGHJ6*02
  • the human JH gene segment is IGHJ6 (e.g. IGHJ6*02).
  • the CDRH3 is of from 10 to 17 amino acids and the human JH gene segment is IGHJ6 (e.g. IGHJ6*02).
  • the human JH gene segment is IGHJ4 (e.g. IGHJ4*02).
  • the CDRH3 is from 7 to 17 amino acids and the human JH gene segment is IGHJ4 (e.g. IGHJ4*02).
  • the antibody of concept 10 or 10a has any of the features of concepts 1 to 9, including the binding affinities, Kon and Koff rates, expression levels, half-life etc.
  • concept 11a an antibody or fragment according to concept 10 or 10a, wherein the human VH gene segment is selected from IGHV3 (e.g. IGHV3-9, such as IGHV3-
  • IGHV3-7 such as IGHV3-7*01 or e.g. IGHV3-33, such as IGHV3-33*01 or e.g. IGHV3-
  • IGHV3-11*01 such as IGHV3-11*01 or e.g. IGHV3-23, such as IGHV3-23*04
  • IGHV4 e.g. IGHV4-4, such as
  • the human VH gene segment is IGHV3 (e.g. IGHV3-7, such as IGHV3- 7*01). In one embodiment, the human VH gene segment is IGHV3 (e.g. IGHV3-33, such as IGHV3-
  • the human VH gene segment is IGHV3 (e.g. IGHV3-11, such as IGHV3-
  • the human VH gene segment is IGHV3 (e.g. IGHV3-23, such as IGHV3-
  • the human VH gene segment is IGHV4 (e.g. e.g. IGHV4-4, such as IGHV4- 4*02). In one embodiment, the human VH gene segment is IGHV4 (e.g. IGHV4-39, such as IGHV4- 39*01).
  • concept lib an antibody or fragment according to concept 10, 10a, 11 or 11a, wherein the human D gene segment is selected from IGHD1 (e.g. IGHD1-20, such as IGHD1-20*01), IGHD3 (e.g. IGHD3-10, such as IGHD3-10*01), IGHD4 (e.g. IGHD4-11, such as IGHD4-11*01), IGHD5 (e.g. IGHD5-7, such as IGHD5-18*01), and IGHD6 (e.g. IGHD6-13, such as IGHD6-13*01).
  • IGHD1 e.g. IGHD1-20, such as IGHD1-20*01
  • IGHD3 e.g. IGHD3-10, such as IGHD3-10*01
  • IGHD4 e.g. IGHD4-11, such as IGHD4-11*01
  • IGHD5 e.g. IGHD5-7, such as IGHD5
  • the human D gene segment is IGHD1 (e.g. IGHD1-20, such as IGHD1- 20*01).
  • the human D gene segment is IGHD3 (e.g. IGHD3-10, such as IGHD3- 10*01).
  • the human D gene segment is IGHD4 (e.g. IGHD4-11, such as IGHD4- 11*01).
  • the human D gene segment is IGHD5 (e.g. IGHD5-18, such as IGHD5- 19*01).
  • the human D gene segment is IGHD6 (e.g. IGHD6-13, such as IGHD6- 13*01).
  • the VH, DH and JH gene segments are as described in the combinations for the antibodies in Table 5 hereinbelow.
  • the antibody heavy chain is derived from a combination of IGHV3 (e.g. IGHV3-7 such as IGHV3-7*01), IGHD4 (e.g. IGHD4-11 such as IGHD4-11*01) and IGHJ4 (e.g. IGHJ4*02).
  • the antibody heavy chain is derived from a combination of IGHV4 (e.g. IGHV4-4 such as IGHV4-4*02), IGHD3 (e.g.
  • the antibody heavy chain is derived from a combination of IGHV4 (e.g. IGHV4-39 such as IGHV4-39*01), IGHD6 (e.g. IGHD6-13 such as IGHD6-13*01) and IGHJ1 (e.g. IGHJ1*01).
  • the antibody heavy chain is derived from a combination of IGHV3 (e.g. IGHV3-33 such as IGHV3-33*01), IGHD5 (e.g. IGHD5-18 such as IGHD5-18*01) and IGHJ6 (e.g.
  • the antibody heavy chain is derived from a combination of IGHV3 (e.g. IGHV3-11 such as IGHV3-11*01), IGHD1 (e.g. IGHD1-20 such as IGHD1-20*01) and IGHJ6 (e.g. IGHJ6*02).
  • the antibody heavy chain is derived from a combination of IGHV3 (e.g. IGHV3-23 such as IGHV3-23*04), IGHD5 (e.g. IGHD5-18 such as IGHD5-18*01) and IGHJ4 (e.g. IGHJ4*02).
  • the antibody heavy chain is derived from a combination of IGHV3 (e.g. IGHV3-7 such as IGHV3-7*01), IGHD5 (e.g. IGHD5-24 such as IGHD5-24*01) and IGHJ4 (e.g. IGHJ4*02).
  • IGHV3 e.g. IGHV3-23 such as IGHV3-23*04
  • IGHD6 e.g. IGHD6-13 such as IGHD6-13*01
  • IGHJ4 e.g. IGHJ4*02.
  • concept 12a an antibody or fragment according to any of concepts
  • IGKVI e.g. IGKVI- 17, such as IGKV1-17*01 or e.g. IGKV1-9, such as IGKVl-9*d01 or e.g. IGKV1D-12, such as IGKVID- 12*02 or e.g. IGKVID-39, such as IGKV1D-39*01
  • IGKV4 e.g. IGKV4-1, such as IGKV4-1*01.
  • the human VK gene segment is IGKVI (e.g. IGKV1-17, such as IGKVI- 17*01). In one embodiment, the human VK gene segment is IGKVI (e.g. IGKV1-9, such as IGKVI- 9*d01). In one embodiment, the human VK gene segment is IGKVI (e.g. IGKVID- 12, such as IGKVID- 12*02). In one embodiment, the human VK gene segment is IGKVI (e.g. IGKVID- 39, such as IGKVID- 39*01).
  • the human VK gene segment is IGKVI IGKV4 (e.g. IGKV4-1, such as IGKV4-1*01)
  • concept 12b an antibody or fragment according to concept 10, 10a, 11 or 11a, wherein the human JK gene segment is selected from IGKJ I (e.g. IGKJ1*01), IGKJ2 (e.g. IGKJ2*04), IGKJ3 (e.g. IGKJ3*01), IGKJ4 (e.g. IGKJ4*01) or IGKJ5 (e.g. IGKJ5*01).
  • IGKJ I e.g. IGKJ1*01
  • IGKJ2 e.g. IGKJ2*04
  • IGKJ3 e.g. IGKJ3*01
  • IGKJ4 e.g. IGKJ4*01
  • IGKJ5 e.g. IGKJ
  • the human JK gene segment is IGKJ I (e.g. IGKJ1*01). In one embodiment, the human JK gene segment is IGKJ2 (e.g. IGKJ2*04). In one embodiment, the human JK gene segment is IGKJ3 (e.g. IGKJ3*01). In one embodiment, the human JK gene segment is IGKJ4 (e.g. IGKJ4*01). In one embodiment, the human JK gene segment is IGKJ5 (e.g. IGKJ5*01).
  • the VK and JK gene segments are as described in the combinations for the antibodies in Table 5 hereinbelow.
  • the antibody light chain is derived from a combination of IGKV1D (e.g. IGKV1D-12 such as IGKV1D-12*02) and IGKJ3 (e.g. IGKJ3*01).
  • the antibody light chain is derived from a combination of IGKV4 (e.g. IGKV4-1 such as IGKV14-1*01) and IGKJ2 (e.g. IGKJ2*04).
  • the antibody light chain is derived from a combination of IGKV1 (e.g.
  • the antibody light chain is derived from a combination of IGKV1D (e.g. IGKVlD-12 such as IGKV1D-12*02) and IGKJ4 (e.g. IGKJ4*01).
  • the antibody light chain is derived from a combination of IGKV1 (e.g. IGKV1-9 such as IGKVl-9*d01) and IGKJ5 (e.g. IGKJ5*01).
  • the antibody light chain is derived from a combination of IGKV1D (e.g. IGKVlD-12 such as IGKV1D-12*02) and IGKJ5 (e.g. IGKJ5*01).
  • Concept 13h An antibody or fragment thereof which specifically binds to an epitope that is identical to an epitope to which the antibody 413D08 specifically binds.
  • Concept 13i An antibody or fragment thereof which specifically binds to an epitope that is identical to an epitope to which the antibody 413G05 specifically binds.
  • an antibody which specifically binds to an epitope which is substantially similar to an epitope to which any of the antibodies in concept 13, 13 a to 131 bind.
  • sequential replacement of the amino acids of the antigen sequence may provide residues whose mutation would reduce or ablate the ability of the antibody to recognise the antigen in question. Binding may be assessed using standard techniques, such as, but not limited to, SPR, HTRF, ELISA (which are described elsewhere herein). Other substitutions could be made to enhance the disruption of binding such as changing the charge on the side chain of antigen sequence amino acids (e.g. Lysine change to glutamic acid), switching polar and non-polar residues (e.g. Serine change to leucine).
  • the alanine scan or other amino substitution method may be carried out either with recombinant soluble antigen, or where the target is a cell membrane target, directly on cells using transient or stable expression of the mutated versions.
  • protein crystallography may be used to determine contact residues between antibody and antigen (i.e. to determine the epitope to which the antibody binds), crystallography allows the direct visualisation of contact residues involved in the antibody-antigen interaction.
  • cryo-electro microscopy has been used to determine contact residues between antibodies and HIV capsid protein (see Lee, Jeong Hyun, eta/. "Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike.”, Nature communications, 6, (2015)).
  • short peptides based on the antigen sequence can be produced and binding of the antibody to these peptides can be assessed using standard techniques, such as, but not limited to, SPR, HTRF, ELISA (which are described elsewhere herein). Further investigation of the epitope could be provided by performing an Alanine scan on any peptides that show binding.
  • Conformational scans could be carried out using Pepscan technology (http://www.pepscan.com/) using their chemical linkage of peptides onto scaffolds, which has been used to determine discontinuous epitopes on CD20 targeting antibodies (Niederfellner, Gerhard, et al. "Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies.”, Blood, 118.2, (2011), 358-367.).
  • limited proteolytic digestion and mass spectrophotometry can be used to identify binding epitopes.
  • the antibody-antigen complex is digested by a protease, such as, but not limited to, trypsin.
  • the digested complex peptides are compared to antibody-alone and antigen-alone digestion mass spectrophotometry to determine if a particular epitope is protected by the complexation. Further work involving amino acid substitution, competition binding, may then be employed to narrow down to individual amino acid residues involved in the interaction (see, for example, Suckau, Detlev, et al. "Molecular epitope identification by limited proteolysis of an immobilized antigen-antibody complex and mass spectrometric peptide mapping.”, Proceedings of the National Academy of Sciences, 87.24, (1990), 9848-9852).
  • the contact residues of the epitope are identified with an unrelated amino acid scan (e.g. alanine scan).
  • an unrelated amino acid scan e.g. alanine scan
  • an unrelated amino acid scan is carried out using a technique selected from SPR, HTRF, ELISA, X-ray crystallography, cryo-electro microscopy and a combination of limited proteolytic digestion and mass spectrometry.
  • the unrelated amino acid scan e.g. alanine scan
  • the unrelated amino acid scan is carried out using HTRF.
  • the unrelated amino acid scan e.g. alanine scan
  • ELISA ELISA
  • the reduction in signal is at least 25%.
  • the reduction in signal is at least 30%.
  • the reduction in signal is at least 35%.
  • the reduction in signal is at least 40%.
  • the reduction in signal is at least 45%.
  • the reduction in signal is at least 50%.
  • the reduction in signal is at least 55%.
  • the reduction in signal is at least 60%.
  • the reduction in signal is at least 70%.
  • the reduction in signal is at least 75%.
  • the reduction in signal is at least 80%.
  • the reduction in signal is at least 85%.
  • the reduction in signal is at least 90%.
  • the reduction in affinity is at least 15-fold. In one embodiment, the reduction in affinity is at least 20-fold. In one embodiment, the reduction in affinity is at least 30-fold. In one embodiment, the reduction in affinity is at least 40-fold. In one embodiment, the reduction in affinity is at least 50-fold. In one embodiment, the reduction in affinity is at least 100-fold.
  • the contact residues of the epitope are identified by X-ray crystallography. In one embodiment, the contact residues of the epitope are identified by cryo-electro microscopy. In one embodiment, the contact residues of the epitope are identified by a combination of limited proteolytic digestion and mass spectrometry.
  • Concept 14 The antibody or fragment according to concept 13, wherein the epitope is identified by unrelated amino acid scanning, or by X-ray crystallography.
  • Concept 15 The antibody or fragment according to concept 14, wherein the contact residues of the epitope are defined by a reduction in affinity of at least 10-fold in an unrelated amino acid scan, e.g. an alanine scan as determined by SPR.
  • the reduction in affinity is at least 15-fold. In one embodiment, the reduction in affinity is at least 20-fold. In one embodiment, the reduction in affinity is at least 30-fold. In one embodiment, the reduction in affinity is at least 40-fold. In one embodiment, the reduction in affinity is at least 50-fold. In one embodiment, the reduction in affinity is at least 100-fold.
  • SPR may be carried out as described hereinabove.
  • Competition may be determined by surface plasmon resonance (SPR), such techniques being readily apparent to the skilled person.
  • SPR may be carried out using BiacoreTM, ProteonTM or another standard SPR technique.
  • Such competition may be due, for example, to the antibodies or fragments binding to identical or overlapping epitopes of hPD-Ll.
  • competition is determined by ELISA, such techniques being readily apparent to the skilled person.
  • competition is determined by homogenous time resolved fluorescence (HTRF), such techniques being readily apparent to the skilled person.
  • competition is determined by fluorescence activated cell sorting (FACS), such techniques being readily apparent to the skilled person.
  • competition is determined by ForteBio Octet ® Bio-Layer Interferometry (BLI) such techniques being readily apparent to the skilled person.
  • the antibody or fragment competes (e.g. in a dose-dependent manner) with hPD-1 (or a fusion protein thereof) for binding to cell surface-expressed hPD-Ll. In one embodiment, the antibody or fragment competes (e.g. in a dose-dependent manner) with hPD-1 (or a fusion protein thereof) for binding to soluble hPDL-1.
  • the antibody or fragment partially or completely inhibits binding of PD-1 and/or CD80 to cell surface-expressed PD-L1, such as hPD-Ll. In another embodiment, the antibody or fragment partially or completely inhibits binding of hPD-1 and/or CD80 to soluble hPD-Ll. In some embodiments, the antibody or fragment partially or completely increases the secretion of IFNy, CD25 and IL-2 from a cell having cell surface-expressed PD-1. In one embodiment, the antibody or fragment partially or completely inhibits binding of CD80 to soluble hPD-Ll, but does not show any detectable inhibition of the binding of PD-1 to cell surface-expressed PD-L1. In one embodiment, the antibody or fragment partially or completely inhibits binding of CD80 to soluble hPD-Ll, but does not show any detectable inhibition of the binding of PD-1 to soluble PD-L1.
  • inhibitors refers to the ability of an antagonist (e.g. an antibody or fragment thereof) to bind to an epitope which either partially or completely prevents the binding of the receptor (e.g. CD80 or PD-1) to the ligand (e.g. PD-L1). If the epitope to which the antagonist binds completely blocks the binding site of the ligand, then ligand binding is completely prevented (which may be a physical blocking - in the case of overlapping epitopes - or steric blocking - where the antagonist is large such that it prevents the ligand binding to its distinct epitope), and the ligand is not removed from circulation.
  • an antagonist e.g. an antibody or fragment thereof
  • the concentration of circulating ligand may therefore appear to be increased. If the epitope to which the antagonist binds partially blocks the binding site of the ligand, the the ligand may be able to bind, but only weakly (in the case of partial inhibition), or in a different orientation to the natural binding interaction. In this case, some of the ligand may be removed from circulation, but not as much as when the ligand binding site is completely free and available for binding. Inhibition thus refers to the physical interaction of ligand and receptor. Inhibition can be measured by HTRF, which is described in more detail elsewhere herein and in Mathis (1995) Clinical Chemistry 41(9), 1391-1397. Inhibition can also be measured by flow cytometry, where receptor is expressed on cells, or by ELISA, where receptor is adsorbed onto plates.
  • Concept 16i An antibody or fragment thereof which competes for binding to hPD-Ll with the antibody 413G05.
  • Concept 16j An antibody or fragment thereof which competes for binding to hPD-Ll with the antibody 413F09.
  • the antibodies have the sequences as described hereinabove.
  • VH domain comprises the CDRH3 sequence of SEQ ID NO: 29 or 32, or the CDRH3 sequence of SEQ ID NO: 29 or 32 comprising 6 or fewer amino acid substitutions.
  • Concept 17a An antibody or a fragment thereof according to any one of concepts 10 to 16 (but when dependent on concept 13, it is dependent on concept 13a, and when dependent on concept 16, it is dependent on concept 16a), wherein the VH domain comprises the CDRH3 sequence of SEQ ID NO:9 or 12, or the CDRH3 sequence of SEQ ID NO:9 or 12 comprising 6 or fewer amino acid substitutions.
  • Concept 17b An antibody or a fragment thereof according to any one of concepts 10 to 16 (but when dependent on concept 13, it is dependent on concept 13b, and when dependent on concept 16, it is dependent on concept 16b), wherein the VH domain comprises the CDRH3 sequence of SEQ ID NO: 54 or 57, or the CDRH3 sequence of SEQ ID NO: 54 or 57 comprising 6 or fewer amino acid substitutions.
  • Concept 17c An antibody or a fragment thereof according to any one of concepts 10 to 16 (but when dependent on concept 13, it is dependent on concept 13c, and when dependent on concept 16, it is dependent on concept 16c), wherein the a VH domain comprises the CDRH3 sequence of SEQ ID NO:74 or 77, or the CDRH3 sequence of SEQ ID NO:74 or 77 comprising 6 or fewer amino acid substitutions.
  • Concept 17d An antibody or a fragment thereof according to any one of concepts 10 to 16 (but when dependent on concept 13, it is dependent on concept 13d, and when dependent on concept 16, it is dependent on concept 16d), wherein the VH domain comprises the CDRH3 sequence of SEQ ID NO:94 or 97, or the CDRH3 sequence of SEQ ID NO:94 or 97 comprising 3 or fewer amino acid substitutions.
  • Concept 17e An antibody or a fragment thereof according to any one of concepts 10 to 16 (but when dependent on concept 13, it is dependent on concept 13e, and when dependent on concept 16, it is dependent on concept 16e), wherein the VH domain comprises the CDRH3 sequence of SEQ ID NO: 114 or 117, or the CDRH3 sequence of SEQ ID NO: 114 or 117 comprising 6 or fewer amino acid substitutions.
  • Concept 17f An antibody or a fragment thereof according to any one of concepts 10 to 16 (but when dependent on concept 13, it is dependent on concept 13f, and when dependent on concept 16, it is dependent on concept 16f), wherein the VH domain comprises the CDRH3 sequence of SEQ ID NO: 144 or 147, or the CDRH3 sequence of SEQ ID NO: 144 or 147 comprising 3 or fewer amino acid substitutions.
  • Concept 17g An antibody or a fragment thereof according to any one of concepts 10 to 16 (but when dependent on concept 13, it is dependent on concept 13g, and when dependent on concept 16, it is dependent on concept 16g), wherein the VH domain comprises the CDRH3 sequence of SEQ ID NO: 174 or 177, or the CDRH3 sequence of SEQ ID NO: 174 or 177 comprising 6 or fewer amino acid substitutions.
  • Concept 17h An antibody or a fragment thereof according to any one of concepts 10 to 16 (but when dependent on concept 13, it is dependent on concept 13h, and when dependent on concept 16, it is dependent on concept 16h), wherein the VH domain comprises the CDRH3 sequence of SEQ ID NO: 134 or 137, or the CDRH3 sequence of SEQ ID NO: 134 or 137 comprising 5 or fewer amino acid substitutions.
  • Concept 17i An antibody or a fragment thereof according to any one of concepts 10 to 16 (but when dependent on concept 13, it is dependent on concept 13i, and when dependent on concept 16, it is dependent on concept 16i), wherein the VH domain comprises the CDRH3 sequence of SEQ ID NO:240 or 243, or the CDRH3 sequence of SEQ ID NO:240 or 243 comprising 6 or fewer amino acid substitutions.
  • Concept 17j An antibody or a fragment thereof according to any one of concepts 10 to 16 (but when dependent on concept 13, it is dependent on concept 13j, and when dependent on concept 16, it is dependent on concept 16j), wherein the a VH domain comprises the CDRH3 sequence of SEQ ID NO:260 or 263, or the CDRH3 sequence of SEQ ID NO:260 or 263 comprising 6 or fewer amino acid substitutions.
  • Concept 17k An antibody or a fragment thereof according to any one of concepts 10 to 16 (but when dependent on concept 13, it is dependent on concept 13k, and when dependent on concept 16, it is dependent on concept 16k), wherein the VH domain comprises the CDRH3 sequence of SEQ ID NO:280 or 283, or the CDRH3 sequence of SEQ ID NO:280 or 283 comprising 6 or fewer amino acid substitutions.
  • Concept 171 An antibody or a fragment thereof according to any one of concepts 10 to 16 (but when dependent on concept 13, it is dependent on concept 131, and when dependent on concept 16, it is dependent on concept 161), wherein the VH domain comprises the CDRH3 sequence of SEQ ID NO:345 or 348, or the CDRH3 sequence of SEQ ID NO:345 or 348 comprising 6 or fewer amino acid substitutions.
  • Concept 18 The antibody or fragment according to any preceding concept, wherein the VH domain comprises the CD H1 sequence of SEQ ID NO: 27 or 30 or the CDRH1 sequence of SEQ ID NO:27 or 30 comprising 3, 2 or 1 amino acid substitution(s).
  • VH domain comprises the CDRH1 sequence of SEQ ID NO:7 or 10, or the CDRH1 sequence of SEQ ID NO:7 or 10 comprising 3, 2 or 1 amino acid substitution(s).
  • VH domain comprises the CDRH1 sequence of SEQ ID NO:52 or 55, or the CDRH1 sequence of SEQ ID NO: 52 or 55 comprising 3, 2 or 1 amino acid substitution(s).
  • VH domain comprises the CDRH1 sequence of SEQ ID NO:72 or 75, or the CDRH1 sequence of SEQ ID NO:72 or 75 comprising 3, 2 or 1 amino acid substitution(s).
  • VH domain comprises the CDRH1 sequence of SEQ ID NO:92 or 95, or the CDRH1 sequence of SEQ ID NO:92 or 95 comprising 3, 2 or 1 amino acid substitution(s).
  • VH domain comprises the CDRH1 sequence of SEQ ID NO: 112 or 115, or the CDRH1 sequence of SEQ ID NO: 112 or 115 comprising 3, 2 or 1 amino acid substitution(s).
  • Concept 18f An antibody or a fragment thereof according to any preceding concept (but when dependent on concept 9, it is dependent on concept 9f, when dependent on concept 13, it is dependent on concept 13f, when dependent on concept 16, it is dependent on concept 16f, and when dependent on concept 17, it is dependent on concept 17f), wherein the VH domain comprises the CDRHl sequence of SEQ ID NO: 142 or 145, or the CDRHl sequence of SEQ ID NO: 142 or 145 comprising 3, 2 or 1 amino acid substitution(s).
  • VH domain comprises the CDRHl sequence of SEQ ID NO: 172 or 175, or the CDRHl sequence of SEQ ID NO: 172 or 175 comprising 3, 2 or 1 amino acid substitution(s).
  • VH domain comprises the CDRHl sequence of SEQ ID NO: 132 or 135, or the CDRHl sequence of SEQ ID NO: 132 or 135 comprising 3, 2 or 1 amino acid substitution(s).
  • VH domain comprises the CDRHl sequence of SEQ ID NO:238 or 241, or the CDRHl sequence of SEQ ID NO:238 or 241 comprising 3, 2 or 1 amino acid substitution(s).
  • VH domain comprises the CDRHl sequence of SEQ ID NO: 258 or 261, or the CDRHl sequence of SEQ ID NO:258 or 261 comprising 3, 2 or 1 amino acid substitution(s).
  • VH domain comprises the CDRHl sequence of SEQ ID NO: 278 or 281, or the CDRHl sequence of SEQ ID NO: 278 or 281 comprising 3, 2 or 1 amino acid substitution(s).
  • VH domain comprises the CDRHl sequence of SEQ ID NO: 343 or 346, or the CDRH1 sequence of SEQ ID NO: 343 or 346 comprising 3, 2 or 1 amino acid substitution(s).
  • VH domain comprises the CDRH2 sequence of SEQ ID NO:28 or 31, or the CDRH2 sequence of SEQ ID NO:28 or 31 comprising 4 or fewer amino acid substitutions.
  • VH domain comprises the CDRH2 sequence of SEQ ID NO:8 or 11, or the CDRH2 sequence of SEQ ID NO:8 or 11 comprising 4 or fewer amino acid substitutions.
  • VH domain comprises the CDRH2 sequence of SEQ ID NO: 53 or 56, or the CDRH2 sequence of SEQ ID NO: 53 or 56 comprising 3, 2 or 1 amino acid substitution(s).
  • VH domain comprises the CDRH2 sequence of SEQ ID NO:73 or 76, or the CDRH2 sequence of SEQ ID NO: 73 or 76 comprising 3, 2 or 1 amino acid substitution(s).
  • VH domain comprises the CDRH2 sequence of SEQ ID NO:93 or 96, or the CDRH2 sequence of SEQ ID NO:93 or 96 comprising 3, 2 or 1 amino acid substitution(s).
  • VH domain comprises the CDRH2 sequence of SEQ ID NO: 113 or 116, or the CDRH2 sequence of SEQ ID NO: 113 or 116 comprising 3, 2 or 1 amino acid substitution(s).
  • VH domain comprises the CDRH2 sequence of SEQ ID NO: 143 or 146, or the CDRH2 sequence of SEQ ID NO: 143 or 146 comprising 3, 2 or 1 amino acid substitution(s).
  • VH domain comprises the CDRH2 sequence of SEQ ID NO: 173 or 176, or the CDRH2 sequence of SEQ ID NO: 173 or 176 comprising 3, 2 or 1 amino acid substitution(s).
  • VH domain comprises the CDRH2 sequence of SEQ ID NO: 133 or 136, or the CDRH2 sequence of SEQ ID NO: 133 or 136 comprising 3, 2 or 1 amino acid substitution(s).
  • VH domain comprises the CDRH2 sequence of SEQ ID NO:239 or 242, or the CDRH2 sequence of SEQ ID NO:239 or 242 comprising 3, 2 or 1 amino acid substitution(s).
  • VH domain comprises the CDRH2 sequence of SEQ ID NO:259 or 262, or the CDRH2 sequence of SEQ ID NO:259 or 262 comprising 3, 2 or 1 amino acid substitution(s).
  • VH domain comprises the CDRH2 sequence of SEQ ID NO:279 or 282, or the CDRH2 sequence of SEQ ID NO:279 or 282 comprising 3, 2 or 1 amino acid substitution(s).
  • VH domain comprises the CDRH2 sequence of SEQ ID NO:344 or 347, or the CDRH2 sequence of SEQ ID NO:344 or 347 comprising 3, 2 or 1 amino acid substitution(s).
  • VH domain comprises an amino acid sequence of SEQ ID NO:33, or a heavy chain variable domain amino acid sequence that is at least 80% (e.g. at least 85%, or at least 90%) identical to SEQ ID NO:33.
  • VH domain comprises an amino acid sequence of SEQ ID NO: 13, or a heavy chain variable domain amino acid sequence that is at least 80% (e.g. at least 85%, or at least 90%) identical to SEQ ID NO: 13.
  • VH domain comprises an amino acid sequence of SEQ ID NO: 58, or a heavy chain variable domain amino acid sequence that is at least 80% (e.g. at least 85%, or at least 90%) identical to SEQ ID NO:58.
  • VH domain comprises an amino acid sequence of SEQ ID NO:78, or a heavy chain variable domain amino acid sequence that is at least 80% (e.g. at least 85%, or at least 90%) identical to SEQ ID NO:78.
  • VH domain comprises an amino acid sequence of SEQ ID NO:98, or a heavy chain variable domain amino acid sequence that is at least 80% (e.g. at least 85%, or at least 90%) identical to SEQ ID NO:98.
  • VH domain comprises an amino acid sequence of SEQ ID NO: 118, or a heavy chain variable domain amino acid sequence that is at least 80% (e.g. at least 85%, or at least 90%) identical to SEQ ID NO: 118.
  • VH domain comprises an amino acid sequence of SEQ ID NO: 158, or a heavy chain variable domain amino acid sequence that is at least 80% (e.g. at least 85%, or at least 90%) identical to SEQ ID NO: 158.
  • VH domain comprises an amino acid sequence of SEQ ID NO: 178, or a heavy chain variable domain amino acid sequence that is at least 80% (e.g. at least 85%, or at least 90%) identical to SEQ ID NO: 178.
  • VH domain comprises an amino acid sequence of SEQ ID NO: 138, or a heavy chain variable domain amino acid sequence that is at least 80% (e.g. at least 85%, or at least 90%) identical to SEQ ID NO: 138.
  • VH domain comprises an amino acid sequence of SEQ ID NO:244, or a heavy chain variable domain amino acid sequence that is at least 80% (e.g. at least 85%, or at least 90%) identical to SEQ ID NO:244.
  • VH domain comprises an amino acid sequence of SEQ ID NO:264, or a heavy chain variable domain amino acid sequence that is at least 80% (e.g. at least 85%, or at least 90%) identical to SEQ ID NO:264.
  • VH domain comprises an amino acid sequence of SEQ ID NO:284, or a heavy chain variable domain amino acid sequence that is at least 80% (e.g. at least 85%, or at least 90%) identical to SEQ ID NO:284.
  • VH domain comprises an amino acid sequence of SEQ ID NO:349, or a heavy chain variable domain amino acid sequence that is at least 80% (e.g. at least 85%, or at least 90%) identical to SEQ ID NO:349.
  • the amino acid sequence is at least 70% identical to the specified Seq ID No. In one embodiment, the amino acid sequence is at least 75% identical to the specified Seq ID No. In one embodiment, the amino acid sequence is at least 95% identical to the specified Seq ID No. In one embodiment, the amino acid sequence is at least 96% identical to the specified Seq ID No. In one embodiment, the amino acid sequence is at least 97% identical to the specified Seq ID No. In one embodiment, the amino acid sequence is at least 98% identical to the specified Seq ID No. In one embodiment, the amino acid sequence is at least 99% identical to the specified Seq ID No. In one embodiment, the amino acid sequence is at least 99.5% identical to the specified Seq ID No.
  • Concept 22a An antibody or a fragment thereof according to any preceding concept (but when dependent on concept 9, it is dependent on concept 9a, when dependent on concept 13, it is dependent on concept 13a, when dependent on concept 16, it is dependent on concept 16a, when dependent on concept 17, it is dependent on concept 17a, when dependent on concept 18, it is dependent on concept 18a, when dependent on concept 19, it is dependent on concept 19a, and when dependent on concept 20, it is dependent on concept 20a), comprising a VL domain, which comprises the CDRLl sequence of SEQ ID NO: 17 or 20, or the CDRLl sequence of SEQ ID NO: 17 or 20 comprising 3 or fewer amino acid substitutions.
  • Concept 22b An antibody or a fragment thereof according to any preceding concept (but when dependent on concept 9, it is dependent on concept 9b, when dependent on concept 13, it is dependent on concept 13b, when dependent on concept 16, it is dependent on concept 16b, when dependent on concept 17, it is dependent on concept 17b, when dependent on concept 18, it is dependent on concept 18b, when dependent on concept 19, it is dependent on concept 19b, and when dependent on concept 20, it is dependent on concept 20b), comprising a VL domain which comprises the CDRLl sequence of SEQ ID NO:62 or 65, or the CDRLl sequence of SEQ ID NO:62 or 65 comprising 3 or fewer amino acid substitutions.
  • Concept 22c An antibody or a fragment thereof according to any preceding concept (but when dependent on concept 9, it is dependent on concept 9c, when dependent on concept 13, it is dependent on concept 13c, when dependent on concept 16, it is dependent on concept 16c, when dependent on concept 17, it is dependent on concept 17c, when dependent on concept 18, it is dependent on concept 18c, when dependent on concept 19, it is dependent on concept 19c, and when dependent on concept 20, it is dependent on concept 20c), comprising a VL domain which comprises the CDRLl sequence of SEQ ID NO:82 or 85, or the CDRLl sequence of SEQ ID NO:82 or 85 comprising 2 or 1 amino acid substitution(s).
  • Concept 22d An antibody or a fragment thereof according to any preceding concept (but when dependent on concept 9, it is dependent on concept 9d, when dependent on concept 13, it is dependent on concept 13d, when dependent on concept 16, it is dependent on concept 16d, when dependent on concept 17, it is dependent on concept 17d, when dependent on concept 18, it is dependent on concept 18d, when dependent on concept 19, it is dependent on concept 19d, and when dependent on concept 20, it is dependent on concept 20d), comprising a VL domain which comprises the CDRL1 sequence of SEQ ID NO: 102 or 105, or the CDRL1 sequence of SEQ ID NO: 102 or 105 comprising 5 or fewer amino acid substitutions.
  • Concept 22e An antibody or a fragment thereof according to any preceding concept (but when dependent on concept 9, it is dependent on concept 9e, when dependent on concept 13, it is dependent on concept 13e, when dependent on concept 16, it is dependent on concept 16e, when dependent on concept 17, it is dependent on concept 17e, when dependent on concept 18, it is dependent on concept 18e, when dependent on concept 19, it is dependent on concept 19e, and when dependent on concept 20, it is dependent on concept 20e), comprising a VL domain which comprises the CDRL1 sequence of SEQ ID NO: 122 or 125, or the CDRL1 sequence of SEQ ID NO: 122 or 125 comprising 2 or 1 amino acid substitution(s).
  • Concept 22f An antibody or a fragment thereof according to any preceding concept (but when dependent on concept 9, it is dependent on concept 9f, when dependent on concept 13, it is dependent on concept 13f, when dependent on concept 16, it is dependent on concept 16f, when dependent on concept 17, it is dependent on concept 17f, when dependent on concept 18, it is dependent on concept 18f, when dependent on concept 19, it is dependent on concept 19f, and when dependent on concept 20, it is dependent on concept 20f), comprising a VL domain which comprises the CDRL1 sequence of SEQ ID NO: 162 or 165, or the CDRL1 sequence of SEQ ID NO: 162 or 165 comprising 5 or fewer amino acid substitutions.
  • Concept 22g An antibody or a fragment thereof according to any preceding concept (but when dependent on concept 9, it is dependent on concept 9g, when dependent on concept 13, it is dependent on concept 13g, when dependent on concept 16, it is dependent on concept 16g, when dependent on concept 17, it is dependent on concept 17g, when dependent on concept 18, it is dependent on concept 18g, when dependent on concept 19, it is dependent on concept 19g, and when dependent on concept 20, it is dependent on concept 20g), comprising a VL domain which comprises the CDRL1 sequence of SEQ ID NO: 182 or 185, or the CDRL1 sequence of SEQ ID NO: 182 or 185 comprising 5 or fewer amino acid substitutions.
  • Concept 22h An antibody or a fragment thereof according to any preceding concept (but when dependent on concept 9, it is dependent on concept 9h, when dependent on concept 13, it is dependent on concept 13h, when dependent on concept 16, it is dependent on concept 16h, when dependent on concept 17, it is dependent on concept 17h, when dependent on concept 18, it is dependent on concept 18h, when dependent on concept 19, it is dependent on concept 19h, and when dependent on concept 20, it is dependent on concept 20h), comprising a VL domain which comprises the CDRLl sequence of SEQ ID NO: 142 or 145, or the CDRLl sequence of SEQ ID NO: 142 or 145 comprising 2 or 1 amino acid substitution(s).
  • Concept 22i An antibody or a fragment thereof according to any preceding concept (but when dependent on concept 9, it is dependent on concept 9i, when dependent on concept 13, it is dependent on concept 13i, when dependent on concept 16, it is dependent on concept 16i, when dependent on concept 17, it is dependent on concept 17i, when dependent on concept 18, it is dependent on concept 18i, when dependent on concept 19, it is dependent on concept 19i, and when dependent on concept 20, it is dependent on concept 20i), comprising a VL domain which comprises the CDRLl sequence of SEQ ID NO:248 or 251, or the CDRLl sequence of SEQ ID NO:248 or 251 comprising 2 or 1 amino acid substitution(s).
  • Concept 22j An antibody or a fragment thereof according to any preceding concept (but when dependent on concept 9, it is dependent on concept 9j, when dependent on concept 13, it is dependent on concept 13j, when dependent on concept 16, it is dependent on concept 16j, when dependent on concept 17, it is dependent on concept 17j, when dependent on concept 18, it is dependent on concept 18j, when dependent on concept 19, it is dependent on concept 19j, and when dependent on concept 20, it is dependent on concept 20j), comprising a VL domain which comprises the CDRLl sequence of SEQ ID NO:268 or 271, or the CDRLl sequence of SEQ ID NO:268 or 271 comprising 2 or 1 amino acid substitution(s).
  • Concept 22k An antibody or a fragment thereof according to any preceding concept (but when dependent on concept 9, it is dependent on concept 9k, when dependent on concept 13, it is dependent on concept 13k, when dependent on concept 16, it is dependent on concept 16k, when dependent on concept 17, it is dependent on concept 17k, when dependent on concept 18, it is dependent on concept 18k, when dependent on concept 19, it is dependent on concept 19k, and when dependent on concept 20, it is dependent on concept 20k), comprising a VL domain which comprises the CDRLl sequence of SEQ ID NO:288 or 291, or the CDRLl sequence of SEQ ID NO:288 or 291 comprising 2 or 1 amino acid substitution(s).
  • Concept 221 An antibody or a fragment thereof according to any preceding concept (but when dependent on concept 9, it is dependent on concept 91, when dependent on concept 13, it is dependent on concept 131, when dependent on concept 16, it is dependent on concept 161, when dependent on concept 17, it is dependent on concept 171, when dependent on concept 18, it is dependent on concept 181, when dependent on concept 19, it is dependent on concept 191, and when dependent on concept 20, it is dependent on concept 201), comprising a VL domain which comprises the CDRLl sequence of SEQ ID NO:353 or 356, or the CDRLl sequence of SEQ ID NO:353 or 356 comprising 2 or 1 amino acid substitution(s).
  • VL domain comprises the CDRL2 sequence of SEQ ID NO:38 or 41, or the CRDL2 sequence of SEQ ID NO: 38 or 41 comprising 2 or 1 amino acid substitution(s), for example a CDRL2 sequence of Seq ID No: 50.
  • Concept 23a An antibody or a fragment thereof according to any preceding concept (but when dependent on concept 9, it is dependent on concept 9a, when dependent on concept 13, it is dependent on concept 13a, when dependent on concept 16, it is dependent on concept 16a, when dependent on concept 17, it is dependent on concept 17a, when dependent on concept 18, it is dependent on concept 18a, when dependent on concept 19, it is dependent on concept 19a, when dependent on concept 20, it is dependent on concept 20a, and when dependent on concept 22, it is dependent on concept 22a), comprising a or said VL domain, which VL domain comprises the CDRL2 sequence of SEQ ID NO:18 or 21, or the CDRL2 sequence of SEQ ID NO:18 or 21 comprising 2 or 1 amino acid substitution(s).
  • Concept 23b An antibody or a fragment thereof according to any preceding concept (but when dependent on concept 9, it is dependent on concept 9b, when dependent on concept 13, it is dependent on concept 13b, when dependent on concept 16, it is dependent on concept 16b, when dependent on concept 17, it is dependent on concept 17b, when dependent on concept 18, it is dependent on concept 18b, when dependent on concept 19, it is dependent on concept 19b, when dependent on concept 20, it is dependent on concept 20b, and when dependent on concept 22, it is dependent on concept 22b), comprising a or said VL domain, which VL domain comprises the CDRL2 sequence of SEQ ID NO:63 or 66, or the CDRL2 sequence of SEQ ID NO:63 or 66 comprising one amino acid substitution.
  • Concept 23c An antibody or a fragment thereof according to any preceding concept (but when dependent on concept 9, it is dependent on concept 9c, when dependent on concept 13, it is dependent on concept 13c, when dependent on concept 16, it is dependent on concept 16c, when dependent on concept 17, it is dependent on concept 17c, when dependent on concept 18, it is dependent on concept 18c, when dependent on concept 19, it is dependent on concept 19c, when dependent on concept 20, it is dependent on concept 20c, and when dependent on concept 22, it is dependent on concept 22c), comprising a or said VL domain, which VL domain comprises the CDRL2 sequence of SEQ ID NO:83 or 86, or the CDRL2 sequence of SEQ ID NO:83 or 86 comprising one amino acid substitution.
  • Concept 23d An antibody or a fragment thereof according to any preceding concept (but when dependent on concept 9, it is dependent on concept 9d, when dependent on concept 13, it is dependent on concept 13d, when dependent on concept 16, it is dependent on concept 16d, when dependent on concept 17, it is dependent on concept 17d, when dependent on concept 18, it is dependent on concept 18d, when dependent on concept 19, it is dependent on concept 19d, when dependent on concept 20, it is dependent on concept 20d, and when dependent on concept 22, it is dependent on concept 22d), comprising a or said VL domain, which VL domain comprises the CDRL2 sequence of SEQ ID NO: 103 or 106, or the CDRL2 sequence of SEQ ID NO: 103 or 106 comprising one amino acid substitution.
  • Concept 23e An antibody or a fragment thereof according to any preceding concept (but when dependent on concept 9, it is dependent on concept 9e, when dependent on concept 13, it is dependent on concept 13e, when dependent on concept 16, it is dependent on concept 16e, when dependent on concept 17, it is dependent on concept 17e, when dependent on concept 18, it is dependent on concept 18e, when dependent on concept 19, it is dependent on concept 19e, when dependent on concept 20, it is dependent on concept 20e, and when dependent on concept 22, it is dependent on concept 22e), comprising a or said VL domain, which VL domain comprises the CDRL2 sequence of SEQ ID NO: 123 or 126, or the CDRL2 sequence of SEQ ID NO: 123 or 126 comprising one amino acid substitution.
  • Concept 23f An antibody or a fragment thereof according to any preceding concept (but when dependent on concept 9, it is dependent on concept 9f, when dependent on concept 13, it is dependent on concept 13f, when dependent on concept 16, it is dependent on concept 16f, when dependent on concept 17, it is dependent on concept 17f, when dependent on concept 18, it is dependent on concept 18f, when dependent on concept 19, it is dependent on concept 19f, when dependent on concept 20, it is dependent on concept 20f, and when dependent on concept 22, it is dependent on concept 22f), comprising a or said VL domain, which VL domain comprises the CDRL2 sequence of SEQ ID NO: 153 or 156, or the CDRL2 sequence of SEQ ID NO: 153 or 156 comprising one amino acid substitution.
  • Concept 23g An antibody or a fragment thereof according to any preceding concept (but when dependent on concept 9, it is dependent on concept 9g, when dependent on concept 13, it is dependent on concept 13g, when dependent on concept 16, it is dependent on concept 16g, when dependent on concept 17, it is dependent on concept 17g, when dependent on concept 18, it is dependent on concept 18g, when dependent on concept 19, it is dependent on concept 19g, when dependent on concept 20, it is dependent on concept 20g, and when dependent on concept 22, it is dependent on concept 22g), comprising a or said VL domain, which VL domain comprises the CDRL2 sequence of SEQ ID NO: 183 or 186, or the CDRL2 sequence of SEQ ID NO: 183 or 186 comprising one amino acid substitution.
  • Concept 23h An antibody or a fragment thereof according to any preceding concept (but when dependent on concept 9, it is dependent on concept 9h, when dependent on concept 13, it is dependent on concept 13h, when dependent on concept 16, it is dependent on concept 16h, when dependent on concept 17, it is dependent on concept 17h, when dependent on concept 18, it is dependent on concept 18h, when dependent on concept 19, it is dependent on concept 19h, when dependent on concept 20, it is dependent on concept 20h, and when dependent on concept 22, it is dependent on concept 22h), comprising a or said VL domain, which VL domain comprises the CDRL2 sequence of SEQ ID NO: 143 or 146, or the CDRL2 sequence of SEQ ID NO: 143 or 146 comprising one amino acid substitution.
  • Concept 23i An antibody or a fragment thereof according to any preceding concept (but when dependent on concept 9, it is dependent on concept 9i, when dependent on concept 13, it is dependent on concept 13i, when dependent on concept 16, it is dependent on concept 16i, when dependent on concept 17, it is dependent on concept 17i, when dependent on concept 18, it is dependent on concept 18i, when dependent on concept 19, it is dependent on concept 19i, when dependent on concept 20, it is dependent on concept 20i, and when dependent on concept 22, it is dependent on concept 22i), comprising a or said VL domain, which VL domain comprises the CDRL2 sequence of SEQ ID NO:249 or 252, or the CDRL2 sequence of SEQ ID NO:249 or 252 comprising one amino acid substitution.
  • Concept 23j An antibody or a fragment thereof according to any preceding concept (but when dependent on concept 9, it is dependent on concept 9j, when dependent on concept 13, it is dependent on concept 13j, when dependent on concept 16, it is dependent on concept 16j, when dependent on concept 17, it is dependent on concept 17j, when dependent on concept 18, it is dependent on concept 18j, when dependent on concept 19, it is dependent on concept 19j, when dependent on concept 20, it is dependent on concept 20j, and when dependent on concept 22, it is dependent on concept 22j), comprising a or said VL domain, which VL domain comprises the CDRL2 sequence of SEQ ID NO:269 or 272, or the CDRL2 sequence of SEQ ID NO:269 or 272 comprising one amino acid substitution.
  • Concept 23k An antibody or a fragment thereof according to any preceding concept (but when dependent on concept 9, it is dependent on concept 9k, when dependent on concept 13, it is dependent on concept 13k, when dependent on concept 16, it is dependent on concept 16k, when dependent on concept 17, it is dependent on concept 17k, when dependent on concept 18, it is dependent on concept 18k, when dependent on concept 19, it is dependent on concept 19k, when dependent on concept 20, it is dependent on concept 20k, and when dependent on concept 22, it is dependent on concept 22k), comprising a or said VL domain, which VL domain comprises the CDRL2 sequence of SEQ ID NO:289 or 292, or the CDRL2 sequence of SEQ ID NO:289 or 292 comprising one amino acid substitution.
  • Concept 231 An antibody or a fragment thereof according to any preceding concept (but when dependent on concept 9, it is dependent on concept 91, when dependent on concept 13, it is dependent on concept 131, when dependent on concept 16, it is dependent on concept 161, when dependent on concept 17, it is dependent on concept 171, when dependent on concept 18, it is dependent on concept 181, when dependent on concept 19, it is dependent on concept 191, when dependent on concept 20, it is dependent on concept 201, and when dependent on concept 22, it is dependent on concept 221), comprising a or said VL domain, which VL domain comprises the CDRL2 sequence of SEQ ID NO:354 or 357, or the CDRL2 sequence of SEQ ID NO: 354 or 357 comprising one amino acid substitution.
  • Concept 24 comprises the CDRL2 sequence of SEQ ID NO:354 or 357, or the CDRL2 sequence of SEQ ID NO: 354 or 357 comprising one amino acid substitution.
  • VL domain comprises the CDRL3 sequence of SEQ ID NO:39 or 42, or the CRDL3 sequence of SEQ ID NO:39 or 42 comprising 4 or fewer amino acid substitutions.
  • Concept 24a An antibody or a fragment thereof according to any preceding concept (but when dependent on concept 9, it is dependent on concept 9a, when dependent on concept 13, it is dependent on concept 13a, when dependent on concept 16, it is dependent on concept 16a, when dependent on concept 17, it is dependent on concept 17a, when dependent on concept 18, it is dependent on concept 18a, when dependent on concept 19, it is dependent on concept 19a, when dependent on concept 20, it is dependent on concept 20a, when dependent on concept 22, it is dependent on concept 22a, and when dependent on concept 23, it is dependent on concept 23a), comprising a or said VL domain, which VL domain comprises the CDRL3 sequence of SEQ ID NO: 19 or 22, or the CDRL3 sequence of SEQ ID NO: 19 or 22 comprising 4 or fewer amino acid substitutions.
  • Concept 24b An antibody or a fragment thereof according to any preceding concept (but when dependent on concept 9, it is dependent on concept 9b, when dependent on concept 13, it is dependent on concept 13b, when dependent on concept 16, it is dependent on concept 16b, when dependent on concept 17, it is dependent on concept 17b, when dependent on concept 18, it is dependent on concept 18b, when dependent on concept 19, it is dependent on concept 19b, when dependent on concept 20, it is dependent on concept 20b, when dependent on concept 22, it is dependent on concept 22b, and when dependent on concept 23, it is dependent on concept 23b), comprising a or said VL domain, which VL domain comprises the CDRL3 sequence of SEQ ID NO:64 or 67, or the CDRL3 sequence of SEQ ID NO:64 or 67 comprising 4 or fewer amino acid substitutions.
  • Concept 24c An antibody or a fragment thereof according to any preceding concept (but when dependent on concept 9, it is dependent on concept 9c, when dependent on concept 13, it is dependent on concept 13c, when dependent on concept 16, it is dependent on concept 16c, when dependent on concept 17, it is dependent on concept 17c, when dependent on concept 18, it is dependent on concept 18c, when dependent on concept 19, it is dependent on concept 19c, when dependent on concept 20, it is dependent on concept 20c, when dependent on concept 22, it is dependent on concept 22c, and when dependent on concept 23, it is dependent on concept 23c), comprising a or said VL domain, which VL domain comprises the CDRL3 sequence of SEQ ID NO:84 or 87, or the CDRL3 sequence of SEQ ID NO:84 or 87 comprising 4 or fewer amino acid substitutions.
  • Concept 24d An antibody or a fragment thereof according to any preceding concept (but when dependent on concept 9, it is dependent on concept 9d, when dependent on concept 13, it is dependent on concept 13d, when dependent on concept 16, it is dependent on concept 16d, when dependent on concept 17, it is dependent on concept 17d, when dependent on concept 18, it is dependent on concept 18d, when dependent on concept 19, it is dependent on concept 19d, when dependent on concept 20, it is dependent on concept 20d, when dependent on concept 22, it is dependent on concept 22d, and when dependent on concept 23, it is dependent on concept 23d), comprising a or said VL domain, which VL domain comprises the CDRL3 sequence of SEQ ID NO: 104 or 107, or the CDRL3 sequence of SEQ ID NO: 104 or 107 comprising 4 or fewer amino acid substitutions.
  • Concept 24e An antibody or a fragment thereof according to any preceding concept (but when dependent on concept 9, it is dependent on concept 9e, when dependent on concept 13, it is dependent on concept 13e, when dependent on concept 16, it is dependent on concept 16e, when dependent on concept 17, it is dependent on concept 17e, when dependent on concept 18, it is dependent on concept 18e, when dependent on concept 19, it is dependent on concept 19e, when dependent on concept 20, it is dependent on concept 20e, when dependent on concept 22, it is dependent on concept 22e, and when dependent on concept 23, it is dependent on concept 23e), comprising a or said VL domain, which VL domain comprises the CDRL3 sequence of SEQ ID NO: 124 or 127, or the CDRL3 sequence of SEQ ID NO: 124 or 127 comprising 4 or fewer amino acid substitutions.
  • Concept 24f An antibody or a fragment thereof according to any preceding concept (but when dependent on concept 9, it is dependent on concept 9f, when dependent on concept 13, it is dependent on concept 13f, when dependent on concept 16, it is dependent on concept 16f, when dependent on concept 17, it is dependent on concept 17f, when dependent on concept 18, it is dependent on concept 18f, when dependent on concept 19, it is dependent on concept 19f, when dependent on concept 20, it is dependent on concept 20f, when dependent on concept 22, it is dependent on concept 22f, and when dependent on concept 23, it is dependent on concept 23f), comprising a or said VL domain, which VL domain comprises the CDRL3 sequence of SEQ ID NO: 164 or 167, or the CDRL3 sequence of SEQ ID NO: 164 or 167 comprising 4 or fewer amino acid substitutions.
  • Concept 24g An antibody or a fragment thereof according to any preceding concept (but when dependent on concept 9, it is dependent on concept 9g, when dependent on concept 13, it is dependent on concept 13g, when dependent on concept 16, it is dependent on concept 16g, when dependent on concept 17, it is dependent on concept 17g, when dependent on concept 18, it is dependent on concept 18g, when dependent on concept 19, it is dependent on concept 19g, when dependent on concept 20, it is dependent on concept 20g, when dependent on concept 22, it is dependent on concept 22g, and when dependent on concept 23, it is dependent on concept 23g), comprising a or said VL domain, which VL domain comprises the CDRL3 sequence of SEQ ID NO: 184 or 187, or the CDRL3 sequence of SEQ ID NO: 184 or 187 comprising 4 or fewer amino acid substitutions.
  • Concept 24h An antibody or a fragment thereof according to any preceding concept (but when dependent on concept 9, it is dependent on concept 9h, when dependent on concept 13, it is dependent on concept 13h, when dependent on concept 16, it is dependent on concept 16h, when dependent on concept 17, it is dependent on concept 17h, when dependent on concept 18, it is dependent on concept 18h, when dependent on concept 19, it is dependent on concept 19h, when dependent on concept 20, it is dependent on concept 20h, when dependent on concept 22, it is dependent on concept 22h, and when dependent on concept 23, it is dependent on concept 23h), comprising a or said VL domain, which VL domain comprises the CDRL3 sequence of SEQ ID NO: 144 or 147, or the CDRL3 sequence of SEQ ID NO: 144 or 147 comprising 4 or fewer amino acid substitutions.
  • Concept 24i An antibody or a fragment thereof according to any preceding concept (but when dependent on concept 9, it is dependent on concept 9i, when dependent on concept 13, it is dependent on concept 13i, when dependent on concept 16, it is dependent on concept 16i, when dependent on concept 17, it is dependent on concept 17i, when dependent on concept 18, it is dependent on concept 18i, when dependent on concept 19, it is dependent on concept 19i, when dependent on concept 20, it is dependent on concept 20i, when dependent on concept 22, it is dependent on concept 22i, and when dependent on concept 23, it is dependent on concept 23i), comprising a or said VL domain, which VL domain comprises the CDRL3 sequence of SEQ ID NO:250 or 253, or the CDRL3 sequence of SEQ ID NO: 250 or 253 comprising 4 or fewer amino acid substitutions.
  • Concept 24j An antibody or a fragment thereof according to any preceding concept (but when dependent on concept 9, it is dependent on concept 9j, when dependent on concept 13, it is dependent on concept 13j, when dependent on concept 16, it is dependent on concept 16j, when dependent on concept 17, it is dependent on concept 17j, when dependent on concept 18, it is dependent on concept 18j, when dependent on concept 19, it is dependent on concept 19j, when dependent on concept 20, it is dependent on concept 20j, when dependent on concept 22, it is dependent on concept 22j, and when dependent on concept 23, it is dependent on concept 23j), comprising a or said VL domain, which VL domain comprises the CDRL3 sequence of SEQ ID NO:270 or 273, or the CDRL3 sequence of SEQ ID NO:270 or 273 comprising 4 or fewer amino acid substitutions.
  • Concept 24k An antibody or a fragment thereof according to any preceding concept (but when dependent on concept 9, it is dependent on concept 9k, when dependent on concept 13, it is dependent on concept 13k, when dependent on concept 16, it is dependent on concept 16k, when dependent on concept 17, it is dependent on concept 17k, when dependent on concept 18, it is dependent on concept 18k, when dependent on concept 19, it is dependent on concept 19k, when dependent on concept 20, it is dependent on concept 20k, when dependent on concept 22, it is dependent on concept 22k, and when dependent on concept 23, it is dependent on concept 23k), comprising a or said VL domain, which VL domain comprises the CDRL3 sequence of SEQ ID NO:290 or 293, or the CDRL3 sequence of SEQ ID NO:290 or 293 comprising 4 or fewer amino acid substitutions.
  • Concept 241 An antibody or a fragment thereof according to any preceding concept (but when dependent on concept 9, it is dependent on concept 91, when dependent on concept 13, it is dependent on concept 131, when dependent on concept 16, it is dependent on concept 161, when dependent on concept 17, it is dependent on concept 171, when dependent on concept 18, it is dependent on concept 181, when dependent on concept 19, it is dependent on concept 191, when dependent on concept 20, it is dependent on concept 201, when dependent on concept 22, it is dependent on concept 221, and when dependent on concept 23, it is dependent on concept 231), comprising a or said VL domain, which VL domain comprises the CDRL3 sequence of SEQ ID NO:355 or 358, or the CDRL3 sequence of SEQ ID NO: 355 or 358 comprising 4 or fewer amino acid substitutions.
  • VL domain comprises an amino acid sequence of SEQ ID NO:43, or a light chain variable domain amino acid sequence that is at least 80% (e.g. at least 85%, or at least 90%) identical to SEQ ID NO:43 (for example the VL domain sequence in the light chain sequence of Seq ID No:50, 51 or 298).
  • VL domain comprises an amino acid sequence of SEQ ID NO: 23, or a light chain variable domain amino acid sequence that is at least 80% (e.g. at least 85%, or at least 90%) identical to SEQ ID NO:23.
  • VL domain comprises an amino acid sequence of SEQ ID NO:68, or a light chain variable domain amino acid sequence that is at least 80% (e.g. at least 85%, or at least 90%) identical to SEQ ID NO:68.
  • VL domain comprises an amino acid sequence of SEQ ID NO:88, or a light chain variable domain amino acid sequence that is at least 80% (e.g. at least 85%, or at least 90%) identical to SEQ ID NO:88.
  • VL domain comprises an amino acid sequence of SEQ ID NO: 108, or a light chain variable domain amino acid sequence that is at least 80% (e.g. at least 85%, or at least 90%) identical to SEQ ID NO: 108.
  • VL domain comprises an amino acid sequence of SEQ ID NO: 128, or a light chain variable domain amino acid sequence that is at least 80% (e.g. at least 85%, or at least 90%) identical to SEQ ID NO: 128.
  • VL domain comprises an amino acid sequence of SEQ ID NO: 168, or a light chain variable domain amino acid sequence that is at least 80% (e.g. at least 85%, or at least 90%) identical to SEQ ID NO: 168.
  • VL domain comprises an amino acid sequence of SEQ ID NO: 188, or a light chain variable domain amino acid sequence that is at least 80% (e.g. at least 85%, or at least 90%) identical to SEQ ID NO: 188.
  • VL domain comprises an amino acid sequence of SEQ ID NO: 148, or a light chain variable domain amino acid sequence that is at least 80% (e.g. at least 85%, or at least 90%) identical to SEQ ID NO: 148.
  • VL domain comprises an amino acid sequence of SEQ ID NO:254, or a light chain variable domain amino acid sequence that is at least 80% (e.g. at least 85%, or at least 90%) identical to SEQ ID NO:254.
  • VL domain comprises an amino acid sequence of SEQ ID NO:274, or a light chain variable domain amino acid sequence that is at least 80% (e.g. at least 85%, or at least 90%) identical to SEQ ID NO:274.
  • VL domain comprises an amino acid sequence of SEQ ID NO:294, or a light chain variable domain amino acid sequence that is at least 80% (e.g. at least 85%, or at least 90%) identical to SEQ ID NO:294.
  • VL domain comprises an amino acid sequence of SEQ ID NO:359, or a light chain variable domain amino acid sequence that is at least 80% (e.g. at least 85%, or at least 90%) identical to SEQ ID NO:359.
  • the amino acid sequence is at least 70% identical to the specified Seq ID No. In one embodiment, the amino acid sequence is at least 75% identical to the specified Seq ID No. In one embodiment, the amino acid sequence is at least 95% identical to the specified Seq ID No. In one embodiment, the amino acid sequence is at least 96% identical to the specified Seq ID No. In one embodiment, the amino acid sequence is at least 97% identical to the specified Seq ID No. In one embodiment, the amino acid sequence is at least 98% identical to the specified Seq ID No. In one embodiment, the amino acid sequence is at least 99% identical to the specified Seq ID No. In one embodiment, the amino acid sequence is at least 99.5% identical to the specified Seq ID No.
  • the antibody or fragment according to any preceding concept which specifically binds to cynomolgus PD-L1 as defined by Seq ID No:2.
  • the antibody or fragment binds to cynomolgus PD-Ll with an affinity of less than 1 nM (e.g. from 1 nM to 0.01 pM or from 1 nM to 0.1 pM, or from 1 nM to IpM).
  • the antibody or fragment binds to cynomolgus PD-Ll with an affinity of less than 10 nM (e.g. from 10 nM to 0.01 pM or from 10 nM to 0.1 pM, or from 10 nM to IpM).
  • the antibody or fragment binds to cynomolgus PD-Ll with an affinity of less than 0.1 nM (e.g. from 0.1 nM to 0.01 pM or from 0.1 nM to 0.1 pM, or from 0.1 nM to IpM). In one embodiment, the antibody or fragment binds to cynomolgus PD-Ll with an affinity of less than 0.01 nM (e.g. from 0.011 nM to 0.01 pM or from 0.01 nM to 0.1 pM).
  • the antibody or fragment binds to cynomolgus PD-Ll with an affinity of within 2-fold of the affinity to hPD-Ll. In one embodiment, the antibody or fragment binds to cynomolgus PD-Ll with an affinity of within 4-fold of the affinity to hPD-Ll. In one embodiment, the antibody or fragment binds to cynomolgus PD-Ll with an affinity of within 5-fold of the affinity to hPD-Ll. In one embodiment, the antibody or fragment binds to cynomolgus PD-Ll with an affinity of within 6-fold of the affinity to hPD-Ll.
  • the antibody or fragment binds to cynomolgus PD-Ll with an affinity of within 8-fold of the affinity to hPD-Ll. In one embodiment, the antibody or fragment binds to cynomolgus PD-Ll with an affinity of within 10-fold of the affinity to hPD-Ll.
  • the antibody or fragment does not detectably bind to cynomolgus PD- Ll. In one embodiment, the antibody or fragment does not detectably bind to murine PD-Ll.
  • the antibody or fragment binds to murine PD-Ll with an affinity of less than 1 nM (e.g. from 1 nM to 0.01 pM or from 1 nM to 0.1 pM, or from 1 nM to IpM). In one embodiment, the antibody or fragment binds to murine PD-Ll with an affinity of less than 10 nM (e.g. from 10 nM to 0.01 pM or from 10 nM to 0.1 pM, or from 10 nM to IpM). In one embodiment, the antibody or fragment binds to murine PD-Ll with an affinity of less than 0.1 nM (e.g.
  • the antibody or fragment binds to murine PD-Ll with an affinity of less than 0.01 nM (e.g. from 0.011 nM to 0.01 pM or from 0.01 nM to 0.1 pM).
  • the light chain may be a lambda light chain.
  • Lambda light chain constant region amino acid and nucleotide sequences can be found in Seq ID Nos:216 to 237 and Seq ID No:535, Seq ID No:536 and Seq ID No:538.
  • the antibody or fragment comprises a constant region, such as a human constant region, for example an effector-null human constant region, e.g. an IgG4 constant region or an IgGl constant region, optionally wherein the constant region is IgG4-PE (Seq ID No: 199), or a disabled IgGl as defined in Seq ID No:205.
  • a human constant region for example an effector-null human constant region, e.g. an IgG4 constant region or an IgGl constant region, optionally wherein the constant region is IgG4-PE (Seq ID No: 199), or a disabled IgGl as defined in Seq ID No:205.
  • the antibody or fragment is any of the isotypes or constant regions as defined hereinabove.
  • the constant region is wild-type human IgGl (Seq ID No:340).
  • the constant region is an effector-enabled IgGl constant region, optionally having ADCC and/or CDC activity.
  • the constant region is engineered for enhanced ADCC and/or CDC and/or ADCP.
  • the constant region is engineered for enhanced effector function.
  • the IgG4 constant region may be any of the IgG4 constant region amino acid sequences, or encoded by any of the nucleic acid sequences of Seq ID Nos: 192 to 203.
  • a heavy chain constant region may be an IgG4 comprising both the Leu235Glu mutation and the Ser228Pro mutation. This "IgG4-PE" heavy chain constant region (Seq ID Nos: 198, encoded by Seq ID Nos:199, 200 and 201) is effector null.
  • an alternative effector null human constant region is a disabled IgGl being an IgGl*01 allele comprising the L235A and/or G237A mutations (e.g. LAGA, Seq ID No: 204, encoded by Seq ID No:205).
  • the antibodies or antibody fragments disclosed herein comprise an IgGl heavy chain constant region, wherein the sequence contains alanine at position 235 and/or 237 (EU index numbering).
  • ADCP antibody-dependent cell phagocytosis
  • the potency of Fc-mediated effects may be enhanced by engineering the Fc domain by various established techniques. Such methods increase the affinity for certain Fc-receptors, thus creating potential diverse profiles of activation enhancement. This can be achieved by modification of one or several amino acid residues (e.g. as described in Lazar eta/., 2006, Proc. Natl. Acad. Sci. U.S.A., Mar 14; 103(11):4005-10; the modifications disclosed therein are incorporated herein by reference). Human IgGl constant regions containing specific mutations or altered glycosylation on residue Asn297 (e.g. N297Q, EU index numbering) have been shown to enhance binding to Fc receptors.
  • such mutations are one or more of the residues selected from 239, 332 and 330 for human IgGl constant regions (or the equivalent positions in other IgG isotypes).
  • the antibody or fragment comprises a human IgGl constant region having one or more mutations independently selected from N297Q, S239D, I332E and A330L (EU index numbering).
  • the increase in affinity for Fc-receptors is achieved by altering the natural glycosylation profile of the Fc domain by, for example, generating under fucosylated or de- fucosylated variants (as described in Natsume eta/., 2009, Drug Des. Devel. Ther., 3:7-16 or by Zhou Q., Biotechnol. Bioeng., 2008, Feb 15, 99(3):652-65, the modifications described therein are incorporated herein by reference).
  • Non-fucosylated antibodies harbour a tri-mannosyl core structure of complex-type N-glycans of Fc without fucose residue.
  • glycoengineered antibodies that lack core fucose residue from the Fc N-glycans may exhibit stronger ADCC than fucosylated equivalents due to enhancement of FcyRIIIa binding capacity.
  • residues in the hinge region can be altered to increase binding to Fc-yRIII (see, for example, Shields eta/., 2001, J. Biol. Chem., Mar 2; 276(9):6591-604; the modifications described therein are incorporated herein by reference).
  • the antibody or fragment comprises a human IgG heavy chain constant region that is a variant of a wild-type human IgG heavy chain constant region, wherein the variant human IgG heavy chain constant region binds to human Fcy receptors selected from the group consisting of FcyRIIB and FcyRIIA with higher affinity than the wild type human IgG heavy chain constant region binds to the human Fcy receptors.
  • the antibody or fragment comprises a human IgG heavy chain constant region that is a variant of a wild type human IgG heavy chain constant region, wherein the variant human IgG heavy chain constant region binds to human FcyRIIB with higher affinity than the wild type human IgG heavy chain constant region binds to human FcyRIIB.
  • the variant human IgG heavy chain constant region is a variant human IgGl, a variant human IgG2, or a variant human IgG4 heavy chain constant region.
  • the variant human IgG heavy chain constant region comprises one or more amino acid mutations selected from G236D, P238D, S239D, S267E, L328F, and L328E (EU index numbering system).
  • the variant human IgG heavy chain constant region comprises a set of amino acid mutations selected from the group consisting of: S267E and L328F; P238D and L328E; P238D and one or more substitutions selected from the group consisting of E233D, G237D, H268D, P271G, and A330R; P238D, E233D, G237D, H268D, P271G, and A330R; G236D and S267E; S239D and S267E; V262E, S267E, and L328F; and V264E, S267E, and L328F (EU index numbering system).
  • the variant human IgG heavy chain constant region further comprises one or more amino acid mutations that reduce the affinity of the IgG for human FcyRIIIA, human FcyRIIA, or human FcyRI.
  • the FcyRIIB is expressed on a cell selected from the group consisting of macrophages, monocytes, B-cells, dendritic cells, endothelial cells, and activated T-cells.
  • the variant human IgG heavy chain constant region comprises one or more of the following amino acid mutations G236A, S239D, F243L, T256A, K290A, R292P, S298A, Y300L, V305I, A330L, I332E, E333A, K334A, A339T, and P396L (EU index numbering system).
  • the variant human IgG heavy chain constant region comprises a set of amino acid mutations selected from the group consisting of: S239D; T256A; K290A; S298A; I332E; E333A; K334A; A339T; S239D and I332E; S239D, A330L, and I332E; S298A, E333A, and K334A; G236A, S239D, and I332E; and F243L, R292P, Y300L, V305I, and P396L (EU index numbering system).
  • the variant human IgG heavy chain constant region comprises a S239D, A330L, or I332E amino acid mutations (EU index numbering system). In one embodiment, the variant human IgG heavy chain constant region comprises an S239D and I332E amino acid mutations (EU index numbering system). In one embodiment, the variant human IgG heavy chain constant region is a variant human IgGl heavy chain constant region comprising the S239D and I332E amino acid mutations (EU index numbering system). In one embodiment, the antibody or fragment comprises an afucosylated Fc region. In another embodiment, the antibody or fragment thereof is defucosylated. In another embodiment, the antibody or fragment is under fucosylated.
  • the antibodies and fragments disclosed herein may comprise a triple mutation (M252Y/S254T/T256E) which enhances binding to FcRn. See Dall et a/., Immunol 2002; 169:5171-5180 for a discussion of mutations affection FcRn binding in table 2, the mutations described therien are incorporated herein by reference.
  • the enhancement of CDC may be achieved by amino acid changes that increase affinity for Clq, the first component of the classic complement activation cascade (see Idusogie eta/., J. Immunol., 2001, 166:2571-2575; the modifications described are incorporated herein by reference).
  • Another approach is to create a chimeric Fc domain created from human IgGl and human IgG3 segments that exploit the higher affinity if IgG3 for Clq (Natsume eta/., 2008, Cancer Res., 68: 3863-3872; the modifications are incorporated herein by reference).
  • the antibody or antibody fragments disclosed herein may comprise mutated amino acids at residues 329, 331 and/or 322 to alter the Clq binding and/or reduced or abolished CDC activity.
  • the antibodies or antibody fragments disclosed herein may contain Fc regions with modifications at residues 231 and 239, whereby the amino acids are replaced to alter the ability of the antibody to fix complement.
  • the antibody or fragment has a constant region comprising one or more mutations selected from E345K, E430G, R344D and D356R, in particular a double mutation comprising R344D and D356R (EU index numbering system).
  • An antibody may have a heavy chain constant region that binds one or more types of Fc receptor but does not induce cellular effector functions, i.e. which does not mediate ADCC, CDC or ADCP activity. Such a constant region may be unable to bind the particular Fc receptor(s) responsible for triggering ADCC, CDC or ADCP activity.
  • An antibody may have a heavy chain constant region that does not bind Fey receptors.
  • the constant region may comprise a Leu235Glu mutation (EU index numbering system).
  • the antibodies and fragments disclosed herein are modified to increase or decrease serum half-life.
  • one or more of the following mutations: T252L, T254S or T256F are introduced to increase biological half-life of the antibody.
  • Biological half- life can also be increased by altering the heavy chain constant region CHi domain or CL region to contain a salvage receptor binding epitope taken from two loops of a CH 2 domain of an Fc region of an IgG, as described in U.S. Patent Numbers. 5,869,046 and 6,121,022, the modifications described therein are incorporated herein by reference.
  • the Fc hinge region of an antibody or antigen-binding fragment of the invention is mutated to decrease the biological half-life of the antibody or fragment.
  • the antibody or fragment is PEGylated.
  • the antibody or fragment is fused to an albumin-bidnig domain, e.g. an albumin binding single domain antibody (dAb).
  • the antibody or fragment is PASylated (i.e. genetic fusion of polypeptide sequences composed of PAS (XL-Protein GmbH) which forms uncharged random coil structures with large hydrodynamic volume).
  • the antibody or fragment is XTENylated ® /rPEGylated (i.e. genetic fusion of non-exact repeat peptide sequence (Amunix, Versartis) to the therapeutic peptide).
  • the antibody or fragment is ELPylated (i.e. genetic fusion to ELP repeat sequence (PhaseBio)).
  • the antibody may have a modified constant region which increases stabililty.
  • the heavy chain constant region comprises a Ser228Pro mutation.
  • the antibodies and fragments disclosed herein comprise a heavy chain hinge region that has been modified to alter the number of cysteine residues. This modification can be used to facilitate assembly of the light and heavy chains or to increase or decrease the stability of the antibody.
  • the constant region may be of any non-human mammalian origin, e.g. rat, mouse, hamster, guinea pig, dog, cat, horse, chicken, llama, dromedary, etc.
  • the constant region is a rat constant region.
  • the constant region is a llama constant region.
  • the murine constant region may be any of the isotypes or alleles described hereinabove.
  • Concept 32. The antibody or fragment according to concept 30 or concept 31, wherein the constant region has CDC and/or ADCC activity.
  • Concept 33 The antibody according to any preceding concept wherein the:
  • VH domain comprises an amino acid sequence of SEQ ID No:33 and the VL domain comprises an amino acid sequence of SEQ ID No:43;
  • VH domain comprises an amino acid sequence that is at least 85% identical to SEQ ID No:33, and the VL domain comprises an amino acid sequence that is at least 85% identical to SEQ ID No:43;
  • VH domain comprises an amino acid sequence of the VH domain of SEQ ID No:47 and the VL domain comprises an amino acid sequence of SEQ ID No:43; d) VH domain comprises an amino acid sequence of the VH domain of SEQ ID No:48 and the VL domain comprises an amino acid sequence of SEQ ID No:43; e) VH domain comprises an amino acid sequence of the VH domain of SEQ ID No:49 and the VL domain comprises an amino acid sequence of SEQ ID No:43; f) VH domain comprises an amino acid sequence of the VH domain of SEQ ID No: 342 and the VL domain comprises an amino acid sequence of SEQ ID No:43; g) VH domain comprises an amino acid sequence of SEQ ID No:33 and the VL domain comprises an amino acid sequence of the VL domain of SEQ ID No:50; h) VH domain comprises an amino acid sequence of the VH domain of SEQ ID No:47 and the VL domain comprises an amino acid sequence of the VL domain of SEQ ID No: 50; i)
  • VH domain comprises an amino acid sequence that is at least 85% identical to SEQ ID No: 58, and the VL domain comprise an amino acid sequence that is at least 85% identical to SEQ ID No:68;
  • VH domain comprises an amino acid sequence of SEQ ID No:78 and the VL domain comprises an amino acid sequence of SEQ ID No:88;
  • VH domain comprises an amino acid sequence that is at least 85% identical to SEQ ID No:78, and the VL domain comprises an amino acid sequence that is at least 85% identical to SEQ ID No:88;
  • VH domain comprises an amino acid sequence of SEQ ID No:98 and the VL domain comprises an amino acid sequence of SEQ ID No: 108;
  • VH domain comprises an amino acid sequence that is at least 85% identical to SEQ ID No:98
  • VL domain comprises an amino acid sequence that is at least 85% identical to SEQ ID No: 108;
  • VH domain comprises an amino acid sequence of SEQ ID No: 118 and the VL domain comprises an amino acid sequence of SEQ ID No: 128;
  • VH domain comprises an amino acid sequence that is at least 85% identical to SEQ ID No: 118
  • VL domain comprises an amino acid sequence that is at least 85% identical to SEQ ID No: 128;
  • VH domain comprises an amino acid sequence of SEQ ID No: 158 and the VL domain comprises an amino acid sequence of SEQ ID No: 168;
  • VH domain comprises an amino acid sequence that is at least 85% identical to SEQ ID No: 158
  • VL domain comprises an amino acid sequence that is at least 85% identical to SEQ ID No: 168;
  • VH domain comprises an amino acid sequence of SEQ ID No: 178 and the VL domain comprises an amino acid sequence of SEQ ID No: 188;
  • VH domain comprises an amino acid sequence that is at least 85% identical to SEQ ID No: 178
  • VL domain comprises an amino acid sequence that is at least 85% identical to SEQ ID No: 188;
  • VH domain comprises an amino acid sequence of SEQ ID No: 138 and the VL domain comprises an amino acid sequence of SEQ ID No: 148; ii) VH domain comprises an amino acid sequence that is at least 85% identical to SEQ ID No: 148;
  • VL domain comprises an amino acid sequence that is at least 85% identical to SEQ ID No: 148;
  • VH domain comprises an amino acid sequence of SEQ ID No:244 and the VL domain comprises an amino acid sequence of SEQ ID No:254;
  • VH domain comprises an amino acid sequence that is at least 85% identical to SEQ ID NO: 1
  • VL domain comprises an amino acid sequence that is at least 85% identical to SEQ ID No:254;
  • VH domain comprises an amino acid sequence of SEQ ID No:264 and the VL domain comprises an amino acid sequence of SEQ ID No:274;
  • VH domain comprises an amino acid sequence that is at least 85% identical to
  • VL domain comprises an amino acid sequence that is at least
  • VH domain comprises an amino acid sequence of SEQ ID No:284 and the VL domain comprises an amino acid sequence of SEQ ID No:294;
  • VH domain comprises an amino acid sequence that is at least 85% identical to SEQ ID No:284, and the VL domain comprises an amino acid sequence that is at least 85% identical to SEQ ID No:294;
  • VH domain comprises an amino acid sequence of SEQ ID No: 349 and the VL domain comprises an amino acid sequence of SEQ ID No:359;
  • VH domain comprises an amino acid sequence that is at least 85% identical to SEQ ID No:349
  • VL domain comprises an amino acid sequence that is at least 85% identical to SEQ ID No:359.
  • the amino acid sequence is at least 70% identical to the specified Seq ID No. In one embodiment, the amino acid sequence is at least 75% identical to the specified Seq ID No. In one embodiment, the amino acid sequence is at least 95% identical to the specified Seq ID No. In one embodiment, the amino acid sequence is at least 96% identical to the specified Seq ID No. In one embodiment, the amino acid sequence is at least 97% identical to the specified Seq ID No. In one embodiment, the amino acid sequence is at least 98% identical to the specified Seq ID No. In one embodiment, the amino acid sequence is at least 99% identical to the specified Seq ID No. In one embodiment, the amino acid sequence is at least 99.5% identical to the specified Seq ID No.
  • the heavy chain amino acid sequence comprises an amino acid sequence that is at least 85% identical to SEQ ID No:35 and the light chain amino acid sequence comprises an amino acid sequence that is at least 85% identical to SEQ ID No:45;
  • the heavy chain amino acid sequence comprises an amino acid sequence of SEQ ID No:47 and the light chain amino acid sequence comprises an amino acid sequence of SEQ ID No:45;
  • the heavy chain amino acid sequence comprises an amino acid sequence of SEQ ID No:48 and the light chain amino acid sequence comprises an amino acid sequence of SEQ ID No:45;
  • the heavy chain amino acid sequence comprises an amino acid sequence of SEQ ID No:49 and the light chain amino acid sequence comprises an amino acid sequence of SEQ ID No:45;
  • the heavy chain amino acid sequence comprises an amino acid sequence of SEQ ID No: 342 and the light chain amino acid sequence comprises an amino acid sequence of SEQ ID No:45;
  • the heavy chain amino acid sequence comprises an amino acid sequence of SEQ ID No:35 and the light chain amino acid sequence comprises an amino acid sequence of SEQ ID No:50;
  • the heavy chain amino acid sequence comprises an amino acid sequence of SEQ ID No:47 and the light chain amino acid sequence comprises an amino acid sequence of SEQ ID No:50;
  • the heavy chain amino acid sequence comprises an amino acid sequence of SEQ ID No:48 and the light chain amino acid sequence comprises an amino acid sequence of SEQ ID No:50;
  • the heavy chain amino acid sequence comprises an amino acid sequence of SEQ ID No:49 and the light chain amino acid sequence comprises an amino acid sequence of SEQ ID No:50;
  • the heavy chain amino acid sequence comprises an amino acid sequence of SEQ ID No: 342 and the light chain amino acid sequence comprises an amino acid sequence of SEQ ID No:50;
  • the heavy chain amino acid sequence comprises an amino acid sequence of SEQ ID No:35 and the light chain amino acid sequence comprises an amino acid sequence of SEQ ID No:51;
  • the heavy chain amino acid sequence comprises an amino acid sequence of SEQ ID No:47 and the light chain amino acid sequence comprises an amino acid sequence of SEQ ID No:51; n) the heavy chain amino acid sequence comprises an amino acid sequence of SEQ ID No:48 and the light chain amino acid sequence comprises an amino acid sequence of SEQ ID No:51;
  • the heavy chain amino acid sequence comprises an amino acid sequence of SEQ ID No:49 and the light chain amino acid sequence comprises an amino acid sequence of SEQ ID No:51;
  • the heavy chain amino acid sequence comprises an amino acid sequence of SEQ ID No: 342 and the light chain amino acid sequence comprises an amino acid sequence of SEQ ID No:51;
  • the heavy chain amino acid sequence comprises an amino acid sequence of SEQ ID No:35 and the light chain amino acid sequence comprises an amino acid sequence of SEQ ID No:298;
  • the heavy chain amino acid sequence comprises an amino acid sequence of SEQ ID No:47 and the light chain amino acid sequence comprises an amino acid sequence of SEQ ID No:298;
  • the heavy chain amino acid sequence comprises an amino acid sequence of SEQ ID No:48 and the light chain amino acid sequence comprises an amino acid sequence of SEQ ID No:298;
  • the heavy chain amino acid sequence comprises an amino acid sequence of SEQ ID No:49 and the light chain amino acid sequence comprises an amino acid sequence of SEQ ID No:298;
  • the heavy chain amino acid sequence comprises an amino acid sequence of SEQ ID No: 342 and the light chain amino acid sequence comprises an amino acid sequence of SEQ ID No:298;
  • the heavy chain amino acid sequence comprises an amino acid sequence of SEQ ID No:60 and the light chain amino acid sequence comprises an amino acid sequence of SEQ ID No:70;
  • the heavy chain amino acid sequence comprises an amino acid sequence that is at least 85% identical to SEQ ID No:60
  • the light chain amino acid sequence comprises an amino acid sequence that is at least 85% identical to SEQ ID No:70
  • the heavy chain amino acid sequence comprises an amino acid sequence of SEQ ID No:80 and the light chain amino acid sequence comprises an amino acid sequence of SEQ ID No:90;
  • the heavy chain amino acid sequence comprises an amino acid sequence that is at least 85% identical to SEQ ID No:80, and the light chain amino acid sequence comprises an amino acid sequence that is at least 85% identical to SEQ ID No:90; z) the heavy chain amino acid sequence comprises an amino acid sequence of SEQ ID No: 100 and the light chain amino acid sequence comprises an amino acid sequence of SEQ ID No: 110;
  • the heavy chain amino acid sequence comprises an amino acid sequence that is at least 85% identical to SEQ ID No: 100
  • the light chain amino acid sequence comprises an amino acid sequence that is at least 85% identical to SEQ ID No: 110;
  • the heavy chain amino acid sequence comprises an amino acid sequence of SEQ ID NO: 1
  • the heavy chain amino acid sequence comprises an amino acid sequence that is at least
  • the light chain amino acid sequence comprises an amino acid sequence that is at least 85% identical to SEQ ID No: 130;
  • the heavy chain amino acid sequence comprises an amino acid sequence of SEQ ID No: 160 and the light chain amino acid sequence comprises an amino acid sequence of SEQ ID No: 170;
  • the heavy chain amino acid sequence comprises an amino acid sequence that is at least 85% identical to SEQ ID No: 160, and the light chain amino acid sequence comprises an amino acid sequence that is at least 85% identical to SEQ ID No: 170;
  • the heavy chain amino acid sequence comprises an amino acid sequence of SEQ ID No: 180 and the light chain amino acid sequence comprises an amino acid sequence of
  • the heavy chain amino acid sequence comprises an amino acid sequence that is at least 85% identical to SEQ ID No: 180
  • the light chain amino acid sequence comprises an amino acid sequence that is at least 85% identical to SEQ ID No: 190
  • the heavy chain amino acid sequence comprises an amino acid sequence of SEQ ID NO: 1
  • the heavy chain amino acid sequence comprises an amino acid sequence that is at least 85% identical to SEQ ID No: 140, and the light chain amino acid sequence comprises an amino acid sequence that is at least 85% identical to SEQ ID No: 150;
  • the heavy chain amino acid sequence comprises an amino acid sequence of SEQ ID No:246 and the light chain amino acid sequence comprises an amino acid sequence of SEQ ID No:256;
  • the heavy chain amino acid sequence comprises an amino acid sequence that is at least 85% identical to SEQ ID No:246, and the light chain amino acid sequence comprises an amino acid sequence that is at least 85% identical to SEQ ID No:256; II) the heavy chain amino acid sequence comprises an amino acid sequence of SEQ ID No:266 and the light chain amino acid sequence comprises an amino acid sequence of SEQ ID No:276;
  • the heavy chain amino acid sequence comprises an amino acid sequence that is at least 85% identical to SEQ ID No:266, and the light chain amino acid sequence comprises an amino acid sequence that is at least 85% identical to SEQ ID No:276; nn) the heavy chain amino acid sequence comprises an amino acid sequence of SEQ ID No:266, and the light chain amino acid sequence comprises an amino acid sequence that is at least 85% identical to SEQ ID No:276; nn) the heavy chain amino acid sequence comprises an amino acid sequence of SEQ ID
  • the heavy chain amino acid sequence comprises an amino acid sequence that is at least 85% identical to SEQ ID No:286, and the light chain amino acid sequence comprises an amino acid sequence that is at least 85% identical to SEQ ID No:296;
  • the heavy chain amino acid sequence comprises an amino acid sequence of SEQ ID No:351 and the light chain amino acid sequence comprises an amino acid sequence of SEQ ID No:361;
  • the heavy chain amino acid sequence comprises an amino acid sequence that is at least 85% identical to SEQ ID No:351
  • the light chain amino acid sequence comprises an amino acid sequence that is at least 85% identical to SEQ ID No:361.
  • the amino acid sequence is at least 70% identical to the specified Seq ID No. In one embodiment, the amino acid sequence is at least 75% identical to the specified Seq ID No. In one embodiment, the amino acid sequence is at least 95% identical to the specified Seq ID No. In one embodiment, the amino acid sequence is at least 96% identical to the specified Seq ID No. In one embodiment, the amino acid sequence is at least 97% identical to the specified Seq ID No. In one embodiment, the amino acid sequence is at least 98% identical to the specified Seq ID No. In one embodiment, the amino acid sequence is at least 99% identical to the specified Seq ID No. In one embodiment, the amino acid sequence is at least 99.5% identical to the specified Seq ID No.
  • SPR may be carried out as described hereinabove, or as described in concept 16.
  • the antibody or fragment according to any preceding concept wherein the antibody or fragment is capable of inhibiting PD-Ll-mediated suppression of T-cells, optionally wherein the suppression of T-cells is measured by an increase in one or more of IFNy, IL-2, CD25 or proliferation of T-cells in an assay that provides co-stimulation by either direct CD3/CD28 stimulation, superantigen stimulation or provides co-stimulation by co-incubation with cells capable of inducing a T-cell response.
  • the measurements may be carried out with any suitable technique. For example, the measurements may be taken with ELISA, HTRF, BRDU incorporation (proliferation), electrochemiluminescence (ECL) or flow cytometry (e.g. FACS). These techniques are well-known to those skilled in the art and are described elsewhere herein.
  • the assay is flow cytometry.
  • the assay is ELISA.
  • the assay is HTRF.
  • the suppression of T-cells is measured by an increase in IFNy. In one embodiment, the suppression of T-cells is measured by an increase in IL-2. In one embodiment, the suppression of T-cells is measured by an increase in CD25. In one embodiment, the suppression of T- cells is measured by an increase in IFNy and IL-2. In one embodiment, the suppression of T-cells is measured by an increase in IFNy and CD25. In one embodiment, the suppression of T-cells is measured by an increase in CD25 and IL-2. In one embodiment, the suppression of T-cells is measured by an increase in IFNy, IL-2 and CD25.
  • the co-stimulation is provided by direct CD3/CD28 stimulation.
  • the co-stimulation is provided by a superantigen, such as staphylococcal enterotoxin B (SEB).
  • SEB staphylococcal enterotoxin B
  • the assay provides co-stimulation by co-incubation with cells capable of inducing a T-cell response.
  • cells may be antigen-presenting cells (APCs), for example monocytes, B-cells or dendritic cells.
  • APCs antigen-presenting cells
  • the assay provides co-stimulation by co-incubation with APCs.
  • the assay provides co-stimulation by co-incubation with monocytes.
  • the assay provides co-stimulation by co-incubation with B-cells.
  • the assay provides co-stimulation by co-incubation with dendritic cells.
  • a dual binding antibody has the meaning as set out above.
  • the bispecific format is selected from DVD-Ig, mAb 2 , FIT-Ig, mAb-dAb, dock and lock, Fab-arm exchange, SEEDbody, Triomab, LUZ-Y, Fcab, ⁇ -body, orthogonal Fab, scDiabody-Fc, diabody-Fc, tandem scFv-Fc, Fab-scFv-Fc, Fab-scFv, intrabody, BiTE, diabody, DART, TandAb, scDiabody, scDiabody-CI-b, Diabody-CI-b, Triple body, Miniantibody, minibody, TriBi minibody, scFv-CI-b KIH, scFv-CH-CL-scFv, F(ab 2-scFv, scFv-KIH, Fab-scFv-Fc, tetravalent HCab, ImmTAC, knobs-in-hole
  • the bispecific format is selected from DVD-Ig, FIT-Ig, imAb-dAb, dock and lock, Fab-arm exchange, SEEDbody, Triomab, LUZ-Y, Fcab, ⁇ -body, orthogonal Fab, scDiabody- Fc, diabody-Fc, tandem scFv-Fc, Fab-scFv-Fc, Fab-scFv, intrabody, BiTE, diabody, DART, TandAb, scDiabody, scDiabody-CFb, Diabody-Ch , Triple body, Miniantibody, minibody, TriBi minibody, scFv- CH3 KIH, scFv-CH-CL-scFv, F(ab')2-scFv, scFv-KIH, Fab-scFv-Fc, tetravalent HCab, ImmTAC, knobs- in-holes, knobs-in-hole
  • the bispecific format is selected from DVD-Ig, mAb 2 , imAb-dAb, dock and lock, Fab-arm exchange, SEEDbody, Triomab, LUZ-Y, Fcab, ⁇ -body, orthogonal Fab, scDiabody-Fc, diabody-Fc, tandem scFv-Fc, Fab-scFv-Fc, Fab-scFv, intrabody, BiTE, diabody, DART, TandAb, scDiabody, scDiabody-CH3, Diabody-CH3, Triple body, Miniantibody, minibody, TriBi minibody, scFv- CH3 KIH, scFv-CH-CL-scFv, F(ab')2-scFv, scFv-KIH, Fab-scFv-Fc, tetravalent HCab, ImmTAC, knobs- in-holes, knobs-in-holes with
  • the bispecific format is selected from DVD-Ig, mAb-dAb, dock and lock,
  • Fab-arm exchange SEEDbody, Triomab, LUZ-Y, Fcab, ⁇ -body, orthogonal Fab, scDiabody-Fc, diabody-Fc, tandem scFv-Fc, Fab-scFv-Fc, Fab-scFv, intrabody, BiTE, diabody, DART, TandAb, scDiabody, scDiabody-CH3, Diabody-CH3, Triple body, Miniantibody, minibody, TriBi minibody, scFv- CH3 KIH, scFv-CH-CL-scFv, F(ab')2-scFv, scFv-KIH, Fab-scFv-Fc, tetravalent HCab, ImmTAC, knobs- in-holes, knobs-in-holes with common light chain, knobs-in-holes with common light chain and charge pairs, charge pairs, charge pairs with common light chain, DT-
  • Concept 39 The bispecific antibody according to concept 37 or concept 38, wherein the bispecific antibody specifically binds to hPD-Ll and another target antigen selected from immune checkpoint inhibitors (such as PD-1, CTLA-4, TIGIT, TIM-3, LAG-3 and VISTA, e.g. TIGIT, TIM-3 and LAG-3), immune modulators (such as BTLA, hHVEM, CSF1R, CCR4, CD39, CD40, CD73, CD96, CXCR2, CXCR4, CD200, GARP, SIRPa, CXCL9, CXCLIO, CXCLll and CD155, e.g.
  • immune checkpoint inhibitors such as PD-1, CTLA-4, TIGIT, TIM-3, LAG-3 and VISTA, e.g. TIGIT, TIM-3 and LAG-3
  • immune modulators such as BTLA, hHVEM, CSF1R, CCR4, CD39, CD40, CD73, CD96, CXCR2,
  • immune activators such as CD137, GITR, OX40, CD40, CXCR3 (e.g. agonistic anti-CXCR3 antibodies), CD27, CD3, ICOS (e.g. agonistic anti-ICOS antibodies), for example.
  • ICOS e.g. agonistic anti-ICOS antibodies
  • VL comprising one or more of the CDRs (e.g. CDRH3 and CDRL3) or variable region sequences of any of the antibodies described in Aspect la hereinbelow, and another target antigen selected from immune checkpoint inhibitors (such as PD-1, CTLA-4, TIGIT, TIM-3, LAG-3 and VISTA, e.g. TIGIT, TIM-3 and LAG-3), immune modulators (such as BTLA, hHVEM, CSF1R, CCR4, CD39, CD40, CD73, CD96, CXCR2, CXCR4, CD200, GARP, SIRPa, CXCL9, CXCLIO, CXCLll and CD155, e.g.
  • immune checkpoint inhibitors such as PD-1, CTLA-4, TIGIT, TIM-3, LAG-3 and VISTA, e.g. TIGIT, TIM-3 and LAG-3
  • immune modulators such as BTLA, hHVEM, CSF1R, CCR4, CD39
  • immune activators such as CD137, GITR, OX40, CD40, CXCR3 (e.g. agonistic anti-CXCR3 antibodies), CD27, CD3, ICOS (e.g. agonistic anti-ICOS antibodies), for example.
  • ICOS e.g. agonistic anti-ICOS antibodies
  • Concept 39b The bispecific antibody according to concept 37 or concept 38, wherein the bispecific antibody specifically binds to hPD-Ll and another target antigen selected from immune checkpoint inhibitors (such as PD-1, CTLA-4, TIGIT, TIM-3, LAG-3 and VISTA, e.g. TIGIT, TIM-3 and LAG-3), immune modulators (such as BTLA, hHVEM, CSF1R, CCR4, CD39, CD40, CD73, CD96, CXCR2, CXCR4, CD200, GARP, SIRPa, CXCL9, CXCLIO and CD155, e.g.
  • immune checkpoint inhibitors such as PD-1, CTLA-4, TIGIT, TIM-3, LAG-3 and VISTA, e.g. TIGIT, TIM-3 and LAG-3
  • immune modulators such as BTLA, hHVEM, CSF1R, CCR4, CD39, CD40, CD73, CD96, CXCR2, CXCR4,
  • the another target antigen is an immune checkpoint inhibitor, such as PD-1, CTLA-4, TIGIT, TIM-3, LAG-3 and VISTA, e.g. TIGIT, CTLA-4, TIM-3 and LAG-3.
  • the another target antigen is an immune modulator, such as BTLA, hHVEM, CSF1R, CCR4, CD39, CD40, CD73, CD96, CXCR2, CXCR4, CD200, GARP, SIRPa, CXCL9, CXCL10, CXCL11 and CD155, or such as BTLA, hHVEM, CSF1R, CCR4, CD39, CD40, CD73, CD96, CXCR2, CXCR4, CD200, GARP, SIRPa, CXCL9, CXCL10 and CD155, e.g. GARP, SIRPa, CXCR4, BTLA, hVEM and CSF1R.
  • an immune modulator such as BTLA, hHVEM, CSF1R, CCR4, CD39, CD40, CD73, CD96, CXCR2, CXCR4, CD200, GARP, SIRPa, CXCL9, CXCL10 and CD155, e.g. GARP, SIRPa,
  • the another target antigen is an immune activator, such as CD137, GITR, OX40, CD40, CXCR3 (e.g. agonistic anti-CXCR3 antibodies), CD27, CD3 and ICOS (e.g. agonistic anti-ICOS antibodies), or CD137, GITR, OX40, CD40, CXCR3 (e.g. agonistic anti-CXCR3 antibodies), CD3 and ICOS (e.g. agonistic anti-ICOS antibodies), for example ICOS, CD137, GITR and OX40).
  • the another target antigen is CTLA-4.
  • the another target antigen is TIGIT.
  • the another target antigen is TIM-3.
  • the another target antigen is LAG-3. In one embodiment, the another target antigen is GITR. In one embodiment, the another target antigen is VISTA. In one embodiment, the another target antigen is CD137. In one embodiment, the another target antigen is SIRPa. In one embodiment, the another target antigen is CXCL10. In one embodiment, the another target antigen is CD155. In one embodiment, the another target antigen is CD40.
  • the bispecific antibody binds another target antigen which is PD-1 and the binding to PD-1 is provided by an antigen-binding domain (for example, a VH, a VL or a paired VH and VL) having any of the sequences, including CDR sequences (for example CDRH3 and/or CDRL3) or variable region sequences as described in Aspect 1A hereinbelow.
  • an antigen-binding domain for example, a VH, a VL or a paired VH and VL
  • CDR sequences for example CDRH3 and/or CDRL3
  • variable region sequences as described in Aspect 1A hereinbelow.
  • the bispecific antibody binds another target antigen which is CTLA4 and the binding to CTLA4 is provided by an antigen-binding domain (for example, a VH, a VL or a paired VH and VL) having any of the sequences, including CDR sequences (for example CDRH3 and/or CDRL3) or variable region sequences as described in Aspect 1A hereinbelow.
  • an antigen-binding domain for example, a VH, a VL or a paired VH and VL
  • CDR sequences for example CDRH3 and/or CDRL3
  • variable region sequences as described in Aspect 1A hereinbelow.
  • the bispecific antibody binds another target antigen which is TIGIT and the binding to TIGIT is provided by an antigen-binding domain (for example, a VH, a VL or a paired VH and VL) having any of the sequences, including CDR sequences (for example CDRH3 and/or CDRL3) or variable region sequences as described in Aspect 1A hereinbelow.
  • an antigen-binding domain for example, a VH, a VL or a paired VH and VL
  • CDR sequences for example CDRH3 and/or CDRL3
  • variable region sequences as described in Aspect 1A hereinbelow.
  • the bispecific antibody binds another target antigen which is TIM-3 and the binding to TIM-3 is provided by an antigen-binding domain (for example, a VH, a VL or a paired VH and VL) having any of the sequences, including CDR sequences (for example CDRH3 and/or CDRL3) or variable region sequences as described in Aspect 1A hereinbelow.
  • an antigen-binding domain for example, a VH, a VL or a paired VH and VL
  • CDR sequences for example CDRH3 and/or CDRL3
  • variable region sequences as described in Aspect 1A hereinbelow.
  • the bispecific antibody binds another target antigen which is LAG3 and the binding to LAG3 is provided by an antigen-binding domain (for example, a VH, a VL or a paired VH and VL) having any of the sequences, including CDR sequences (for example CDRH3 and/or CDRL3) or variable region sequences as described in Aspect 1A hereinbelow.
  • an antigen-binding domain for example, a VH, a VL or a paired VH and VL
  • CDR sequences for example CDRH3 and/or CDRL3
  • variable region sequences as described in Aspect 1A hereinbelow.
  • the bispecific antibody binds another target antigen which is VISTA and the binding to VISTA is provided by an antigen-binding domain (for example, a VH, a VL or a paired VH and VL) having any of the sequences, including CDR sequences (for example CDRH3 and/or CDRL3) or variable region sequences as described in Aspect 1A hereinbelow.
  • an antigen-binding domain for example, a VH, a VL or a paired VH and VL
  • CDR sequences for example CDRH3 and/or CDRL3
  • variable region sequences as described in Aspect 1A hereinbelow.
  • the bispecific antibody binds another target antigen which is BTLA and the binding to BTLA is provided by an antigen-binding domain (for example, a VH, a VL or a paired VH and VL) having any of the sequences, including CDR sequences (for example CDRH3 and/or CDRL3) or variable region sequences as described in Aspect 1A hereinbelow.
  • an antigen-binding domain for example, a VH, a VL or a paired VH and VL
  • CDR sequences for example CDRH3 and/or CDRL3
  • variable region sequences as described in Aspect 1A hereinbelow.
  • the bispecific antibody binds another target antigen which is hHVEM and the binding to hHVEM is provided by an antigen-binding domain (for example, a VH, a VL or a paired VH and VL) having any of the sequences, including CDR sequences (for example CDRH3 and/or CDRL3) or variable region sequences as described in Aspect 1A hereinbelow.
  • an antigen-binding domain for example, a VH, a VL or a paired VH and VL
  • CDR sequences for example CDRH3 and/or CDRL3
  • variable region sequences as described in Aspect 1A hereinbelow.
  • the bispecific antibody binds another target antigen which is CSF1R and the binding to CSF1R is provided by an antigen-binding domain (for example, a VH, a VL or a paired VH and VL) having any of the sequences, including CDR sequences (for example CDRH3 and/or CDRL3) or variable region sequences as described in Aspect 1A hereinbelow.
  • an antigen-binding domain for example, a VH, a VL or a paired VH and VL
  • CDR sequences for example CDRH3 and/or CDRL3
  • variable region sequences as described in Aspect 1A hereinbelow.
  • the bispecific antibody binds another target antigen which is CCR4 and the binding to CCR4 is provided by an antigen-binding domain (for example, a VH, a VL or a paired VH and VL) having any of the sequences, including CDR sequences (for example CDRH3 and/or CDRL3) or variable region sequences as described in Aspect 1A hereinbelow.
  • an antigen-binding domain for example, a VH, a VL or a paired VH and VL
  • CDR sequences for example CDRH3 and/or CDRL3
  • variable region sequences as described in Aspect 1A hereinbelow.
  • the bispecific antibody binds another target antigen which is CD39 and the binding to CD39 is provided by an antigen-binding domain (for example, a VH, a VL or a paired VH and VL) having any of the sequences, including CDR sequences (for example CDRH3 and/or CDRL3) or variable region sequences as described in Aspect 1A hereinbelow.
  • an antigen-binding domain for example, a VH, a VL or a paired VH and VL
  • CDR sequences for example CDRH3 and/or CDRL3
  • variable region sequences as described in Aspect 1A hereinbelow.
  • the bispecific antibody binds another target antigen which is CD40 and the binding to CD40 is provided by an antigen-binding domain (for example, a VH, a VL or a paired VH and VL) having any of the sequences, including CDR sequences (for example CDRH3 and/or CDRL3) or variable region sequences as described in Aspect 1A hereinbelow.
  • an antigen-binding domain for example, a VH, a VL or a paired VH and VL
  • CDR sequences for example CDRH3 and/or CDRL3
  • variable region sequences as described in Aspect 1A hereinbelow.
  • the bispecific antibody binds another target antigen which is CD73 and the binding to CD73 is provided by an antigen-binding domain (for example, a VH, a VL or a paired VH and VL) having any of the sequences, including CDR sequences (for example CDRH3 and/or CDRL3) or variable region sequences as described in Aspect 1A hereinbelow.
  • an antigen-binding domain for example, a VH, a VL or a paired VH and VL
  • CDR sequences for example CDRH3 and/or CDRL3
  • variable region sequences as described in Aspect 1A hereinbelow.
  • the bispecific antibody binds another target antigen which is CD96 and the binding to CD96 is provided by an antigen-binding domain (for example, a VH, a VL or a paired VH and VL) having any of the sequences, including CDR sequences (for example CDRH3 and/or CDRL3) or variable region sequences as described in Aspect 1A hereinbelow.
  • an antigen-binding domain for example, a VH, a VL or a paired VH and VL
  • CDR sequences for example CDRH3 and/or CDRL3
  • variable region sequences as described in Aspect 1A hereinbelow.
  • the bispecific antibody binds another target antigen which is CXCR2 and the binding to CXCR2 is provided by an antigen-binding domain (for example, a VH, a VL or a paired VH and VL) having any of the sequences, including CDR sequences (for example CDRH3 and/or CDRL3) or variable region sequences as described in Aspect 1A hereinbelow.
  • an antigen-binding domain for example, a VH, a VL or a paired VH and VL
  • CDR sequences for example CDRH3 and/or CDRL3
  • variable region sequences as described in Aspect 1A hereinbelow.
  • the bispecific antibody binds another target antigen which is CXCR4 and the binding to CXCR4 is provided by an antigen-binding domain (for example, a VH, a VL or a paired VH and VL) having any of the sequences, including CDR sequences (for example CDRH3 and/or CDRL3) or variable region sequences as described in Aspect 1A hereinbelow.
  • an antigen-binding domain for example, a VH, a VL or a paired VH and VL
  • CDR sequences for example CDRH3 and/or CDRL3
  • variable region sequences as described in Aspect 1A hereinbelow.
  • the bispecific antibody binds another target antigen which is CD200 and the binding to CD200 is provided by an antigen-binding domain (for example, a VH, a VL or a paired VH and VL) having any of the sequences, including CDR sequences (for example CDRH3 and/or CDRL3) or variable region sequences as described in Aspect 1A hereinbelow.
  • an antigen-binding domain for example, a VH, a VL or a paired VH and VL
  • CDR sequences for example CDRH3 and/or CDRL3
  • variable region sequences as described in Aspect 1A hereinbelow.
  • the bispecific antibody binds another target antigen which is GARP and the binding to GARP is provided by an antigen-binding domain (for example, a VH, a VL or a paired VH and VL) having any of the sequences, including CDR sequences (for example CDRH3 and/or CDRL3) or variable region sequences as described in Aspect 1A hereinbelow.
  • an antigen-binding domain for example, a VH, a VL or a paired VH and VL
  • CDR sequences for example CDRH3 and/or CDRL3
  • variable region sequences as described in Aspect 1A hereinbelow.
  • the bispecific antibody binds another target antigen which is SIRPa and the binding to SIRPa is provided by an antigen-binding domain (for example, a VH, a VL or a paired VH and VL) having any of the sequences, including CDR sequences (for example CDRH3 and/or CDRL3) or variable region sequences as described in Aspect 1A hereinbelow.
  • an antigen-binding domain for example, a VH, a VL or a paired VH and VL
  • CDR sequences for example CDRH3 and/or CDRL3
  • variable region sequences as described in Aspect 1A hereinbelow.
  • the bispecific antibody binds another target antigen which is CXCL9 and the binding to CXCL9 is provided by an antigen-binding domain (for example, a VH, a VL or a paired VH and VL) having any of the sequences, including CDR sequences (for example CDRH3 and/or CDRL3) or variable region sequences as described in Aspect 1A hereinbelow.
  • an antigen-binding domain for example, a VH, a VL or a paired VH and VL
  • CDR sequences for example CDRH3 and/or CDRL3
  • variable region sequences as described in Aspect 1A hereinbelow.
  • the bispecific antibody binds another target antigen which is CXCL10 and the binding to CXCL10 is provided by an antigen-binding domain (for example, a VH, a VL or a paired VH and VL) having any of the sequences, including CDR sequences (for example CDRH3 and/or CDRL3) or variable region sequences as described in Aspect 1A hereinbelow.
  • an antigen-binding domain for example, a VH, a VL or a paired VH and VL
  • CDR sequences for example CDRH3 and/or CDRL3
  • variable region sequences as described in Aspect 1A hereinbelow.
  • the bispecific antibody binds another target antigen which is CD155 and the binding to CD155 is provided by an antigen-binding domain (for example, a VH, a VL or a paired VH and VL) having any of the sequences, including CDR sequences (for example CDRH3 and/or CDRL3) or variable region sequences as described in Aspect 1A hereinbelow.
  • an antigen-binding domain for example, a VH, a VL or a paired VH and VL
  • CDR sequences for example CDRH3 and/or CDRL3
  • variable region sequences as described in Aspect 1A hereinbelow.
  • the bispecific antibody binds another target antigen which is CD137 and the binding to CD137 is provided by an antigen-binding domain (for example, a VH, a VL or a paired VH and VL) having any of the sequences, including CDR sequences (for example CDRH3 and/or CDRL3) or variable region sequences as described in Aspect 1A hereinbelow.
  • an antigen-binding domain for example, a VH, a VL or a paired VH and VL
  • CDR sequences for example CDRH3 and/or CDRL3
  • variable region sequences as described in Aspect 1A hereinbelow.
  • the bispecific antibody binds another target antigen which is GITR and the binding to GITR is provided by an antigen-binding domain (for example, a VH, a VL or a paired VH and VL) having any of the sequences, including CDR sequences (for example CDRH3 and/or CDRL3) or variable region sequences as described in Aspect 1A hereinbelow.
  • an antigen-binding domain for example, a VH, a VL or a paired VH and VL
  • CDR sequences for example CDRH3 and/or CDRL3
  • variable region sequences as described in Aspect 1A hereinbelow.
  • the bispecific antibody binds another target antigen which is OX40 and the binding to OX40 is provided by an antigen-binding domain (for example, a VH, a VL or a paired VH and VL) having any of the sequences, including CDR sequences (for example CDRH3 and/or CDRL3) or variable region sequences as described in Aspect 1A hereinbelow.
  • an antigen-binding domain for example, a VH, a VL or a paired VH and VL
  • CDR sequences for example CDRH3 and/or CDRL3
  • variable region sequences as described in Aspect 1A hereinbelow.
  • the bispecific antibody binds another target antigen which is CD40 and the binding to CD40 is provided by an antigen-binding domain (for example, a VH, a VL or a paired VH and VL) having any of the sequences, including CDR sequences (for example CDRH3 and/or CDRL3) or variable region sequences as described in Aspect 1A hereinbelow.
  • an antigen-binding domain for example, a VH, a VL or a paired VH and VL
  • CDR sequences for example CDRH3 and/or CDRL3
  • variable region sequences as described in Aspect 1A hereinbelow.
  • the bispecific antibody binds another target antigen which is CXCR3 and the binding to CXCR3 is provided by an antigen-binding domain (for example, a VH, a VL or a paired VH and VL) having any of the sequences, including CDR sequences (for example CDRH3 and/or CDRL3) or variable region sequences as described in Aspect 1A hereinbelow.
  • an antigen-binding domain for example, a VH, a VL or a paired VH and VL
  • CDR sequences for example CDRH3 and/or CDRL3
  • variable region sequences as described in Aspect 1A hereinbelow.
  • the bispecific antibody binds another target antigen which is CD27 and the binding to CD27 is provided by an antigen-binding domain (for example, a VH, a VL or a paired VH and VL) having any of the sequences, including CDR sequences (for example CDRH3 and/or CDRL3) or variable region sequences as described in Aspect 1A hereinbelow.
  • an antigen-binding domain for example, a VH, a VL or a paired VH and VL
  • CDR sequences for example CDRH3 and/or CDRL3
  • variable region sequences as described in Aspect 1A hereinbelow.
  • the bispecific antibody binds another target antigen which is CD3 and the binding to CD3 is provided by an antigen-binding domain (for example, a VH, a VL or a paired VH and VL) having any of the sequences, including CDR sequences (for example CDRH3 and/or CDRL3) or variable region sequences as described in Aspect 1A hereinbelow.
  • an antigen-binding domain for example, a VH, a VL or a paired VH and VL
  • CDR sequences for example CDRH3 and/or CDRL3
  • variable region sequences as described in Aspect 1A hereinbelow.
  • the bispecific antibody binds another target antigen which is ICOS and the binding to ICOS is provided by an antigen-binding domain (for example, a VH, a VL or a paired VH and VL) having any of the sequences, including CDR sequences (for example CDRH3 and/or CDRL3) or variable region sequences as described in arrangement 5 and arrangement 5a hereinbelow, and any of the anti-ICOS antibodies described in sentences 1 to 102 and sentences la to 21a.
  • an antigen-binding domain for example, a VH, a VL or a paired VH and VL
  • the bispecific antibody has a FIT-Ig format which comprises a full antibody (e.g. an antibody comprising a light chain comprising a VL and CL and a heavy chain comprising VH, CHI, CH2 and CH3) which binds hPD-Ll (optionally wherein the antibody has a structure as defined in any one of concepts 1 to 40, or wherein the antibody has a sequence - including CDRs and variable regions - as defined in Aspect la hereinbelow) and a Fab which binds GITR (optionally wherein the GITR Fab has a sequence - including CDRs and variable regions - as defined in Aspect la hereinbelow).
  • a full antibody e.g. an antibody comprising a light chain comprising a VL and CL and a heavy chain comprising VH, CHI, CH2 and CH3
  • the antibody has a structure as defined in any one of concepts 1 to 40, or wherein the antibody has a sequence - including CDRs and variable regions -
  • the bispecific antibody has a FIT-Ig format which comprises a full antibody (e.g. an antibody comprising a light chain comprising a VL and CL and a heavy chain comprising VH, CHI, CH2 and CH3) which binds GITR (optionally wherein the GITR antibody has a sequence - including CDRs and variable regions - as defined in Aspect la hereinbelow) and a Fab which binds hPD-Ll (optionally wherein the antibody has a structure as defined in any one of concepts 1 to 40, or wherein the antibody has a sequence - including CDRs and variable regions - as defined in Aspect la hereinbelow).
  • a full antibody e.g. an antibody comprising a light chain comprising a VL and CL and a heavy chain comprising VH, CHI, CH2 and CH3
  • GITR antibody optionally wherein the GITR antibody has a sequence - including CDRs and variable regions - as defined in Aspect la hereinbelow
  • the FIT-Ig is effector-enabled (e.g. as described in any of concepts 30 to 32). In another embodiment, the FIT-Ig is effector-disabled (e.g. is an IgG4 format, or as described in any of concepts 30 to 31).
  • the bispecific antibody has a FIT-Ig format which comprises a full antibody (e.g. an antibody comprising a light chain comprising a VL and CL and a heavy chain comprising VH, CHI, CH2 and CH3) which binds hPD-Ll (optionally wherein the antibody has a structure as defined in any one of concepts 1 to 40, or wherein the antibody has a sequence - including CDRs and variable regions - as defined in Aspect la hereinbelow) and a Fab which binds ICOS (e.g.
  • the ICOS Fab binds with agonistic activity and optionally wherein the ICOS Fab has a sequence - including CDRs and variable regions - as defined in arrangement 5, or in arrangement 5a, or in sentences 1 to 102, or in sentences la to 21a hereinbelow).
  • the ICOS Fab has a sequence of any of the ICOS antibodies described herein in sentences 1 to 102 or in sentences la to 21a)
  • the bispecific antibody has a FIT-Ig format which comprises a full antibody (e.g. an antibody comprising a light chain comprising a VL and CL and a heavy chain comprising VH, CHI, CH2 and CH3) which binds ICOS (e.g.
  • the ICOS antibody has a sequence - including CDRs and variable regions - as defined in arrangement 5, or in arrangement 5a, or in sentences 1 to 102, or in sentences la to 21a hereinbelow) and a Fab which binds hPD-Ll (optionally wherein the antibody has a structure as defined in any one of concepts 1 to 40, or wherein the antibody has a sequence - including CDRs and variable regions - as defined in Aspect 1A hereinbelow).
  • the FIT-Ig is effector-enabled (e.g. as described in any of concepts 30 to 32).
  • the FIT-Ig is effector-disabled (e.g. is an IgG4 format, or as described in any of concepts 30 or 31).
  • the bispecific antibody has a FIT-Ig format which comprises a full antibody (e.g. an antibody comprising a light chain comprising a VL and CL and a heavy chain comprising VH, CHI, CH2 and CH3) which binds hPD-Ll (optionally wherein the antibody has a structure as defined in any one of concepts 1 to 40, or wherein the antibody has a sequence - including CDRs and variable regions - as defined in Aspect la hereinbelow) and a Fab which binds TIM-3 (optionally wherein the TIM-3 Fab has a sequence - including CDRs and variable regions - as defined in Aspect la hereinbelow).
  • a full antibody e.g. an antibody comprising a light chain comprising a VL and CL and a heavy chain comprising VH, CHI, CH2 and CH3
  • the antibody has a structure as defined in any one of concepts 1 to 40, or wherein the antibody has a sequence - including CDRs and variable regions -
  • the bispecific antibody has a FIT-Ig format which comprises a full antibody (e.g. an antibody comprising a light chain comprising a VL and CL and a heavy chain comprising VH, CHI, CH2 and CH3) which binds TIM-3 (optionally wherein the TIM-3 antibody has a sequence - including CDRs and variable regions - as defined in Aspect la hereinbelow) and a Fab which binds hPD-Ll (optionally wherein the antibody has a structure as defined in any one of concepts 1 to 40, or wherein the antibody has a sequence - including CDRs and variable regions - as defined in Aspect la hereinbelow).
  • a full antibody e.g. an antibody comprising a light chain comprising a VL and CL and a heavy chain comprising VH, CHI, CH2 and CH3
  • the TIM-3 antibody has a sequence - including CDRs and variable regions - as defined in Aspect la hereinbelow
  • a Fab which
  • the FIT-Ig is effector-enabled (e.g. as described in any of concepts 30 to 32). In another embodiment, the FIT-Ig is effector-disabled (e.g. is an IgG4 format, or as described in any of concepts 30 or 31).
  • the bispecific antibody has a FIT-Ig format which comprises a full antibody (e.g. an antibody comprising a light chain comprising a VL and CL and a heavy chain comprising VH, CHI, CH2 and CH3) which binds hPD-Ll (optionally wherein the antibody has a structure as defined in any one of concepts 1 to 40, or wherein the antibody has a sequence - including CDRs and variable regions - as defined in Aspect la hereinbelow) and a Fab which binds CD137 (optionally wherein the CD137 Fab has a sequence - including CDRs and variable regions - as defined in Aspect la hereinbelow).
  • a full antibody e.g. an antibody comprising a light chain comprising a VL and CL and a heavy chain comprising VH, CHI, CH2 and CH3
  • hPD-Ll e.g. an antibody comprising a light chain comprising a VL and CL and a heavy chain comprising VH, CHI
  • the bispecific antibody has a FIT-Ig format which comprises a full antibody (e.g. an antibody comprising a light chain comprising a VL and CL and a heavy chain comprising VH, CHI, CH2 and CH3) which binds CD137 (optionally wherein the CD137 antibody has a sequence - including CDRs and variable regions - as defined in Aspect la hereinbelow) and a Fab which binds hPD-Ll (optionally wherein the antibody has a structure as defined in any one of concepts 1 to 40, or wherein the antibody has a sequence - including CDRs and variable regions - as defined in Aspect la hereinbelow).
  • a full antibody e.g. an antibody comprising a light chain comprising a VL and CL and a heavy chain comprising VH, CHI, CH2 and CH3
  • CD137 antibody has a sequence - including CDRs and variable regions - as defined in Aspect la hereinbelow
  • a Fab which binds h
  • the FIT-Ig is effector-enabled (e.g. as described in any of concepts 30 to 32). In another embodiment, the FIT-Ig is effector-disabled (e.g. is an IgG4 format, or as described in any of concepts 30 or 31).
  • the bispecific antibody has a FIT-Ig format which comprises a full antibody (e.g. an antibody comprising a light chain comprising a VL and CL and a heavy chain comprising VH, CHI, CH2 and CH3) which binds hPD-Ll (optionally wherein the antibody has a structure as defined in any one of concepts 1 to 40, or wherein the antibody has a sequence - including CDRs and variable regions - as defined in Aspect la hereinbelow) and a Fab which binds CD3 (optionally wherein the CD3 Fab has a sequence - including CDRs and variable regions - as defined in Aspect la hereinbelow).
  • the bispecific antibody has a FIT-Ig format which comprises a full antibody (e.g. an antibody comprising a light chain comprising a VL and CL and a heavy chain comprising VH, CHI, CH 2 and CH3) which binds CD3 (optionally wherein the CD3 antibody has a sequence - including CDRs and variable regions - as defined in Aspect la hereinbelow) and a Fab which binds hPD-Ll (optionally wherein the antibody has a structure as defined in any one of concepts 1 to 40, or wherein the antibody has a sequence - including CDRs and variable regions - as defined in Aspect la hereinbelow).
  • a full antibody e.g. an antibody comprising a light chain comprising a VL and CL and a heavy chain comprising VH, CHI, CH 2 and CH3
  • CD3 antibody has a sequence - including CDRs and variable regions - as defined in Aspect la hereinbelow
  • a Fab which binds h
  • the FIT-Ig is effector-enabled (e.g. as described in any of concepts 30 to 32). In another embodiment, the FIT-Ig is effector-disabled (e.g. is an IgG4 format, or as described in any of concepts 30 or 31).
  • the bispecific antibody shall be interpreted as not including a mAb 2 format wherein the Fcab has binding affinity to LAG3.
  • the bispecific antibody has a FIT-Ig format which comprises a full antibody (e.g. an antibody comprising a light chain comprising a VL and CL and a heavy chain comprising VH, CHI, CH2 and CH3) which binds hPD-Ll (optionally wherein the antibody has a structure as defined in any one of concepts 1 to 40, or wherein the antibody has a sequence - including CD s and variable regions - as defined in Aspect la hereinbelow) and a Fab which binds TIGIT (optionally wherein the TIGIT Fab has a sequence - including CDRs and variable regions - as defined in Aspect la hereinbelow).
  • a full antibody e.g. an antibody comprising a light chain comprising a VL and CL and a heavy chain comprising VH, CHI, CH2 and CH3
  • hPD-Ll e.g. an antibody comprising a light chain comprising a VL and CL and a heavy chain comprising VH,
  • the bispecific antibody has a FIT-Ig format which comprises a full antibody (e.g. an antibody comprising a light chain comprising a VL and CL and a heavy chain comprising VH, CHI, CH2 and CH3) which binds TIGIT (optionally wherein the TIGIT antibody has a sequence - including CDRs and variable regions - as defined in Aspect la hereinbelow) and a Fab which binds hPD-Ll (optionally wherein the antibody has a structure as defined in any one of concepts 1 to 40, or wherein the antibody has a sequence - including CDRs and variable regions - as defined in Aspect la hereinbelow).
  • a full antibody e.g. an antibody comprising a light chain comprising a VL and CL and a heavy chain comprising VH, CHI, CH2 and CH3
  • TIGIT antibody has a sequence - including CDRs and variable regions - as defined in Aspect la hereinbelow
  • a Fab which bind
  • the FIT-Ig is effector-enabled (e.g. as described in any of concepts 30 to 32). In another embodiment, the FIT-Ig is effector-disabled (e.g. is an IgG4 format, or as described in any of concepts 30 or 31).
  • the bispecific antibody has a FIT-Ig format which comprises a full antibody (e.g. an antibody comprising a light chain comprising a VL and CL and a heavy chain comprising VH, CHI, CH2 and CH3) which binds hPD-Ll (optionally wherein the antibody has a structure as defined in any one of concepts 1 to 40, or wherein the antibody has a sequence - including CDRs and variable regions - as defined in Aspect la hereinbelow) and a Fab which binds LAG3 (optionally wherein the LAG3 Fab has a sequence - including CDRs and variable regions - as defined in Aspect la hereinbelow).
  • the bispecific antibody has a FIT-Ig format which comprises a full antibody (e.g. an antibody comprising a light chain comprising a VL and CL and a heavy chain comprising VH, CHI, CH2 and CH3) which binds LAG3 (optionally wherein the LAG3 antibody has a sequence - including CDRs and variable regions - as defined in Aspect la hereinbelow) and a Fab which binds hPD-Ll (optionally wherein the antibody has a structure as defined in any one of concepts 1 to 40, or wherein the antibody has a sequence - including CDRs and variable regions - as defined in Aspect la hereinbelow).
  • a full antibody e.g. an antibody comprising a light chain comprising a VL and CL and a heavy chain comprising VH, CHI, CH2 and CH3
  • LAG3 antibody has a sequence - including CDRs and variable regions - as defined in Aspect la hereinbelow
  • a Fab which bind
  • the FIT-Ig is effector-enabled (e.g. as described in any of concepts 30 to 32). In another embodiment, the FIT-Ig is effector-disabled (e.g. is an IgG4 format, or as described in any of concepts 30 or 31).
  • a hPD-Ll-mediated disease or condition e.g. selected from neoplastic or non-neoplastic disease, chronic viral infections, and malignant tumours, such as melanoma, Merkel cell carcinoma, non-small cell lung cancer (squamous and non-squamous), renal cell cancer, bladder cancer, head and neck squamous cell carcinoma, mesothelioma, virally induced cancers (such as cervical cancer and nasopharyngeal cancer), soft tissue sarcomas, haematological malignancies such as Hodgkin's and non-Hodgkin's disease and diffuse large B-cell lymphoma), (for example melanoma, Merkel cell carcinoma, non-small cell lung cancer (squamous and non-squamous), renal cell cancer, bladder cancer, head and neck squamous cell carcinoma and mesothelioma or for example virally
  • a hPD-Ll-mediated disease or condition e.g. selected
  • Concept 42 Use of an antibody or fragment as defined in any one of concepts 1 to 40 in the manufacture of a medicament for administration to a human for treating or preventing a hPD-Ll mediated disease or condition in the human, e.g. selected from neoplastic or non-neoplastic disease, chronic viral infections, and malignant tumours, such as melanoma, Merkel cell carcinoma, non-small cell lung cancer (squamous and non-squamous), renal cell cancer, bladder cancer, head and neck squamous cell carcinoma, mesothelioma, virally induced cancers (such as cervical cancer and nasopharyngeal cancer), soft tissue sarcomas, haematological malignancies such as Hodgkin's and non-Hodgkin's disease and diffuse large B-cell lymphoma (for example melanoma, Merkel cell carcinoma, non-small cell lung cancer (squamous and non-squamous), renal cell cancer, bladder cancer, head and neck squa
  • a method of treating or preventing a hPD-Ll mediated disease or condition e.g. selected from neoplastic or non-neoplastic disease, chronic viral infections, and malignant tumours, such as melanoma, Merkel cell carcinoma, non-small cell lung cancer (squamous and non-squamous), renal cell cancer, bladder cancer, head and neck squamous cell carcinoma, mesothelioma, virally induced cancers (such as cervical cancer and nasopharyngeal cancer), soft tissue sarcomas, haematological malignancies such as Hodgkin's and non-Hodgkin's disease and diffuse large B-cell lymphoma (for example melanoma, Merkel cell carcinoma, non-small cell lung cancer (squamous and non-squamous), renal cell cancer, bladder cancer, head and neck squamous cell carcinoma and mesothelioma or for example virally induced cancers (such as cervical cancer and n
  • the hPD-Ll mediated disease may be any of those as described herein.
  • the hPD-Ll mediated disease is a virally induced cancer, such as cervical cancer and nasopharyngeal cancer, for example cervical cancers caused by HPV infection.
  • the hPD-Ll mediated disease is a chronic viral infection.
  • the hPD-Ll mediated disease is a neoplastic disease.
  • the hPD- Ll mediated disease is a non-neoplastic disease.
  • the hPD-Ll mediated disease is a malignant tumour.
  • the hPD-Ll mediated disease is a cancer which is known to be responsive to PD-L1 therapy, such as melanoma, Merkel cell carcinoma, non-small cell lung cancer (squamous and non-squamous), renal cell cancer, bladder cancer, head and neck squamous cell carcinoma, mesothelioma.
  • the hPD-Ll mediated disease is a cancer which is a soft tissue sarcoma.
  • Concept 44 The antibody or fragment according to concept 41, the use according to concept 42 or the method according to concept 43, wherein the hPD-Ll-mediated disease or condition is cancer.
  • Concept 44a The antibody or fragment according to concept 41, the use according to concept 42 or the method according to concept 43, wherein the hPD-Ll-mediated disease or condition is a neurodegenerative disease, disorder or condition, optionally wherein the neurodegenerative disease, disorder or condition is selected from Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, Huntington's disease, primary progressive multiple sclerosis, secondary progressive multiple sclerosis, corticobasal degeneration, Rett syndrome, a retinal degeneration disorder selected from age-related macular degeneration and retinitis pigmentosa; anterior ischemic optic neuropathy, glaucoma, uveitis, depression, trauma -associated stress or post-traumatic stress disorder, frontotemporal dementia, Lewy body dementias, mild cognitive impairments, posterior cortical atrophy, primary progressive
  • the therapeutically effective amount of an antibody or fragment may comprise an antigen-binding site that specifically binds PD-L1, e.g. hPD-Ll.
  • the antigen-binding site specifically binds PD-L1, e.g. hPD-Ll.
  • the PD-L1 antigen-binding site comprises the CDRH1, CDRH2, CDR3, CDRL1, CDRL2 and CDRL3, or the VH, or the VL or the VH and VL region from any one of the anti-PD-Ll antibodies selected from atezolizumab (Roche), avelumab (Merck), BMS-936559/MDX-1105 (BMS), durvalumab/Medi4736 (Medimmune), KN-035, CA-170, FAZ-053 M7824, ABBV-368, LY-3300054, GNS-1480, YW243.55.S70, REGN3504 and any of the PD-L1 antibodies disclosed in WO2017/034916, WO2017/020291, WO2017/020858, WO2017/020801, WO2016/111645, WO
  • the PD-L1 antigen-binding site comprises the CDRH1, CDRH2, CDR3, CDRLl, CDRL2 and CDRL3, or the VH, or the VL or the VH and VL region from any one of the anti-PD-Ll antibodies selected from an anti-PD-Ll antibody disclosed herein, particularly the anti-PD-Ll antibody clones disclosed in concepts 16a through 161, and more particularly anti-PD-Ll antibody clone 84G09.
  • the PD-L1 antigen-binding site comprises the CDRH1, CDRH2, CDR3, CDRLl, CDRL2 and CDRL3, or the VH, or the VL or the VH and VL region from anti-PD- Ll antibody clone 84G09 and the hPD-Ll-mediated disease or condition is Alzheimer's disease.
  • Concept 45 The antibody or fragment, the use or the method according to concept 44, wherein the cancer is selected from melanoma, Merkel cell carcinoma, non-small cell lung cancer (squamous and non-squamous), renal cell cancer, bladder cancer, head and neck squamous cell carcinoma and mesothelioma or is selected from virally induced cancers (such as cervical cancer and nasopharyngeal cancer) and soft tissue sarcomas.
  • the cancer is selected from melanoma, Merkel cell carcinoma, non-small cell lung cancer (squamous and non-squamous), renal cell cancer, bladder cancer, head and neck squamous cell carcinoma and mesothelioma or is selected from virally induced cancers (such as cervical cancer and nasopharyngeal cancer) and soft tissue sarcomas.
  • immune checkpoint inhibitors such as anti-TIM-3 antibodies, anti-CTLA-4 antibodies, anti-TIGIT antibodies and anti-LAG-3 antibodies;
  • immune stimulators such as anti-OX40 antibodies, anti-GITR antibodies, anti-CD137 antibodies, anti-ICOS antibodies and anti-CD40 antibodies;
  • chemokine receptor antagonists such as CXCR4, CCR4 and CXCR2;
  • targeted kinase inhibitors such as CSF-1R or VEGFR inhibitors
  • angiogenesis inhibitors such as anti-VEGF-A or Delta-like Ligand-4
  • immune stimulating peptides or chemokines such as CXCL9 or CXCL10
  • cytokines such as IL-15 and IL-21
  • bispecific T-cell engagers having at least one specificity against CD3 (e.g. CD3/CD19 BiTE);
  • bi-specific molecules for example IL-15-containing molecules targeted towards tumour associated antigens, for example Epidermal growth factor receptors such as EGFR, Her-2,
  • New York Esophageal Cancer-1 NY-ESO-1
  • GD2 GD2, EpCAM or Melanoma Associated Antigen- 3 (MAGE-A3)
  • MAGE-A3 Melanoma Associated Antigen- 3
  • oncolytic viruses such as HSV virus (optionally which secretes GMCSF), Newcastle disease virus and Vaccinia virus);
  • tumour associated antigens such as New York Esophageal Cancer-1 [NY-
  • ESO-1 Melanoma Associated Antigen-3 [MAGE-3]
  • I. cell-based therapies such as chimeric Antigen Receptor-T-cells (CAR-T) for example expressing anti-CD19, anti-EpCam or anti-mesothelin;
  • CAR-T chimeric Antigen Receptor-T-cells
  • bi-specific NK cell engagers having a specificity against an activating MK receptor such as NKG2D or CD16a;
  • tumour specific T-cells or LAK cells adoptive transfer of tumour specific T-cells or LAK cells
  • tumours are or optionally wherein the further therapy is chemotherapy, radiotherapy and surgical removal of tumours.
  • Radiotherapy may be single dose or in fractionated doses, either delivered to affected tissues directly or to the whole body.
  • Chemotherapeutic agents may any as described hereinabove, in particular, agents that induce immunogenic cell death, for example platinum therapies, such as oxaliplatin.
  • the chemotherapy is a standard of care cytotoxic chemotherapy for the cancer being treated.
  • the bispecific molecules include "bispecific antibodies” and antibody fusion proteins, including those formats and molecules described in concepts 37 to 40.
  • the antibodies may be any of the sequences or antibodies described in arrangement 5, 5a or detailed in Aspect la.
  • the further therapeutic agents of this concept may be delivered by any method, which methods are well-known to those skilled in the art.
  • the further therapeutic agents may be delivered orally, systemically or locally (to the tumour environment).
  • the further therapeutic agent is delivered orally.
  • the further therapeutic agent is delivered systemically (e.g. intravenously).
  • the further therapeutic agent is delivered locally to the tumour environment.
  • compositions and routes of administration are described in more detail hereinbelow.
  • a pharmaceutical composition comprising an antibody of fragment as defined in any one of concepts 1 to 40 and a pharmaceutically acceptable excipient, diluent or carrier and optionally further comprising a further therapeutic agent independently selected from the group consisting of: a) other immune checkpoint inhibitors (such as anti-TIM-3 antibodies, anti-CTLA-4 antibodies, anti-TIGIT antibodies and anti-LAG-3 antibodies);
  • immune stimulators such as anti-OX40 antibodies, anti-GITR antibodies, anti-CD137 antibodies, anti-ICOS antibodies and anti-CD40 antibodies;
  • chemokine receptor antagonists such as CXCR4, CCR4 and CXCR2
  • targeted kinase inhibitors such as CSF-1R or VEGFR inhibitors
  • angiogenesis inhibitors such as anti-VEGF-A or Delta-like Ligand-4
  • immune stimulating peptides or chemokines such as CXCL9 or CXCL10
  • cytokines such as IL-15 and IL-21
  • bispecific T-cell engagers having at least one specificity against CD3 (e.g.
  • bi-specific molecules for example IL-15-containing molecules targeted towards tumour associated antigens, for example Epidermal growth factor receptors such as EGFR, Her-2, New York Esophageal Cancer-1 (NY-ESO-1), GD2, EpCAM or Melanoma Associated Antigen-3 (MAGE-A3);
  • IL-15-containing molecules targeted towards tumour associated antigens for example Epidermal growth factor receptors such as EGFR, Her-2, New York Esophageal Cancer-1 (NY-ESO-1), GD2, EpCAM or Melanoma Associated Antigen-3 (MAGE-A3)
  • IL-15-containing molecules targeted towards tumour associated antigens for example Epidermal growth factor receptors such as EGFR, Her-2, New York Esophageal Cancer-1 (NY-ESO-1), GD2, EpCAM or Melanoma Associated Antigen-3 (MAGE-A3)
  • oncolytic viruses such as HSV virus (optionally which secretes GMCSF), Newcastle disease virus and Vaccinia virus);
  • tumour associated antigens such as New York Esophageal Cancer-1 [NY- ESO-1], Melanoma Associated Antigen-3 [MAGE-3];
  • cell-based therapies such as chimeric Antigen Receptor-T-cells (CAR-T) for example expressing anti-CD19, anti-EpCam or anti-mesothelin;
  • CAR-T chimeric Antigen Receptor-T-cells
  • bi-specific NK cell engagers having a specificity against an activating MK receptor such as
  • tumour specific T-cells or LAK cells adoptive transfer of tumour specific T-cells or LAK cells.
  • the antibody or fragment is administered intravenously. In one embodiment, the antibody or fragment is administered subcutaneously.
  • an antibody or fragment as disclosed herein is contained in a medical container, e.g. a vial, syringe, IV container or an injection device (such as an intraocular or intravitreal injection device).
  • a medical container e.g. a vial, syringe, IV container or an injection device (such as an intraocular or intravitreal injection device).
  • the antibody or fragment is in vitro, for example, in a sterile container.
  • the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings.
  • compositions for intravenous administration are solutions in sterile isotonic aqueous buffer.
  • the composition may also include a solubilizing agent and a local anesthetic such as lignocamne to ease pain at the site of the injection.
  • Such compositions may be administered by a route other than intravenous.
  • compositions are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent.
  • a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent.
  • the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline.
  • an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.
  • the bispecific molecules include "bispecific antibodies” and antibody fusion proteins, including those formats and molecules described in concepts 37 to 40.
  • the further therapeutic agents of this concept may be delivered by any method, which methods are well-known to those skilled in the art.
  • the further therapeutic agents may be delivered orally, systemically or locally (to the tumour environment).
  • the further therapeutic agent is delivered orally.
  • the further therapeutic agent is delivered systemically (e.g. intravenously).
  • the further therapeutic agent is delivered locally to the tumour environment.
  • the antibodies may have any of the sequences or may be any of the antibodies described in arrangement 5, 5a or detailed in aspect la.
  • a hPD-Ll-mediated condition or disease e.g. selected from neoplastic or non-neoplastic disease, chronic viral infections, and malignant tumours, such as
  • a pharmaceutical composition according to concept 48 or concept 49 in combination with, or kit according to concept 49 comprising, a label or instructions for use to treat and/or prevent said disease or condition in a human; optionally wherein the label or instructions comprise a marketing authorisation number (e.g. an FDA or EMA authorisation number); optionally wherein the kit comprises an IV or injection device that comprises the antibody or fragment.
  • a marketing authorisation number e.g. an FDA or EMA authorisation number
  • the kit comprises an IV or injection device that comprises the antibody or fragment.
  • Concept 51 A method of modulating PD-1/PD-L1 interaction in a patient, comprising administering an effective amount of an antibody or fragment as defined in any one of concepts 1 to 40 to said patient.
  • a method of modulating CD80/PD-L1 interaction in a patient comprising administering an effective amount of an antibody or fragment as defined in any one of concepts 1 to 40 to said patient.
  • the antibody or fragment modulates CD80/PD-L1 interaction, but does not modulate PD-1/PD-L1 interaction.
  • the antibody or fragment blocks CD80/PD-L1 interaction, but does not block PD-1/PD-L1 interaction.
  • the antibody or fragment inhibits CD80/PD-L1 interaction, but does not inhibit PD-1/PD-L1 interaction.
  • Ill Concept 52 A method of inhibiting PD-Ll activity in a patient, comprising administering an effective amount of an antibody or fragment as defined in any one of concepts 1 to 40 to said patient.
  • the antibody or fragment blocks or inhibits PD-1 binding to PD-Ll. In one embodiment, the antibody or fragment blocks or inhibits CD80 binding to PD-Ll.
  • Concept 53 A method of treating a proliferative disease in an animal (e.g. a human), comprising administering an effective amount of an antibody or fragment as defined in any one of concepts 1 to 40 to said patient.
  • Proliferative diseases may be any as described elsewhere herein.
  • Concept 54 A method of detecting PD-Ll expression in a sample, comprising contacting the sample with an antibody or fragment as defined in any one of concepts 1 to 40.
  • Concept 55 A method comprising contacting a biological sample with an antibody or fragment as defined in any one of concepts 1 to 40 to form a complex with PD-Ll present in the sample and measuring the presence, absence or level of the complex in the biological sample.
  • Concept 58 The method according to concept 55 or concept 57, wherein the presence, absence and/or level of PD-Ll expression is detected during or after treatment to help determine one or more of: whether treatment has been successful, whether treatment should continue, and/or whether treatment should be modified.
  • Concept 59 The method according to any one of concepts 55 to 58, wherein therapy comprises treatment with an anti-PD-Ll antibody, optionally as defined in any one of concepts 1 to 40.
  • Concept 60 A method for monitoring therapy efficacy, the method comprising detecting expression of surface expressed PD-Ll in a patient prior to therapy, and during or after therapy, wherein an antibody or fragment as defined in any one of concepts 1 to 40 is used to detect expression of surface expressed PD-Ll.
  • Concept 63 A method for identifying binding partners for PD-L1, the method comprising immunoprecipitating an intact protein complex comprising PD-L1 using an antibody or fragment as defined in any one of concepts 1 to 40.
  • Concept 64 A method of diagnosing a disease in a human subject associated with altered PD-L1 expression comprising the steps of contacting a biological sample from the human subject with an antibody as defined in concepts 1 to 40 to form a complex between the antibody and PD-L1 present in the sample; and detecting the amount of the complex.
  • Concept 65 A nucleic acid that encodes the CDRH3 of an antibody or fragment as defined in any one of concepts 1 to 40.
  • the nucleic acid is an isolated and purified nucleic acid.
  • Concept 66 A nucleic acid that encodes a VH domain and/or a VL domain of an antibody or fragment as defined in any one of concepts 1 to 40.
  • the nucleic acid sequence is at least 70% identical to the specified Seq ID No. In one embodiment, the nucleic acid sequence is at least 75% identical to the specified Seq ID No. In one embodiment, the nucleic acid sequence is at least 95% identical to the specified Seq ID No. In one embodiment, the nucleic acid sequence is at least 96% identical to the specified Seq ID No. In one embodiment, the nucleic acid sequence is at least 97% identical to the specified Seq ID No. In one embodiment, the nucleic acid sequence is at least 98% identical to the specified Seq ID No. In one embodiment, the nucleic acid sequence is at least 99% identical to the specified Seq ID No.
  • the nucleic acid sequence is at least 99.5% identical to the specified Seq ID No. Concept 67.
  • the nucleic acid according to concept 66 comprising a nucleotide sequence that is at least 80% identical to the sequence of SEQ ID NO:36 and/or SEQ ID NO:46.
  • a nucleic acid according to concept 66 comprising a nucleotide sequence that is at least 80% identical to the sequence of SEQ ID NO: 16 and/or SEQ ID NO:26.
  • a nucleic acid according to concept 66 comprising a nucleotide sequence that is at least 80% identical to the sequence of SEQ ID NO:61 and/or SEQ ID NO:71.
  • a nucleic acid according to concept 66 comprising a nucleotide sequence that is at least 80% identical to the sequence of SEQ ID NO: 81 and/or SEQ ID NO:91.
  • a nucleic acid according to concept 66 comprising a nucleotide sequence that is at least 80% identical to the sequence of SEQ ID NO: 101 and/or SEQ ID NO: 111.
  • a nucleic acid according to concept 66 comprising a nucleotide sequence that is at least 80% identical to the sequence of SEQ ID NO: 121 and/or SEQ ID NO: 131.
  • a nucleic acid according to concept 66 comprising a nucleotide sequence that is at least 80% identical to the sequence of SEQ ID NO: 161 and/or SEQ ID NO: 171.
  • a nucleic acid according to concept 66 comprising a nucleotide sequence that is at least 80% identical to the sequence of SEQ ID NO: 181 and/or SEQ ID NO: 191.
  • a nucleic acid according to concept 66 comprising a nucleotide sequence that is at least 80% identical to the sequence of SEQ ID NO: 141 and/or SEQ ID NO: 151.
  • a nucleic acid according to concept 66 comprising a nucleotide sequence that is at least 80% identical to the sequence of SEQ ID NO:247 and/or SEQ ID NO:257.
  • a nucleic acid according to concept 66 comprising a nucleotide sequence that is at least 80% identical to the sequence of SEQ ID NO: 267 and/or SEQ ID NO:277.
  • a nucleic acid according to concept 66 comprising a nucleotide sequence that is at least 80% identical to the sequence of SEQ ID NO:287 and/or SEQ ID NO:297.
  • a nucleic acid according to concept 66 comprising a nucleotide sequence that is at least 80% identical to the sequence of SEQ ID NO: 352 and/or SEQ ID NO:362.
  • the nucleic acid sequence is at least 70% identical to the specified Seq ID No. In one embodiment, the nucleic acid sequence is at least 75% identical to the specified Seq ID No. In one embodiment, the nucleic acid sequence is at least 95% identical to the specified Seq ID No. In one embodiment, the nucleic acid sequence is at least 96% identical to the specified Seq ID No. In one embodiment, the nucleic acid sequence is at least 97% identical to the specified Seq ID No. In one embodiment, the nucleic acid sequence is at least 98% identical to the specified Seq ID No. In one embodiment, the nucleic acid sequence is at least 99% identical to the specified Seq ID No. In one embodiment, the nucleic acid sequence is at least 99.5% identical to the specified Seq ID No. Concept 68. A nucleic acid that encodes a heavy chain or a light chain of an antibody as defined in any one of concepts 1 to 40.
  • Concept 69 A vector comprising the nucleic acid of any one of concepts 65 to 68; optionally wherein the vector is a CHO or HEK293 vector.
  • Concept 70 A host comprising the nucleic acid of any one of concepts 65 to 68 or the vector of concept 69.
  • the inventors have described immunoc tokines which comprise an antibody which binds to an immune checkpoint inhibitor, such as PD-L1 fused to either the N-terminus or C-terminus of the heavy chain or the light chain (for example, the C-terminus of the heavy or light chain, and in particular the light chain).
  • the immunocvtokines comprise a cytokine molecule, which may be IL-2 or a variant thereof (including variant having a 1 to 10 amino acid deletion at the N-terminus).
  • the antibodies as described hereinabove may be used in any immunocytokine described herein.
  • immunocytokines of the invention may provide one or more of the following advantageous properties:
  • 1D05 ICK comprises a heavy chain amino acid sequence of Seq ID No:299, and a light chain amino acid sequence of Seq ID No:300.
  • the light chain comprises a VL domain comprising the CDRs and VL sequence of antibody 1D05 described hereinabove, fused at the heavy chain to full length, wild-type, human IL-2 cytokine. It does not contain a linker peptide.
  • the heavy chain comprises a VH domain comprising the CDRs and VH sequence of antibody 1D05 described hereinabove, fused to a disabled IgG constant region (Seq ID No:205).
  • 1D05 D5-9 ICK comprises a heavy chain comprising a VH region amino acid sequence of Seq ID No:33 (comprising the CDRs of 1D05 as described hereinabove) fused to a disabled IgGl constant region with an amino acid sequence of Seq ID No: 205.
  • the light chain comprises a VL amino acid sequence of Seq ID No:43 (comprising the CDRs of 1D05 as described hereinabove) directly fused at the C-terminus to IL-2 D5-9 (Seq ID No:303), which is directly fused to amino acids 21 to 133 of hlL- 2 (Seq ID No:324).
  • 1D05 Dl-9 ICK comprises a heavy chain comprising a VH region amino acid sequence of Seq
  • the light chain comprises a VL amino acid sequence of Seq ID No:43 (comprising the CDRs of 1D05 as described hereinabove) directly fused at the C-terminus to IL-2 Dl-9 (Seq ID No:304), which is directly fused to amino acids 21 to 133 of hlL- 2 (Seq ID No:324).
  • 1D05 D5-7 ICK comprises a heavy chain comprising a VH region amino acid sequence of Seq ID No:33 (comprising the CDRs of 1D05 as described hereinabove) fused to a disabled IgGl constant region with an amino acid sequence of Seq ID No:205.
  • the light chain comprises a VL amino acid sequence of Seq ID No:43 (comprising the CDRs of 1D05 as described hereinabove) directly fused at the C-terminus to IL-2 D5-7 (Seq ID No:305), which is directly fused to amino acids 21 to 133 of hlL- 2 (Seq ID No:324).
  • 1D05 Dl ICK comprises a heavy chain comprising a VH region amino acid sequence of Seq ID No:33 (comprising the CDRs of 1D05 as described hereinabove) fused to a disabled IgGl constant region with an amino acid sequence of Seq ID No:205.
  • the light chain comprises a VL amino acid sequence of Seq ID No:43 (comprising the CDRs of 1D05 as described hereinabove) directly fused at the C-terminus to IL-2 Dl (Seq ID No:306), which is directly fused to amino acids 21 to 133 of hIL-2 (Seq ID No:324).
  • 1D05 Dl-2 ICK comprises a heavy chain comprising a VH region amino acid sequence of Seq ID No:33 (comprising the CDRs of 1D05 as described hereinabove) fused to a disabled IgGl constant region with an amino acid sequence of Seq ID No:205.
  • the light chain comprises a VL amino acid sequence of Seq ID No:43 (comprising the CDRs of 1D05 as described hereinabove) directly fused at the C-terminus to IL-2 Dl-2 (Seq ID No:307), which is directly fused to amino acids 21 to 133 of hlL- 2 (Seq ID No:324).
  • 1D05 Dl-3 ICK comprises a heavy chain comprising a VH region amino acid sequence of Seq ID No:33 (comprising the CDRs of 1D05 as described hereinabove) fused to a disabled IgGl constant region with an amino acid sequence of Seq ID No:205.
  • the light chain comprises a VL amino acid sequence of Seq ID No:43 (comprising the CDRs of 1D05 as described hereinabove) directly fused at the C-terminus to IL-2 Dl-3 (Seq ID No:308), which is directly fused to amino acids 21 to 133 of hlL- 2 (Seq ID No:324).
  • 1D05 Dl-4 ICK comprises a heavy chain comprising a VH region amino acid sequence of Seq ID No:33 (comprising the CDRs of 1D05 as described hereinabove) fused to a disabled IgGl constant region with an amino acid sequence of Seq ID No:205.
  • the light chain comprises a VL amino acid sequence of Seq ID No:43 (comprising the CDRs of 1D05 as described hereinabove) directly fused at the C-terminus to IL-2 Dl-4 (Seq ID No:309), which is directly fused to amino acids 21 to 133 of hlL- 2 (Seq ID No:324).
  • 1D05 Dl-5 ICK comprises a heavy chain comprising a VH region amino acid sequence of Seq ID No:33 (comprising the CDRs of 1D05 as described hereinabove) fused to a disabled IgGl constant region with an amino acid sequence of Seq ID No:205.
  • the light chain comprises a VL amino acid sequence of Seq ID No:43 (comprising the CDRs of 1D05 as described hereinabove) directly fused at the C-terminus to IL-2 Dl-5 (Seq ID No:310), which is directly fused to amino acids 21 to 133 of hlL- 2 (Seq ID No:324).
  • 1D05 Dl-6 ICK comprises a heavy chain comprising a VH region amino acid sequence of Seq
  • the light chain comprises a VL amino acid sequence of Seq ID No:43 (comprising the CDRs of 1D05 as described hereinabove) directly fused at the C-terminus to IL-2 Dl-6 (Seq ID No:311), which is directly fused to amino acids 21 to 133 of hlL- 2 (Seq ID No:324).
  • 1D05 Dl-7 ICK comprises a heavy chain comprising a VH region amino acid sequence of Seq ID No:33 (comprising the CDRs of 1D05 as described hereinabove) fused to a disabled IgGl constant region with an amino acid sequence of Seq ID No:205.
  • the light chain comprises a VL amino acid sequence of Seq ID No:43 (comprising the CDRs of 1D05 as described hereinabove) directly fused at the C-terminus to IL-2 Dl-7 (Seq ID No:312), which is directly fused to amino acids 21 to 133 of hlL- 2 (Seq ID No:324).
  • 1D05 Dl-8 ICK comprises a heavy chain comprising a VH region amino acid sequence of Seq ID No:33 (comprising the CDRs of 1D05 as described hereinabove) fused to a disabled IgGl constant region with an amino acid sequence of Seq ID No:205.
  • the light chain comprises a VL amino acid sequence of Seq ID No:43 (comprising the CDRs of 1D05 as described hereinabove) directly fused at the C-terminus to IL-2 Dl-8 (Seq ID No:313), which is directly fused to amino acids 21 to 133 of hlL- 2 (Seq ID No:324).
  • 1D05 D9 ICK comprises a heavy chain comprising a VH region amino acid sequence of Seq ID No:33 (comprising the CDRs of 1D05 as described hereinabove) fused to a disabled IgGl constant region with an amino acid sequence of Seq ID No:205.
  • the light chain comprises a VL amino acid sequence of Seq ID No:43 (comprising the CDRs of 1D05 as described hereinabove) directly fused at the C-terminus to IL-2 D9 (Seq ID No:314), which is directly fused to amino acids 21 to 133 of hIL-2 (Seq ID No:324).
  • 1D05 D9-8 ICK comprises a heavy chain comprising a VH region amino acid sequence of Seq ID No:33 (comprising the CDRs of 1D05 as described hereinabove) fused to a disabled IgGl constant region with an amino acid sequence of Seq ID No:205.
  • the light chain comprises a VL amino acid sequence of Seq ID No:43 (comprising the CDRs of 1D05 as described hereinabove) directly fused at the C-terminus to IL-2 D9-8 (Seq ID No:315), which is directly fused to amino acids 21 to 133 of hlL- 2 (Seq ID No:324).
  • 1D05 D9-7 ICK comprises a heavy chain comprising a VH region amino acid sequence of Seq ID No:33 (comprising the CDRs of 1D05 as described hereinabove) fused to a disabled IgGl constant region with an amino acid sequence of Seq ID No:205.
  • the light chain comprises a VL amino acid sequence of Seq ID No:43 (comprising the CDRs of 1D05 as described hereinabove) directly fused at the C-terminus to IL-2 D9-7 (Seq ID No:316), which is directly fused to amino acids 21 to 133 of hlL- 2 (Seq ID No:324).
  • 1D05 D9-6 ICK comprises a heavy chain comprising a VH region amino acid sequence of Seq
  • the light chain comprises a VL amino acid sequence of Seq ID No:43 (comprising the CDRs of 1D05 as described hereinabove) directly fused at the C-terminus to IL-2 D9-6 (Seq ID No:317), which is directly fused to amino acids 21 to 133 of hlL- 2 (Seq ID No:324).
  • 1D05 D9-4 ICK comprises a heavy chain comprising a VH region amino acid sequence of Seq ID No:33 (comprising the CDRs of 1D05 as described hereinabove) fused to a disabled IgGl constant region with an amino acid sequence of Seq ID No:205.
  • the light chain comprises a VL amino acid sequence of Seq ID No:43 (comprising the CDRs of 1D05 as described hereinabove) directly fused at the C-terminus to IL-2 D9-4 (Seq ID No:318), which is directly fused to amino acids 21 to 133 of hlL- 2 (Seq ID No:324).
  • 1D05 D9-3 ICK comprises a heavy chain comprising a VH region amino acid sequence of Seq ID No:33 (comprising the CDRs of 1D05 as described hereinabove) fused to a disabled IgGl constant region with an amino acid sequence of Seq ID No:205.
  • the light chain comprises a VL amino acid sequence of Seq ID No:43 (comprising the CDRs of 1D05 as described hereinabove) directly fused at the C-terminus to IL-2 D9-3 (Seq ID No:319), which is directly fused to amino acids 21 to 133 of hlL- 2 (Seq ID No:324).
  • 1D05 D9-2 ICK comprises a heavy chain comprising a VH region amino acid sequence of Seq ID No:33 (comprising the CDRs of 1D05 as described hereinabove) fused to a disabled IgGl constant region with an amino acid sequence of Seq ID No:205.
  • the light chain comprises a VL amino acid sequence of Seq ID No:43 (comprising the CDRs of 1D05 as described hereinabove) directly fused at the C-terminus to IL-2 D9-2 (Seq ID No:320), which is directly fused to amino acids 21 to 133 of hlL- 2 (Seq ID No:324).
  • 1D05 D2-6 ICK comprises a heavy chain comprising a VH region amino acid sequence of Seq ID No:33 (comprising the CDRs of 1D05 as described hereinabove) fused to a disabled IgGl constant region with an amino acid sequence of Seq ID No:205.
  • the light chain comprises a VL amino acid sequence of Seq ID No:43 (comprising the CDRs of 1D05 as described hereinabove) directly fused at the C-terminus to IL-2 D2-6 (Seq ID No:321), which is directly fused to amino acids 21 to 133 of hlL- 2 (Seq ID No:324).
  • 1D05 D3-7 ICK comprises a heavy chain comprising a VH region amino acid sequence of Seq ID No:33 (comprising the CDRs of 1D05 as described hereinabove) fused to a disabled IgGl constant region with an amino acid sequence of Seq ID No:205.
  • the light chain comprises a VL amino acid sequence of Seq ID No:43 (comprising the CDRs of 1D05 as described hereinabove) directly fused at the C-terminus to IL-2 D3-7 (Seq ID No:322), which is directly fused to amino acids 21 to 133 of hlL- 2 (Seq ID No:324).
  • 1D05 D4-8 ICK comprises a heavy chain comprising a VH region amino acid sequence of Seq
  • the light chain comprises a VL amino acid sequence of Seq ID No:43 (comprising the CDRs of 1D05 as described hereinabove) directly fused at the C-terminus to IL-2 D4-8 (Seq ID No:323), which is directly fused to amino acids 21 to 133 of hlL- 2 (Seq ID No:324).
  • the IL-2 binding portion may be a variant IL-2, in particular an IL-2 having an R38A mutation (as described in amino acids 21-133 of the variant IL-2 described as SEQ ID NO: 517) or an R38Q mutation (as described in amino acids 21-133 of the variant IL-2 described as SEQ ID NO:518).
  • the VH region of the 1D05 antibody may be exchanged for the VH region of mutated 1D05 - Heavy Chain mutant 1 (Seq ID No:47), mutated 1D05 - Heavy Chain mutant 2 (Seq ID No:48), mutated 1D05 - Heavy Chain mutant 3 (Seq ID No:49) or mutated 1D05 - Heavy Chain mutant 4 (Seq ID No: 342).
  • a preferred mutated heavy chain VH region of 1D05 is mutated 1D05 - Heavy Chain mutant 4 (Seq ID No:342).
  • Mutated 1D05 - Heavy Chain mutant 4 D5-9 ICK which comprises a heavy chain comprising a VH region amino acid sequence of Seq ID No:342 (comprising the CDRs of mutated 1D05 - Heavy Chain mutant 4 as described herein) fused to a disabled IgGl constant region with an amino acid sequence of Seq ID No:205.
  • the light chain comprises a VL amino acid sequence of Seq ID No:43 (comprising the CDRs of 1D05 as described hereinabove) directly fused at the C-terminus to IL-2 D5- 9 (Seq ID No:303), which is directly fused to amino acids 21 to 133 of hIL-2 (Seq ID No:324).
  • Mutated 1D05 - Heavy Chain mutant 4 Dl-9 ICK which comprises a heavy chain comprising a VH region amino acid sequence of Seq ID No:342 (comprising the CD s of mutated 1D05 - Heavy Chain mutant 4 as described herein) fused to a disabled IgGl constant region with an amino acid sequence of Seq ID No:205.
  • the light chain comprises a VL amino acid sequence of Seq ID No:43 (comprising the CDRs of 1D05 as described hereinabove) directly fused at the C-terminus to IL-2 Dl- 9 (Seq ID No:304), which is directly fused to amino acids 21 to 133 of hIL-2 (Seq ID No:324).
  • Mutated 1D05 - Heavy Chain mutant 4 Dl-8 ICK which comprises a heavy chain comprising a VH region amino acid sequence of Seq ID No:342 (comprising the CDRs of mutated 1D05 - Heavy Chain mutant 4 as described herein) fused to a disabled IgGl constant region with an amino acid sequence of Seq ID No:205.
  • the light chain comprises a VL amino acid sequence of Seq ID No:43 (comprising the CDRs of 1D05 as described hereinabove) directly fused at the C-terminus to IL-2 Dl- 8 (Seq ID No:313), which is directly fused to amino acids 21 to 133 of hIL-2 (Seq ID No:324).
  • Mutated 1D05 - Heavy Chain mutant 4 D9-7 ICK which comprises a heavy chain comprising a VH region amino acid sequence of Seq ID No:342 (comprising the CDRs of mutated 1D05 - Heavy Chain mutant 4 as described herein) fused to a disabled IgGl constant region with an amino acid sequence of Seq ID No:205.
  • the light chain comprises a VL amino acid sequence of Seq ID No:43 (comprising the CDRs of 1D05 as described hereinabove) directly fused at the C-terminus to IL-2 D9- 7 (Seq ID No:316), which is directly fused to amino acids 21 to 133 of hIL-2 (Seq ID No:324).
  • Mutated 1D05 - Heavy Chain mutant 4 D9-2 ICK which comprises a heavy chain comprising a VH region amino acid sequence of Seq ID No:342 (comprising the CDRs of mutated 1D05 - Heavy Chain mutant 4 as described herein) fused to a disabled IgGl constant region with an amino acid sequence of Seq ID No:205.
  • the light chain comprises a VL amino acid sequence of Seq ID No:43 (comprising the CDRs of 1D05 as described hereinabove) directly fused at the C-terminus to IL-2 D9- 2 (Seq ID No:320), which is directly fused to amino acids 21 to 133 of hIL-2 (Seq ID No:324).
  • the VL region of the 1D05 antibody may be exchanged for the VL region of mutated 1D05 - Light Chain mutant 1 (Seq ID No: 50), mutated 1D05 - Light Chain mutant 2 (Seq ID No: 51) or mutated 1D05 - Light Chain mutant 3 (Seq ID No:298).
  • both the VH and VL region of the 1D05 antibody may be exchanged for both the VH and VL regions of any of the other antibodies described herein, i.e. 84G09, 411B08, 411C04, 411D07, 385F01, 413D08, 386H03, 389A03, 413G05, 413F09 and 414B06.
  • the heavy chain constant region of Seq ID No:205 may be exchanged for any of the heavy chain constant regions of Seq ID Nos:193, 195, 197, 199, 203, 205, 340, 524, 526, 528, 530, 532 or 534.
  • Immunocytokine comprising an immunoglobulin heavy chain and an immunoglobulin light chain, wherein the heavy chain comprises in N- to C-terminal direction:
  • VH domain comprising CDRH1, CDRH2 and CDRH3;
  • VL domain comprising CDRL1, CDRL2 and CDRL3;
  • VH domain and VL domain are comprised by an antigen-binding site that specifically binds to hPD-Ll as defined by Seq ID No: l, and competes for binding to said hPD-Ll with the antibody 1D05; and wherein the immunocytokine comprises a VH domain which comprises a CDRH3 comprising the motif X1GSGX2YGX3X4FD, wherein Xi, X2 and X3 are independently any amino acid, and X 4 is either present or absent, and if present, may be any amino acid.
  • CDR sequences may be determined according to any method known to those skilled in the art, such as using the Kabat method, the IMGT method or the Chothia method, each of which are described in more detail herein.
  • the CDR regions are human CDR regions.
  • the VH and/or VL domains may further comprise framework regions, such as FW1, FW2 and FW3.
  • the VH and/or VLdomains may be of any origin described herein, and may be for example, fully human, humanised, murine or camelid .
  • the VH and/or VL domains are human VH and/or VL domains.
  • CDRs may be of a non-human origin (e.g. mouse origin) and be grafted onto human framework regions. In another embodiment, the CDRs are synthetic.
  • VH regions may be selected from the group consisting of an antibody variable domain (e.g. a VL or a VH, an antibody single variable domain (domain antibody or dAb), a camelid VHH antibody single variable domain, a shark immunoglobulin single variable domain (NARV), a NanobodyTM or a camelised VH single variable domain); a T-cell receptor binding domain; an immunoglobulin superfamily domain; an agnathan variable lymphocyte receptor; a fibronectin domain (e.g. an AdnectinTM); an antibody constant domain (e.g. a CH3 domain, e.g.
  • a CH2 and/or CH3 of an FcabTM wherein the constant domain is not a functional CHi domain; an scFv; an (scFv)2; an sc- diabody; an scFab; a centyrin and an epitope binding domain derived from a scaffold selected from CTLA-4 (EvibodyTM); a lipocalin domain; Protein A such as Z-domain of Protein A (e.g. an AffibodyTM or SpA); an A-domain (e.g. an AvimerTM or MaxibodyTM); a heat shock protein (such as and epitope binding domain derived from GroEI and GroES); a transferrin domain (e.g.
  • trans-body a trans-body
  • ankyrin repeat protein e.g. a DARPinTM
  • peptide aptamer e.g. TetranectinTM
  • C-type lectin domain e.g. TetranectinTM
  • human ⁇ - crystallin or human ubiquitin an affilin
  • PDZ domain e.g. scorpion toxin
  • kunitz type domain of a human protease inhibitor e.g. a trans-body
  • ankyrin repeat protein e.g. a DARPinTM
  • peptide aptamer e.g. TetranectinTM
  • human ⁇ - crystallin or human ubiquitin an affilin
  • PDZ domain e.g. PDZ domain
  • scorpion toxin e.g., scorpion toxin
  • kunitz type domain of a human protease inhibitor e.g. a kunitz type domain of a
  • the constant region comprises at least two heavy chain constant region domains selected from CHi, CH2, CH3 and CH4.
  • the constant region comprises (or consists of) a CHi domain and a CH2 domain.
  • the constant region comprises (or consists of) a CHi domain, a hinge region and a CH2 domain.
  • the constant region comprises (or consists of) a CHi domain and a CH3 domain, and optionally a hinge region.
  • the constant region comprises (or consists of) a CHi domain and a CH4 domain, and optionally a hinge region.
  • the constant region comprises (or consists of) a CHi domain, a CH2 domain and a CH3 domain, and optionally a hinge region.
  • the constant region comprises (or consists of) a CHi domain, a CH2 domain and a CH4 domain, and optionally a hinge region. In one embodiment, the constant region comprises (or consists of) a CHi domain, a CH3 domain and a CH4 domain, and optionally a hinge region. In one embodiment, the constant region comprises (or consists of) a full constant region.
  • the constant region may be of any isotype described herein, e.g. IgA, IgD, IgE, IgG, and IgM.
  • the constant region is of any origin described herein, and may be for example, human, murine or camelid. In one embodiment, the constant region is a (full) human constant region. In one embodiment, the constant region is a human IgG constant region. In one embodiment, the constant region is a (full) human IgGl constant region. In one embodiment, the constant region is an effector null (full) human IgGl constant region. In one embodiment, the constant region has CDC and/or ADCC and/or ADCP activity. In one embodiment, the constant region is engineered to enhance the CDC and/or ADCC and/or ADCP activity. The constant region may be any of the constant regions described in concepts 30 to 32 hereinabove.
  • the light chain constant region may be a kappa or lambda light chain constant region.
  • the light chain constant region may be as described in concept 28 hereinabove.
  • An IL-2 cytokine is a cytokine molecule which confers IL-2 activity on one or both of the intermediate affinity IL-2 Receptor ( ⁇ ) and the high affinity IL-2 receptor ( ⁇ ).
  • An IL-2 cytokine includes variant IL-2 cytokines.
  • An IL-2 cytokine may be of human origin or of non-human origin, for example of a non-human mammal, including, but not limited to, primates (e.g.
  • an IL-2 cytokine is a human IL-2 cytokine.
  • a "variant IL-2 cytokine” is a cytokine having up to 10 amino acids deleted from the N terminal sequence, in combination with up to 5 amino acid substitutions, deletions or additions elsewhere in the IL-2 cytokine.
  • the variant IL-2 cytokine comprises (or consists of) up to 10 (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) amino acid deletions from the N-terminal sequence (e.g. within the first 20, or first 15, or first 10 amino acids of the wild-type IL-2 sequence in question), in combination with up to 5 (e.g. 1, 2, 3, 4 or 5) amino acid substitutions elsewhere in the IL-2 cytokine.
  • the variant IL-2 cytokine comprises (or consists of) up to 10 (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) amino acid deletions from the N-terminal sequence (e.g. within the first 15 amino acids of the wild-type IL-2 sequence in question), in combination with up to 5 (e.g. 1, 2, 3, 4 or 5) amino acid substitutions elsewhere in the IL-2 cytokine.
  • the variant IL-2 cytokine comprises (or consists of) up to 10 (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) amino acid deletions from the N-terminal sequence (e.g. within the first 10 amino acids of the wild-type IL-2 sequence in question), in combination with up to 5 (e.g.
  • the variant IL-2 cytokine comprises (or consists of) up to 10 (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) amino acid deletions from the N-terminal sequence (e.g. within the first 20, or first 15, or first 10 amino acids of the wild-type IL-2 sequence in question), in combination with up to 4 (e.g. 1, 2, 3 or 4) amino acid substitutions elsewhere in the IL-2 cytokine.
  • the variant IL-2 cytokine comprises (or consists of) up to 10 (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) amino acid deletions from the N-terminal sequence (e.g.
  • the variant IL-2 cytokine comprises (or consists of) up to 10 (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) amino acid deletions from the N-terminal sequence (e.g. within the first 20, or first 15, or first 10 amino acids of the wild-type IL-2 sequence in question), in combination with up to 2 (e.g. 1 or 2) amino acid substitutions elsewhere in the IL-2 cytokine.
  • the variant IL-2 cytokine comprises (or consists of) up to 10 (e.g.
  • amino acid deletions from the N-terminal sequence e.g. within the first 20, or first 15, or first 10 amino acids of the wild-type IL-2 sequence in question, in combination with 1 amino acid substitution elsewhere in the IL-2 cytokine.
  • the variant IL-2 cytokine comprises (or consists of) up to 9 (e.g. 1, 2, 3, 4, 5, 6, 7, 8 or 9) amino acid deletions from the N-terminal sequence (e.g. within the first 20, or first 15, or first 10 amino acids of the wild-type IL-2 sequence in question), in combination with up to 4 (e.g. 1, 2, 3 or 4) amino acid substitutions elsewhere in the IL-2 cytokine.
  • the variant IL-2 cytokine comprises (or consists of) up to 9 (e.g. 1, 2, 3, 4, 5, 6, 7, 8 or 9) amino acid deletions from the N-terminal sequence (e.g.
  • the variant IL-2 cytokine comprises (or consists of) up to 9 (e.g. 1, 2, 3, 4, 5, 6, 7, 8 or 9) amino acid deletions from the N-terminal sequence (e.g. within the first 20, or first 15, or first 10 amino acids of the wild-type IL-2 sequence in question), in combination with up to 2 (e.g. 1 or 2) amino acid substitutions elsewhere in the IL-2 cytokine.
  • the variant IL-2 cytokine comprises (or consists of) up to 9 (e.g.
  • the variant IL-2 cytokine comprises (or consists of) up to 8 (e.g. 1, 2, 3, 4, 5, 6, 7 or 8) amino acid deletions from the N-terminal sequence (e.g. within the first 20, or first 15, or first 10 amino acids of the wild-type IL-2 sequence in question), in combination with up to 4 (e.g . 1, 2, 3 or 4) amino acid substitutions elsewhere in the IL-2 cytokine.
  • the variant IL-2 cytokine comprises (or consists of) up to 8 (e.g. 1, 2, 3, 4, 5, 6, 7 or 8) amino acid deletions from the N-terminal sequence (e.g. within the first 20, or first 15, or first 10 amino acids of the wild-type IL-2 sequence in question), in combination with up to 3 (e.g. 1, 2 or 3) amino acid substitutions elsewhere in the IL-2 cytokine.
  • the variant IL-2 cytokine comprises (or consists of) up to 8 (e.g. 1, 2, 3, 4, 5, 6, 7 or 8) amino acid deletions from the N-terminal sequence (e.g.
  • the variant IL-2 cytokine comprises (or consists of) up to 8 (e.g. 1, 2, 3, 4, 5, 6, 7 or 8) amino acid deletions from the N-terminal sequence (e.g. within the first 20, or first 15, or first 10 amino acids of the wild-type IL-2 sequence in question), in combination with one amino acid substitution elsewhere in the IL-2 cytokine.
  • the variant IL-2 cytokine comprises (or consists of) up to 7 (e.g. 1, 2, 3, 4, 5, 6 or 7) amino acid deletions from the N-terminal sequence (e.g. within the first 20, or first 15, or first 10 amino acids of the wild-type IL-2 sequence in question), in combination with up to 4 (e.g .
  • the variant IL-2 cytokine comprises (or consists of) up to 7 (e.g . 1, 2, 3, 4, 5, 6 or 7) amino acid deletions from the N-terminal sequence (e.g. within the first 20, or first 15, or first 10 amino acids of the wild-type IL-2 sequence in question), in combination with up to 3 (e.g. 1, 2 or 3) amino acid substitutions elsewhere in the IL-2 cytokine.
  • the variant IL-2 cytokine comprises (or consists of) up to 7 (e.g. 1, 2, 3, 4, 5, 6 or 7) amino acid deletions from the N-terminal sequence (e.g.
  • the variant IL-2 cytokine comprises (or consists of) up to 7 (e.g . 1, 2, 3, 4, 5, 6 or 7) amino acid deletions from the N-terminal sequence (e.g. within the first 20, or first 15, or first 10 amino acids of the wild-type IL-2 sequence in question), in combination with one amino acid substitution elsewhere in the IL-2 cytokine.
  • the variant IL-2 cytokine comprises (or consists of) up to 6 (e.g. 1, 2, 3, 4, 5 or 6) amino acid deletions from the N-terminal sequence (e.g. within the first 20, or first 15, or first 10 amino acids of the wild-type IL-2 sequence in question), in combination with up to 4 (e.g. 1,
  • the variant IL- 2 cytokine comprises (or consists of) up to 6 (e.g. 1, 2, 3, 4, 5 or 6) amino acid deletions from the N- terminal sequence (e.g. within the first 20, or first 15, or first 10 amino acids of the wild-type IL-2 sequence in question), in combination with up to 3 (e.g. 1, 2 or 3) amino acid substitutions elsewhere in the IL-2 cytokine.
  • the variant IL-2 cytokine comprises (or consists of) up to 6 (e.g. 1, 2, 3, 4, 5 or 6) amino acid deletions from the N-terminal sequence (e.g. within the first 20, or first 15, or first 10 amino acids of the wild-type IL-2 sequence in question), in combination with up to
  • the variant IL-2 cytokine comprises (or consists of) up to 5 (e.g. 1, 2, 3,
  • the variant IL-2 cytokine comprises (or consists of) up to 5 (e.g. 1, 2, 3, 4 or 5) amino acid deletions from the N- terminal sequence (e.g. within the first 20, or first 15, or first 10 amino acids of the wild-type IL-2 sequence in question), in combination with up to 4 (e.g. 1, 2, 3 or 4) amino acid substitutions elsewhere in the IL-2 cytokine.
  • the variant IL-2 cytokine comprises (or consists of) up to 5 (e.g. 1, 2, 3, 4 or 5) amino acid deletions from the N- terminal sequence (e.g. within the first 20, or first 15, or first 10 amino acids of the wild-type IL-2 sequence in question), in combination with up to 4 (e.g. 1, 2, 3 or 4) amino acid substitutions elsewhere in the IL-2 cytokine.
  • the variant IL-2 cytokine comprises (or consists of) up to 5 (e.g. 1, 2, 3, 4 or 5) amino acid deletions from the N-terminal sequence (e.g. within the first 20, or first 15, or first 10 amino acids of the wild-type IL-2 sequence in question), in combination with up to 4 (e.g. 1, 2, 3 or 4) amino acid substitutions elsewhere in the IL-2 cytokine.
  • the variant IL-2 cytokine comprises (or consists of) up to 6 (e.g. 1, 2, 3, 4, 5 or 6) amino acid deletions from the N-terminal sequence (e.g. within the first 20, or first 15, or first 10 amino acids of the wild-type IL-2 sequence in question), in combination with one amino acid substitution elsewhere in the IL-2 cytokine.
  • the variant IL-2 cytokine comprises (or consists of) up to 4 (e.g. 1, 2, 3 or 4) amino acid deletions from the N-terminal sequence (e.g. within the first 20, or first 15, or first 10 amino acids of the wild-type IL-2 sequence in question), in combination with up to 4 (e.g. 1, 2, 3 or 4) amino acid substitutions elsewhere in the IL-2 cytokine.
  • the variant IL-2 cytokine comprises (or consists of) up to 4 (e.g. 1, 2, 3 or 4) amino acid deletions from the N-terminal sequence (e.g. within the first 20, or first 15, or first 10 amino acids of the wild-type IL-2 sequence in question), in combination with up to 3 (e.g. 1, 2 or 3) amino acid substitutions elsewhere in the IL-2 cytokine.
  • the variant IL-2 cytokine comprises (or consists of) up to 4 (e.g. 1, 2,
  • the variant IL-2 cytokine comprises (or consists of) up to 4 (e.g. 1, 2, 3 or 4) amino acid deletions from the N-terminal sequence (e.g. within the first 20, or first 15, or first 10 amino acids of the wild-type IL-2 sequence in question), in combination with one amino acid substitution elsewhere in the IL-2 cytokine.
  • the variant IL-2 cytokine comprises (or consists of) up to 3 (e.g. 1, 2 or 3) amino acid deletions from the N-terminal sequence (e.g. within the first 20, or first 15, or first 10 amino acids of the wild-type IL-2 sequence in question), in combination with up to 4 (e.g. 1, 2, 3 or 4) amino acid substitutions elsewhere in the IL-2 cytokine.
  • the variant IL-2 cytokine comprises (or consists of) up to 3 (e.g. 1, 2 or 3) amino acid deletions from the N-terminal sequence (e.g. within the first 20, or first 15, or first 10 amino acids of the wild-type IL-2 sequence in question), in combination with up to 3 (e.g.
  • the variant IL-2 cytokine comprises (or consists of) up to 3 (e.g. 1, 2 or 3) amino acid deletions from the N-terminal sequence (e.g. within the first 20, or first 15, or first 10 amino acids of the wild-type IL-2 sequence in question), in combination with up to 2 (e.g. 1 or 2) amino acid substitutions elsewhere in the IL-2 cytokine.
  • the variant IL-2 cytokine comprises (or consists of) up to 3 (e.g. 1, 2 or 3) amino acid deletions from the N-terminal sequence (e.g. within the first 20, or first 15, or first 10 amino acids of the wild-type IL-2 sequence in question), in combination with one amino acid substitution elsewhere in the IL-2 cytokine.
  • the variant IL-2 cytokine comprises (or consists of) 1 or 2 amino acid deletions from the N-terminal sequence (e.g. within the first 20, or first 15, or first 10 amino acids of the wild-type IL-2 sequence in question), in combination with up to 4 (e.g. 1, 2, 3 or 4) amino acid substitutions elsewhere in the IL-2 cytokine.
  • the variant IL-2 cytokine comprises (or consists of) 1 or 2 amino acid deletions from the N-terminal sequence (e.g. within the first 20, or first 15, or first 10 amino acids of the wild-type IL-2 sequence in question), in combination with up to 3 (e.g. 1, 2 or 3) amino acid substitutions elsewhere in the IL-2 cytokine.
  • the variant IL-2 cytokine comprises (or consists of) 1 or 2 amino acid deletions from the N-terminal sequence (e.g. within the first 20, or first 15, or first 10 amino acids of the wild-type IL-2 sequence in question), in combination with up to 2 (e.g. 1 or 2) amino acid substitutions elsewhere in the IL-2 cytokine. In one embodiment, the variant IL-2 cytokine comprises (or consists of) 1 or 2 amino acid deletions from the N-terminal sequence (e.g. within the first 20, or first 15, or first 10 amino acids of the wild-type IL-2 sequence in question), in combination with one amino acid substitution elsewhere in the IL-2 cytokine.
  • IL-2 cytokines and variant IL-2 cytokines are further defined in aspects 40 to 45 hereinbelow.
  • the amino acid sequence of the a-chain of human IL-2 is provided in Seq ID No: 327.
  • the amino acid sequence of the ⁇ -chain of human IL-2 is provided in Seq ID No:328.
  • the amino acid sequence of the ⁇ -chain of human IL-2 is provided in Seq ID No:239.
  • an immunocytokine or anti-PDLl antibody or fragment may have a half-life of at least 4 hours, 5 hours, 6 hours, 7 hours or 8 hours.
  • the half-life of any of the immunocytokines or anti-PD-Ll antibodies or fragments provided herein is at least 9 hours, or at least 10 hours, or at least 11 hours, or at least 12 hours.
  • the half-life of any of the immunocytokines or anti-PD-Ll antibodies or fragments provided herein is at least 13 hours, or at least 14 hours, or at least 15 hours, or at least 16 hours.
  • the half-life of any of the immunocytokines or anti-PD-Ll antibodies or fragments provided herein is at least 17 hours, or at least 18 hours, or at least 19 hours, or at least 20 hours. In another embodiment, the half-life of any of the immunocytokines or anti-PD-Ll antibodies or fragments provided herein is at least 21 hours, or at least 22 hours, or at least 23 hours, or at least 24 hours. In another embodiment, the half-life of any of the immunocytokines or anti-PD-Ll antibodies or fragments provided herein is at least 25 hours, or at least 26 hours, or at least 27 hours, or at least 30 hours.
  • the half-life of any of the immunocytokines or anti-PD-Ll antibodies or fragments provided herein is at least 32 hours, or at least 34 hours, or at least 36 hours, or at least 40 hours.
  • the half-life is determined in a mouse model (for example a human PD-L1 knock-in mouse, e.g. as described in Example 22 hereinbelow, or in an immunocompromised mouse xenografted with human T-cells).
  • the half life is determined in a single dose study in cynomolgus monkeys (e.g. as described in Example 18 or Example 23 hereinbelow).
  • the half life is determined in an extended single dose study in cynomolgus monkeys (e.g. as described in Example 19 or Example 26 hereinbelow).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
PCT/GB2017/051795 2016-06-20 2017-06-20 Anti-pd-l1 and il-2 cytokines Ceased WO2017220989A1 (en)

Priority Applications (34)

Application Number Priority Date Filing Date Title
JP2019518159A JP7461741B2 (ja) 2016-06-20 2017-06-20 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
CN201780045595.4A CN109475602B (zh) 2016-06-20 2017-06-20 抗pd-l1和il-2细胞因子
EP17734405.8A EP3471753A1 (en) 2016-06-20 2017-06-20 Anti-pd-l1 and il-2 cytokines
RU2018147423A RU2769282C2 (ru) 2016-06-20 2017-06-20 Анти-PD-L1 и IL-2 цитокины
BR112018076281-4A BR112018076281A2 (pt) 2016-06-20 2017-06-20 imunocitocina, uso de uma imunocitocina, método, composição farmacêutica, método para tratar uma doença proliferativa em um animal, ácido nucleico, vetor, hospedeiro e anticorpo ou fragmento do mesmo
US16/311,434 US11965026B2 (en) 2016-06-20 2017-06-20 Anti-PD-L1 and IL-2 cytokines
KR1020197001344A KR102531889B1 (ko) 2016-06-20 2017-06-20 항-pd-l1 및 il-2 사이토카인
CA3026474A CA3026474A1 (en) 2016-06-20 2017-06-20 Anti-pd-l1 and il-2 cytokines
CN201780045638.9A CN109689688B (zh) 2016-08-09 2017-08-09 抗icos抗体
TW106126908A TWI760352B (zh) 2016-08-09 2017-08-09 抗ｉｃｏｓ抗體
EP17752162.2A EP3497128A2 (en) 2016-08-09 2017-08-09 Anti-icos antibodies
KR1020237009918A KR20230044038A (ko) 2016-08-09 2017-08-09 항-icos 항체
JP2019529699A JP7198752B2 (ja) 2016-08-09 2017-08-09 抗ｉｃｏｓ抗体
US16/323,980 US11858996B2 (en) 2016-08-09 2017-08-09 Anti-ICOS antibodies
KR1020197006706A KR102604433B1 (ko) 2016-08-09 2017-08-09 항-icos 항체
CN202310348318.8A CN117736325A (zh) 2016-08-09 2017-08-09 分离抗体及其应用
BR112019002529-4A BR112019002529A2 (pt) 2016-08-09 2017-08-09 anticorpo isolado, composição, método para modular o equilíbrio de células t, método para tratar uma doença ou afecção tratável com terapia, método para tratar câncer, combinação de anticorpo igg1, anticorpo anti-icos, mamífero não humano transgênico, e método para produzir um anticorpo
CA3032897A CA3032897A1 (en) 2016-08-09 2017-08-09 Anti-icos antibodies
CN202310636091.7A CN116640214A (zh) 2016-08-09 2017-08-09 分离抗体及其应用
RU2019104980A RU2764548C2 (ru) 2016-08-09 2017-08-09 Анти-icos антитела
PCT/GB2017/052352 WO2018029474A2 (en) 2016-08-09 2017-08-09 Anti-icos antibodies
US15/698,600 US9957323B2 (en) 2016-06-20 2017-09-07 Anti-ICOS antibodies
EP17840565.0A EP3559041A1 (en) 2016-12-20 2017-12-19 Multispecific antibody with combination therapy for immuno-oncology
US16/471,161 US20200190191A1 (en) 2016-12-20 2017-12-19 Multispecific antibody with combination therapy for immuno-oncology
PCT/GB2017/053826 WO2018115859A1 (en) 2016-12-20 2017-12-19 Multispecific antibody with combination therapy for immuno-oncology
JP2019533195A JP7290568B2 (ja) 2016-12-20 2017-12-19 癌免疫療法のための併用療法での多重特異性抗体
US17/727,309 US20220403029A1 (en) 2016-08-09 2022-04-22 Anti-icos antibodies
US17/727,288 US20220380467A1 (en) 2016-08-09 2022-04-22 Anti-icos antibodies
JP2022089801A JP7448586B2 (ja) 2016-08-09 2022-06-01 抗ｉｃｏｓ抗体
JP2022143907A JP2022180438A (ja) 2016-06-20 2022-09-09 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
JP2023016174A JP7750887B2 (ja) 2016-12-20 2023-02-06 癌免疫療法のための併用療法での多重特異性抗体
US18/499,431 US20240158502A1 (en) 2016-08-09 2023-11-01 Anti-icos antibodies
JP2023205810A JP7781129B2 (ja) 2016-08-09 2023-12-06 抗ｉｃｏｓ抗体
US18/592,425 US20240360218A1 (en) 2016-06-20 2024-02-29 Anti-pd-l1 and il-2 cytokines

Applications Claiming Priority (24)

Application Number Priority Date Filing Date Title
US201662352291P 2016-06-20 2016-06-20
US62/352,291 2016-06-20
US15/211,504 US9567399B1 (en) 2016-06-20 2016-07-15 Antibodies and immunocytokines
US15/211,504 2016-07-15
GB1613683.0 2016-08-09
GB201613683 2016-08-09
GB1615224.1 2016-09-07
GBGB1615224.1A GB201615224D0 (en) 2016-09-07 2016-09-07 Antibodies
GBGB1615335.5A GB201615335D0 (en) 2016-09-09 2016-09-09 Antibodies and immunocytokines
GB1615335.5 2016-09-09
US15/354,971 2016-11-17
US15/354,971 US9617338B1 (en) 2016-06-20 2016-11-17 Antibodies and immunocytokines
GBGB1620414.1A GB201620414D0 (en) 2016-12-01 2016-12-01 Antibodies
GB1620414.1 2016-12-01
GBGB1621782.0A GB201621782D0 (en) 2016-12-20 2016-12-20 Antibodies and immunocytokines PD-L1 specific antibodies and PD-L1 specific immunocytokines
GB1621782.0 2016-12-20
GBGB1702339.1A GB201702339D0 (en) 2017-02-13 2017-02-13 Antibodies and immunocytokines PD-L1 Specific antiboies and PD-L1 Specific immunocytokines
GBGB1702338.3A GB201702338D0 (en) 2017-02-13 2017-02-13 Antibodies and immunocytokines PD-L1 specific antibodies and specific immunocytokines
GB1702339.1 2017-02-13
GB1702338.3 2017-02-13
GBGB1703071.9A GB201703071D0 (en) 2017-02-24 2017-02-24 Antibodies
GB1703071.9 2017-02-24
US15/480,525 US10604576B2 (en) 2016-06-20 2017-04-06 Antibodies and immunocytokines
US15/480,525 2017-04-06

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/311,434 A-371-Of-International US11965026B2 (en) 2016-06-20 2017-06-20 Anti-PD-L1 and IL-2 cytokines
US18/592,425 Continuation US20240360218A1 (en) 2016-06-20 2024-02-29 Anti-pd-l1 and il-2 cytokines

Publications (2)

Publication Number Publication Date
WO2017220989A1 true WO2017220989A1 (en) 2017-12-28
WO2017220989A8 WO2017220989A8 (en) 2018-12-27

Family

ID=59713385

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/GB2017/051795 Ceased WO2017220989A1 (en) 2016-06-20 2017-06-20 Anti-pd-l1 and il-2 cytokines
PCT/GB2017/051794 Ceased WO2017220988A1 (en) 2016-06-20 2017-06-20 Multispecific antibodies for immuno-oncology
PCT/GB2017/051796 Ceased WO2017220990A1 (en) 2016-06-20 2017-06-20 Anti-pd-l1 antibodies

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/GB2017/051794 Ceased WO2017220988A1 (en) 2016-06-20 2017-06-20 Multispecific antibodies for immuno-oncology
PCT/GB2017/051796 Ceased WO2017220990A1 (en) 2016-06-20 2017-06-20 Anti-pd-l1 antibodies

Country Status (16)

Country Link
US (4) US12209128B2 (enExample)
EP (2) EP3471753A1 (enExample)
JP (5) JP7261379B2 (enExample)
KR (2) KR102379464B1 (enExample)
CN (3) CN109475602B (enExample)
AU (1) AU2017281830B2 (enExample)
BR (2) BR112018076260A2 (enExample)
CA (2) CA3026477A1 (enExample)
IL (1) IL263834B2 (enExample)
MX (1) MX2018016364A (enExample)
NZ (2) NZ789594A (enExample)
RU (2) RU2769282C2 (enExample)
SG (1) SG11201810509PA (enExample)
TW (4) TW201803905A (enExample)
WO (3) WO2017220989A1 (enExample)
ZA (1) ZA201900353B (enExample)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019173832A2 (en) 2018-03-09 2019-09-12 AskGene Pharma, Inc. Novel cytokine prodrugs
WO2020020307A1 (en) * 2018-07-25 2020-01-30 I-Mab Biopharma Co., Ltd. Anti-cd73 anti-pd-l1 bispecific antibodies
KR20200032009A (ko) * 2018-09-17 2020-03-25 (주)지아이이노베이션 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도
WO2020088459A1 (en) * 2018-10-29 2020-05-07 1Globe Biomedical Co., Ltd. Novel rationally designed protein compositions
WO2020098785A1 (zh) * 2018-11-16 2020-05-22 南京金斯瑞生物科技有限公司 人源化抗人pd-l1单克隆抗体及其制备方法和用途
WO2020130300A1 (ko) * 2018-12-21 2020-06-25 한미약품 주식회사 신규 면역 억제 인터루킨 2
WO2020264318A1 (en) * 2019-06-26 2020-12-30 The Johns Hopkins University Methods and materials for targeted expansion of regulatory t cells
WO2021062406A1 (en) 2019-09-28 2021-04-01 AskGene Pharma, Inc. Cytokine prodrugs and dual-prodrugs
WO2021097433A1 (en) * 2019-11-14 2021-05-20 Academia Sinica Use of anti-epcaivi antibodies in cancer therapy
KR20210059405A (ko) * 2019-11-15 2021-05-25 주식회사 제넥신 변형된 인터루킨-7 및 인터루킨-2를 포함하는 융합단백질 및 이의 용도
KR20210061956A (ko) * 2019-11-20 2021-05-28 주식회사 지아이셀 T 세포 배양용 배지 조성물 및 이를 이용한 t 세포의 배양 방법
WO2021107635A1 (ko) * 2019-11-27 2021-06-03 주식회사 지아이셀 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 nk 세포를 포함하는 항암 치료용 조성물
WO2021101273A3 (ko) * 2019-11-20 2021-07-15 주식회사 지아이셀 조절 t 세포 배양용 조성물 및 이의 용도
US11401339B2 (en) 2018-08-23 2022-08-02 Seagen Inc. Anti-TIGIT antibodies
US11491205B2 (en) 2020-01-14 2022-11-08 Synthekine, Inc. Biased IL2 muteins methods and compositions
US11642417B2 (en) 2020-05-13 2023-05-09 Bonum Therapeutics, Inc. Compositions of protein complexes and methods of use thereof
US11725034B2 (en) 2019-12-20 2023-08-15 Regeneron Pharmaceuticals, Inc. IL2 agonists and methods of use thereof
EP3983001A4 (en) * 2019-06-14 2023-10-04 Cugene Inc. NOVEL INTERLEUKIN-2 VARIANTS AND BIFUNCTIONAL FUSION MOLECULES THEREOF
US11845801B2 (en) 2019-06-12 2023-12-19 AskGene Pharma, Inc. IL-15 prodrugs and methods of use thereof
RU2811541C2 (ru) * 2018-09-17 2024-01-15 ДжиАй ИННОВЕЙШН, ИНК. Слитый белок, включающий белок il-2 и белок cd80, и его применение
US11897930B2 (en) 2020-04-28 2024-02-13 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
US12091441B2 (en) 2017-11-21 2024-09-17 The Board Of Trustees Of The Leland Stanford Junior University Partial agonists of interleukin-2
US12378526B2 (en) 2019-11-20 2025-08-05 Gi Cell, Inc. Composition for culturing natural killer cells and method for preparing natural killer cells by using same
US12459980B2 (en) 2018-07-25 2025-11-04 AskGene Pharma, Inc. IL-21 prodrugs and methods of use thereof

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
HRP20191865T1 (hr) 2013-01-14 2020-01-10 Xencor, Inc. Novi heterodimerni proteini
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
DK3021869T3 (da) 2013-07-16 2020-09-21 Hoffmann La Roche Fremgangsmåder til behandling af cancer ved anvendelse af PD-1-aksebindende antagonister og TIGIT-hæmmere
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
ES3040431T3 (en) 2014-03-12 2025-10-31 Yeda Res & Dev Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
EP3223907A2 (en) 2014-11-26 2017-10-04 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
CN116333153A (zh) 2014-11-26 2023-06-27 森科股份有限公司 结合cd3和肿瘤抗原的异二聚体抗体
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
CN111234027A (zh) 2015-05-21 2020-06-05 哈普恩治疗公司 三特异性结合蛋白质及使用方法
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US11214620B2 (en) 2016-06-20 2022-01-04 F-Star Therapeutics Limited Binding molecules binding PD-L1 and LAG-3
BR112018076260A2 (pt) * 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
US11214618B2 (en) 2016-06-20 2022-01-04 F-Star Therapeutics Limited LAG-3 binding members
KR20190020341A (ko) 2016-06-28 2019-02-28 젠코어 인코포레이티드 소마토스타틴 수용체 2에 결합하는 이종이량체 항체
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
CN116640214A (zh) * 2016-08-09 2023-08-25 科马布有限公司 分离抗体及其应用
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
CN110177875B (zh) 2016-11-28 2023-11-28 中外制药株式会社 包含抗原结合结构域和运送部分的多肽
CA3039316A1 (en) 2016-11-28 2018-05-31 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand binding activity
WO2018115859A1 (en) * 2016-12-20 2018-06-28 Kymab Limited Multispecific antibody with combination therapy for immuno-oncology
EP3585431A4 (en) 2017-02-24 2020-12-16 MacroGenics, Inc. BISPECIFIC BINDING MOLECULES CAPABLE OF BINDING TO CD137 AND TUMOR ANTIGENS, AND THEIR USES
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
AU2018252193B2 (en) 2017-04-14 2024-12-12 Tallac Therapeutics, Inc. Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
EP3630838A1 (en) 2017-06-01 2020-04-08 CytomX Therapeutics, Inc. Activatable anti-pdl1 antibodies, and methods of use thereof
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
UA129446C2 (uk) 2017-10-13 2025-04-30 Гарпун Терап'Ютікс, Інк. Триспецифічні білки і способи їх застосування
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
BR112020010450A2 (pt) 2017-11-28 2020-11-24 Chugai Seiyaku Kabushiki Kaisha polipeptídeo que inclui domínio de ligação a antígeno e seção transportadora
WO2019107384A1 (ja) 2017-11-28 2019-06-06 中外製薬株式会社 リガンド結合活性が調整可能なリガンド結合分子
EP3728314A1 (en) 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
CN111741976B (zh) 2017-12-19 2024-09-17 英沃克斯制药有限公司 包括pd-l1抗原结合位点的fc结合片段
KR20200058322A (ko) * 2018-01-25 2020-05-27 아이-맵 바이오파마 유에스 리미티드 항-pd-l1 항체 및 il-7 융합체
CA3090236A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
AU2019225249A1 (en) * 2018-02-26 2020-09-17 Genentech, Inc. Dosing for treatment with anti-tigit and anti-PD-L1 antagonist antibodies
JP7351845B2 (ja) 2018-03-23 2023-09-27 ブリストル－マイヤーズ スクイブ カンパニー Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
CN112469477A (zh) 2018-04-04 2021-03-09 Xencor股份有限公司 与成纤维细胞活化蛋白结合的异源二聚体抗体
JP2021527138A (ja) * 2018-06-14 2021-10-11 ベス イスラエル デアコネス メディカル センター インコーポレイティッド エクトヌクレオチダーゼの阻害及び抗体媒介性標的膜動輸送を通じてｔ細胞疲弊を予防又は解除するための組成物及び方法
WO2020006516A1 (en) * 2018-06-29 2020-01-02 Gensun Biopharma, Inc. Antitumor immune checkpoint regulator antagonists
GB201811403D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
CN112423845B (zh) 2018-07-12 2024-07-30 F-星治疗有限公司 结合pd-l1和cd137的抗体分子
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
CA3106048A1 (en) 2018-07-12 2020-01-16 F-Star Beta Limited Antibody molecules that bind cd137 and ox40
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
CN110790839B (zh) * 2018-08-03 2023-05-12 江苏恒瑞医药股份有限公司 抗pd-1抗体、其抗原结合片段及医药用途
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
EP3856771A4 (en) 2018-09-25 2022-06-29 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
MX2021005594A (es) * 2018-11-13 2021-10-22 Compass Therapeutics Llc Constructos multiespecificos de union contra moleculas de puntos de control y usos de los mismos.
BR112021010402A2 (pt) * 2018-11-30 2021-08-24 Abl Bio Inc. Anticorpos biespecíficos anti-pd-l1/anti-4-1bb e uso dos mesmos
BR112021012631A2 (pt) 2018-12-26 2021-12-14 Xilio Dev Inc Anticorpos anti-ctla4 e métodos de uso dos mesmos
EP3927728A2 (en) 2019-02-21 2021-12-29 Xencor, Inc. Untargeted and targeted il-10 fc-fusion proteins
KR20210145254A (ko) * 2019-03-29 2021-12-01 유니베르시태트 취리히 구획, 특히 cns로의 국소 전달을 위한 fc 변형 생물학적 제제
CN109929037B (zh) * 2019-04-01 2023-03-17 华博生物医药技术（上海）有限公司 针对程序性死亡配体的结合物及其应用
GB201905552D0 (en) 2019-04-18 2019-06-05 Kymab Ltd Antagonists
EP3725370A1 (en) * 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
CN110128550B (zh) * 2019-05-30 2023-01-13 南京惟亚德生物医药有限公司 一种新型的同时阻断免疫检查点pd-l1和tigit的复制型溶瘤腺病毒和应用
JP2022534982A (ja) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー 細胞局在化シグネチャーおよびその使用
US20220363760A1 (en) 2019-05-30 2022-11-17 Bristol-Myers Squibb Company Multi-tumor gene signature for suitability to immuno-oncology therapy
WO2020243570A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Cell localization signature and combination therapy
CA3144617A1 (en) * 2019-06-26 2020-12-30 Ap Biosciences, Inc. Antibodies for t-cell activation
EP3990479A4 (en) * 2019-06-26 2023-08-02 The Johns Hopkins University METHODS AND MATERIALS FOR TARGETED EXPANSION OF IMMUNE EFFECTIVE CELLS
CN116574183A (zh) * 2019-08-22 2023-08-11 盛禾(中国)生物制药有限公司 多功能抗体、其制备及其用途
WO2021037007A1 (zh) 2019-08-29 2021-03-04 荣昌生物制药(烟台)股份有限公司 抗pd-l1抗体及其应用
CA3152776A1 (en) * 2019-08-30 2021-03-04 Dragonfly Therapeutics, Inc. Pharmaceutical formulations and dosage regimens for multi-specific binding proteins that bind her2, nkg2d, and cd16 for cancer treatment
PH12022550460A1 (en) * 2019-08-30 2023-02-27 Agenus Inc Anti-cd96 antibodies and methods of use thereof
CN114616247B (zh) * 2019-10-17 2024-06-28 江苏康宁杰瑞生物制药有限公司 Ox40/pd-l1双特异性抗体
EP4045087A4 (en) * 2019-10-18 2024-03-27 University of Utah Research Foundation Polymeric drug delivery conjugates and methods of making and using thereof
CA3158527A1 (en) * 2019-10-23 2021-04-29 Lyvgen Biopharma Holdings Limited Anti-cd40 binding molecules and bi-specific antibodies comprising such
EP3816185A1 (en) * 2019-11-04 2021-05-05 Numab Therapeutics AG Multispecific antibody directed against pd-l1 and a tumor-associated antigen
US11639383B2 (en) * 2019-11-27 2023-05-02 Gi Innovation, Inc. Pharmaceutical composition for treatment of cancer, comprising an immune checkpoint inhibitor antibody and a fusion protein comprising an IL-2 mutant and a CD80 extracellular domain
WO2021139776A1 (en) * 2020-01-10 2021-07-15 Shanghai Henlius Biotech, Inc. Anti-tigit antibodies, multispecific antibodies comprising the same and methods of using the same
EP4093875A4 (en) * 2020-01-20 2024-02-28 Chugai Seiyaku Kabushiki Kaisha Ligand-binding fusion proteins
KR102559355B1 (ko) * 2020-01-31 2023-07-25 주식회사 제넥신 항-taa 항체, 항-pd-l1 항체 및 il-2를 포함하는 융합단백질 및 이의 용도
EP4106813A4 (en) 2020-02-21 2024-03-27 MacroGenics, Inc. CD137 BINDING MOLECULES AND THEIR USES
TWI859420B (zh) 2020-02-26 2024-10-21 美商維爾生物科技股份有限公司 抗sars-cov-2抗體及使用其之方法
US11920136B2 (en) 2020-02-28 2024-03-05 Tallac Therapeutics, Inc. Transglutaminase-mediated conjugation
US20230139890A1 (en) * 2020-03-18 2023-05-04 Gi Innovation, Inc. Fusion protein comprising il-2 protein and cd80 protein fragment or variant thereof, and uses thereof
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
GB202007099D0 (en) * 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
KR102313505B1 (ko) * 2020-06-30 2021-10-18 (주)지아이이노베이션 항-lag-3 항체 및 il-2를 포함하는 융합단백질 및 이의 용도
US20230257706A1 (en) * 2020-07-07 2023-08-17 Fapon Biotherapy Inc. T lymphocyte and use thereof
IL300062A (en) 2020-07-20 2023-03-01 Deka Biosciences Inc Dual fused cytokine proteins containing IL-10
CA3187850A1 (en) * 2020-08-04 2022-02-10 Bryan Glaser Pd-l1 binding agents and uses thereof
KR102607909B1 (ko) 2020-08-19 2023-12-01 젠코어 인코포레이티드 항-cd28 조성물
CN111705038B (zh) * 2020-08-24 2020-11-03 江苏集萃药康生物科技有限公司 一种稳定表达人源pdl1/cd73蛋白细胞株的构建方法及其应用
EP4204453A1 (en) 2020-08-31 2023-07-05 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
EP4219553A4 (en) * 2020-09-22 2024-11-27 Nanjing Sanhome Pharmaceutical Co., Ltd. ANTI-TIGIT ANTIBODIES AND DUAL ANTIBODIES AND THEIR APPLICATION
US20220135684A1 (en) * 2020-10-14 2022-05-05 Xencor, Inc. Bispecific antibodies that bind pd-l1 and cd28
CN114437228B (zh) * 2020-10-30 2024-02-06 中国科学院生物物理研究所 一种il-2与抗体亚单位构成的双功能融合蛋白
CN114539418A (zh) * 2020-11-26 2022-05-27 上海华奥泰生物药业股份有限公司 双特异性抗体及其用途
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
RS66849B1 (sr) 2020-12-28 2025-06-30 Bristol Myers Squibb Co Kompozicije antitela i postupci njihove upotrebe
US20220233689A1 (en) 2020-12-28 2022-07-28 Bristol-Myers Squibb Company Methods of treating tumors
WO2022157773A2 (en) * 2021-01-21 2022-07-28 Biolojic Design Ltd. Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof
WO2022169274A2 (ko) 2021-02-04 2022-08-11 주식회사 지뉴브 항 pd-1 항체 및 그의 용도
JP2024511319A (ja) 2021-03-09 2024-03-13 ゼンコア インコーポレイテッド Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
JP2024509274A (ja) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
US20240376224A1 (en) 2021-04-02 2024-11-14 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
US20240415884A1 (en) * 2022-02-01 2024-12-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Molecules that bind to cd276 polypeptides
CN119110809A (zh) 2022-02-23 2024-12-10 Xencor股份有限公司 抗CD28 x抗PSMA抗体
KR20240159621A (ko) 2022-03-18 2024-11-05 브리스톨-마이어스 스큅 컴퍼니 폴리펩티드를 단리하는 방법
JP2025511356A (ja) * 2022-04-02 2025-04-15 ハーバー・バイオメド・（シャンハイ）・カンパニー・リミテッド Ｐｄ－ｌ１及びｃｄ４０を標的とする抗原結合タンパク質及びその製造と応用
CN119768435A (zh) * 2022-04-11 2025-04-04 旗舰先锋创新有限责任Vii公司 组合物和方法
JPWO2023219147A1 (enExample) * 2022-05-13 2023-11-16
AU2023281061A1 (en) 2022-06-02 2024-12-05 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2023238949A1 (ja) 2022-06-10 2023-12-14 富士フイルム株式会社 細胞の作出方法、ヘテロ多量体タンパク質の製造方法、バイスペシフィック抗体の製造方法、ベクターセット、哺乳動物細胞、ｃｈｏ細胞、及び細胞プールの作出方法
KR20250039519A (ko) 2022-06-16 2025-03-20 세파론 엘엘씨 항-pd-1 항체-약화된 il-2 면역접합체 및 그의 용도
WO2024015733A1 (en) * 2022-07-13 2024-01-18 10X Genomics, Inc. Improved methods and systems for identification and characterization of antigen-binding molecules from single cells
WO2024054992A1 (en) 2022-09-09 2024-03-14 Bristol-Myers Squibb Company Methods of separating chelator
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
WO2025006973A2 (en) * 2023-06-29 2025-01-02 Board Of Regents, The University Of Texas System Methods for treating immune related adverse events
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent

Citations (482)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
WO1991009968A1 (en) 1989-12-21 1991-07-11 Celltech Limited Cd3 specific recombinant antibody
WO1992006193A1 (en) 1990-10-05 1992-04-16 Scott David Gorman Antibodies directed against cd3
WO1992019244A2 (en) 1991-05-01 1992-11-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine A method for treating infectious respiratory diseases
WO1993019196A1 (en) 1992-03-24 1993-09-30 British Technology Group Ltd. ANTI-CD3 AGLYCOSYLATED IgG ANTIBODY
WO1993020849A1 (en) 1992-04-14 1993-10-28 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
WO1995009653A1 (en) 1993-10-01 1995-04-13 Immunex Corporation Antibodies to cd40
WO1995017202A1 (en) 1993-12-23 1995-06-29 Immunex Corporation Method of preventing or treating disease characterized by neoplastic cells expressing cd40
WO1995030750A2 (fr) 1994-05-06 1995-11-16 Institut Gustave Roussy Fractions polypeptidiques solubles de la proteine lag-3; procede de production; composition therapeutique; anticorps anti-idiotype
WO1996032471A2 (en) 1995-04-10 1996-10-17 Universite De Sherbrooke Atp-diphosphohydrolases, process of purification thereof and process of producing thereof by recombinant technology
WO1997031025A1 (en) 1996-02-23 1997-08-28 Chiron Corporation Humanized anti-cd40 monoclonal antibodies and fragments capable of blocking b cell activation
WO1997032572A2 (en) 1996-03-04 1997-09-12 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
WO1997044013A1 (en) 1996-05-24 1997-11-27 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
WO1997044362A1 (en) 1996-05-20 1997-11-27 Protein Design Labs, Inc. MUTATED NONACTIVATING IgG2 DOMAINS AND ANTI-CD3 ANTIBODIES INCORPORATING THE SAME
WO1997048723A2 (en) 1996-06-17 1997-12-24 MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. Hofgartenstrasse 2 Ptp-20, pcp-2, bdp1, clk and sirp proteins and related products
WO1997049424A1 (en) 1996-06-25 1997-12-31 The Trustees Of The University Of Pennsylvania Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same
WO1998003821A2 (en) 1996-07-19 1998-01-29 Carino Cornelis Sunderman Space heating device provided with a combustion space and a device for assisting flue gas discharge through a flue duct connected to the combustion space
WO1998031346A1 (en) 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
WO1999015553A2 (de) 1997-09-23 1999-04-01 Bundesrepublik Deutschland Letztvertreten Durch Den Direktor Des Robert-Koch-Instituts Ko-stimulierendes polypeptid von t-zellen, monoklonale antikörper sowie die herstellung und deren verwendung
US5897862A (en) 1994-01-31 1999-04-27 Mor Research Applications Ltd. Immuno-stimulatory monoclonal antibodies
WO1999024565A1 (en) 1997-11-07 1999-05-20 Transplantation Technologies Inc. Methods and compositions for immunomodulation
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
WO1999042075A2 (en) 1998-02-19 1999-08-26 Bristol-Myers Squibb Company Antibodies against human cd40
WO1999050461A1 (en) 1998-03-30 1999-10-07 Northwest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
WO1999060128A1 (en) 1998-05-15 1999-11-25 Bayer Corporation Il-2 selective agonists and antagonists
WO1999061057A2 (en) 1998-05-23 1999-12-02 Tanox, Inc. Molecules targeting cd40 and tumor cells
WO1999066903A2 (en) 1998-06-24 1999-12-29 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
WO2000004041A2 (en) 1998-07-16 2000-01-27 Hyseq, Inc. Methods and molecules relating to cd39-like polypeptides
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
WO2000005268A1 (en) 1998-07-21 2000-02-03 Btg International Ltd. Hybrid human/rodent igg antibody to cd3, and methods of its construction
WO2000024869A2 (en) 1998-10-23 2000-05-04 Yale University Methods for modulating cell fusion
WO2000037504A2 (en) 1998-12-23 2000-06-29 Pfizer Inc. Human monoclonal antibodies to ctla-4
WO2000042074A1 (en) 1999-01-15 2000-07-20 Millennium Pharmaceuticals, Inc. Anti-ccr4 antibodies and methods of use therefor
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
WO2000066159A1 (en) 1999-04-28 2000-11-09 Faculteit Der Geneeskunde Van De Vrije Universiteit Method for inhibiting cell functioning for use in anti-inflammatory and anti-tumour therapies
WO2000075348A1 (en) 1999-06-08 2000-12-14 Seattle Genetics, Inc. Recombinant anti-cd40 antibody and uses thereof
WO2001010205A1 (en) 1999-08-09 2001-02-15 Hyseq Inc. Methods and materials relating to cd39-like polypeptides
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
WO2001016180A2 (en) 1999-08-27 2001-03-08 Board Of Regents, The University Of Texas System Cd40 agonist compositions and methods of use
WO2001015732A1 (en) 1999-08-30 2001-03-08 Japan Tobacco Inc. Remedies for immunological diseases
WO2001037870A1 (en) 1999-11-25 2001-05-31 Kennedy Rheumatology Inst Treatment of autoimmune diseases by an agonistic cd40-binding protein
WO2001040307A1 (de) 1999-11-30 2001-06-07 Eberhard-Karls-Universität Tübingen Universitätsklinikum Antikörper gegen signal-regulator-proteine
US6245332B1 (en) 1999-01-15 2001-06-12 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
WO2001042308A2 (en) 1999-12-08 2001-06-14 Novartis Ag Methods and compositions useful for inhibiting ccr5-dependent infection of cells by hiv-1
WO2001051644A2 (de) 2000-01-14 2001-07-19 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts ANTI-CD3-EINZELKETTEN-ANTIKÖRPER MIT HUMANEN Cν3- und Cν4- DOMÄNEN
WO2001054732A1 (en) 2000-01-27 2001-08-02 Genetics Institute, Llc. Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
WO2001064754A1 (en) 2000-03-03 2001-09-07 Kyowa Hakko Kogyo Co., Ltd. Gene recombinant antibody and its fragment
WO2001078708A1 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Treating graft rejection with cxcr3 inhibitors
WO2001083755A2 (en) 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
WO2001087981A2 (en) 2000-05-18 2001-11-22 Japan Tobacco, Inc. Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof
WO2002011762A2 (en) 2000-08-03 2002-02-14 Gorczynski Reginald M Methods and compositions for modulating tumor growth
WO2002015932A1 (en) 2000-08-18 2002-02-28 The Regents Of The University Of California Methods for treating demyelinating diseases
WO2002026249A2 (en) 2000-09-26 2002-04-04 The Regents Of The University Of Michigan Methods for inhibition of viral infection
WO2002028904A2 (en) 2000-10-02 2002-04-11 Chiron Corporation Human anti-cd40 antibodies
WO2002070010A1 (fr) 2001-03-01 2002-09-12 Japan Tobacco, Inc. Inhibiteurs de rejet du greffon
US20020156242A1 (en) 1997-02-27 2002-10-24 Japan Tobacco, Inc., A Japanese Corporation Cell surface molecule mediating cell adhesion and signal transmission
WO2002088186A1 (fr) 2001-04-27 2002-11-07 Kirin Beer Kabushiki Kaisha Anticorps monoclonal anti-cd40
WO2002092784A2 (en) 2001-05-15 2002-11-21 Emory University POLYNUCLEOTIDES AND POLYPEPTIDES RELATING TO THE MODULATION OF SIRP α-CD47
WO2003006058A1 (en) 2001-07-12 2003-01-23 Wyeth Cd25+ differential markers and uses thereof
WO2003006045A2 (en) 2001-07-12 2003-01-23 The Regents Of The University Of California Cxcl10 treatment of secondary tissue degeneration
WO2003015697A2 (en) 2001-08-13 2003-02-27 University Of Southern California Interleukin-2 mutants with reduced toxicity
WO2003018635A1 (fr) 2001-08-31 2003-03-06 Kyowa Hakko Kogyo Co., Ltd. Anticorps greffes cdr humains et fragments de ces anticorps
WO2003029296A1 (en) 2001-10-02 2003-04-10 Chiron Corporation Human anti-cd40 antibodies
WO2003040170A2 (en) 2001-11-09 2003-05-15 Pfizer Products Inc. Antibodies to cd40
WO2003063792A2 (en) 2002-01-30 2003-08-07 The Brigham And Women's Hospital, Inc. Compositions and methods related to tim-3, a th1-specific cell surface molecule
WO2003066830A2 (en) 2002-02-08 2003-08-14 Genetastix Corporation Human monoclonal antibodies against membrane proteins
WO2004004771A1 (ja) 2002-07-03 2004-01-15 Ono Pharmaceutical Co., Ltd. 免疫賦活組成物
WO2004010947A2 (en) 2002-07-30 2004-02-05 Bristol-Myers Squibb Company Humanized antibodies against human 4-1bb
WO2004024771A1 (en) 2002-09-10 2004-03-25 Affimed Therapeutics Ag Human cd3-specific antibody with immunosuppressive properties
WO2004029069A2 (en) 2002-09-30 2004-04-08 Pfizer Products Inc. Hybridomas producing high levels of human sequence antibody
WO2004045525A2 (en) 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
WO2004045526A2 (en) 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
WO2004052397A1 (en) 2002-12-05 2004-06-24 Protein Design Labs, Inc. Methods of treatment of ulcerative colitis with anti-cd3 antibodies
WO2004055513A2 (en) 2002-12-16 2004-07-01 Herbert Schwarz Use of cd137 antagonists for the treatment of tumors
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
WO2004059285A2 (en) 2002-12-23 2004-07-15 Protein Design Labs, Inc. Tumor killing/tumor regression using cxcr4 antagonists
WO2004060295A2 (en) 2002-12-27 2004-07-22 Schering Corporation Methods of inducing and maintaining immune tolerance
WO2004078938A2 (en) 2003-03-04 2004-09-16 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2004078928A2 (en) 2003-02-28 2004-09-16 The Johns Hopkins University T cell regulation
WO2004082714A1 (en) 2003-03-17 2004-09-30 The Regents Of The University Of California Methods for treating ocular inflammation by neutralizing cxcl10 activity
WO2004084942A2 (en) 2003-03-28 2004-10-07 Universiteit Utrecht Holding B.V. Methods and means to suppress symptoms of an allergic disease by inhibiting the glucocorticoid-induced tumor necrosis factor receptor (gitr or tnfrsf18)
WO2004101511A2 (en) 2003-05-09 2004-11-25 Protein Design Labs, Inc Anti-ip-10 antibodies and methods of using thereof for the treatment of inflamatory bowel diseases
WO2004108923A1 (ja) 2003-06-02 2004-12-16 Japan Science And Technology Agency Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体
WO2004108158A1 (en) 2003-06-02 2004-12-16 Alexion Pharmaceuticals, Inc. De-immunized anti-cd3 antibody
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
WO2005009238A1 (en) 2003-07-29 2005-02-03 Htl Strefa Spolka Zo.O. Puncturing device
WO2005011605A2 (en) 2003-08-01 2005-02-10 Medarex, Inc. Combination therapies for multiple sclerosis
WO2005023201A2 (en) 2003-09-09 2005-03-17 Medarex, Inc. Methods for treating rheumatoid arthritis
WO2005035582A1 (ja) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Ｃｃｒ４に特異的に結合する抗体組成物
WO2005035584A1 (en) 2003-10-10 2005-04-21 Bristol-Myers Squibb Company Fully human antibodies against human 4-1bb (cd137)
WO2005044854A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Antagonist anti-cd40 monoclonal antibodies and methods for their use
WO2005044855A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
WO2005044305A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
WO2005044304A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia
WO2005044307A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Methods of therapy for b cell-related cancers
WO2005053741A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. ケモカイン受容体ｃｃｒ４に対する遺伝子組換え抗体を含む医薬
WO2005058815A2 (en) 2003-12-10 2005-06-30 Medarex, Inc. Ip-10 antibodies and their uses
WO2005060457A2 (en) 2003-12-04 2005-07-07 Pdl Biopharma, Inc. Treatment of inflammatory bowel diseases with anti-ip-10 antibodies
WO2005063981A1 (ja) 2003-12-25 2005-07-14 Kirin Beer Kabushiki Kaisha 抗cd40抗体の変異体
WO2005063289A1 (en) 2003-12-22 2005-07-14 Pfizer Products Inc. Cd40 antibody formulation and methods
WO2005084708A1 (ja) 2004-03-09 2005-09-15 Kyoto University Ｃｘｃｒ３阻害剤を含有する医薬組成物
WO2005086798A2 (en) 2004-03-05 2005-09-22 Chiron Corporation Improved interleukin-2 muteins
WO2005103086A1 (en) 2004-04-23 2005-11-03 Bundesrepublik Deutschland letztvertreten durch das Robert-Koch-Institut vertreten durch seinen Präsidenten Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo
US6974863B2 (en) 1988-11-07 2005-12-13 Indiana University Research And Technology Corporation Antibody for 4-1BB
WO2005118635A2 (en) 2004-06-03 2005-12-15 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
WO2006020266A2 (en) 2004-07-20 2006-02-23 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2006029219A2 (en) 2004-09-08 2006-03-16 Ohio State University Research Foundation Human monoclonal anti-ctla4 antibodies in cancer treatment
US7030225B1 (en) 1997-02-27 2006-04-18 Japan Tobacco, Inc. Antibodies to JTT-1 protein, cells secreting such antibodies, and methods of making such antibodies
WO2006039819A1 (en) 2004-10-15 2006-04-20 St. Michael's Hospital Markers of lung injury
WO2006050172A2 (en) 2004-10-29 2006-05-11 University Of Southern California Combination cancer immunotherapy with co-stimulatory molecules
WO2006048749A1 (en) 2004-11-04 2006-05-11 Pfizer Products Inc. Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer
WO2006066568A2 (de) 2004-12-23 2006-06-29 Tegenero Ag Monokonale agonistische anti-ctla-4 antikörper
WO2006073443A2 (en) 2004-04-27 2006-07-13 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-cd40 monoclonal antibodies and methods for their use
WO2006089141A2 (en) 2005-02-18 2006-08-24 Dana-Farber Cancer Institute Antibodies against cxcr4 and methods of use thereof
WO2006096491A2 (en) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Anti-ctla-4 antibody compositions
WO2006101691A1 (en) 2005-03-23 2006-09-28 Pfizer Products Inc. Therapy of prostate cancer with ctla4 antibodies and hormonal therapy
WO2006101692A1 (en) 2005-03-23 2006-09-28 Pfizer Products Inc. Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer
WO2006105021A2 (en) 2005-03-25 2006-10-05 Tolerrx, Inc. Gitr binding molecules and uses therefor
US7125551B2 (en) 1997-09-23 2006-10-24 Bundersrepublik Deutschalnd Methods for treatment of asthmatic disorders using a monoclonal antibody to 8F4 polypeptide
WO2006118085A1 (ja) 2005-04-26 2006-11-09 Stelic Institute Of Regenerative Medicine 肝細胞複製促進剤およびインスリン抵抗性改善剤
WO2006121168A1 (en) 2005-05-09 2006-11-16 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
WO2006128103A2 (en) 2005-05-26 2006-11-30 Seattle Genetics, Inc. Humanized anti-cd40 antibodies and their methods of use
WO2007005605A2 (en) 2005-07-01 2007-01-11 Washington University In St. Louis Phosphospecific chemokine receptor antibodies
WO2007005874A2 (en) 2005-07-01 2007-01-11 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
WO2007008463A2 (en) 2005-07-07 2007-01-18 Coley Pharmaceutical Group, Inc. Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
WO2007053661A2 (en) 2005-11-01 2007-05-10 Novartis Ag Uses of anti-cd40 antibodies
WO2007053767A1 (en) 2005-11-01 2007-05-10 Novartis Ag Uses of anti-cd40 antibodies
WO2007062245A2 (en) 2005-11-25 2007-05-31 Kirin Pharma Kabushiki Kaisha Human monoclonal antibody human cd134 (ox40) and methods of making and using same
WO2007084321A2 (en) 2006-01-12 2007-07-26 Alexion Pharmaceuticals, Inc. Antibodies to ox-2/cd200 and uses thereof
WO2007113301A1 (en) 2006-04-03 2007-10-11 Medizinische Hochschule Hannover Pharmaceuticals for influencing the reaction of the human immune system
WO2007124299A2 (en) 2006-04-21 2007-11-01 Novartis Ag Antagonist anti-cd40 antibody pharmaceutical compositions
WO2007129895A2 (en) 2006-05-09 2007-11-15 Pangenetics B.V. Deimmunized antagonistic anti-human cd40 monoclonal antibody from the ch5d12 antibody
WO2007130493A2 (en) 2006-05-03 2007-11-15 Regents Of The University Of Colorado Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
WO2007133822A1 (en) 2006-01-19 2007-11-22 Genzyme Corporation Gitr antibodies for the treatment of cancer
WO2008003103A2 (en) 2006-07-05 2008-01-10 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. Novel multivalent immunoglobulins
WO2008044824A1 (en) 2006-10-13 2008-04-17 Seoul National University Industry Foundation Antibodies to ip-10 for treating bone diseases with bone destruction
WO2008047486A1 (fr) 2006-10-19 2008-04-24 Stelic Institute Of Regenerative Medicine Agent de lutte contre les lésions myocardiques
WO2008051424A2 (en) 2006-10-20 2008-05-02 University Of Southampton Human immune therapies using a cd27 agonist alone or in combination with other immune modulators
WO2008060367A2 (en) 2006-10-02 2008-05-22 Medarex, Inc. Human antibodies that bind cxcr4 and uses thereof
WO2008073316A2 (en) 2006-12-07 2008-06-19 The Board Of Trustees Of The Leland Stanford Junior University Identification and isolation of acute myeloid leukemia stem cells
WO2008076560A2 (en) 2006-11-15 2008-06-26 Medarex, Inc. Human monoclonal antibodies to btla and methods of use
WO2008083169A2 (en) 2006-12-26 2008-07-10 The Johns Hopkins University Compositions and methods for the treatment of immunologic disorders
WO2008091954A2 (en) 2007-01-23 2008-07-31 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
WO2008106200A2 (en) 2007-02-28 2008-09-04 Novimmune Sa Human anti-ip-10 antibodies and uses thereof
WO2008106116A2 (en) 2007-02-27 2008-09-04 Genentech, Inc. Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
WO2008132601A1 (en) 2007-04-30 2008-11-06 Immutep Cytotoxic anti-lag-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
WO2008142303A2 (fr) 2007-04-23 2008-11-27 Pierre Fabre Medicament Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
WO2008156712A1 (en) 2007-06-18 2008-12-24 N. V. Organon Antibodies to human programmed death receptor pd-1
WO2009007124A1 (en) 2007-07-10 2009-01-15 Friedrich-Alexander-Universität Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
WO2009009547A2 (en) 2007-07-09 2009-01-15 Qualcomm Incorporated Methods for sending small packets in a peer-to-peer (p2p) network
WO2009009116A2 (en) 2007-07-12 2009-01-15 Tolerx, Inc. Combination therapies employing gitr binding molecules
WO2009014745A1 (en) 2007-07-25 2009-01-29 Alexion Pharmaceuticals, Inc. Antibodies to cd200 and uses thereof in inhibiting immune responses
WO2009023566A2 (en) 2007-08-09 2009-02-19 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
WO2009026303A1 (en) 2007-08-21 2009-02-26 Amgen Inc. Human c-fms antigen binding proteins
WO2009046541A1 (en) 2007-10-11 2009-04-16 University Health Network MODULATION OF SIRPα - CD47 INTERACTION FOR INCREASING HUMAN HEMATOPOIETIC STEM CELL ENGRAFTMENT AND COMPOUNDS THEREFOR
WO2009062054A1 (en) 2007-11-09 2009-05-14 Novartis Ag Uses of anti-cd40 antibodies
WO2009062125A1 (en) 2007-11-07 2009-05-14 Genentech, Inc. Methods and compositions for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
WO2009061853A2 (en) 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
WO2009086514A1 (en) 2007-12-28 2009-07-09 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
WO2009094391A1 (en) 2008-01-23 2009-07-30 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
WO2009095478A1 (en) 2008-01-31 2009-08-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
WO2009100140A1 (en) 2008-02-04 2009-08-13 Medarex, Inc. Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
WO2009112245A1 (en) 2008-03-14 2009-09-17 Transgene S.A. Antibody against the csf-1 r
WO2009117706A2 (en) 2008-03-20 2009-09-24 Carolus Therapeutics, Inc. Methods of treatment using anti-mif antibodies
WO2009120186A1 (en) 2008-03-24 2009-10-01 Carolus Therapeutics, Inc. Methods and compositions for treating atherosclerosis and related conditions
WO2009126688A2 (en) 2008-04-09 2009-10-15 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
WO2009135019A2 (en) 2008-05-01 2009-11-05 Beth Israel Deaconess Medical Center Methods and compositions for prostate cancer immunotherapy
WO2009138519A1 (en) 2008-05-16 2009-11-19 Ablynx Nv AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
WO2009140124A1 (en) 2008-05-14 2009-11-19 Eli Lilly And Company Anti-cxcr4 antibodies
WO2010001908A1 (ja) 2008-06-30 2010-01-07 協和発酵キリン株式会社 抗cd27抗体
WO2010019570A2 (en) 2008-08-11 2010-02-18 Medarex, Inc. Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
WO2010024676A1 (en) 2008-08-29 2010-03-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Delivery of a cd40 agonist to a tumor draining lymph node of a subject
WO2010029435A1 (en) 2008-09-12 2010-03-18 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
WO2010029434A1 (en) 2008-09-12 2010-03-18 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
WO2010037831A1 (en) 2008-10-01 2010-04-08 Pierre Fabre Medicament Anti cxcr4 antibodies and their use for the treatment of cancer
WO2010056804A1 (en) 2008-11-12 2010-05-20 Medimmune, Llc Antibody formulation
WO2010077634A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
WO2010096418A2 (en) 2009-02-17 2010-08-26 Ucb Pharma S.A. Antibody molecules having specificity for human ox40
WO2010097597A1 (en) 2009-02-26 2010-09-02 The University Court Of The University Of Aberdeen Antibodies specifically directed to the soluble form of ctla-4
WO2010104749A2 (en) 2009-03-10 2010-09-16 Baylor Research Institute Antigen presenting cell targeted cancer vaccines
WO2010104761A2 (en) 2009-03-10 2010-09-16 Baylor Research Institute Anti-cd40 antibodies and uses thereof
WO2010106051A1 (en) 2009-03-17 2010-09-23 Universite De La Mediterranee Btla antibodies and uses thereof
WO2010121231A1 (en) 2009-04-18 2010-10-21 Genentech, Inc. Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
WO2010123012A1 (ja) 2009-04-20 2010-10-28 協和発酵キリン株式会社 アミノ酸変異が導入されたIgG2を有する抗体
WO2010125162A1 (en) 2009-04-29 2010-11-04 Pierre Fabre Medicament Anti cxcr4 antibodies for the treatment of hiv
WO2010142952A2 (en) 2009-06-09 2010-12-16 Affitech Research As Antibodies
WO2011004192A1 (en) 2009-07-08 2011-01-13 Genome Research Limited Animal models and therapeutic molecules
WO2011014438A1 (en) 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
WO2011020024A2 (en) 2009-08-13 2011-02-17 The Johns Hopkins University Methods of modulating immune function
WO2011028683A1 (en) 2009-09-03 2011-03-10 Schering Corporation Anti-gitr antibodies
WO2011042398A1 (en) 2009-10-09 2011-04-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
WO2011051726A2 (en) 2009-10-30 2011-05-05 Isis Innovation Ltd Treatment of obesity
WO2011066389A1 (en) 2009-11-24 2011-06-03 Medimmmune, Limited Targeted binding agents against b7-h1
WO2011070024A1 (en) 2009-12-10 2011-06-16 F. Hoffmann-La Roche Ag Antibodies binding preferentially human csf1r extracellular domain 4 and their use
WO2011073180A1 (en) 2009-12-14 2011-06-23 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
WO2011076781A1 (en) 2009-12-22 2011-06-30 Novartis Ag Tetravalent cd47-antibody constant region fusion protein for use in therapy
WO2011081164A1 (ja) 2009-12-29 2011-07-07 協和発酵キリン株式会社 抗ｃｄ２７抗体
WO2011083140A1 (en) 2010-01-08 2011-07-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4
WO2011098762A2 (en) 2010-02-10 2011-08-18 Affitech Research As Antibodies against cxcr4
WO2011100538A1 (en) 2010-02-11 2011-08-18 Alexion Pharmaceuticals, Inc. Therapeutic methods using an ti-cd200 antibodies
WO2011107553A1 (en) 2010-03-05 2011-09-09 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
WO2011110604A1 (en) 2010-03-11 2011-09-15 Ucb Pharma, S.A. Pd-1 antibody
WO2011110621A1 (en) 2010-03-11 2011-09-15 Ucb Pharma, S.A. Biological products: humanised agonistic anti-pd-1 antibodies
WO2011121040A1 (en) 2010-03-30 2011-10-06 Pierre Fabre Medicament Humanized anti cxcr4 antibodies for the treatment of cancer
WO2011123489A2 (en) 2010-03-31 2011-10-06 Boehringer Ingelheim International Gmbh Anti-cd40 antibodies
WO2011123381A1 (en) 2010-04-01 2011-10-06 Imclone Llc Antibodies against csf-1r
WO2011130434A2 (en) 2010-04-13 2011-10-20 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
WO2011131407A1 (en) 2010-03-05 2011-10-27 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
WO2011140249A2 (en) 2010-05-04 2011-11-10 Five Prime Therapeutics, Inc. Antibodies that bind csf1r
WO2011155607A1 (ja) 2010-06-11 2011-12-15 協和発酵キリン株式会社 抗ｔｉｍ－３抗体
WO2011158009A1 (en) 2010-06-17 2011-12-22 Kymab Limited Animal models and therapeutic molecules
WO2011161266A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Improved immunoglobulin single variable domains and constructs thereof directed against cxcr4
WO2012004367A1 (en) 2010-07-09 2012-01-12 N.V. Organon Agonistic antibody to cd27
WO2012027328A2 (en) 2010-08-23 2012-03-01 Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same
WO2012032433A1 (en) 2010-09-09 2012-03-15 Pfizer Inc. 4-1bb binding molecules
WO2012040207A2 (en) 2010-09-20 2012-03-29 Yale University HUMAM SIRPAα TRANSGENIC ANIMALS AND THEIR METHODS OF USE
WO2012041635A1 (en) 2010-09-29 2012-04-05 Universite De Liege Combination of an agonistic anti-cd40 monoclonal antibody or a cd40 ligand and inactivated or attenuated bacteria for use in the treatment and/or prevention of mastitis
WO2012055980A1 (en) 2010-10-27 2012-05-03 Pierre Fabre Medicament Antibodies for the treatment of hiv
WO2012062713A1 (en) 2010-11-08 2012-05-18 Novartis Ag Cxcr2 binding polypeptides
WO2012062228A2 (es) 2010-11-12 2012-05-18 Centro De Inmunologia Molecular Polipéptidos derivados de la il-2 con actividad agonista para la terapia del cáncer e infecciones crónicas.
WO2012065950A1 (en) 2010-11-15 2012-05-24 Novartis Ag Silent fc variants of anti-cd40 antibodies
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
WO2012076883A1 (en) 2010-12-07 2012-06-14 Affitech Research As Anti ccr4 antibodies and uses thereof
WO2012088446A1 (en) 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
WO2012085132A1 (en) 2010-12-22 2012-06-28 Orega Biotech Antibodies against human cd39 and use thereof
WO2012107417A1 (en) 2011-02-10 2012-08-16 Roche Glycart Ag Mutant interleukin-2 polypeptides
WO2012110360A1 (en) 2011-02-14 2012-08-23 Transgene Sa Antibody against the csf-1r
WO2012111762A1 (ja) 2011-02-17 2012-08-23 協和発酵キリン株式会社 抗ｃｄ４０抗体の高濃度製剤
WO2012119093A1 (en) 2011-03-03 2012-09-07 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
WO2012120125A1 (en) 2011-03-09 2012-09-13 Antitope Ltd Humanised anti ctla-4 antibodies
WO2012125569A2 (en) 2011-03-11 2012-09-20 Beth Israel Deaconess Medical Center, Inc. Anti-cd40 antibodies and uses thereof
WO2012131004A2 (en) 2011-03-31 2012-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies directed against icos and uses thereof
WO2012135408A1 (en) 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
WO2012145673A1 (en) 2011-04-21 2012-10-26 Bristol-Myers Squibb Company Antibody polypeptides that antagonize cd40
WO2012145183A2 (en) 2011-04-19 2012-10-26 Pfizer Inc. Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
WO2012145493A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
WO2012149320A1 (en) 2011-04-29 2012-11-01 Bristol-Myers Squibb Company Ip-10 antibody dosage escalation regimens
WO2012149356A2 (en) 2011-04-29 2012-11-01 Apexigen, Inc. Anti-cd40 antibodies and methods of use
WO2012162067A2 (en) 2011-05-21 2012-11-29 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
WO2012174338A2 (en) 2011-06-15 2012-12-20 Glaxosmithkline Llc Method of selecting therapeutic indications
WO2012172521A1 (en) 2011-06-16 2012-12-20 Novartis Ag Soluble proteins for use as therapeutics
WO2012173819A2 (en) 2011-06-14 2012-12-20 Mayo Foundation For Medical Education And Research Anti-cd3 therapies
WO2012178137A1 (en) 2011-06-24 2012-12-27 Gillies Stephen D Light chain immunoglobulin fusion proteins and methods of use thereof
WO2012177788A1 (en) 2011-06-20 2012-12-27 La Jolla Institute For Allergy And Immunology Modulators of 4-1bb and immune responses
WO2012175576A1 (en) 2011-06-20 2012-12-27 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer.
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
WO2013008171A1 (en) 2011-07-11 2013-01-17 Glenmark Pharmaceuticals S.A. Antibodies that bind to ox40 and their uses
WO2013013025A2 (en) 2011-07-20 2013-01-24 Medimmune Limited Anti-cxcr4 antibodies and methods of use
WO2013017562A1 (en) 2011-07-29 2013-02-07 Pierre Fabre Medicament Use of the antibody i-3859 for the detection and diagnosis of cancer
WO2013017566A1 (en) 2011-07-29 2013-02-07 Pierre Fabre Medicament Novel anti-cxcr4 antibody and its use for the detection and diagnosis of cancer
WO2013028231A1 (en) 2011-08-23 2013-02-28 Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same
WO2013034904A1 (en) 2011-09-05 2013-03-14 Alligator Bioscience Ab Anti-cd40 antibodies, uses and methods
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
WO2013038191A2 (en) 2011-09-16 2013-03-21 Bioceros B.V. Anti-cd134 (ox40) antibodies and uses thereof
WO2013057281A2 (en) 2011-10-21 2013-04-25 Transgene Sa Modulation of macrophage activation
WO2013056352A1 (en) 2011-10-19 2013-04-25 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
WO2013061098A2 (en) 2011-12-02 2013-05-02 Kymab Limited Functional isotype switching of chimaeric antibody chains & chimaeric animals expressing different igh isotypes
WO2013071068A2 (en) 2011-11-09 2013-05-16 Bristol-Myers Squibb Company Treatment of hematologic malignancies with an anti-cxcr4 antibody
WO2013068563A2 (en) 2011-11-11 2013-05-16 Ucb Pharma S.A. Antibody molecules having specificity for human ox40
WO2013079174A1 (en) 2011-11-28 2013-06-06 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
WO2013087699A1 (en) 2011-12-15 2013-06-20 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
US8497244B2 (en) 2005-10-24 2013-07-30 Domantis Limited Methods for targeting pulmonary diseases with agents that bind a target in pulmonary tissue
WO2013132044A1 (en) 2012-03-08 2013-09-12 F. Hoffmann-La Roche Ag Combination therapy of antibodies against human csf-1r and uses thereof
WO2013138586A1 (en) 2012-03-15 2013-09-19 Janssen Biotech, Inc. Human anti-cd27 antibodies, methods and uses
WO2013158856A2 (en) 2012-04-20 2013-10-24 Emergent Product Development Seattle, Llc Cd3 binding polypeptides
WO2013164789A2 (en) 2012-05-04 2013-11-07 Novartis Ag Antibody formulatoin
WO2013166500A1 (en) 2012-05-04 2013-11-07 Dana-Farber Cancer Institute, Inc. Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
WO2013168108A2 (en) 2012-05-09 2013-11-14 Novartis Ag Chemokine receptor binding polypeptides
WO2013169264A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
WO2013173223A1 (en) 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
WO2013170735A1 (zh) 2012-05-15 2013-11-21 中国医学科学院基础医学研究所 治疗和/或预防肺损伤的方法
WO2013181634A2 (en) 2012-05-31 2013-12-05 Sorrento Therapeutics Inc. Antigen binding proteins that bind pd-l1
WO2013184912A2 (en) 2012-06-06 2013-12-12 Oncomed Pharmaceuticals, Inc. Binding agents that modulate the hippo pathway and uses thereof
WO2013188693A1 (en) 2012-06-15 2013-12-19 Imaginab, Inc. Antigen binding constructs to cd3
WO2013186613A1 (en) 2012-06-14 2013-12-19 Nasvax Ltd. Humanized antibodies to cluster of differentiation 3 (cd3)
WO2014003742A1 (en) 2012-06-27 2014-01-03 Morehouse School Of Medicine Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation
WO2014004298A1 (en) 2012-06-29 2014-01-03 Invista Technologies S.À.R.L. Gas scrubber and related processes
WO2014008218A1 (en) 2012-07-02 2014-01-09 Bristol-Myers Squibb Company Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
WO2014008911A1 (en) 2012-07-09 2014-01-16 Iwis Motorsysteme Gmbh & Co. Kg Lantern-type planetary gearing
WO2014022332A1 (en) 2012-07-31 2014-02-06 The Brigham And Women's Hospital, Inc. Modulation of the immune response
WO2014036357A1 (en) 2012-08-31 2014-03-06 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
WO2014033327A1 (en) 2012-09-03 2014-03-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies directed against icos for treating graft-versus-host disease
WO2014047231A1 (en) 2012-09-21 2014-03-27 Regeneron Pharmaceuticals, Inc. Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
WO2014055897A2 (en) 2012-10-04 2014-04-10 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
WO2014065403A1 (ja) 2012-10-26 2014-05-01 株式会社ペルセウスプロテオミクス 抗ヒトｃｄ４０モノクローナル抗体及びその利用
WO2014065402A1 (ja) 2012-10-26 2014-05-01 株式会社ペルセウスプロテオミクス 抗ヒトｃｄ４０モノクローナル抗体及びその利用
WO2014070934A1 (en) 2012-10-30 2014-05-08 Apexigen, Inc. Anti-cd40 antibodies and methods of use
WO2014072441A1 (en) 2012-11-09 2014-05-15 Transgene Sa Modulation of monocytes, or precursors thereof, differentiation
WO2014089169A2 (en) 2012-12-04 2014-06-12 Oncomed Pharmaceuticals, Inc. Immunotherapy with binding agents
WO2014100079A1 (en) 2012-12-21 2014-06-26 Merck Sharp & Dohme Corp. Antibodies that bind to human programmed death ligand 1 (pd-l1)
WO2014140374A2 (en) 2013-03-15 2014-09-18 Novo Nordisk A/S Monovalent cd27 antibodies
WO2014140180A1 (en) 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property Development Limited Anti-lag-3 binding proteins
US8840885B2 (en) 2000-12-08 2014-09-23 Alexion Pharmaceuticals, Inc. Methods for treating chronic lymphocytic leukemia
WO2014148895A1 (en) 2013-03-18 2014-09-25 Biocerox Products B.V. Humanized anti-cd134 (ox40) antibodies and uses thereof
WO2014149310A1 (en) 2013-03-15 2014-09-25 Allied Innovative Systems, Llc A flow-through cell counting assay
WO2014159562A1 (en) 2013-03-14 2014-10-02 Bristol-Myers Squibb Company Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
WO2014165082A2 (en) 2013-03-13 2014-10-09 Medimmune, Llc Antibodies and methods of detection
WO2014169255A1 (en) 2013-04-11 2014-10-16 The Brigham And Women's Hospital, Inc. Methods and compositions of treating autoimmune diseases
WO2014170317A1 (en) 2013-04-17 2014-10-23 Morphosys Ag Antibodies targeting specifically human cxcr2
WO2014173814A1 (en) 2013-04-22 2014-10-30 F. Hoffmann-La Roche Ag Combination therapy of antibodies against human csf-1r and tlr9 agonist
WO2014179664A2 (en) 2013-05-02 2014-11-06 Anaptysbio, Inc. Antibodies directed against programmed death-1 (pd-1)
WO2014190356A2 (en) 2013-05-24 2014-11-27 Amplimmune, Inc. Anti-b7-h5 antibodies and their uses
WO2014189306A1 (ko) 2013-05-22 2014-11-27 메타볼랩(주) 항 ＴＮＦ-α/ＣＸＣＬ10 이중 타겟 항체 및 그의 용도
WO2014194302A2 (en) 2013-05-31 2014-12-04 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
WO2014206107A1 (zh) 2013-06-26 2014-12-31 上海君实生物医药科技有限公司 抗pd-1抗体及其应用
WO2015001085A1 (en) 2013-07-05 2015-01-08 Genmab B.V. Humanized or chimeric cd3 antibodies
WO2015015401A2 (en) 2013-08-02 2015-02-05 Pfizer Inc. Anti-cxcr4 antibodies and antibody-drug conjugates
WO2015016718A1 (en) 2013-08-02 2015-02-05 Bionovion Holding B.V. Combining cd27 agonists and immune checkpoint inhibition for immune stimulation
WO2015015003A1 (en) 2013-08-01 2015-02-05 Université Catholique de Louvain Anti-garp protein and uses thereof
WO2015024042A1 (en) 2013-08-22 2015-02-26 The Council Of The Queensland Institute Of Medical Research Immunoreceptor modulation for treating cancer and viral infections
WO2015024060A1 (en) 2013-08-22 2015-02-26 The Council Of The Queensland Institute Of Medical Research Immunoreceptor modulation for treating cancer and viral infections
WO2015026684A1 (en) 2013-08-20 2015-02-26 Merck Sharp & Dohme Corp. Modulation of tumor immunity
WO2015028455A1 (en) 2013-08-30 2015-03-05 Ucb Biopharma Sprl Antibodies
WO2015028454A2 (en) 2013-08-30 2015-03-05 Ucb Biopharma Sprl Method for the treatment of fibrotic disease
WO2015031667A2 (en) 2013-08-30 2015-03-05 Amgen Inc. Gitr antigen binding proteins
WO2015036511A1 (en) 2013-09-12 2015-03-19 F. Hoffmann-La Roche Ag Combination therapy of antibodies against human csf-1r and antibodies against human pd-l1
WO2015036394A1 (en) 2013-09-10 2015-03-19 Medimmune Limited Antibodies against pd-1 and uses thereof
WO2015035606A1 (en) 2013-09-13 2015-03-19 Beigene, Ltd. Anti-pd1 antibodies and their use as therapeutics and diagnostics
WO2015040401A1 (en) 2013-09-19 2015-03-26 Kymab Limited Expression vector production and high-throughput cell screening
WO2015042246A1 (en) 2013-09-20 2015-03-26 Bristol-Myers Squibb Company Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
WO2015058573A1 (zh) 2013-10-25 2015-04-30 苏州思坦维生物技术有限责任公司 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途
WO2015061668A1 (en) 2013-10-25 2015-04-30 Dana-Farber Cancer Institute, Inc. Anti-pd-l1 monoclonal antibodies and fragments thereof
WO2015063187A1 (en) 2013-10-30 2015-05-07 Sergej Michailovic Kiprijanov Multivalent antigen-binding proteins
WO2015069874A1 (en) 2013-11-06 2015-05-14 Bristol-Myers Squibb Company Treatment of c1013g/cxcr4-associated waldenström's macroglobulinemia with an anti-cxcr4 antibody
WO2015085847A1 (zh) 2013-12-12 2015-06-18 上海恒瑞医药有限公司 Pd-1抗体、其抗原结合片段及其医药用途
WO2015091910A2 (en) 2013-12-20 2015-06-25 Intervet International B.V. Caninized antibodies
WO2015091853A2 (en) 2013-12-19 2015-06-25 Alligator Bioscience Ab Antibodies
WO2015095392A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Anti-cd3 antibodies and methods of use
WO2015097536A2 (en) 2013-12-24 2015-07-02 Janssen Pharmaceutical Nv Anti-vista antibodies and fragments
WO2015103072A1 (en) 2013-12-30 2015-07-09 Epimab Biotherapeutics Fabs-in-tandem immunoglobulin and uses thereof
WO2015109124A2 (en) 2014-01-15 2015-07-23 Kadmon Corporation, Llc Immunomodulatory agents
US20150203579A1 (en) 2014-01-23 2015-07-23 Regeneron Pharmaceuticals, Inc. Human Antibodies to PD-1
WO2015112900A1 (en) 2014-01-24 2015-07-30 Dana-Farber Cancer Institue, Inc. Antibody molecules to pd-1 and uses thereof
WO2015112805A1 (en) 2014-01-23 2015-07-30 Regeneron Pharmaceuticals, Inc. Human antibodies to pd-l1
WO2015117002A1 (en) 2014-01-31 2015-08-06 Novartis Ag Antibody molecules to tim-3 and uses thereof
WO2015116539A1 (en) 2014-01-28 2015-08-06 Bristol-Myers Squibb Company Anti-lag-3 antibodies to treat hematological malignancies
WO2015134988A1 (en) 2014-03-07 2015-09-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
WO2015138600A2 (en) 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
WO2015136541A2 (en) 2014-03-12 2015-09-17 Yeda Research And Development Co. Ltd Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
WO2015153513A1 (en) 2014-03-31 2015-10-08 Genentech, Inc. Anti-ox40 antibodies and methods of use
WO2015164815A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
WO2015169811A2 (en) 2014-05-06 2015-11-12 Medimmune Limited Anti-cxc chemokine receptor-2 binding molecules and uses thereof
WO2015173267A1 (en) 2014-05-13 2015-11-19 Medimmune Limited Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
WO2015179654A1 (en) 2014-05-22 2015-11-26 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti b7-h1 antibodies
WO2015179236A1 (en) 2014-05-21 2015-11-26 Pfizer Inc. Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer
WO2015184099A1 (en) 2014-05-28 2015-12-03 4-Antibody Ag Anti-gitr antibodies and methods of use thereof
WO2015181342A1 (en) 2014-05-29 2015-12-03 Spring Bioscience Corporation Pd-l1 antibodies and uses thereof
WO2015187835A2 (en) 2014-06-06 2015-12-10 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
WO2015195163A1 (en) 2014-06-20 2015-12-23 R-Pharm Overseas, Inc. Pd-l1 antagonist fully human antibody
WO2015198312A1 (en) 2014-06-24 2015-12-30 Ccam Therapeutics Ltd. Compositions comprising antibodies to ceacam-1 and lag-3 for cancer therapy
WO2016000619A1 (en) 2014-07-03 2016-01-07 Beigene, Ltd. Anti-pd-l1 antibodies and their use as therapeutics and diagnostics
WO2016007235A1 (en) 2014-07-11 2016-01-14 Genentech, Inc. Anti-pd-l1 antibodies and diagnostic uses thereof
WO2016014688A2 (en) 2014-07-22 2016-01-28 Junzhuan Qiu Anti-pd-1 antibodies
WO2016014974A2 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
WO2016015675A1 (zh) 2014-08-01 2016-02-04 中山康方生物医药有限公司 抗ctla4的单克隆抗体或其抗原结合片段、药物组合物及用途
WO2016015685A1 (zh) 2014-07-30 2016-02-04 珠海市丽珠单抗生物技术有限公司 抗pd-1抗体及其应用
WO2016022630A1 (en) 2014-08-05 2016-02-11 Jiping Zha Anti-pd-l1 antibodies
WO2016023875A1 (en) 2014-08-14 2016-02-18 F. Hoffmann-La Roche Ag Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1
WO2016023960A1 (en) 2014-08-12 2016-02-18 Alligator Bioscience Ab Combination therapies with anti cd40 antibodies
WO2016028810A1 (en) 2014-08-18 2016-02-25 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
WO2016028656A1 (en) 2014-08-19 2016-02-25 Merck Sharp & Dohme Corp. Anti-tigit antibodies
WO2016028672A1 (en) 2014-08-19 2016-02-25 Merck Sharp & Dohme Corp. Anti-lag3 antibodies and antigen-binding fragments
WO2016030350A1 (en) * 2014-08-29 2016-03-03 F. Hoffmann-La Roche Ag Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
WO2016050721A1 (en) 2014-09-30 2016-04-07 Intervet International B.V. Pd-l1 antibodies binding canine pd-l1
WO2016054638A1 (en) 2014-10-03 2016-04-07 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
WO2016057488A1 (en) 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof
WO2016057667A1 (en) 2014-10-10 2016-04-14 Medimmune, Llc Humanized anti-ox40 antibodies and uses thereof
WO2016055609A1 (en) 2014-10-10 2016-04-14 Innate Pharma Cd73 blockade
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
WO2016063233A1 (en) 2014-10-24 2016-04-28 Effimune Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
WO2016068801A1 (en) 2014-10-27 2016-05-06 Agency For Science, Technology And Research Anti-pd-1 antibodies
WO2016068802A1 (en) 2014-10-27 2016-05-06 Agency For Science, Technology And Research Anti-tim-3 antibodies
WO2016068803A1 (en) 2014-10-27 2016-05-06 Agency For Science, Technology And Research Anti-tim-3 antibodies
WO2016071448A1 (en) 2014-11-06 2016-05-12 F. Hoffmann-La Roche Ag Anti-tim3 antibodies and methods of use
WO2016073845A1 (en) 2014-11-07 2016-05-12 Igenica Biotherapeutics, Inc. Anti-cd39 antibodies and uses thereof
WO2016075099A1 (en) 2014-11-10 2016-05-19 Medimmune Limited Binding molecules specific for cd73 and uses thereof
WO2016077397A2 (en) 2014-11-11 2016-05-19 Sutro Biopharma, Inc. Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies
WO2016075176A1 (en) 2014-11-11 2016-05-19 Medimmune Limited Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
WO2016081748A2 (en) 2014-11-21 2016-05-26 Bristol-Myers Squibb Company Antibodies against cd73 and uses thereof
US20160145344A1 (en) 2014-10-20 2016-05-26 University Of Southern California Murine and human innate lymphoid cells and lung inflammation
WO2016079050A1 (en) 2014-11-20 2016-05-26 F. Hoffmann-La Roche Ag Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
WO2016092419A1 (en) 2014-12-09 2016-06-16 Rinat Neuroscience Corp. Anti-pd-1 antibodies and methods of use thereof
WO2016106302A1 (en) 2014-12-23 2016-06-30 Bristol-Myers Squibb Company Antibodies to tigit
WO2016106180A1 (en) 2014-12-22 2016-06-30 Five Prime Therapeutics, Inc. Anti-csf1r antibodies for treating pvns
WO2016106159A1 (en) 2014-12-22 2016-06-30 Enumeral Biomedical Holding, Inc. Anti-pd-1 antibodies
WO2016111947A2 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
WO2016109872A1 (en) 2015-01-09 2016-07-14 Adalta Pty Ltd Cxcr4 binding molecules
WO2016111645A1 (en) 2015-01-09 2016-07-14 Agency For Science, Technology And Research Anti-pd-l1 antibodies
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
US20160215059A1 (en) 2015-01-28 2016-07-28 Glaxosmithkline Intellectual Property Development Limited Icos binding proteins
WO2016116626A1 (en) 2015-01-23 2016-07-28 Sanofi Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
WO2016127179A2 (en) 2015-02-06 2016-08-11 Kadmon Corporation, Llc Immunomodulatory agents
WO2016126858A2 (en) 2015-02-03 2016-08-11 Anaptysbio, Inc. Antibodies directed against lymphocyte activation gene 3 (lag-3)
WO2016130898A2 (en) 2015-02-13 2016-08-18 Sorrento Therapeutics, Inc. Antibody therapeutics that bind ctla4
WO2016134358A1 (en) 2015-02-22 2016-08-25 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd137
WO2016131950A1 (en) 2015-02-20 2016-08-25 Innate Pharma Cd73 blockade
WO2016145085A2 (en) 2015-03-09 2016-09-15 Celldex Therapeutics, Inc. Cd27 agonists
WO2016149201A2 (en) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
WO2016154177A2 (en) 2015-03-23 2016-09-29 Jounce Therapeutics, Inc. Antibodies to icos
WO2016156570A1 (en) 2015-04-02 2016-10-06 Ablynx N.V. Bispecific cxcr4-cd-4 polypeptides with potent anti-hiv activity
WO2016161270A1 (en) 2015-04-01 2016-10-06 Anaptysbio, Inc. Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
WO2016160792A1 (en) 2015-03-30 2016-10-06 Stcube & Co., Inc. Antibodies specific to glycosylated pd-l1 and methods of use thereof
WO2016168149A1 (en) 2015-04-13 2016-10-20 Five Prime Therapeutics, Inc. Combination therapy for cancer
WO2016171722A1 (en) 2015-04-24 2016-10-27 The Brigham And Women's Hospital, Inc. Interactions between ceacam and tim family members
WO2016176583A1 (en) 2015-04-29 2016-11-03 Sanford-Burnham Medical Research Institute Modulation of immune response using btla agonist antibodies
WO2016179194A1 (en) 2015-05-04 2016-11-10 Jounce Therapeutics, Inc. Lilra3 and method of using the same
WO2016178779A1 (en) 2015-05-01 2016-11-10 Dana-Farber Cancer Institute, Inc. Methods of mediating cytokine expression with anti ccr4 antibodies
WO2016179003A1 (en) 2015-05-01 2016-11-10 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
WO2016179517A1 (en) 2015-05-07 2016-11-10 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
WO2016180721A1 (en) 2015-05-08 2016-11-17 Miltenyi Biotec Gmbh Humanized antibody or fragment thereof specific for cd3
WO2016191643A2 (en) 2015-05-28 2016-12-01 Oncomed Pharmaceuticals, Inc. Tigit-binding agents and uses thereof
WO2016196173A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer
WO2016196237A1 (en) 2015-05-29 2016-12-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
WO2016196228A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Antibodies against ox40 and uses thereof
WO2016196792A1 (en) 2015-06-03 2016-12-08 Bristol-Myers Squibb Company Anti-gitr antibodies for cancer diagnostics
WO2016196314A1 (en) 2015-05-29 2016-12-08 Abbvie Inc. Anti-cd40 antibodies and uses thereof
WO2016200836A1 (en) 2015-06-08 2016-12-15 Genentech, Inc. Methods of treating cancer using anti-ox40 antibodies
WO2016200782A1 (en) 2015-06-08 2016-12-15 Macrogenics, Inc. Lag-3-binding molecules and methods of use thereof
WO2016200835A1 (en) 2015-06-08 2016-12-15 Genentech, Inc. Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
WO2016197367A1 (en) 2015-06-11 2016-12-15 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2016197497A1 (zh) 2015-06-09 2016-12-15 北京东方百泰生物科技有限公司 一种抗pd-1的单克隆抗体及其获得方法
WO2016201051A1 (en) 2015-06-12 2016-12-15 Macrogenics, Inc. Combination therapy for the treatment of cancer
WO2016204966A1 (en) 2015-06-16 2016-12-22 Genentech, Inc. Anti-cd3 antibodies and methods of use
WO2016205042A1 (en) 2015-06-16 2016-12-22 The Board Of Trustees Of The Leland Stanford Junior University SIRPα AGONIST ANTIBODY
WO2016207312A1 (en) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
WO2016207717A1 (en) 2015-06-24 2016-12-29 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
WO2017004016A1 (en) 2015-06-29 2017-01-05 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
WO2017004006A1 (en) 2015-06-29 2017-01-05 Bristol-Myers Squibb Company Antibodies to cd40
WO2017004945A1 (zh) 2015-07-03 2017-01-12 中兴通讯股份有限公司 一种拍摄终端和拍摄方法
WO2017010874A1 (en) 2015-07-10 2017-01-19 Merus N.V. Human cd3 binding antibody
WO2017009442A1 (en) 2015-07-15 2017-01-19 Genmab A/S Humanized or chimeric cd3 antibodies
WO2017015560A2 (en) 2015-07-22 2017-01-26 Sorrento Therapeutics, Inc. Antibody therapeutics that bind lag3
WO2017019896A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to pd-1
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
WO2017019846A1 (en) 2015-07-30 2017-02-02 Macrogenics, Inc. Pd-1-binding molecules and methods use thereof
WO2017016497A1 (en) 2015-07-28 2017-02-02 Harbour Biomed Limited Anti-pd-1 antibodies and uses thereof
WO2017019894A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to lag-3
WO2017021910A1 (en) 2015-08-04 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
WO2017021912A1 (en) 2015-08-06 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Combined tlrs modulators with anti ox40 antibodies
WO2017020801A1 (zh) 2015-07-31 2017-02-09 苏州康宁杰瑞生物科技有限公司 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
WO2017020858A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2017024515A1 (en) 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
WO2017025051A1 (en) 2015-08-11 2017-02-16 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-1 antibodies
WO2017030823A2 (en) 2015-08-14 2017-02-23 Merck Sharp & Dohme Corp. Anti-tigit antibodies
WO2017031242A1 (en) 2015-08-20 2017-02-23 Sutro Biopharma, Inc. Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies
WO2017034916A1 (en) 2015-08-24 2017-03-02 Eli Lilly And Company Pd-l1 ("programmed death-ligand 1") antibodies
WO2017040932A1 (en) 2015-09-04 2017-03-09 Primatope Therapeutics Inc. Humanized anti-cd40 antibodies and uses thereof
WO2017040566A1 (en) 2015-09-01 2017-03-09 Boehringer Ingelheim International Gmbh Use of anti-cd40 antibodies for treatment of lupus nephritis
WO2017037707A1 (en) 2015-09-02 2017-03-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
WO2017037203A1 (en) 2015-09-02 2017-03-09 Immutep S.A.S. Anti-LAG-3 Antibodies
WO2017040790A1 (en) 2015-09-01 2017-03-09 Agenus Inc. Anti-pd-1 antibodies and methods of use thereof
WO2017049038A2 (en) 2015-09-16 2017-03-23 Ablexis, Llc Anti-cd115 antibodies
WO2017051888A1 (ja) 2015-09-24 2017-03-30 第一三共株式会社 抗ｇａｒｐ抗体
WO2017050729A1 (en) 2015-09-22 2017-03-30 Spring Bioscience Corporation Anti-ox40 antibodies and diagnostic uses thereof
WO2017053748A2 (en) 2015-09-25 2017-03-30 Genentech, Inc. Anti-tigit antibodies and methods of use
WO2017058859A1 (en) 2015-09-29 2017-04-06 Celgene Corporation Pd-1 binding proteins and methods of use thereof
WO2017058115A1 (en) 2015-09-29 2017-04-06 Asia Biotech Pte. Ltd. Pd-1 antibodies and uses thereof
WO2017059196A2 (en) 2015-09-30 2017-04-06 Janssen Biotech, Inc. Antagonistic antibodies specifically binding human cd40 and methods of use
WO2017055404A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific antibodies specific for pd1 and tim3
WO2017055547A1 (en) 2015-10-02 2017-04-06 Symphogen A/S Anti-pd-1 antibodies and compositions
WO2017062888A1 (en) 2015-10-09 2017-04-13 Regeneron Pharmaceuticals, Inc. Anti-lag3 antibodies and uses thereof
WO2017063162A1 (zh) 2015-10-15 2017-04-20 苏州丁孚靶点生物技术有限公司 抗ox40抗体及其应用
WO2017064043A1 (en) 2015-10-12 2017-04-20 Innate Pharma Cd73 blocking agents
WO2017071625A1 (zh) 2015-10-30 2017-05-04 中山康方生物医药有限公司 一种抗pd-1单克隆抗体、其药物组合物及其用途
WO2017079115A1 (en) 2015-11-03 2017-05-11 Janssen Biotech, Inc. Antibodies specifically binding tim-3 and their uses
WO2017077085A2 (en) 2015-11-04 2017-05-11 Cancer Research Technology Immunomodulatory antibodies
WO2017087588A1 (en) 2015-11-18 2017-05-26 Merck Sharp & Dohme Corp. Ctla4 binders
WO2017087678A2 (en) 2015-11-19 2017-05-26 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
WO2017087599A1 (en) 2015-11-18 2017-05-26 Lyvgen Biopharma Holdings Limited Anti-pd-1 antibodies and therapeutic uses thereof
WO2017087589A2 (en) 2015-11-18 2017-05-26 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
WO2017084078A1 (en) 2015-11-19 2017-05-26 Zeling Cai Ctla-4 antibodies and uses thereof
WO2017087901A2 (en) 2015-11-19 2017-05-26 Sutro Biopharma, Inc. Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
WO2017089334A1 (en) 2015-11-23 2017-06-01 Innate Pharma Cd39 vascular isoform targeting agents

Family Cites Families (336)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4663281A (en) 1984-03-22 1987-05-05 Mass Institute Of Technology Enhanced production of proteinaceous materials in eucaryotic cells
US4789633A (en) 1984-04-19 1988-12-06 University Of Tennessee Research Corporation Fused liposome and acid induced method for liposome fusion
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
EP1997891A1 (en) 1988-09-02 2008-12-03 Dyax Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0493418B1 (en) 1989-09-20 1997-04-23 Abbott Laboratories Method of producing fusion proteins
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
CA2077348A1 (en) 1990-03-02 1991-09-03 Stephen D. Gillies Antibody constructs with enhanced binding affinity
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2095842A1 (en) 1990-11-09 1992-05-10 Stephen D. Gillies Bridging antibody fusion constructs
ATE218889T1 (de) 1990-11-09 2002-06-15 Stephen D Gillies Cytokine immunokonjugate
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
DE69233750D1 (de) 1991-04-10 2009-01-02 Scripps Research Inst Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
DE69233204T2 (de) 1991-12-13 2004-07-15 Xoma Corp., Berkeley Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994021679A1 (en) 1993-03-25 1994-09-29 Merck & Co., Inc. Inhibitor of vascular endothelial cell growth factor
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
DK1231268T3 (da) 1994-01-31 2005-11-21 Univ Boston Polyklonale antistofbiblioteker
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
GB9410534D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US6576754B2 (en) 1995-11-09 2003-06-10 Dana-Farber Cancer Institute CD100 antigen and uses therefor
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
CA2258518C (en) 1996-06-27 2011-11-22 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Recognition molecules interacting specifically with the active site or cleft of a target molecule
US6028176A (en) 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
ES2274549T3 (es) 1996-09-24 2007-05-16 MERCK & CO., INC. Compuestos para la inhibicion de la angiogenesis por terapia de genes .
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US20060223090A1 (en) 1997-03-07 2006-10-05 Rosen Craig A Polynucleotides encoding human secreted proteins
US20070015696A1 (en) 1997-03-07 2007-01-18 Rosen Craig A 621 human secreted proteins
US20060223088A1 (en) 1997-03-07 2006-10-05 Rosen Craig A Human secreted proteins
US7411051B2 (en) 1997-03-07 2008-08-12 Human Genome Sciences, Inc. Antibodies to HDPPA04 polypeptide
US20050197285A1 (en) 1997-03-07 2005-09-08 Rosen Craig A. Human secreted proteins
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US20080103090A1 (en) 1997-03-07 2008-05-01 Human Genome Sciences, Inc. Human Secreted Proteins
US20070055056A1 (en) 1997-03-07 2007-03-08 Rosen Craig A 251 human secreted proteins
US20070224663A1 (en) 1997-03-07 2007-09-27 Human Genome Sciences, Inc. Human Secreted Proteins
US20060246483A1 (en) 1997-03-07 2006-11-02 Rosen Craig A 337 human secreted proteins
US7968689B2 (en) 1997-03-07 2011-06-28 Human Genome Sciences, Inc. Antibodies to HSDEK49 polypeptides
KR100634847B1 (ko) 1997-06-20 2006-10-17 바이오겐 아이덱 엠에이 인코포레이티드 췌장도 조직 이식을 위한 ｃｄ154 차단 요법
US6075007A (en) 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
CA2320403A1 (en) 1998-02-25 1999-09-02 Lexigen Pharmaceuticals Corporation Enhancing the circulating half-life of antibody-based fusion proteins
WO1999048927A1 (en) 1998-03-25 1999-09-30 Cornell Research Foundation, Inc. Methods for designing specific ion channel blockers
HK1038882A1 (zh) 1998-04-15 2002-04-04 利思进药品公司 通过共同给予血管生成抑制剂增强抗体-细胞因子融合蛋白介导的免疫应答
MXPA00010151A (es) 1998-04-17 2002-08-06 Lexigen Pharm Corp Mejoramiento de las respuestas inmunes mediadas por proteina de fusion de anticuerpo-citocina mediante la soadministracion con inhibidores de prostaglandina.
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
PL202057B1 (pl) 1998-08-25 2009-05-29 Merck Patent Gmbh Homodimeryczne białko fuzyjne będące inhibitorem angiogenezy, sposób jego otrzymywania oraz cząsteczka DNA i wektor ekspresyjny zawierający to DNA
JP2002534962A (ja) 1999-01-07 2002-10-22 レキシジェン ファーマシューティカルズ コーポレイション Ｆｃ融合タンパク質としての抗肥満症タンパク質の発現および輸送
AU2507700A (en) 1999-01-15 2000-08-01 Biogen, Inc. Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
RU2236251C2 (ru) 1999-02-12 2004-09-20 Дзе Скриппс Рисерч Инститьют Способы лечения опухолей и метастазов с использованием комбинации антиангиогенной терапии и иммунотерапии
GB9907965D0 (en) 1999-04-09 1999-06-02 Glaxo Group Ltd Medical use
CN1308347C (zh) 1999-04-28 2007-04-04 德克萨斯大学董事会 用于通过选择性抑制vegf来治疗癌症的组合物和方法
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
EP1514933A1 (en) 1999-07-08 2005-03-16 Research Association for Biotechnology Secretory protein or membrane protein
US7129338B1 (en) 1999-07-08 2006-10-31 Research Association For Biotechnology Secretory protein or membrane protein
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
AU778611B2 (en) 1999-08-09 2004-12-16 Merck Patent Gmbh Multiple cytokine-antibody complexes
US20030119038A1 (en) 1999-09-09 2003-06-26 Bingham Brendan William NARC1, novel subtilase-like homologs
US7029895B2 (en) 1999-09-27 2006-04-18 Millennium Pharmaceuticals, Inc. 27411, a novel human PGP synthase
US20100291099A1 (en) 1999-09-27 2010-11-18 Millennium Pharmaceuticals, Inc. Novel 27411, 23413, 22438, 23553, 25278, 26212, narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc 9, narc 10c, narc 8b, narc 9, narc2a, narc 16b, narc 1c, narc 1a, narc 25, 86604 and 32222 molecules and uses therefor
US20110230392A1 (en) 1999-10-22 2011-09-22 Millennium Pharmaceuticals, Inc. Novel narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc 9, narc 10c, narc 8b, narc 9, narc2a, narc 16b, narc 1c, narc 1a, and narc 25 molecules and uses therefor
CA2388617A1 (en) 1999-10-22 2001-05-03 Millennium Pharmaceuticals, Inc. Nucleic acid molecules derived from rat brain and programmed cell death models
US20020081679A1 (en) 1999-10-22 2002-06-27 Millennium Pharmaceuticals, Inc. NARC8 programmed cell-death-associated molecules and uses thereof
TWI263496B (en) 1999-12-10 2006-10-11 Novartis Ag Pharmaceutical combinations and their use in treating gastrointestinal disorders
EP1257572A2 (en) 2000-02-07 2002-11-20 Millennium Pharmaceuticals, Inc. Narc-1, subtilase-like homologs
ATE336514T1 (de) 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US6680315B2 (en) 2000-06-15 2004-01-20 Synta Pharmaceuticals Corp. Triazine compounds
AU2001269836A1 (en) 2000-06-16 2002-01-02 Incyte Genomics, Inc. Proteases
US6689353B1 (en) 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
ATE368475T1 (de) 2000-06-29 2007-08-15 Emd Lexigen Res Ct Corp Steigerung von durch antikörper-zytokin- fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
WO2002014358A2 (en) 2000-08-11 2002-02-21 Eli Lilly And Company Novel secreted proteins and their uses
CN1284536C (zh) 2000-09-18 2006-11-15 威克斯医药有限公司 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用
CN1203857C (zh) 2000-09-18 2005-06-01 威克斯医药有限公司 局部麻醉与镇痛的新方法
AU2001296908A1 (en) 2000-09-29 2002-04-08 Geneva Pharmaceuticals, Inc. Proton pump inhibitor formulation
IL155002A0 (en) 2000-10-12 2003-10-31 Genentech Inc Reduced-viscosity concentrated protein formulations
EP1358325A2 (en) 2000-12-08 2003-11-05 Incyte Genomics, Inc. Protein modification and maintenance molecules
HUP0401300A3 (en) 2001-01-18 2005-06-28 Merck Patent Gmbh Bifunctional fusion proteins with glucocerebrosidase activity
AU2002233340B2 (en) 2001-02-19 2008-05-22 Merck Patent Gmbh Artificial fusion proteins with reduced immunogenicity
BR0207854A (pt) 2001-03-07 2004-08-24 Merck Patent Gmbh Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido
EP1414845A4 (en) 2001-03-21 2009-07-08 Human Genome Sciences SEPARATE HUMAN PROTEINS
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
WO2002086083A2 (en) 2001-04-20 2002-10-31 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
DK1383785T3 (da) 2001-05-03 2011-05-23 Merck Patent Gmbh Rekombinant tumorspecifikt antistof og anvendelse deraf
ATE390931T1 (de) 2001-05-23 2008-04-15 Bristol Myers Squibb Co Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen
US20040023243A1 (en) 2001-06-13 2004-02-05 Yue Henry Proteases
IL159177A0 (en) 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20030124149A1 (en) 2001-07-06 2003-07-03 Shalaby Shalaby W. Bioactive absorbable microparticles as therapeutic vaccines
US20040038242A1 (en) 2001-07-30 2004-02-26 Edmonds Brian Taylor Novel secreted proteins and their uses
EP1441758A2 (de) 2001-11-09 2004-08-04 MediGene Aktiengesellschaft Allogene vakzine enthaltend eine ein costimulatorisches polypeptid exprimierende tumorzelle
PT1454138E (pt) 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
AU2002351896A1 (en) 2001-12-11 2003-06-23 Ablynx N.V. Method for displaying loops from immunoglobulin domains in different contexts
WO2003059245A2 (en) 2001-12-18 2003-07-24 J & J Research Pty Ltd Method of treating asthma
US20060093771A1 (en) 2002-02-15 2006-05-04 Frantisek Rypacek Polymer coating for medical devices
US7659082B2 (en) 2002-02-19 2010-02-09 Xenon Pharmaceuticals Inc. Methods for identifying analgesic agents
WO2003074679A2 (en) 2002-03-01 2003-09-12 Xencor Antibody optimization
US6875433B2 (en) 2002-08-23 2005-04-05 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
US7291331B1 (en) 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
EP1570267B1 (en) 2002-12-03 2011-10-12 UCB Pharma, S.A. Assay for identifying antibody producing cells
DK1572748T3 (da) 2002-12-17 2010-08-23 Merck Patent Gmbh Humaniseret antistof (H14.18) af muse-14.18-antistof der binder til GD2 og dets fusionsprotein med IL-2
AU2003299971A1 (en) 2002-12-30 2004-07-29 Amgen Inc. Combination therapy with co-stimulatory factors
US7608260B2 (en) 2003-01-06 2009-10-27 Medimmune, Llc Stabilized immunoglobulins
EP1618181B1 (en) 2003-04-22 2014-10-15 IBC Pharmaceuticals Polyvalent protein complex
EP1471152A1 (en) 2003-04-25 2004-10-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutations in the human PCSK9 gene associated to hypercholesterolemia
JP4999158B2 (ja) 2003-05-21 2012-08-15 メダレツクス・インコーポレーテツド 炭疽菌（ｂａｃｈｉｌｌｕｓａｎｔｈｒａｃｉｓ）の感染防御抗原に対するヒトモノクローナル抗体
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
WO2005007809A2 (en) 2003-05-30 2005-01-27 Alexion Pharmaceuticals, Inc. Antibodies and fusion proteins that include engineered constant regions
US7354578B2 (en) 2003-06-06 2008-04-08 Regeneron Pharmaceuticals, Inc. Method of tumor regression with VEGF inhibitors
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
CA2527020A1 (en) 2003-07-01 2005-01-13 Celltech R & D Limited Modified antibody fab fragments
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
US20050069521A1 (en) 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
US20050118625A1 (en) 2003-10-02 2005-06-02 Mounts William M. Nucleic acid arrays for detecting gene expression associated with human osteoarthritis and human proteases
JP2005130764A (ja) 2003-10-30 2005-05-26 Pharmaceuticals & Medical Devices Agency Ｎａｒｃ−１遺伝子上の多型を利用した脂質代謝異常に起因する疾患の検査方法、および創薬のための用途
ES2305886T3 (es) 2003-12-30 2008-11-01 Merck Patent Gmbh Proteinas de fusion de il-7 con porciones de anticuerpo, su preparacion y su empleo.
KR20060124656A (ko) 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 개선된 약물동태를 가지는 Ｆｃ-에리스로포이에틴 융합단백질
US8420087B2 (en) 2004-01-05 2013-04-16 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
JP2007530045A (ja) 2004-03-23 2007-11-01 アムジエン・インコーポレーテツド ヒトｏｘ４０ｌ（ｃｄ１３４ｌ）特異性モノクローナル抗体
US7998481B2 (en) 2004-04-05 2011-08-16 The Regents Of The University Of California Modulation of NKG2D for treating or preventing solid organ allograft rejection
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
EP1755645A2 (en) 2004-06-18 2007-02-28 Regeneron Pharmaceuticals, Inc. Vegf inhibitors for the treatment of malignant pleural effusion
AU2005259958A1 (en) 2004-06-29 2006-01-12 The Johns Hopkins University Amelioration of drug-induced toxicity
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
CN101023102B (zh) 2004-09-17 2013-05-29 霍夫曼-拉罗奇有限公司 抗-ox40l抗体
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
PT3428191T (pt) 2004-10-06 2024-12-30 Mayo Found Medical Education & Res B7-h1 e tratamento do carcinona de células renais
JP4937132B2 (ja) 2004-12-09 2012-05-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 免疫原性の低下したｉｌ−７変種
HRP20110859T1 (hr) 2004-12-21 2011-12-31 Medimmune Limited Protutijela usmjerena na angiopoietin-2 i njihova upotreba
US20060147945A1 (en) 2005-01-06 2006-07-06 Edmonds Brian T Novel secreted proteins and their uses
TW200641353A (en) 2005-02-14 2006-12-01 Wyeth Corp Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor
KR20070106029A (ko) 2005-02-24 2007-10-31 암젠 인코포레이티드 상피세포 성장 인자 수용체 돌연변이
CA2598452A1 (en) 2005-03-11 2006-09-21 Regeneron Pharmaceuticals, Inc. Treating anemia by inhibition of vegf
EP3130350A1 (en) 2005-06-08 2017-02-15 Dana-Farber Cancer Institute, Inc. Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway
MX2008001966A (es) 2005-08-12 2008-03-26 Regeneron Pharma Tratamiento de enfermedades mediante administracion subcutanea de un antagonista vegf.
GB0517487D0 (en) 2005-08-26 2005-10-05 Isis Innovation Antibodies
US7972813B2 (en) 2005-09-30 2011-07-05 Vertex Pharmaceuticals Incorporated Tetrodotoxin-resistant sodium channel alpha subunit
AR057253A1 (es) 2005-12-16 2007-11-21 Genentech Inc Anticuerpos anti-ox40l y metodos que los utilizan
TWI423986B (zh) 2005-12-20 2014-01-21 必治妥美雅史谷比公司 組合物及製造組合物之方法
WO2007109324A2 (en) 2006-03-21 2007-09-27 Xenon Pharmaceuticals, Inc. Potent and selective nav 1.7 sodium channel blockers
EP2007423A2 (en) 2006-04-05 2008-12-31 Pfizer Products Incorporated Ctla4 antibody combination therapy
EP2021467A4 (en) 2006-05-08 2010-01-20 Adaerata Ltd Partnership CHIMERIC PCSK9 PROTEINS, THESE INCLUDING CELLS AND TEST METHODS THEREWITH
SG171676A1 (en) 2006-05-11 2011-06-29 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of the pcsk9 gene
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
CA2656700A1 (en) 2006-07-06 2008-01-10 Merck Patent Gesellschaft Mit Beschraenkter Haftung Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
EP2484696B1 (en) 2006-08-28 2017-08-16 Kyowa Hakko Kirin Co., Ltd. Antagonistic hLIGHT-specific human monoclonal antibodies
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
WO2008050962A1 (en) 2006-10-24 2008-05-02 College Of Medicine Pochon Cha University Industry-Academic Cooperation Foundation Composition for in vivo transplantation for treatment of human cervical cancer comprising mononuclear cells derived from umbilical cord blood
JP5588175B2 (ja) 2006-11-07 2014-09-10 メルク・シャープ・アンド・ドーム・コーポレーション Ｐｃｓｋ９のアンタゴニスト
CA2667869A1 (en) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
CA2667989A1 (en) 2006-11-07 2008-11-06 Merck & Co., Inc. Antagonists of pcsk9
CA2668131A1 (en) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
NZ720288A (en) 2006-12-27 2020-02-28 Harvard College Compositions and methods for the treatment of infections and tumors
CN101600457B (zh) 2007-01-09 2014-01-08 惠氏公司 抗il-13抗体调配物和其用途
WO2008090958A1 (ja) 2007-01-24 2008-07-31 Kyowa Hakko Kirin Co., Ltd. ドメイン交換された遺伝子組換え抗体組成物
WO2008109871A2 (en) 2007-03-08 2008-09-12 Irm Llc Crystal structure of proprotein convertase 9 (pcsk9) and uses thereof
TW200906439A (en) 2007-04-13 2009-02-16 Novartis Ag Molecules and methods for modulating proprotein convertase subtilisin/kexin type 9 (PCSK9)
BRPI0810374A2 (pt) 2007-04-17 2014-10-29 Imclone Llc Inibidores específicos do pdgfrbeta
BRPI0811466A2 (pt) 2007-05-07 2014-10-14 Medimmune Llc Anticorpo anti-icos isolado, ácido nucleico, vetor, célula isolada, métodos para produzir um anticorpo, para tratar uma doença ou distúrbio, para tratar ou prevenir a rejeição em um paciente de transplante humano, para tratar uma malignidade de célula t em um ser humano, para esgotar células t que expressam icos em um paciente humano, para romper a arquitetura do centro germinal em um órgão linfóide secundário de um primata, para esgotar células b centrais germinais de órgão linfóide secundário de um primata, e para esgotar células b comutadas em classes circulantes em um primata, e, composição farmacêutica.
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US20130072665A1 (en) 2007-08-23 2013-03-21 Simon Mark Jackson Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
WO2009033027A2 (en) 2007-09-05 2009-03-12 Medtronic, Inc. Suppression of scn9a gene expression and/or function for the treatment of pain
CN102232088A (zh) 2007-10-26 2011-11-02 先灵公司 用于治疗脂类和胆固醇疾病的抗pcsk9及方法
US9308257B2 (en) 2007-11-28 2016-04-12 Medimmune, Llc Protein formulation
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
US9176122B2 (en) 2008-03-24 2015-11-03 University Of South Florida Biomarkers for predicting response to immunosuppressive therapy
WO2009131740A2 (en) 2008-04-23 2009-10-29 Amgen Inc. Neutralizing proprotein convertase subtilisin kexin type 9 (pcsk9) variants and uses thereof
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
WO2009141239A1 (en) 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
SG2014011365A (en) 2008-09-19 2014-05-29 Hoffmann La Roche Novel antibody formulation
WO2010035012A1 (en) 2008-09-26 2010-04-01 Ucb Pharma S.A. Biological products
EP2356270B1 (en) 2008-11-07 2016-08-24 Fabrus Llc Combinatorial antibody libraries and uses thereof
US8357371B2 (en) 2008-12-15 2013-01-22 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to PCSK9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
WO2010073180A1 (en) 2008-12-23 2010-07-01 Koninklijke Philips Electronics N.V. Combining body-coupled communication and radio frequency communication
JP2012521216A (ja) 2009-03-24 2012-09-13 テバ バイオファーマスーティカルズ ユーエスエー，インコーポレーテッド Ｌｉｇｈｔに対するヒト化抗体およびその使用
WO2010117448A2 (en) 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Chimeric immunocytokines and methods of use thereof
WO2011003780A1 (en) 2009-07-06 2011-01-13 F. Hoffmann-La Roche Ag Bi-specific digoxigenin binding antibodies
PE20120630A1 (es) 2009-08-17 2012-05-26 Roche Glycart Ag Inmunoconjugados dirigidos
CN102481348A (zh) 2009-08-31 2012-05-30 Ibc药品公司 双特异性免疫细胞因子停靠-和-加锁(dnl)复合物及其治疗性用途
US20120283116A1 (en) 2009-09-11 2012-11-08 Leppert Mark F Mutant Sodium Channel Nav1.7 and Methods Related Thereto
WO2011037791A1 (en) 2009-09-25 2011-03-31 Merck Sharp & Dohme Corp. Antagonists of pcsk9
CA2775761C (en) 2009-09-30 2018-08-28 Memorial Sloan-Kettering Cancer Center Combination immunotherapy for the treatment of cancer
GB0922435D0 (en) 2009-12-22 2010-02-03 Ucb Pharma Sa Method
WO2011051350A1 (en) 2009-10-27 2011-05-05 Ucb Pharma S.A. Function modifying nav 1.7 antibodies
IN2012DN03824A (enExample) 2009-10-30 2015-08-28 Merck Sharp & Dohme
US20120208208A1 (en) 2009-10-30 2012-08-16 Ni Yan G Pcsk9 immunoassay
US8802827B2 (en) 2009-10-30 2014-08-12 Merck Sharp & Dohme Corp. AX1 PCSK9 antagonists
JP2013509591A (ja) 2009-10-30 2013-03-14 メルク・シャープ・エンド・ドーム・コーポレイション Ｐｃｓｋ９イムノアッセイ
US20120316071A1 (en) 2009-11-04 2012-12-13 Vaughn Smider Methods for affinity maturation-based antibody optimization
KR101853702B1 (ko) 2009-12-07 2018-05-03 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 항-종양 항체 치료를 향상시키는 방법
AR079336A1 (es) 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
US9133436B2 (en) 2010-02-04 2015-09-15 The Trustees Of The University Of Pennsylvania ICOS critically regulates the expansion and function of inflammatory human Th17 cells
CN105218674A (zh) 2010-03-11 2016-01-06 瑞纳神经科学公司 呈pH依赖性抗原结合的抗体
EP2371857A1 (en) 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
EP3424949A1 (en) 2010-04-13 2019-01-09 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind pcsk9
PT2558499T (pt) 2010-04-16 2017-07-14 Biogen Ma Inc Anticorpos anti-vla-4
US8486647B2 (en) 2010-06-09 2013-07-16 Regeneron Pharmaceuticals, Inc. Neuropeptide release assay for sodium channels
US8871996B2 (en) 2010-06-09 2014-10-28 Regeneron Pharmaceuticals, Inc. Mice expressing human voltage-gated sodium channels
ES2979168T3 (es) * 2010-07-23 2024-09-24 Univ Boston Inhibidores anti-DEspR como productos terapéuticos para inhibición de angiogénesis patológica e invasividad de células tumorales y para imagenología molecular y administración dirigida
CA2805054A1 (en) 2010-08-25 2012-03-01 F. Hoffmann-La Roche Ag Antibodies against il-18r1 and uses thereof
WO2012054438A1 (en) 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
WO2012088313A1 (en) 2010-12-22 2012-06-28 Genentech, Inc. Anti-pcsk9 antibodies and methods of use
EA201370161A1 (ru) 2011-01-18 2013-12-30 Амген Инк. НОКАУТНЫЕ ПО Na1.7 МЫШИ И ИХ ПРИМЕНЕНИЕ
EP2650016A1 (en) 2011-01-28 2013-10-16 Sanofi Human antibodies to PSCK9 for use in methods of treatment based on particular dosage regimens (11565)
HRP20180959T1 (hr) 2011-01-28 2018-07-27 Sanofi Biotechnology Ljudska protutijela za pcsk9 za uporabu u postupcima liječenja određenih skupina subjekata
EP2481758A1 (en) 2011-01-28 2012-08-01 Sanofi Human antibodies to PSCK9 for use in methods of treating particular groups of subjects (11566)
AU2012215572A1 (en) 2011-02-10 2013-05-02 Roche Glycart Ag Improved immunotherapy
EP2673302A1 (en) 2011-02-11 2013-12-18 Irm Llc Pcsk9 antagonists
WO2012132067A1 (ja) 2011-03-30 2012-10-04 中外製薬株式会社 抗原結合分子の血漿中滞留性と免疫原性を改変する方法
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US9732196B2 (en) 2011-05-10 2017-08-15 Sabic Global Technologies B.V. Adhesive for bonding polyimide resins
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
WO2012162583A1 (en) 2011-05-26 2012-11-29 Ibc Pharmaceuticals, Inc. Design and construction of novel multivalent antibodies
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
WO2012168491A1 (en) 2011-06-10 2012-12-13 Novartis Ag Pharmaceutical formulations of pcsk9 antagonists
WO2012170607A2 (en) 2011-06-10 2012-12-13 Novartis Ag Use of pcsk9 antagonists
CN103717615A (zh) 2011-06-20 2014-04-09 霍夫曼-拉罗奇有限公司 结合pcsk9的多肽及使用方法
HK1202804A1 (en) 2011-07-14 2015-10-09 辉瑞公司 Treatment with anti-pcsk9 antibodies
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
CA2848201C (en) 2011-09-16 2020-10-27 Regeneron Pharmaceuticals, Inc. Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
AR087715A1 (es) 2011-09-16 2014-04-09 Lilly Co Eli Anticuerpos anti pcsk9 y usos de los mismos
EP2757875B2 (en) 2011-09-19 2023-03-22 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
SMT202000091T1 (it) 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
JP6526414B2 (ja) 2011-10-26 2019-06-05 アムジエン・インコーポレーテツド Ｕｖ光曝露から生じるタンパク質の改変と分解を減ずるまたは排除する方法
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
US20130115171A1 (en) 2011-11-09 2013-05-09 Stefan I. McDonough Nav1.7-related assays
AU2012369202A1 (en) 2012-02-06 2014-09-25 Providence Health & Services - Oregon Cancer treatment and monitoring methods using OX40 agonists
GB201203442D0 (en) * 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
WO2013148350A2 (en) 2012-03-26 2013-10-03 Sanofi Anti-light antibody therapy for inflammatory bowel disease
WO2013148284A1 (en) 2012-03-29 2013-10-03 Genentech, Inc. Antibodies that bind to a pcsk9 cleavage site and methods of use
WO2013172933A1 (en) 2012-05-15 2013-11-21 University Of Southern California Ethnic gene profile of genes involved in angiogenesis may predict regional bevacizumab efficacy difference in gastric cancer
WO2013170367A1 (en) 2012-05-17 2013-11-21 The University Of British Columbia Methods and uses for proprotein convert ase subtilisin kexin 9 (pcsk9) inhibitors
US9102751B2 (en) 2012-05-18 2015-08-11 Janssen Biotech, Inc. Huwentoxin-IV variants and methods of use
DK2857419T3 (da) 2012-05-30 2021-03-29 Chugai Pharmaceutical Co Ltd Antigen-bindende molekyle til eliminering af aggregerede antigener
EP2854845B1 (en) 2012-06-01 2018-03-28 IBC Pharmaceuticals, Inc. Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy
AU2013301582B2 (en) 2012-08-07 2018-09-06 Roche Glycart Ag Composition comprising two antibodies engineered to have reduced and increased effector function
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
BR112015005772A2 (pt) 2012-09-17 2017-08-08 Galectin Therapeutics Inc método para a intensificação de imunoterapias específicas no tratamento de câncer
DK2925350T3 (da) 2012-12-03 2019-05-13 Bristol Myers Squibb Co Øgning af virksomheden mod cancer af immunomodulatoriske fc- fusionsproteiner
MX2015008117A (es) * 2012-12-21 2016-03-31 Amplimmune Inc Anticuerpos anti-h7cr.
US20140193410A1 (en) 2013-01-09 2014-07-10 University Of Miami Compositions and Methods for the Regulation of T Regulatory Cells Using TL1A-Ig Fusion Protein
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
CA2906003C (en) 2013-03-13 2021-07-06 Bioasis Technologies Inc. Fragments of p97 and uses thereof
WO2014159595A2 (en) 2013-03-14 2014-10-02 Regeneron Pharmaceuticals, Inc. Human antibodies to nav1.7
TWI682780B (zh) 2013-05-30 2020-01-21 美商再生元醫藥公司 醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
RU2701327C2 (ru) 2013-09-11 2019-09-25 Медиммьюн Лимитед Антитела к b7-h1 для лечения опухолей
GB201317622D0 (en) 2013-10-04 2013-11-20 Star Biotechnology Ltd F Cancer biomarkers and uses thereof
EP3091991B1 (en) 2013-12-13 2019-11-06 IsletOne AB Immunomodulatory compositions
PE20161324A1 (es) 2014-02-06 2016-11-25 Hoffmann La Roche Proteinas de fusion de interleucina-2 y usos de las mismas
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
RU2016142476A (ru) 2014-03-31 2018-05-07 Дженентек, Инк. Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
US20150307620A1 (en) 2014-04-16 2015-10-29 University Of Connecticut Linked immunotherapeutic agonists that costimulate multiple pathways
CN107074951B (zh) 2014-08-04 2021-08-03 贝勒研究院 拮抗性抗-ox40l抗体及其使用方法
US9512229B2 (en) 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
US9434785B1 (en) 2015-04-30 2016-09-06 Kymab Limited Anti-human OX40L antibodies and methods of treating graft versus host disease with the same
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
ES2937020T3 (es) 2015-03-03 2023-03-23 Kymab Ltd Anticuerpos, usos y métodos
SG10201912736UA (en) 2015-10-01 2020-02-27 Potenza Therapeutics Inc Anti-tigit antigen-binding proteins and methods of use thereof
US10968277B2 (en) 2015-10-22 2021-04-06 Jounce Therapeutics, Inc. Gene signatures for determining ICOS expression
US20180346571A1 (en) 2015-11-17 2018-12-06 Oncomed Pharmaceuticals, Inc. Pd-l1-binding agents and uses thereof
CN109071639B (zh) 2015-11-18 2022-07-08 默沙东公司 Pd1/ctla4结合剂
JP2018531278A (ja) 2015-11-24 2018-10-25 イーライ リリー アンド カンパニー 癌のための併用療法
CN106939047B (zh) 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
BR112018015480A2 (pt) 2016-01-29 2019-05-21 Sorrento Therapeutics, Inc. proteínas de ligação ao antígeno que se ligam a pd-l1
AU2017226510C1 (en) 2016-03-04 2019-05-16 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. A pdl-1 antibody, pharmaceutical composition thereof and use thereof
WO2017196867A1 (en) 2016-05-09 2017-11-16 Igm Biosciences, Inc. Anti-pd-l1 antibodies
CN105968200B (zh) 2016-05-20 2019-03-15 瑞阳(苏州)生物科技有限公司 抗人pd-l1人源化单克隆抗体及其应用
EP3463482B1 (en) 2016-06-07 2021-10-06 The Brigham and Women's Hospital, Inc. Methods relating to t peripheral helper cells in autoantibody-associated conditions
CN109414500B (zh) 2016-06-13 2022-02-25 奥美药业有限公司 治疗和诊断用pd-l1特异性单克隆抗体
MX2018015584A (es) 2016-06-13 2019-09-18 I Mab Anticuerpos anti-pd-l1 y usos de los mismos.
US9567399B1 (en) * 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US11214620B2 (en) 2016-06-20 2022-01-04 F-Star Therapeutics Limited Binding molecules binding PD-L1 and LAG-3
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
IL321335A (en) 2016-06-29 2025-08-01 Checkpoint Therapeutics Inc PD-L1-specific antibodies and methods of using them
SG11201900138TA (en) 2016-07-07 2019-02-27 Iovance Biotherapeutics Inc Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
WO2018024237A1 (zh) 2016-08-04 2018-02-08 信达生物制药(苏州)有限公司 抗pd-l1纳米抗体及其应用
EP3494140A1 (en) 2016-08-04 2019-06-12 GlaxoSmithKline Intellectual Property Development Ltd Anti-icos and anti-pd-1 antibody combination therapy
US10919966B2 (en) 2016-08-05 2021-02-16 Y-Biologics Inc. Antibody to programmed death-ligand 1 (PD-L1) and use thereof
WO2018045110A1 (en) 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
KR20250158824A (ko) 2016-09-10 2025-11-06 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Cns의 질병 또는 손상의 치료를 위한 전신 조절 t 세포 수준 또는 활성 감소
AU2017329780B2 (en) 2016-09-20 2024-11-14 Merck Patent Gmbh Diagnostic anti-PD-L1 antibody and use thereof
RU2770590C2 (ru) 2016-10-30 2022-04-18 Шанхай Хенлиус Байотек, Инк. Антитела против pd-l1 и их варианты
TWI781120B (zh) 2016-11-02 2022-10-21 美商永斯醫療股份有限公司 Ｐｄ-１之抗體及其用途
WO2018115859A1 (en) 2016-12-20 2018-06-28 Kymab Limited Multispecific antibody with combination therapy for immuno-oncology
RU2766582C2 (ru) 2016-12-23 2022-03-15 Ремд Биотерапьютикс, Инк. Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
WO2018136553A1 (en) 2017-01-18 2018-07-26 Genentech, Inc. Idiotypic antibodies against anti-pd-l1 antibodies and uses thereof
CN116836285A (zh) 2017-03-09 2023-10-03 健玛保 针对pd-l1的抗体
US20200024351A1 (en) 2017-04-03 2020-01-23 Jounce Therapeutics, Inc. Compositions and Methods for the Treatment of Cancer
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
CA3059447A1 (en) 2017-04-18 2018-10-25 R-Pharm Overseas Inc. Anti-pd-l1 antibody and use thereof
EP3630838A1 (en) 2017-06-01 2020-04-08 CytomX Therapeutics, Inc. Activatable anti-pdl1 antibodies, and methods of use thereof
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
US11492384B2 (en) * 2018-09-17 2022-11-08 Gi Innovation, Inc. Fusion protein comprising IL-2 protein and CD80 protein, and use thereof
US10442866B1 (en) 2019-01-23 2019-10-15 Beijing Mabworks Biotech Co. Ltd Antibodies binding OX40 and uses thereof

Patent Citations (550)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US6974863B2 (en) 1988-11-07 2005-12-13 Indiana University Research And Technology Corporation Antibody for 4-1BB
WO1991009968A1 (en) 1989-12-21 1991-07-11 Celltech Limited Cd3 specific recombinant antibody
WO1992006193A1 (en) 1990-10-05 1992-04-16 Scott David Gorman Antibodies directed against cd3
WO1992019244A2 (en) 1991-05-01 1992-11-12 Henry M. Jackson Foundation For The Advancement Of Military Medicine A method for treating infectious respiratory diseases
US5290540A (en) 1991-05-01 1994-03-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method for treating infectious respiratory diseases
WO1993019196A1 (en) 1992-03-24 1993-09-30 British Technology Group Ltd. ANTI-CD3 AGLYCOSYLATED IgG ANTIBODY
WO1993020849A1 (en) 1992-04-14 1993-10-28 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
WO1995009653A1 (en) 1993-10-01 1995-04-13 Immunex Corporation Antibodies to cd40
WO1995017202A1 (en) 1993-12-23 1995-06-29 Immunex Corporation Method of preventing or treating disease characterized by neoplastic cells expressing cd40
US5897862A (en) 1994-01-31 1999-04-27 Mor Research Applications Ltd. Immuno-stimulatory monoclonal antibodies
WO1995030750A2 (fr) 1994-05-06 1995-11-16 Institut Gustave Roussy Fractions polypeptidiques solubles de la proteine lag-3; procede de production; composition therapeutique; anticorps anti-idiotype
WO1996032471A2 (en) 1995-04-10 1996-10-17 Universite De Sherbrooke Atp-diphosphohydrolases, process of purification thereof and process of producing thereof by recombinant technology
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
WO1997031025A1 (en) 1996-02-23 1997-08-28 Chiron Corporation Humanized anti-cd40 monoclonal antibodies and fragments capable of blocking b cell activation
US5985320A (en) 1996-03-04 1999-11-16 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
WO1997032572A2 (en) 1996-03-04 1997-09-12 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
WO1997044362A1 (en) 1996-05-20 1997-11-27 Protein Design Labs, Inc. MUTATED NONACTIVATING IgG2 DOMAINS AND ANTI-CD3 ANTIBODIES INCORPORATING THE SAME
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
WO1997044013A1 (en) 1996-05-24 1997-11-27 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
WO1997048723A2 (en) 1996-06-17 1997-12-24 MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. Hofgartenstrasse 2 Ptp-20, pcp-2, bdp1, clk and sirp proteins and related products
WO1997049424A1 (en) 1996-06-25 1997-12-31 The Trustees Of The University Of Pennsylvania Antibodies directed against cellular coreceptors for human immunodeficiency virus and methods of using the same
WO1998003821A2 (en) 1996-07-19 1998-01-29 Carino Cornelis Sunderman Space heating device provided with a combustion space and a device for assisting flue gas discharge through a flue duct connected to the combustion space
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
WO1998031346A1 (en) 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation
US7226909B2 (en) 1997-02-27 2007-06-05 Japan Tobacco Inc. Methods of inhibiting transmission of a costimulatory signal of lymphocytes
US7279560B2 (en) 1997-02-27 2007-10-09 Japan Tobacco Inc. Antibody fragments to JTT-1 protein and cells secreting such antibody fragments
US7932358B2 (en) 1997-02-27 2011-04-26 Japan Tobacco Inc. Antibodies to JTT-1 protein and cells secreting such antibodies
US7196175B2 (en) 1997-02-27 2007-03-27 Japan Tobacco Inc. Antibodies to JTT-1 protein and cells secreting such antibodies
US8389690B2 (en) 1997-02-27 2013-03-05 Japan Tobacco Inc. Antibodies to JTT-1 protein and cells secreting such antibodies
US20020156242A1 (en) 1997-02-27 2002-10-24 Japan Tobacco, Inc., A Japanese Corporation Cell surface molecule mediating cell adhesion and signal transmission
US7045615B2 (en) 1997-02-27 2006-05-16 Japan Tobacco, Inc. Nucleic acids encoding JTT-1 protein
US7030225B1 (en) 1997-02-27 2006-04-18 Japan Tobacco, Inc. Antibodies to JTT-1 protein, cells secreting such antibodies, and methods of making such antibodies
US7132099B2 (en) 1997-09-23 2006-11-07 Bundersrepublik Deutschland Methods of modulating T lymphocyte costimulation with an antibody to an 8F4 polypeptide
US7125551B2 (en) 1997-09-23 2006-10-24 Bundersrepublik Deutschalnd Methods for treatment of asthmatic disorders using a monoclonal antibody to 8F4 polypeptide
US7722872B2 (en) 1997-09-23 2010-05-25 Bundersrepublik Deutschland Letztvertreten Durch Den Direktor Des Robert-Koch-Institutes Treatment of cancer with antibodies to costimulating polypeptide of T cells
WO1999015553A2 (de) 1997-09-23 1999-04-01 Bundesrepublik Deutschland Letztvertreten Durch Den Direktor Des Robert-Koch-Instituts Ko-stimulierendes polypeptid von t-zellen, monoklonale antikörper sowie die herstellung und deren verwendung
US7306800B2 (en) 1997-09-23 2007-12-11 Bundersrepublik Deutschland Treatment of autoimmune disorders with antibodies to costimulating polypeptide of T cells
US7259247B1 (en) 1997-09-23 2007-08-21 Bundersrespublik Deutschaland Letztvertreten Durch Den Direktor Des Robert-Koch-Institutes Anti-human T-cell costimulating polypeptide monoclonal antibodies
WO1999024565A1 (en) 1997-11-07 1999-05-20 Transplantation Technologies Inc. Methods and compositions for immunomodulation
WO1999042075A2 (en) 1998-02-19 1999-08-26 Bristol-Myers Squibb Company Antibodies against human cd40
WO1999050461A1 (en) 1998-03-30 1999-10-07 Northwest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis
WO1999060128A1 (en) 1998-05-15 1999-11-25 Bayer Corporation Il-2 selective agonists and antagonists
WO1999061057A2 (en) 1998-05-23 1999-12-02 Tanox, Inc. Molecules targeting cd40 and tumor cells
WO1999066903A2 (en) 1998-06-24 1999-12-29 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
WO2000004041A2 (en) 1998-07-16 2000-01-27 Hyseq, Inc. Methods and molecules relating to cd39-like polypeptides
WO2000005268A1 (en) 1998-07-21 2000-02-03 Btg International Ltd. Hybrid human/rodent igg antibody to cd3, and methods of its construction
WO2000024869A2 (en) 1998-10-23 2000-05-04 Yale University Methods for modulating cell fusion
WO2000037504A2 (en) 1998-12-23 2000-06-29 Pfizer Inc. Human monoclonal antibodies to ctla-4
US6488930B1 (en) 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
US6881406B2 (en) 1999-01-15 2005-04-19 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
US7138117B1 (en) 1999-01-15 2006-11-21 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
US6245332B1 (en) 1999-01-15 2001-06-12 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
WO2000042074A1 (en) 1999-01-15 2000-07-20 Millennium Pharmaceuticals, Inc. Anti-ccr4 antibodies and methods of use therefor
WO2000066159A1 (en) 1999-04-28 2000-11-09 Faculteit Der Geneeskunde Van De Vrije Universiteit Method for inhibiting cell functioning for use in anti-inflammatory and anti-tumour therapies
WO2000075348A1 (en) 1999-06-08 2000-12-14 Seattle Genetics, Inc. Recombinant anti-cd40 antibody and uses thereof
WO2001010205A1 (en) 1999-08-09 2001-02-15 Hyseq Inc. Methods and materials relating to cd39-like polypeptides
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
WO2001016180A2 (en) 1999-08-27 2001-03-08 Board Of Regents, The University Of Texas System Cd40 agonist compositions and methods of use
US7998478B2 (en) 1999-08-30 2011-08-16 Japan Tobacco, Inc. Pharmaceutical composition for treating immune diseases
US7465445B2 (en) 1999-08-30 2008-12-16 Japan Tobacco Inc. Methods of preventing or treating graft versus host reaction by administering an antibody or portion thereof that binds to AILIM
WO2001015732A1 (en) 1999-08-30 2001-03-08 Japan Tobacco Inc. Remedies for immunological diseases
WO2001037870A1 (en) 1999-11-25 2001-05-31 Kennedy Rheumatology Inst Treatment of autoimmune diseases by an agonistic cd40-binding protein
WO2001040307A1 (de) 1999-11-30 2001-06-07 Eberhard-Karls-Universität Tübingen Universitätsklinikum Antikörper gegen signal-regulator-proteine
WO2001042308A2 (en) 1999-12-08 2001-06-14 Novartis Ag Methods and compositions useful for inhibiting ccr5-dependent infection of cells by hiv-1
WO2001051644A2 (de) 2000-01-14 2001-07-19 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts ANTI-CD3-EINZELKETTEN-ANTIKÖRPER MIT HUMANEN Cν3- und Cν4- DOMÄNEN
WO2001054732A1 (en) 2000-01-27 2001-08-02 Genetics Institute, Llc. Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
US6989145B2 (en) 2000-03-03 2006-01-24 Kyowa Hakko Kogyo Co., Ltd. Recombinant antibody and antibody fragment
US8632996B2 (en) 2000-03-03 2014-01-21 Kyowa Hakko Kirin Co., Ltd. Method for producing recombinant antibody and antibody fragment thereof
US8197814B2 (en) 2000-03-03 2012-06-12 Kyowa Hakko Kirin Co., Ltd. Method for treating the Th2-mediated disease
WO2001064754A1 (en) 2000-03-03 2001-09-07 Kyowa Hakko Kogyo Co., Ltd. Gene recombinant antibody and its fragment
US7666418B2 (en) 2000-03-03 2010-02-23 Kyowa Hakko Kirin Co., Ltd. Method for treating Th2-mediated disease
WO2001078708A1 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Treating graft rejection with cxcr3 inhibitors
WO2001083755A2 (en) 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
US7166283B2 (en) 2000-05-18 2007-01-23 Japan Tobacco Inc. Methods of treating an inflammatory disorder and prohibiting proliferation, cytokine production, and signal transduction with antibody against costimulatory signal transduction molecule AILIM
WO2001087981A2 (en) 2000-05-18 2001-11-22 Japan Tobacco, Inc. Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof
US7988965B2 (en) 2000-05-18 2011-08-02 Japan Tobacco, Inc. Methods of treating systemic lupus erythematosus with an antibody against costimulatory signal transduction molecule ailim
US6803039B2 (en) 2000-05-18 2004-10-12 Japan Tobacco Inc. Human monoclonal antibody against a costimulatory signal transduction molecule AILIM
WO2002011762A2 (en) 2000-08-03 2002-02-14 Gorczynski Reginald M Methods and compositions for modulating tumor growth
WO2002015932A1 (en) 2000-08-18 2002-02-28 The Regents Of The University Of California Methods for treating demyelinating diseases
WO2002026249A2 (en) 2000-09-26 2002-04-04 The Regents Of The University Of Michigan Methods for inhibition of viral infection
WO2002028904A2 (en) 2000-10-02 2002-04-11 Chiron Corporation Human anti-cd40 antibodies
WO2002028905A2 (en) 2000-10-02 2002-04-11 Chiron Corporation Human anti-cd40 antibodies
WO2002028480A2 (en) 2000-10-02 2002-04-11 Chiron Corporation Methods of therapy for b-cell malignancies
WO2002028481A2 (en) 2000-10-02 2002-04-11 Chiron Corporation Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
US8840885B2 (en) 2000-12-08 2014-09-23 Alexion Pharmaceuticals, Inc. Methods for treating chronic lymphocytic leukemia
WO2002070010A1 (fr) 2001-03-01 2002-09-12 Japan Tobacco, Inc. Inhibiteurs de rejet du greffon
US7438905B2 (en) 2001-03-01 2008-10-21 Japan Tobacco, Inc. Methods of suppressing, treating, or preventing graft rejection with an antibody or a portion thereof that binds to AILIM
WO2002088186A1 (fr) 2001-04-27 2002-11-07 Kirin Beer Kabushiki Kaisha Anticorps monoclonal anti-cd40
WO2002092784A2 (en) 2001-05-15 2002-11-21 Emory University POLYNUCLEOTIDES AND POLYPEPTIDES RELATING TO THE MODULATION OF SIRP α-CD47
WO2003006058A1 (en) 2001-07-12 2003-01-23 Wyeth Cd25+ differential markers and uses thereof
WO2003006045A2 (en) 2001-07-12 2003-01-23 The Regents Of The University Of California Cxcl10 treatment of secondary tissue degeneration
WO2003015697A2 (en) 2001-08-13 2003-02-27 University Of Southern California Interleukin-2 mutants with reduced toxicity
WO2003018635A1 (fr) 2001-08-31 2003-03-06 Kyowa Hakko Kogyo Co., Ltd. Anticorps greffes cdr humains et fragments de ces anticorps
WO2003029296A1 (en) 2001-10-02 2003-04-10 Chiron Corporation Human anti-cd40 antibodies
US20130024956A1 (en) 2001-11-09 2013-01-24 Pfizer Inc. Antibodies to cd40
US7626012B2 (en) 2001-11-09 2009-12-01 Amgen Fremont Inc. Nucleic acid molecules which encode antibodies that bind CD40
US7288251B2 (en) 2001-11-09 2007-10-30 Abgenix, Inc. Antibodies to CD40
US8388971B2 (en) 2001-11-09 2013-03-05 Amgen Fremont Inc. Antibodies that bind CD40 and methods of treating cancer and enhancing immune responses
WO2003040170A2 (en) 2001-11-09 2003-05-15 Pfizer Products Inc. Antibodies to cd40
US7563442B2 (en) 2001-11-09 2009-07-21 Abgenix, Inc. Antibodies to CD40 and methods of treating cancer and enhancing immune responses
US7338660B2 (en) 2001-11-09 2008-03-04 Abgenix, Inc. Methods of treating cancer and enhancing immune responses with antibodies that bind CD40
US7618633B2 (en) 2001-11-09 2009-11-17 Amgen Fremont Inc. Antibodies that bind CD40 and methods of treating cancer and enhancing immune responses
WO2003063792A2 (en) 2002-01-30 2003-08-07 The Brigham And Women's Hospital, Inc. Compositions and methods related to tim-3, a th1-specific cell surface molecule
WO2003066830A2 (en) 2002-02-08 2003-08-14 Genetastix Corporation Human monoclonal antibodies against membrane proteins
WO2004004771A1 (ja) 2002-07-03 2004-01-15 Ono Pharmaceutical Co., Ltd. 免疫賦活組成物
WO2004010947A2 (en) 2002-07-30 2004-02-05 Bristol-Myers Squibb Company Humanized antibodies against human 4-1bb
WO2004024771A1 (en) 2002-09-10 2004-03-25 Affimed Therapeutics Ag Human cd3-specific antibody with immunosuppressive properties
WO2004029069A2 (en) 2002-09-30 2004-04-08 Pfizer Products Inc. Hybridomas producing high levels of human sequence antibody
WO2004045526A2 (en) 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
WO2004045525A2 (en) 2002-11-15 2004-06-03 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
WO2004052397A1 (en) 2002-12-05 2004-06-24 Protein Design Labs, Inc. Methods of treatment of ulcerative colitis with anti-cd3 antibodies
WO2004055513A2 (en) 2002-12-16 2004-07-01 Herbert Schwarz Use of cd137 antagonists for the treatment of tumors
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
US7488802B2 (en) 2002-12-23 2009-02-10 Wyeth Antibodies against PD-1
WO2004059285A2 (en) 2002-12-23 2004-07-15 Protein Design Labs, Inc. Tumor killing/tumor regression using cxcr4 antagonists
US20040213783A1 (en) 2002-12-27 2004-10-28 Janet Liversidge Methods of inducing and maintaining immune tolerance
WO2004060295A2 (en) 2002-12-27 2004-07-22 Schering Corporation Methods of inducing and maintaining immune tolerance
WO2004078928A2 (en) 2003-02-28 2004-09-16 The Johns Hopkins University T cell regulation
WO2004078938A2 (en) 2003-03-04 2004-09-16 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2004082714A1 (en) 2003-03-17 2004-09-30 The Regents Of The University Of California Methods for treating ocular inflammation by neutralizing cxcl10 activity
WO2004084942A2 (en) 2003-03-28 2004-10-07 Universiteit Utrecht Holding B.V. Methods and means to suppress symptoms of an allergic disease by inhibiting the glucocorticoid-induced tumor necrosis factor receptor (gitr or tnfrsf18)
WO2004101511A2 (en) 2003-05-09 2004-11-25 Protein Design Labs, Inc Anti-ip-10 antibodies and methods of using thereof for the treatment of inflamatory bowel diseases
WO2004108923A1 (ja) 2003-06-02 2004-12-16 Japan Science And Technology Agency Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体
WO2004108158A1 (en) 2003-06-02 2004-12-16 Alexion Pharmaceuticals, Inc. De-immunized anti-cd3 antibody
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
WO2005009238A1 (en) 2003-07-29 2005-02-03 Htl Strefa Spolka Zo.O. Puncturing device
WO2005011605A2 (en) 2003-08-01 2005-02-10 Medarex, Inc. Combination therapies for multiple sclerosis
WO2005023201A2 (en) 2003-09-09 2005-03-17 Medarex, Inc. Methods for treating rheumatoid arthritis
WO2005035582A1 (ja) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Ｃｃｒ４に特異的に結合する抗体組成物
WO2005035584A1 (en) 2003-10-10 2005-04-21 Bristol-Myers Squibb Company Fully human antibodies against human 4-1bb (cd137)
WO2005044304A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia
WO2005044306A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Use of antagonist anti-cd40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection
WO2005044854A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Antagonist anti-cd40 monoclonal antibodies and methods for their use
WO2005044855A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
WO2005044294A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Method of therapy for cancers expressing the cd40 antigen
WO2005044305A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
WO2005044307A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Methods of therapy for b cell-related cancers
WO2005053741A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. ケモカイン受容体ｃｃｒ４に対する遺伝子組換え抗体を含む医薬
WO2005060457A2 (en) 2003-12-04 2005-07-07 Pdl Biopharma, Inc. Treatment of inflammatory bowel diseases with anti-ip-10 antibodies
WO2005058815A2 (en) 2003-12-10 2005-06-30 Medarex, Inc. Ip-10 antibodies and their uses
WO2005063289A1 (en) 2003-12-22 2005-07-14 Pfizer Products Inc. Cd40 antibody formulation and methods
US20120263732A1 (en) 2003-12-22 2012-10-18 Pfizer Inc. Cd40 antibody formulation and methods
WO2005063981A1 (ja) 2003-12-25 2005-07-14 Kirin Beer Kabushiki Kaisha 抗cd40抗体の変異体
WO2005086751A2 (en) 2004-03-05 2005-09-22 Chiron Corporation Combinatorial interleukin-2 muteins
WO2005086798A2 (en) 2004-03-05 2005-09-22 Chiron Corporation Improved interleukin-2 muteins
WO2005084708A1 (ja) 2004-03-09 2005-09-15 Kyoto University Ｃｘｃｒ３阻害剤を含有する医薬組成物
WO2005103086A1 (en) 2004-04-23 2005-11-03 Bundesrepublik Deutschland letztvertreten durch das Robert-Koch-Institut vertreten durch seinen Präsidenten Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo
US8916155B2 (en) 2004-04-23 2014-12-23 Bundesrepublik Deutschland letztvertreten durch das Robert-Koch-Institut vertreten durch seinen Präsidenten Method for the treatment of T cell mediated conditions by depletion of ICOS-positive cells in vivo
US8318905B2 (en) 2004-04-23 2012-11-27 Richard Kroczek Antibodies for depletion of ICOS-positive cells in vivo
WO2006073443A2 (en) 2004-04-27 2006-07-13 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-cd40 monoclonal antibodies and methods for their use
WO2005118635A2 (en) 2004-06-03 2005-12-15 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
WO2006020266A2 (en) 2004-07-20 2006-02-23 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2006029219A2 (en) 2004-09-08 2006-03-16 Ohio State University Research Foundation Human monoclonal anti-ctla4 antibodies in cancer treatment
WO2006039819A1 (en) 2004-10-15 2006-04-20 St. Michael's Hospital Markers of lung injury
WO2006050172A2 (en) 2004-10-29 2006-05-11 University Of Southern California Combination cancer immunotherapy with co-stimulatory molecules
WO2006048749A1 (en) 2004-11-04 2006-05-11 Pfizer Products Inc. Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer
WO2006066568A2 (de) 2004-12-23 2006-06-29 Tegenero Ag Monokonale agonistische anti-ctla-4 antikörper
WO2006089141A2 (en) 2005-02-18 2006-08-24 Dana-Farber Cancer Institute Antibodies against cxcr4 and methods of use thereof
WO2006096491A2 (en) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Anti-ctla-4 antibody compositions
WO2006101691A1 (en) 2005-03-23 2006-09-28 Pfizer Products Inc. Therapy of prostate cancer with ctla4 antibodies and hormonal therapy
WO2006101692A1 (en) 2005-03-23 2006-09-28 Pfizer Products Inc. Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer
WO2006105021A2 (en) 2005-03-25 2006-10-05 Tolerrx, Inc. Gitr binding molecules and uses therefor
WO2006118085A1 (ja) 2005-04-26 2006-11-09 Stelic Institute Of Regenerative Medicine 肝細胞複製促進剤およびインスリン抵抗性改善剤
WO2006121168A1 (en) 2005-05-09 2006-11-16 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
WO2006128103A2 (en) 2005-05-26 2006-11-30 Seattle Genetics, Inc. Humanized anti-cd40 antibodies and their methods of use
WO2007005874A2 (en) 2005-07-01 2007-01-11 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
WO2007005605A2 (en) 2005-07-01 2007-01-11 Washington University In St. Louis Phosphospecific chemokine receptor antibodies
WO2007008463A2 (en) 2005-07-07 2007-01-18 Coley Pharmaceutical Group, Inc. Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
US8497244B2 (en) 2005-10-24 2013-07-30 Domantis Limited Methods for targeting pulmonary diseases with agents that bind a target in pulmonary tissue
WO2007053767A1 (en) 2005-11-01 2007-05-10 Novartis Ag Uses of anti-cd40 antibodies
WO2007053661A2 (en) 2005-11-01 2007-05-10 Novartis Ag Uses of anti-cd40 antibodies
WO2007062245A2 (en) 2005-11-25 2007-05-31 Kirin Pharma Kabushiki Kaisha Human monoclonal antibody human cd134 (ox40) and methods of making and using same
WO2007084321A2 (en) 2006-01-12 2007-07-26 Alexion Pharmaceuticals, Inc. Antibodies to ox-2/cd200 and uses thereof
US8709415B2 (en) 2006-01-12 2014-04-29 Alexion Pharmaceuticals, Inc. Antibodies to OX-2/CD200 and uses thereof
WO2007133822A1 (en) 2006-01-19 2007-11-22 Genzyme Corporation Gitr antibodies for the treatment of cancer
WO2007113301A1 (en) 2006-04-03 2007-10-11 Medizinische Hochschule Hannover Pharmaceuticals for influencing the reaction of the human immune system
WO2007124299A2 (en) 2006-04-21 2007-11-01 Novartis Ag Antagonist anti-cd40 antibody pharmaceutical compositions
WO2007130493A2 (en) 2006-05-03 2007-11-15 Regents Of The University Of Colorado Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
WO2007129895A2 (en) 2006-05-09 2007-11-15 Pangenetics B.V. Deimmunized antagonistic anti-human cd40 monoclonal antibody from the ch5d12 antibody
WO2008003103A2 (en) 2006-07-05 2008-01-10 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. Novel multivalent immunoglobulins
WO2008060367A2 (en) 2006-10-02 2008-05-22 Medarex, Inc. Human antibodies that bind cxcr4 and uses thereof
WO2008044824A1 (en) 2006-10-13 2008-04-17 Seoul National University Industry Foundation Antibodies to ip-10 for treating bone diseases with bone destruction
WO2008047486A1 (fr) 2006-10-19 2008-04-24 Stelic Institute Of Regenerative Medicine Agent de lutte contre les lésions myocardiques
WO2008051424A2 (en) 2006-10-20 2008-05-02 University Of Southampton Human immune therapies using a cd27 agonist alone or in combination with other immune modulators
WO2008076560A2 (en) 2006-11-15 2008-06-26 Medarex, Inc. Human monoclonal antibodies to btla and methods of use
WO2008073316A2 (en) 2006-12-07 2008-06-19 The Board Of Trustees Of The Leland Stanford Junior University Identification and isolation of acute myeloid leukemia stem cells
WO2008083169A2 (en) 2006-12-26 2008-07-10 The Johns Hopkins University Compositions and methods for the treatment of immunologic disorders
WO2008091954A2 (en) 2007-01-23 2008-07-31 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
WO2008106116A2 (en) 2007-02-27 2008-09-04 Genentech, Inc. Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
WO2008106200A2 (en) 2007-02-28 2008-09-04 Novimmune Sa Human anti-ip-10 antibodies and uses thereof
WO2008142303A2 (fr) 2007-04-23 2008-11-27 Pierre Fabre Medicament Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
WO2008132601A1 (en) 2007-04-30 2008-11-06 Immutep Cytotoxic anti-lag-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
WO2008156712A1 (en) 2007-06-18 2008-12-24 N. V. Organon Antibodies to human programmed death receptor pd-1
WO2009009547A2 (en) 2007-07-09 2009-01-15 Qualcomm Incorporated Methods for sending small packets in a peer-to-peer (p2p) network
WO2009007124A1 (en) 2007-07-10 2009-01-15 Friedrich-Alexander-Universität Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
WO2009009116A2 (en) 2007-07-12 2009-01-15 Tolerx, Inc. Combination therapies employing gitr binding molecules
WO2009014745A1 (en) 2007-07-25 2009-01-29 Alexion Pharmaceuticals, Inc. Antibodies to cd200 and uses thereof in inhibiting immune responses
WO2009023566A2 (en) 2007-08-09 2009-02-19 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
WO2009026303A1 (en) 2007-08-21 2009-02-26 Amgen Inc. Human c-fms antigen binding proteins
WO2009046541A1 (en) 2007-10-11 2009-04-16 University Health Network MODULATION OF SIRPα - CD47 INTERACTION FOR INCREASING HUMAN HEMATOPOIETIC STEM CELL ENGRAFTMENT AND COMPOUNDS THEREFOR
WO2009061853A2 (en) 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
WO2009062125A1 (en) 2007-11-07 2009-05-14 Genentech, Inc. Methods and compositions for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
WO2009062054A1 (en) 2007-11-09 2009-05-14 Novartis Ag Uses of anti-cd40 antibodies
WO2009086514A1 (en) 2007-12-28 2009-07-09 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
WO2009094391A1 (en) 2008-01-23 2009-07-30 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
WO2009095478A1 (en) 2008-01-31 2009-08-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
WO2009100140A1 (en) 2008-02-04 2009-08-13 Medarex, Inc. Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
WO2009112245A1 (en) 2008-03-14 2009-09-17 Transgene S.A. Antibody against the csf-1 r
WO2009117706A2 (en) 2008-03-20 2009-09-24 Carolus Therapeutics, Inc. Methods of treatment using anti-mif antibodies
WO2009120186A1 (en) 2008-03-24 2009-10-01 Carolus Therapeutics, Inc. Methods and compositions for treating atherosclerosis and related conditions
US20130251720A1 (en) 2008-04-09 2013-09-26 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
WO2009126688A2 (en) 2008-04-09 2009-10-15 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
WO2009135019A2 (en) 2008-05-01 2009-11-05 Beth Israel Deaconess Medical Center Methods and compositions for prostate cancer immunotherapy
WO2009140124A1 (en) 2008-05-14 2009-11-19 Eli Lilly And Company Anti-cxcr4 antibodies
WO2009138519A1 (en) 2008-05-16 2009-11-19 Ablynx Nv AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
WO2010001908A1 (ja) 2008-06-30 2010-01-07 協和発酵キリン株式会社 抗cd27抗体
WO2010019570A2 (en) 2008-08-11 2010-02-18 Medarex, Inc. Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
WO2010024676A1 (en) 2008-08-29 2010-03-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Delivery of a cd40 agonist to a tumor draining lymph node of a subject
WO2010029434A1 (en) 2008-09-12 2010-03-18 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
WO2010029435A1 (en) 2008-09-12 2010-03-18 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
WO2010037831A1 (en) 2008-10-01 2010-04-08 Pierre Fabre Medicament Anti cxcr4 antibodies and their use for the treatment of cancer
WO2010056804A1 (en) 2008-11-12 2010-05-20 Medimmune, Llc Antibody formulation
WO2010077634A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
WO2010096418A2 (en) 2009-02-17 2010-08-26 Ucb Pharma S.A. Antibody molecules having specificity for human ox40
WO2010097597A1 (en) 2009-02-26 2010-09-02 The University Court Of The University Of Aberdeen Antibodies specifically directed to the soluble form of ctla-4
WO2010104761A2 (en) 2009-03-10 2010-09-16 Baylor Research Institute Anti-cd40 antibodies and uses thereof
WO2010104747A2 (en) 2009-03-10 2010-09-16 Baylor Research Institute Antigen presenting cell targeted vaccines
WO2010104748A2 (en) 2009-03-10 2010-09-16 Baylor Research Institute Antigen presenting cell targeted anti-viral vaccines
WO2010104749A2 (en) 2009-03-10 2010-09-16 Baylor Research Institute Antigen presenting cell targeted cancer vaccines
WO2010106051A1 (en) 2009-03-17 2010-09-23 Universite De La Mediterranee Btla antibodies and uses thereof
WO2010121231A1 (en) 2009-04-18 2010-10-21 Genentech, Inc. Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
WO2010123012A1 (ja) 2009-04-20 2010-10-28 協和発酵キリン株式会社 アミノ酸変異が導入されたIgG2を有する抗体
WO2010125162A1 (en) 2009-04-29 2010-11-04 Pierre Fabre Medicament Anti cxcr4 antibodies for the treatment of hiv
WO2010142952A2 (en) 2009-06-09 2010-12-16 Affitech Research As Antibodies
WO2011004192A1 (en) 2009-07-08 2011-01-13 Genome Research Limited Animal models and therapeutic molecules
WO2011014438A1 (en) 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
US8840889B2 (en) 2009-08-13 2014-09-23 The Johns Hopkins University Methods of modulating immune function
WO2011020024A2 (en) 2009-08-13 2011-02-17 The Johns Hopkins University Methods of modulating immune function
US20160002336A1 (en) 2009-08-13 2016-01-07 The Johns Hopkins University Methods of Modulating Immune Function
US20160024211A1 (en) 2009-08-13 2016-01-28 The Johns Hopkins University Methods of Modulating Immune Function
WO2011028683A1 (en) 2009-09-03 2011-03-10 Schering Corporation Anti-gitr antibodies
WO2011042398A1 (en) 2009-10-09 2011-04-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
WO2011051726A2 (en) 2009-10-30 2011-05-05 Isis Innovation Ltd Treatment of obesity
WO2011066389A1 (en) 2009-11-24 2011-06-03 Medimmmune, Limited Targeted binding agents against b7-h1
WO2011070024A1 (en) 2009-12-10 2011-06-16 F. Hoffmann-La Roche Ag Antibodies binding preferentially human csf1r extracellular domain 4 and their use
WO2011073180A1 (en) 2009-12-14 2011-06-23 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
WO2011076781A1 (en) 2009-12-22 2011-06-30 Novartis Ag Tetravalent cd47-antibody constant region fusion protein for use in therapy
WO2011081164A1 (ja) 2009-12-29 2011-07-07 協和発酵キリン株式会社 抗ｃｄ２７抗体
WO2011083140A1 (en) 2010-01-08 2011-07-14 Ablynx Nv Immunoglobulin single variable domain directed against human cxcr4
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
WO2011098762A2 (en) 2010-02-10 2011-08-18 Affitech Research As Antibodies against cxcr4
WO2011100538A1 (en) 2010-02-11 2011-08-18 Alexion Pharmaceuticals, Inc. Therapeutic methods using an ti-cd200 antibodies
US20130189258A1 (en) 2010-02-11 2013-07-25 Alexion Pharmaceuticals, Inc. Therapeutic methods using anti-cd200 antibodies
WO2011131407A1 (en) 2010-03-05 2011-10-27 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
WO2011107553A1 (en) 2010-03-05 2011-09-09 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
WO2011110604A1 (en) 2010-03-11 2011-09-15 Ucb Pharma, S.A. Pd-1 antibody
WO2011110621A1 (en) 2010-03-11 2011-09-15 Ucb Pharma, S.A. Biological products: humanised agonistic anti-pd-1 antibodies
WO2011121040A1 (en) 2010-03-30 2011-10-06 Pierre Fabre Medicament Humanized anti cxcr4 antibodies for the treatment of cancer
WO2011123489A2 (en) 2010-03-31 2011-10-06 Boehringer Ingelheim International Gmbh Anti-cd40 antibodies
WO2011123381A1 (en) 2010-04-01 2011-10-06 Imclone Llc Antibodies against csf-1r
WO2011130434A2 (en) 2010-04-13 2011-10-20 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
WO2011140249A2 (en) 2010-05-04 2011-11-10 Five Prime Therapeutics, Inc. Antibodies that bind csf1r
WO2011155607A1 (ja) 2010-06-11 2011-12-15 協和発酵キリン株式会社 抗ｔｉｍ－３抗体
WO2011158009A1 (en) 2010-06-17 2011-12-22 Kymab Limited Animal models and therapeutic molecules
WO2011161266A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Improved immunoglobulin single variable domains and constructs thereof directed against cxcr4
WO2012004367A1 (en) 2010-07-09 2012-01-12 N.V. Organon Agonistic antibody to cd27
WO2012027328A2 (en) 2010-08-23 2012-03-01 Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same
WO2012032433A1 (en) 2010-09-09 2012-03-15 Pfizer Inc. 4-1bb binding molecules
WO2012040207A2 (en) 2010-09-20 2012-03-29 Yale University HUMAM SIRPAα TRANSGENIC ANIMALS AND THEIR METHODS OF USE
WO2012041635A1 (en) 2010-09-29 2012-04-05 Universite De Liege Combination of an agonistic anti-cd40 monoclonal antibody or a cd40 ligand and inactivated or attenuated bacteria for use in the treatment and/or prevention of mastitis
WO2012055980A1 (en) 2010-10-27 2012-05-03 Pierre Fabre Medicament Antibodies for the treatment of hiv
WO2012062713A1 (en) 2010-11-08 2012-05-18 Novartis Ag Cxcr2 binding polypeptides
WO2012062228A2 (es) 2010-11-12 2012-05-18 Centro De Inmunologia Molecular Polipéptidos derivados de la il-2 con actividad agonista para la terapia del cáncer e infecciones crónicas.
WO2012065950A1 (en) 2010-11-15 2012-05-24 Novartis Ag Silent fc variants of anti-cd40 antibodies
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
WO2012076883A1 (en) 2010-12-07 2012-06-14 Affitech Research As Anti ccr4 antibodies and uses thereof
WO2012088446A1 (en) 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
WO2012085132A1 (en) 2010-12-22 2012-06-28 Orega Biotech Antibodies against human cd39 and use thereof
WO2012107417A1 (en) 2011-02-10 2012-08-16 Roche Glycart Ag Mutant interleukin-2 polypeptides
WO2012110360A1 (en) 2011-02-14 2012-08-23 Transgene Sa Antibody against the csf-1r
WO2012111762A1 (ja) 2011-02-17 2012-08-23 協和発酵キリン株式会社 抗ｃｄ４０抗体の高濃度製剤
WO2012119093A1 (en) 2011-03-03 2012-09-07 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
WO2012120125A1 (en) 2011-03-09 2012-09-13 Antitope Ltd Humanised anti ctla-4 antibodies
WO2012125569A2 (en) 2011-03-11 2012-09-20 Beth Israel Deaconess Medical Center, Inc. Anti-cd40 antibodies and uses thereof
WO2012135408A1 (en) 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
US9376493B2 (en) 2011-03-31 2016-06-28 INSERM (Institut National de la Sante et de la Recherche Mediacale) Antibodies directed against ICOS and uses thereof
US20160264666A1 (en) 2011-03-31 2016-09-15 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies Directed Against ICOS and Uses Thereof
WO2012131004A2 (en) 2011-03-31 2012-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies directed against icos and uses thereof
WO2012145183A2 (en) 2011-04-19 2012-10-26 Pfizer Inc. Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
WO2012145493A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
WO2012145673A1 (en) 2011-04-21 2012-10-26 Bristol-Myers Squibb Company Antibody polypeptides that antagonize cd40
WO2012149320A1 (en) 2011-04-29 2012-11-01 Bristol-Myers Squibb Company Ip-10 antibody dosage escalation regimens
WO2012149356A2 (en) 2011-04-29 2012-11-01 Apexigen, Inc. Anti-cd40 antibodies and methods of use
WO2012162067A2 (en) 2011-05-21 2012-11-29 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
WO2012173819A2 (en) 2011-06-14 2012-12-20 Mayo Foundation For Medical Education And Research Anti-cd3 therapies
WO2012174338A2 (en) 2011-06-15 2012-12-20 Glaxosmithkline Llc Method of selecting therapeutic indications
WO2012172521A1 (en) 2011-06-16 2012-12-20 Novartis Ag Soluble proteins for use as therapeutics
WO2012177788A1 (en) 2011-06-20 2012-12-27 La Jolla Institute For Allergy And Immunology Modulators of 4-1bb and immune responses
WO2012175576A1 (en) 2011-06-20 2012-12-27 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer.
WO2012178137A1 (en) 2011-06-24 2012-12-27 Gillies Stephen D Light chain immunoglobulin fusion proteins and methods of use thereof
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
WO2013008171A1 (en) 2011-07-11 2013-01-17 Glenmark Pharmaceuticals S.A. Antibodies that bind to ox40 and their uses
WO2013013025A2 (en) 2011-07-20 2013-01-24 Medimmune Limited Anti-cxcr4 antibodies and methods of use
WO2013017566A1 (en) 2011-07-29 2013-02-07 Pierre Fabre Medicament Novel anti-cxcr4 antibody and its use for the detection and diagnosis of cancer
WO2013017562A1 (en) 2011-07-29 2013-02-07 Pierre Fabre Medicament Use of the antibody i-3859 for the detection and diagnosis of cancer
WO2013028231A1 (en) 2011-08-23 2013-02-28 Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same
WO2013034904A1 (en) 2011-09-05 2013-03-14 Alligator Bioscience Ab Anti-cd40 antibodies, uses and methods
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
WO2013038191A2 (en) 2011-09-16 2013-03-21 Bioceros B.V. Anti-cd134 (ox40) antibodies and uses thereof
WO2013056352A1 (en) 2011-10-19 2013-04-25 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
WO2013057281A2 (en) 2011-10-21 2013-04-25 Transgene Sa Modulation of macrophage activation
WO2013071068A2 (en) 2011-11-09 2013-05-16 Bristol-Myers Squibb Company Treatment of hematologic malignancies with an anti-cxcr4 antibody
WO2013068563A2 (en) 2011-11-11 2013-05-16 Ucb Pharma S.A. Antibody molecules having specificity for human ox40
WO2013079174A1 (en) 2011-11-28 2013-06-06 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
WO2013061098A2 (en) 2011-12-02 2013-05-02 Kymab Limited Functional isotype switching of chimaeric antibody chains & chimaeric animals expressing different igh isotypes
WO2013087699A1 (en) 2011-12-15 2013-06-20 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
WO2013132044A1 (en) 2012-03-08 2013-09-12 F. Hoffmann-La Roche Ag Combination therapy of antibodies against human csf-1r and uses thereof
WO2013138586A1 (en) 2012-03-15 2013-09-19 Janssen Biotech, Inc. Human anti-cd27 antibodies, methods and uses
WO2013158856A2 (en) 2012-04-20 2013-10-24 Emergent Product Development Seattle, Llc Cd3 binding polypeptides
WO2013164789A2 (en) 2012-05-04 2013-11-07 Novartis Ag Antibody formulatoin
WO2013166500A1 (en) 2012-05-04 2013-11-07 Dana-Farber Cancer Institute, Inc. Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
WO2013168108A2 (en) 2012-05-09 2013-11-14 Novartis Ag Chemokine receptor binding polypeptides
WO2013169264A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
WO2013170735A1 (zh) 2012-05-15 2013-11-21 中国医学科学院基础医学研究所 治疗和/或预防肺损伤的方法
WO2013173223A1 (en) 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
WO2013181634A2 (en) 2012-05-31 2013-12-05 Sorrento Therapeutics Inc. Antigen binding proteins that bind pd-l1
WO2013184912A2 (en) 2012-06-06 2013-12-12 Oncomed Pharmaceuticals, Inc. Binding agents that modulate the hippo pathway and uses thereof
WO2013186613A1 (en) 2012-06-14 2013-12-19 Nasvax Ltd. Humanized antibodies to cluster of differentiation 3 (cd3)
WO2013188693A1 (en) 2012-06-15 2013-12-19 Imaginab, Inc. Antigen binding constructs to cd3
WO2014003742A1 (en) 2012-06-27 2014-01-03 Morehouse School Of Medicine Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation
WO2014004298A1 (en) 2012-06-29 2014-01-03 Invista Technologies S.À.R.L. Gas scrubber and related processes
WO2014008218A1 (en) 2012-07-02 2014-01-09 Bristol-Myers Squibb Company Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
WO2014008911A1 (en) 2012-07-09 2014-01-16 Iwis Motorsysteme Gmbh & Co. Kg Lantern-type planetary gearing
WO2014022332A1 (en) 2012-07-31 2014-02-06 The Brigham And Women's Hospital, Inc. Modulation of the immune response
WO2014036357A1 (en) 2012-08-31 2014-03-06 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
WO2014033327A1 (en) 2012-09-03 2014-03-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies directed against icos for treating graft-versus-host disease
US20150239978A1 (en) 2012-09-03 2015-08-27 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies directed against icos for treating graft-versus-host disease
WO2014047231A1 (en) 2012-09-21 2014-03-27 Regeneron Pharmaceuticals, Inc. Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
WO2014055897A2 (en) 2012-10-04 2014-04-10 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
WO2014065402A1 (ja) 2012-10-26 2014-05-01 株式会社ペルセウスプロテオミクス 抗ヒトｃｄ４０モノクローナル抗体及びその利用
WO2014065403A1 (ja) 2012-10-26 2014-05-01 株式会社ペルセウスプロテオミクス 抗ヒトｃｄ４０モノクローナル抗体及びその利用
WO2014070934A1 (en) 2012-10-30 2014-05-08 Apexigen, Inc. Anti-cd40 antibodies and methods of use
WO2014072441A1 (en) 2012-11-09 2014-05-15 Transgene Sa Modulation of monocytes, or precursors thereof, differentiation
WO2014089169A2 (en) 2012-12-04 2014-06-12 Oncomed Pharmaceuticals, Inc. Immunotherapy with binding agents
WO2014100079A1 (en) 2012-12-21 2014-06-26 Merck Sharp & Dohme Corp. Antibodies that bind to human programmed death ligand 1 (pd-l1)
WO2014165082A2 (en) 2013-03-13 2014-10-09 Medimmune, Llc Antibodies and methods of detection
WO2014159562A1 (en) 2013-03-14 2014-10-02 Bristol-Myers Squibb Company Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
WO2014149310A1 (en) 2013-03-15 2014-09-25 Allied Innovative Systems, Llc A flow-through cell counting assay
WO2014140180A1 (en) 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property Development Limited Anti-lag-3 binding proteins
WO2014140374A2 (en) 2013-03-15 2014-09-18 Novo Nordisk A/S Monovalent cd27 antibodies
WO2014148895A1 (en) 2013-03-18 2014-09-25 Biocerox Products B.V. Humanized anti-cd134 (ox40) antibodies and uses thereof
WO2014169255A1 (en) 2013-04-11 2014-10-16 The Brigham And Women's Hospital, Inc. Methods and compositions of treating autoimmune diseases
WO2014170317A1 (en) 2013-04-17 2014-10-23 Morphosys Ag Antibodies targeting specifically human cxcr2
WO2014173814A1 (en) 2013-04-22 2014-10-30 F. Hoffmann-La Roche Ag Combination therapy of antibodies against human csf-1r and tlr9 agonist
WO2014179664A2 (en) 2013-05-02 2014-11-06 Anaptysbio, Inc. Antibodies directed against programmed death-1 (pd-1)
WO2014189306A1 (ko) 2013-05-22 2014-11-27 메타볼랩(주) 항 ＴＮＦ-α/ＣＸＣＬ10 이중 타겟 항체 및 그의 용도
WO2014190356A2 (en) 2013-05-24 2014-11-27 Amplimmune, Inc. Anti-b7-h5 antibodies and their uses
WO2014194302A2 (en) 2013-05-31 2014-12-04 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
WO2014206107A1 (zh) 2013-06-26 2014-12-31 上海君实生物医药科技有限公司 抗pd-1抗体及其应用
WO2015001085A1 (en) 2013-07-05 2015-01-08 Genmab B.V. Humanized or chimeric cd3 antibodies
WO2015015003A1 (en) 2013-08-01 2015-02-05 Université Catholique de Louvain Anti-garp protein and uses thereof
WO2015016718A1 (en) 2013-08-02 2015-02-05 Bionovion Holding B.V. Combining cd27 agonists and immune checkpoint inhibition for immune stimulation
WO2015015401A2 (en) 2013-08-02 2015-02-05 Pfizer Inc. Anti-cxcr4 antibodies and antibody-drug conjugates
WO2015026684A1 (en) 2013-08-20 2015-02-26 Merck Sharp & Dohme Corp. Modulation of tumor immunity
WO2015024060A1 (en) 2013-08-22 2015-02-26 The Council Of The Queensland Institute Of Medical Research Immunoreceptor modulation for treating cancer and viral infections
WO2015024042A1 (en) 2013-08-22 2015-02-26 The Council Of The Queensland Institute Of Medical Research Immunoreceptor modulation for treating cancer and viral infections
WO2015031667A2 (en) 2013-08-30 2015-03-05 Amgen Inc. Gitr antigen binding proteins
WO2015028454A2 (en) 2013-08-30 2015-03-05 Ucb Biopharma Sprl Method for the treatment of fibrotic disease
WO2015028455A1 (en) 2013-08-30 2015-03-05 Ucb Biopharma Sprl Antibodies
WO2015036394A1 (en) 2013-09-10 2015-03-19 Medimmune Limited Antibodies against pd-1 and uses thereof
WO2015036511A1 (en) 2013-09-12 2015-03-19 F. Hoffmann-La Roche Ag Combination therapy of antibodies against human csf-1r and antibodies against human pd-l1
WO2015035606A1 (en) 2013-09-13 2015-03-19 Beigene, Ltd. Anti-pd1 antibodies and their use as therapeutics and diagnostics
WO2015040401A1 (en) 2013-09-19 2015-03-26 Kymab Limited Expression vector production and high-throughput cell screening
WO2015042246A1 (en) 2013-09-20 2015-03-26 Bristol-Myers Squibb Company Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
WO2015061668A1 (en) 2013-10-25 2015-04-30 Dana-Farber Cancer Institute, Inc. Anti-pd-l1 monoclonal antibodies and fragments thereof
WO2015058573A1 (zh) 2013-10-25 2015-04-30 苏州思坦维生物技术有限责任公司 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途
WO2015063187A1 (en) 2013-10-30 2015-05-07 Sergej Michailovic Kiprijanov Multivalent antigen-binding proteins
WO2015069874A1 (en) 2013-11-06 2015-05-14 Bristol-Myers Squibb Company Treatment of c1013g/cxcr4-associated waldenström's macroglobulinemia with an anti-cxcr4 antibody
WO2015085847A1 (zh) 2013-12-12 2015-06-18 上海恒瑞医药有限公司 Pd-1抗体、其抗原结合片段及其医药用途
WO2015095392A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Anti-cd3 antibodies and methods of use
WO2015091853A2 (en) 2013-12-19 2015-06-25 Alligator Bioscience Ab Antibodies
WO2015091911A2 (en) 2013-12-20 2015-06-25 Intervet International B.V. Antibodies against canine pd-1
WO2015091910A2 (en) 2013-12-20 2015-06-25 Intervet International B.V. Caninized antibodies
WO2015091914A2 (en) 2013-12-20 2015-06-25 Intervet International B.V. Caninized murine antibodies to human pd-1
WO2015097536A2 (en) 2013-12-24 2015-07-02 Janssen Pharmaceutical Nv Anti-vista antibodies and fragments
WO2015103072A1 (en) 2013-12-30 2015-07-09 Epimab Biotherapeutics Fabs-in-tandem immunoglobulin and uses thereof
WO2015104346A1 (en) 2014-01-09 2015-07-16 Genmab B.V. Humanized or chimeric cd3 antibodies
WO2015109124A2 (en) 2014-01-15 2015-07-23 Kadmon Corporation, Llc Immunomodulatory agents
WO2015112805A1 (en) 2014-01-23 2015-07-30 Regeneron Pharmaceuticals, Inc. Human antibodies to pd-l1
WO2015112800A1 (en) 2014-01-23 2015-07-30 Regeneron Pharmaceuticals, Inc. Human antibodies to pd-1
US20150203579A1 (en) 2014-01-23 2015-07-23 Regeneron Pharmaceuticals, Inc. Human Antibodies to PD-1
US20150210769A1 (en) 2014-01-24 2015-07-30 Novartis Ag Antibody molecules to pd-1 and uses thereof
WO2015112900A1 (en) 2014-01-24 2015-07-30 Dana-Farber Cancer Institue, Inc. Antibody molecules to pd-1 and uses thereof
WO2015116539A1 (en) 2014-01-28 2015-08-06 Bristol-Myers Squibb Company Anti-lag-3 antibodies to treat hematological malignancies
WO2015117002A1 (en) 2014-01-31 2015-08-06 Novartis Ag Antibody molecules to tim-3 and uses thereof
WO2015134988A1 (en) 2014-03-07 2015-09-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
WO2015138600A2 (en) 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
WO2015136541A2 (en) 2014-03-12 2015-09-17 Yeda Research And Development Co. Ltd Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
WO2015153513A1 (en) 2014-03-31 2015-10-08 Genentech, Inc. Anti-ox40 antibodies and methods of use
WO2015164815A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
WO2015169811A2 (en) 2014-05-06 2015-11-12 Medimmune Limited Anti-cxc chemokine receptor-2 binding molecules and uses thereof
WO2015173267A1 (en) 2014-05-13 2015-11-19 Medimmune Limited Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
WO2015179236A1 (en) 2014-05-21 2015-11-26 Pfizer Inc. Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer
WO2015179654A1 (en) 2014-05-22 2015-11-26 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti b7-h1 antibodies
WO2015184099A1 (en) 2014-05-28 2015-12-03 4-Antibody Ag Anti-gitr antibodies and methods of use thereof
WO2015181342A1 (en) 2014-05-29 2015-12-03 Spring Bioscience Corporation Pd-l1 antibodies and uses thereof
WO2015187835A2 (en) 2014-06-06 2015-12-10 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
WO2015195163A1 (en) 2014-06-20 2015-12-23 R-Pharm Overseas, Inc. Pd-l1 antagonist fully human antibody
WO2015198312A1 (en) 2014-06-24 2015-12-30 Ccam Therapeutics Ltd. Compositions comprising antibodies to ceacam-1 and lag-3 for cancer therapy
WO2016000619A1 (en) 2014-07-03 2016-01-07 Beigene, Ltd. Anti-pd-l1 antibodies and their use as therapeutics and diagnostics
WO2016007235A1 (en) 2014-07-11 2016-01-14 Genentech, Inc. Anti-pd-l1 antibodies and diagnostic uses thereof
WO2016014688A2 (en) 2014-07-22 2016-01-28 Junzhuan Qiu Anti-pd-1 antibodies
WO2016014974A2 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
WO2016015685A1 (zh) 2014-07-30 2016-02-04 珠海市丽珠单抗生物技术有限公司 抗pd-1抗体及其应用
WO2016015675A1 (zh) 2014-08-01 2016-02-04 中山康方生物医药有限公司 抗ctla4的单克隆抗体或其抗原结合片段、药物组合物及用途
WO2016022630A1 (en) 2014-08-05 2016-02-11 Jiping Zha Anti-pd-l1 antibodies
WO2016023960A1 (en) 2014-08-12 2016-02-18 Alligator Bioscience Ab Combination therapies with anti cd40 antibodies
WO2016023875A1 (en) 2014-08-14 2016-02-18 F. Hoffmann-La Roche Ag Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1
WO2016028810A1 (en) 2014-08-18 2016-02-25 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
WO2016028656A1 (en) 2014-08-19 2016-02-25 Merck Sharp & Dohme Corp. Anti-tigit antibodies
WO2016028672A1 (en) 2014-08-19 2016-02-25 Merck Sharp & Dohme Corp. Anti-lag3 antibodies and antigen-binding fragments
WO2016030350A1 (en) * 2014-08-29 2016-03-03 F. Hoffmann-La Roche Ag Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
WO2016050721A1 (en) 2014-09-30 2016-04-07 Intervet International B.V. Pd-l1 antibodies binding canine pd-l1
WO2016054638A1 (en) 2014-10-03 2016-04-07 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
WO2016057488A1 (en) 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof
WO2016055609A1 (en) 2014-10-10 2016-04-14 Innate Pharma Cd73 blockade
WO2016057667A1 (en) 2014-10-10 2016-04-14 Medimmune, Llc Humanized anti-ox40 antibodies and uses thereof
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US20160145344A1 (en) 2014-10-20 2016-05-26 University Of Southern California Murine and human innate lymphoid cells and lung inflammation
WO2016063233A1 (en) 2014-10-24 2016-04-28 Effimune Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
WO2016068802A1 (en) 2014-10-27 2016-05-06 Agency For Science, Technology And Research Anti-tim-3 antibodies
WO2016068803A1 (en) 2014-10-27 2016-05-06 Agency For Science, Technology And Research Anti-tim-3 antibodies
WO2016068801A1 (en) 2014-10-27 2016-05-06 Agency For Science, Technology And Research Anti-pd-1 antibodies
WO2016071448A1 (en) 2014-11-06 2016-05-12 F. Hoffmann-La Roche Ag Anti-tim3 antibodies and methods of use
WO2016073845A1 (en) 2014-11-07 2016-05-12 Igenica Biotherapeutics, Inc. Anti-cd39 antibodies and uses thereof
WO2016075099A1 (en) 2014-11-10 2016-05-19 Medimmune Limited Binding molecules specific for cd73 and uses thereof
WO2016077397A2 (en) 2014-11-11 2016-05-19 Sutro Biopharma, Inc. Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies
WO2016075176A1 (en) 2014-11-11 2016-05-19 Medimmune Limited Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
WO2016079050A1 (en) 2014-11-20 2016-05-26 F. Hoffmann-La Roche Ag Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
WO2016081748A2 (en) 2014-11-21 2016-05-26 Bristol-Myers Squibb Company Antibodies against cd73 and uses thereof
WO2016092419A1 (en) 2014-12-09 2016-06-16 Rinat Neuroscience Corp. Anti-pd-1 antibodies and methods of use thereof
WO2016106159A1 (en) 2014-12-22 2016-06-30 Enumeral Biomedical Holding, Inc. Anti-pd-1 antibodies
WO2016106180A1 (en) 2014-12-22 2016-06-30 Five Prime Therapeutics, Inc. Anti-csf1r antibodies for treating pvns
WO2016106302A1 (en) 2014-12-23 2016-06-30 Bristol-Myers Squibb Company Antibodies to tigit
WO2016111947A2 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
WO2016109872A1 (en) 2015-01-09 2016-07-14 Adalta Pty Ltd Cxcr4 binding molecules
WO2016111645A1 (en) 2015-01-09 2016-07-14 Agency For Science, Technology And Research Anti-pd-l1 antibodies
WO2016116626A1 (en) 2015-01-23 2016-07-28 Sanofi Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
US20160215059A1 (en) 2015-01-28 2016-07-28 Glaxosmithkline Intellectual Property Development Limited Icos binding proteins
WO2016120789A1 (en) 2015-01-28 2016-08-04 Glaxosmithkline Intellectual Property Development Limited Agonistic icos binding proteins
WO2016126858A2 (en) 2015-02-03 2016-08-11 Anaptysbio, Inc. Antibodies directed against lymphocyte activation gene 3 (lag-3)
WO2016127179A2 (en) 2015-02-06 2016-08-11 Kadmon Corporation, Llc Immunomodulatory agents
WO2016130986A1 (en) 2015-02-13 2016-08-18 Sorrento Therapeutics, Inc. Antibody therapeutics that bind ctla4
WO2016130898A2 (en) 2015-02-13 2016-08-18 Sorrento Therapeutics, Inc. Antibody therapeutics that bind ctla4
WO2016131950A1 (en) 2015-02-20 2016-08-25 Innate Pharma Cd73 blockade
WO2016134358A1 (en) 2015-02-22 2016-08-25 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd137
WO2016145085A2 (en) 2015-03-09 2016-09-15 Celldex Therapeutics, Inc. Cd27 agonists
WO2016149201A2 (en) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
US20160304610A1 (en) 2015-03-23 2016-10-20 Jounce Therapeutics, Inc. Antibodies to icos
WO2016154177A2 (en) 2015-03-23 2016-09-29 Jounce Therapeutics, Inc. Antibodies to icos
WO2016160792A1 (en) 2015-03-30 2016-10-06 Stcube & Co., Inc. Antibodies specific to glycosylated pd-l1 and methods of use thereof
WO2016161270A1 (en) 2015-04-01 2016-10-06 Anaptysbio, Inc. Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
WO2016156570A1 (en) 2015-04-02 2016-10-06 Ablynx N.V. Bispecific cxcr4-cd-4 polypeptides with potent anti-hiv activity
WO2016168149A1 (en) 2015-04-13 2016-10-20 Five Prime Therapeutics, Inc. Combination therapy for cancer
WO2016171722A1 (en) 2015-04-24 2016-10-27 The Brigham And Women's Hospital, Inc. Interactions between ceacam and tim family members
WO2016176583A1 (en) 2015-04-29 2016-11-03 Sanford-Burnham Medical Research Institute Modulation of immune response using btla agonist antibodies
WO2016178779A1 (en) 2015-05-01 2016-11-10 Dana-Farber Cancer Institute, Inc. Methods of mediating cytokine expression with anti ccr4 antibodies
WO2016179003A1 (en) 2015-05-01 2016-11-10 Genentech, Inc. Masked anti-cd3 antibodies and methods of use
WO2016179194A1 (en) 2015-05-04 2016-11-10 Jounce Therapeutics, Inc. Lilra3 and method of using the same
WO2016179517A1 (en) 2015-05-07 2016-11-10 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
WO2016180721A1 (en) 2015-05-08 2016-11-17 Miltenyi Biotec Gmbh Humanized antibody or fragment thereof specific for cd3
WO2016191643A2 (en) 2015-05-28 2016-12-01 Oncomed Pharmaceuticals, Inc. Tigit-binding agents and uses thereof
WO2016196314A1 (en) 2015-05-29 2016-12-08 Abbvie Inc. Anti-cd40 antibodies and uses thereof
WO2016196237A1 (en) 2015-05-29 2016-12-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
WO2016196228A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Antibodies against ox40 and uses thereof
WO2016196173A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer
WO2016196792A1 (en) 2015-06-03 2016-12-08 Bristol-Myers Squibb Company Anti-gitr antibodies for cancer diagnostics
WO2016200836A1 (en) 2015-06-08 2016-12-15 Genentech, Inc. Methods of treating cancer using anti-ox40 antibodies
WO2016200782A1 (en) 2015-06-08 2016-12-15 Macrogenics, Inc. Lag-3-binding molecules and methods of use thereof
WO2016200835A1 (en) 2015-06-08 2016-12-15 Genentech, Inc. Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
WO2016197497A1 (zh) 2015-06-09 2016-12-15 北京东方百泰生物科技有限公司 一种抗pd-1的单克隆抗体及其获得方法
WO2016197367A1 (en) 2015-06-11 2016-12-15 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2016201051A1 (en) 2015-06-12 2016-12-15 Macrogenics, Inc. Combination therapy for the treatment of cancer
WO2016204966A1 (en) 2015-06-16 2016-12-22 Genentech, Inc. Anti-cd3 antibodies and methods of use
WO2016205042A1 (en) 2015-06-16 2016-12-22 The Board Of Trustees Of The Leland Stanford Junior University SIRPα AGONIST ANTIBODY
WO2016207312A1 (en) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
WO2016207717A1 (en) 2015-06-24 2016-12-29 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
WO2017004016A1 (en) 2015-06-29 2017-01-05 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
WO2017004006A1 (en) 2015-06-29 2017-01-05 Bristol-Myers Squibb Company Antibodies to cd40
WO2017004945A1 (zh) 2015-07-03 2017-01-12 中兴通讯股份有限公司 一种拍摄终端和拍摄方法
WO2017010874A1 (en) 2015-07-10 2017-01-19 Merus N.V. Human cd3 binding antibody
WO2017009442A1 (en) 2015-07-15 2017-01-19 Genmab A/S Humanized or chimeric cd3 antibodies
WO2017015560A2 (en) 2015-07-22 2017-01-26 Sorrento Therapeutics, Inc. Antibody therapeutics that bind lag3
WO2017016497A1 (en) 2015-07-28 2017-02-02 Harbour Biomed Limited Anti-pd-1 antibodies and uses thereof
WO2017019896A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to pd-1
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
WO2017019894A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to lag-3
WO2017019846A1 (en) 2015-07-30 2017-02-02 Macrogenics, Inc. Pd-1-binding molecules and methods use thereof
WO2017020801A1 (zh) 2015-07-31 2017-02-09 苏州康宁杰瑞生物科技有限公司 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
WO2017021910A1 (en) 2015-08-04 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
WO2017021912A1 (en) 2015-08-06 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Combined tlrs modulators with anti ox40 antibodies
WO2017020858A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2017025016A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2017024515A1 (en) 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
WO2017025051A1 (en) 2015-08-11 2017-02-16 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-1 antibodies
WO2017030823A2 (en) 2015-08-14 2017-02-23 Merck Sharp & Dohme Corp. Anti-tigit antibodies
WO2017031242A1 (en) 2015-08-20 2017-02-23 Sutro Biopharma, Inc. Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies
WO2017034916A1 (en) 2015-08-24 2017-03-02 Eli Lilly And Company Pd-l1 ("programmed death-ligand 1") antibodies
WO2017040790A1 (en) 2015-09-01 2017-03-09 Agenus Inc. Anti-pd-1 antibodies and methods of use thereof
WO2017040566A1 (en) 2015-09-01 2017-03-09 Boehringer Ingelheim International Gmbh Use of anti-cd40 antibodies for treatment of lupus nephritis
WO2017037707A1 (en) 2015-09-02 2017-03-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
WO2017037203A1 (en) 2015-09-02 2017-03-09 Immutep S.A.S. Anti-LAG-3 Antibodies
WO2017040932A1 (en) 2015-09-04 2017-03-09 Primatope Therapeutics Inc. Humanized anti-cd40 antibodies and uses thereof
WO2017049038A2 (en) 2015-09-16 2017-03-23 Ablexis, Llc Anti-cd115 antibodies
WO2017050729A1 (en) 2015-09-22 2017-03-30 Spring Bioscience Corporation Anti-ox40 antibodies and diagnostic uses thereof
WO2017051888A1 (ja) 2015-09-24 2017-03-30 第一三共株式会社 抗ｇａｒｐ抗体
WO2017053748A2 (en) 2015-09-25 2017-03-30 Genentech, Inc. Anti-tigit antibodies and methods of use
WO2017058859A1 (en) 2015-09-29 2017-04-06 Celgene Corporation Pd-1 binding proteins and methods of use thereof
WO2017058115A1 (en) 2015-09-29 2017-04-06 Asia Biotech Pte. Ltd. Pd-1 antibodies and uses thereof
WO2017059196A2 (en) 2015-09-30 2017-04-06 Janssen Biotech, Inc. Antagonistic antibodies specifically binding human cd40 and methods of use
WO2017059243A2 (en) 2015-09-30 2017-04-06 Janssen Biotech, Inc. Agonistic antibodies specifically binding human cd40 and methods of use
WO2017055404A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific antibodies specific for pd1 and tim3
WO2017055547A1 (en) 2015-10-02 2017-04-06 Symphogen A/S Anti-pd-1 antibodies and compositions
WO2017062888A1 (en) 2015-10-09 2017-04-13 Regeneron Pharmaceuticals, Inc. Anti-lag3 antibodies and uses thereof
WO2017064043A1 (en) 2015-10-12 2017-04-20 Innate Pharma Cd73 blocking agents
WO2017063162A1 (zh) 2015-10-15 2017-04-20 苏州丁孚靶点生物技术有限公司 抗ox40抗体及其应用
WO2017071625A1 (zh) 2015-10-30 2017-05-04 中山康方生物医药有限公司 一种抗pd-1单克隆抗体、其药物组合物及其用途
WO2017079112A1 (en) 2015-11-03 2017-05-11 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
WO2017079115A1 (en) 2015-11-03 2017-05-11 Janssen Biotech, Inc. Antibodies specifically binding tim-3 and their uses
WO2017077085A2 (en) 2015-11-04 2017-05-11 Cancer Research Technology Immunomodulatory antibodies
WO2017087588A1 (en) 2015-11-18 2017-05-26 Merck Sharp & Dohme Corp. Ctla4 binders
WO2017087599A1 (en) 2015-11-18 2017-05-26 Lyvgen Biopharma Holdings Limited Anti-pd-1 antibodies and therapeutic uses thereof
WO2017087589A2 (en) 2015-11-18 2017-05-26 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
WO2017087678A2 (en) 2015-11-19 2017-05-26 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
WO2017084078A1 (en) 2015-11-19 2017-05-26 Zeling Cai Ctla-4 antibodies and uses thereof
WO2017087901A2 (en) 2015-11-19 2017-05-26 Sutro Biopharma, Inc. Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
WO2017089334A1 (en) 2015-11-23 2017-06-01 Innate Pharma Cd39 vascular isoform targeting agents

Non-Patent Citations (71)

* Cited by examiner, † Cited by third party
Title
"PD-L1, a third member of the B7 family, co-stimulates T- cell proliferation and interleukin-10 secretion", NAT. MED., vol. 5, no. 12, 1999, pages 1365 - 1369
"Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING CO.
"The Merck Manual of Diagnosis and Therapy, 19th Edition,", 2006, MERCK RESEARCH LABORATORIES, ISBN: 0-911910-19-0
BARUCH K.: "PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer's disease", NATURE MEDICINE, vol. 22, no. 2, 2016, pages 137 - 137, XP055395595, DOI: doi:10.1038/nm.4022
BECKER JC, J. EXP. MED., vol. 183, 1996, pages 2361 - 6
BECKER JC, PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 2702 - 7
BECKER JC, PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 7826 - 31
BENJAMIN LEWIN: "Genes X", 2009, JONES & BARTLETT PUBLISHING, ISBN: 10:0763766321
BRAHMER, JOURNAL OF CLINICAL ONCOLOGY, 2010
C. WANG ET AL: "In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates", CANCER IMMUNOLOGY RESEARCH, vol. 2, no. 9, 28 May 2014 (2014-05-28), pages 846 - 856, XP055206944, ISSN: 2326-6066, DOI: 10.1158/2326-6066.CIR-14-0040 *
CHOTHIA, C.; LESK, A. M.: "Canonical structures for the hypervariable regions of immunoglobulins", J. MOL. BIOL., vol. 196, 1987, pages 901 - 917, XP024010426, DOI: doi:10.1016/0022-2836(87)90412-8
COLIGAN: "Current Protocols in Protein Sciences", 2009, WILEY INTERSCIENCES
DALL, IMMUNOL, vol. 169, 2002, pages 5171 - 5180
DAVIS: "Basic Methods in Molecular Biology", 1995, ELSEVIER SCIENCE PUBLISHING, INC.
DENARDO, CLIN. CANCER RES., vol. 4, no. 10, 1998, pages 2483 - 90
DIGIAMMARINO: "Design and generation of DVD-IgTM molecules for dual-specific targeting", METH. MO. BIOL., vol. 889, 2012, pages 145 - 156, XP009169361, DOI: doi:10.1007/978-1-61779-921-1_9
DONG, H.: "PD-L1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion", NAT. MED, vol. 5, no. 12, 1999, pages 1365 - 1369, XP002942544, DOI: doi:10.1038/70932
ERIN E. WEST ET AL: "PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells", JOURNAL OF CLINICAL INVESTIGATION, vol. 123, no. 6, 15 May 2013 (2013-05-15), US, pages 2604 - 2615, XP055404072, ISSN: 0021-9738, DOI: 10.1172/JCI67008 *
FEHRENBACHER, THE LANCET, 2016, Retrieved from the Internet <URL:http://doi.org/10.1016/S0140-6736(16)00587-0>
GILLES, PROTEIN ENGINEERING, DESIGN AND SELECTION, vol. 26, no. 10, 2013, pages 561 - 569
GILLIES, CLINICAL CANCER RESEARCH, vol. 17, no. 11, 2011, pages 3673 - 3685
GUL: "Antibody-Dependent Phagocytosis of Tumor Cells by Macrophages: A Potent Effector Mechanism of Monoclonal Antibody Therapy of Cancer", CANCER RES., vol. 75, no. 23, 1 December 2015 (2015-12-01)
HERBST RS: "Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients", NATURE, vol. 515, no. 7528, 27 November 2014 (2014-11-27), pages 563 - 7, XP055262130, DOI: doi:10.1038/nature14011
IDUSOGIE, J. IMMUNOL., vol. 166, 2001, pages 2571 - 2575
ISHIDA, ANNALS OF ONCOLOGY, vol. 19, no. 4, 2008, pages 513
JENNIE P. MATHER AND DAVID BARNES: "Methods in Cell Biology", vol. 57, 1998, ACADEMIC PRESS
JOHN E. COLIGAN,: "Current Protocols in Protein Science (CPPS)", JOHN WILEY AND SONS, INC
JUAN S. BONIFACINO: "Current Protocols in Cell Biology (CPCB)", JOHN WILEY AND SONS, INC
KABAT, ANN. NY ACAD. SCI., vol. 190, 1971, pages 382 - 391
KABAT, E. A.: "Sequences of Proteins of Immunological Interest", 1991, NIH PUBLICATION NO. 91-3242
KABAT: "Sequences of Proteins of Immunological Interest, Fifth Edition,", 1991, NIH PUBLICATION NO. 91-3242
KENDREW: "Molecular Biology and Biotechnology: a Comprehensive Desk Reference", 1995, VCH PUBLISHERS, INC., ISBN: 1-56081-569-8
KILPATRICK: "Rapid development of affinity matured monoclonal antibodies using RIMMS", HYBRIDOMA, vol. 16, no. 4, August 1997 (1997-08-01), pages 381 - 9, XP055010201, DOI: doi:10.1089/hyb.1997.16.381
LAURENT, JOURNAL OF TRANSLATIONAL MEDICINE, vol. 11, no. 1, 2013, pages 5, Retrieved from the Internet <URL:http://doi.org/10.1186/1479-5876-11-5>
LAZAR, PROC. NATL. ACAD. SCI. U.S.A., vol. 103, no. 11, 14 March 2006 (2006-03-14), pages 4005 - 10
LEE, NATURE BIOTECHNOLOGY, vol. 32, 2014, pages 6 - 363
LEFRANC, M. P.: "Unique database numbering system for immunogenetic analysis", IMMUNOL. TODAY, vol. 18, 1997, pages 50, XP004093509, DOI: doi:10.1016/S0167-5699(97)01163-8
MATHIS, CLINICAL CHEMISTRY, vol. 41, no. 9, 1995, pages 1391 - 1397
MORRIS, MOL IMMUNOL., vol. 44, no. 12, May 2007 (2007-05-01), pages 3112 - 3121
NATSUME, CANCER RES., vol. 68, 2008, pages 3863 - 3872
NATSUME, DRUG DES. DEVEL. THER., vol. 3, 2009, pages 7 - 16
NEAL, CLIN. CANCER RES., vol. 1010, 2004, pages 4839 - 4847
NERI DARIO ET AL: "Immunocytokines for cancer treatment: past, present and future", CURRENT OPINION IN IMMUNOLOGY, ELSEVIER, OXFORD, GB, vol. 40, 6 April 2016 (2016-04-06), pages 96 - 102, XP029551352, ISSN: 0952-7915, DOI: 10.1016/J.COI.2016.03.006 *
NIEDERFELLNER, GERHARD: "Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies.", BLOOD, vol. 118.2, 2011, pages 358 - 367, XP055047547, DOI: doi:10.1182/blood-2010-09-305847
NIWA, CANCER RESEARCH, vol. 64, 2004, pages 2127 - 2133
PANCOOK JD, CANCER IMMUNOL. IMMUNOTHER, vol. 42, 1996, pages 88 - 92
PAUL,: "Fundamental Immunology Second Edition,", 1989, RAVEN PRESS, pages: 332 - 336
PETERSON, BIOCONJUG. CHEM., vol. 10, no. 4, 1999, pages 553 - 7
R. IAN FRESHNEY: "Culture of Animal Cells: A Manual of Basic Technique", PUBLISHER: WILEY-LISS
RITTMEYER, THE LANCET, vol. 389, no. 10066, 2017, pages 255 - 265
ROBERT S. PORTER: "The Encyclopedia of Molecular Biology", 1994, BLACKWELL SCIENCE LTD., ISBN: 0-632-02182-9
ROSENBERG, THE LANCET, 2016, Retrieved from the Internet <URL:http://doi.org/10.1016/S0140-6736(16)00561-4>
RUDIKOFF S ET AL: "Single amino acid substitution altering antigen-binding specificity", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 79, 1 March 1982 (1982-03-01), pages 1979 - 1983, XP007901436, ISSN: 0027-8424, DOI: 10.1073/PNAS.79.6.1979 *
S. L. BERGER AND A. R. KIMMEL: "Methods in Enzymology: Guide to Molecular Cloning Techniques", vol. 152, 1987, ACADEMIC PRESS INC.
SABZEVARI H, PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 9626 - 30
SAMBROOK: "Molecular Cloning: A Laboratory Manual (4 ed.),", 2012, COLD SPRING HARBOR LABORATORY PRESS
SHIELDS, J. BIOL. CHEM., vol. 276, no. 9, 2 March 2001 (2001-03-02), pages 6591 - 604
SHUSTERMAN, JOURNAL OF CLINICAL ONCOLOGY, vol. 28, no. 33, 2010, pages 4969 - 4975
STEWART R ., CANCER IMMUNOL. RES., vol. 3, no. 9, September 2015 (2015-09-01), pages 1052 - 62
STROHL, BIODRUGS, vol. 29, 2015, pages 215 - 239
SUCKAU, DETLEV: "Molecular epitope identification by limited proteolysis of an immobilized antigen-antibody complex and mass spectrometric peptide mapping", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 87.24, 1990, pages 9848 - 9852
TOPALIAN, NEJM, 2012
VASQUEZ-LOMBARDI, NAT COMM, 2017
VAZQUEZ-LOMBARDI RODRIGO ET AL: "Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells", NATURE COMMUNICATIONS, vol. 8, 12 May 2017 (2017-05-12), XP002773463, ISSN: 2041-1723 *
WEINBERG, A.D., J IMMUNOTHER, vol. 29, 2006, pages 575 - 585
WU; WU, J. BIOL. CHEM., vol. 262, 1987, pages 4429 - 4432
YAMANE, EXPERT OPI, INVESTIG. DRUGS, vol. 18, no. 7, 2009, pages 991 - 1000
YUSA K.: "A hyperactive piggyBac transposase for mammalian applications", PROC. NATL. ACAD. SCI. U S A., vol. 108, no. 4, 25 January 2011 (2011-01-25), pages 1531 - 6, XP055035951, DOI: doi:10.1073/pnas.1008322108
YUSA K.: "A hyperactive transposase for mammalian applications", PROC. NATL. ACAD. SCI. U S A., vol. 108, no. 4, 25 January 2011 (2011-01-25), pages 1531 - 6, XP055035951, DOI: doi:10.1073/pnas.1008322108
ZHOU Q., BIOTECHNOL. BIOENG., vol. 99, no. 3, 15 February 2008 (2008-02-15), pages 652 - 65
ZIMMERMAN, NUCL. MED. BIOL., vol. 26, no. 8, 1999, pages 943 - 50

Cited By (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12091441B2 (en) 2017-11-21 2024-09-17 The Board Of Trustees Of The Leland Stanford Junior University Partial agonists of interleukin-2
WO2019173832A2 (en) 2018-03-09 2019-09-12 AskGene Pharma, Inc. Novel cytokine prodrugs
CN112041348A (zh) * 2018-07-25 2020-12-04 天境生物科技(上海)有限公司 抗cd73抗pd-l1双特异性抗体
WO2020020307A1 (en) * 2018-07-25 2020-01-30 I-Mab Biopharma Co., Ltd. Anti-cd73 anti-pd-l1 bispecific antibodies
CN112041348B (zh) * 2018-07-25 2023-09-22 天境生物科技(上海)有限公司 抗cd73抗pd-l1双特异性抗体
US12459980B2 (en) 2018-07-25 2025-11-04 AskGene Pharma, Inc. IL-21 prodrugs and methods of use thereof
US11034771B2 (en) 2018-07-25 2021-06-15 I-Mab Biopharma Us Limited Anti-CD73 anti-PD-L1 bispecific antibodies
US11401339B2 (en) 2018-08-23 2022-08-02 Seagen Inc. Anti-TIGIT antibodies
US12286464B2 (en) 2018-09-17 2025-04-29 Gi Innovation, Inc. Fusion protein comprising IL-2 protein and CD80 protein, and use thereof
TWI824258B (zh) * 2018-09-17 2023-12-01 南韓商Ｇｉ創新股份有限公司 包含il-2蛋白及cd80蛋白之融合蛋白及其用途
KR102201086B1 (ko) * 2018-09-17 2021-01-11 (주)지아이이노베이션 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도
KR20210008110A (ko) * 2018-09-17 2021-01-20 (주)지아이이노베이션 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도
JP2022115876A (ja) * 2018-09-17 2022-08-09 ジーアイ・イノベイション・インコーポレイテッド Ｉｌ－２タンパク質およびｃｄ８０タンパク質を含む融合タンパク質およびその使用
JP2021511081A (ja) * 2018-09-17 2021-05-06 ジーアイ・イノベイション・インコーポレイテッドＧｉ Ｉｎｎｏｖａｔｉｏｎ， Ｉｎｃ． Ｉｌ−２タンパク質およびｃｄ８０タンパク質を含む融合タンパク質およびその使用
CN111971295A (zh) * 2018-09-17 2020-11-20 Gi 医诺微新 包含il-2蛋白和cd80蛋白的融合蛋白及其用途
KR20200032009A (ko) * 2018-09-17 2020-03-25 (주)지아이이노베이션 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도
RU2811541C2 (ru) * 2018-09-17 2024-01-15 ДжиАй ИННОВЕЙШН, ИНК. Слитый белок, включающий белок il-2 и белок cd80, и его применение
US12291555B2 (en) 2018-09-17 2025-05-06 Gi Innovation, Inc. Fusion protein comprising IL-2 protein and CD80 protein, and use thereof
WO2020060122A1 (ko) * 2018-09-17 2020-03-26 (주)지아이이노베이션 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도
JP7085644B2 (ja) 2018-09-17 2022-06-16 ジーアイ・イノベイション・インコーポレイテッド Ｉｌ－２タンパク質およびｃｄ８０タンパク質を含む融合タンパク質およびその使用
KR102558191B1 (ko) * 2018-09-17 2023-07-24 (주)지아이이노베이션 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도
US11492384B2 (en) 2018-09-17 2022-11-08 Gi Innovation, Inc. Fusion protein comprising IL-2 protein and CD80 protein, and use thereof
TWI755630B (zh) * 2018-09-17 2022-02-21 南韓商Ｇｉ創新股份有限公司 包含il-2蛋白及cd80蛋白之融合蛋白及其用途
JP2022512043A (ja) * 2018-10-29 2022-02-01 １グローブ バイオメディカル カンパニー， リミテッド 合理的に設計された新規なタンパク質組成物
WO2020088459A1 (en) * 2018-10-29 2020-05-07 1Globe Biomedical Co., Ltd. Novel rationally designed protein compositions
US12378295B2 (en) 2018-10-29 2025-08-05 1Globe Biomedical Co., Ltd. Rationally designed protein compositions
TWI840433B (zh) * 2018-10-29 2024-05-01 大陸商北京強新生物科技有限公司 新穎合理設計的蛋白質組合物
CN113039207B (zh) * 2018-11-16 2022-10-28 南京金斯瑞生物科技有限公司 人源化抗人pd-l1单克隆抗体及其制备方法和用途
CN113039207A (zh) * 2018-11-16 2021-06-25 南京金斯瑞生物科技有限公司 人源化抗人pd-l1单克隆抗体及其制备方法和用途
WO2020098785A1 (zh) * 2018-11-16 2020-05-22 南京金斯瑞生物科技有限公司 人源化抗人pd-l1单克隆抗体及其制备方法和用途
US12098204B2 (en) 2018-11-16 2024-09-24 Nanjing GenScript Biotech Co., Ltd. Humanized anti-human PD-L1 monoclonal antibody and preparation method therefor and use thereof
WO2020130300A1 (ko) * 2018-12-21 2020-06-25 한미약품 주식회사 신규 면역 억제 인터루킨 2
US11845801B2 (en) 2019-06-12 2023-12-19 AskGene Pharma, Inc. IL-15 prodrugs and methods of use thereof
EP3983001A4 (en) * 2019-06-14 2023-10-04 Cugene Inc. NOVEL INTERLEUKIN-2 VARIANTS AND BIFUNCTIONAL FUSION MOLECULES THEREOF
JP2022539351A (ja) * 2019-06-26 2022-09-08 ザ・ジョンズ・ホプキンス・ユニバーシティ 制御性ｔ細胞をターゲットとして増殖させるための方法及び材料
WO2020264318A1 (en) * 2019-06-26 2020-12-30 The Johns Hopkins University Methods and materials for targeted expansion of regulatory t cells
AU2020304654B2 (en) * 2019-06-26 2025-10-09 The Johns Hopkins University Methods and materials for targeted expansion of regulatory T cells
US20220242946A1 (en) * 2019-06-26 2022-08-04 The Johns Hopkins University Methods and materials for targeted expansion of regulatory t cells
WO2021062406A1 (en) 2019-09-28 2021-04-01 AskGene Pharma, Inc. Cytokine prodrugs and dual-prodrugs
TWI828951B (zh) * 2019-11-14 2024-01-11 中央研究院 抗上皮細胞黏附分子抗體於癌症治療之用途
WO2021097433A1 (en) * 2019-11-14 2021-05-20 Academia Sinica Use of anti-epcaivi antibodies in cancer therapy
KR20210059405A (ko) * 2019-11-15 2021-05-25 주식회사 제넥신 변형된 인터루킨-7 및 인터루킨-2를 포함하는 융합단백질 및 이의 용도
KR102400884B1 (ko) 2019-11-15 2022-05-23 주식회사 제넥신 변형된 인터루킨-7 및 인터루킨-2를 포함하는 융합단백질 및 이의 용도
US11702633B2 (en) 2019-11-20 2023-07-18 Gi Cell, Inc. Composition for culturing regulatory T cells and use thereof
KR102843822B1 (ko) 2019-11-20 2025-08-12 주식회사 지아이셀 T 세포 배양용 배지 조성물 및 이를 이용한 t 세포의 배양 방법
KR20210061956A (ko) * 2019-11-20 2021-05-28 주식회사 지아이셀 T 세포 배양용 배지 조성물 및 이를 이용한 t 세포의 배양 방법
US12378526B2 (en) 2019-11-20 2025-08-05 Gi Cell, Inc. Composition for culturing natural killer cells and method for preparing natural killer cells by using same
WO2021101273A3 (ko) * 2019-11-20 2021-07-15 주식회사 지아이셀 조절 t 세포 배양용 조성물 및 이의 용도
WO2021107635A1 (ko) * 2019-11-27 2021-06-03 주식회사 지아이셀 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 nk 세포를 포함하는 항암 치료용 조성물
RU2832136C1 (ru) * 2019-11-27 2024-12-19 ДжиАй СЕЛЛ, ИНК. Композиция для противоракового лечения, содержащая nk-клетки и слитый белок, который содержит белок il-2 и белок cd80
US11725034B2 (en) 2019-12-20 2023-08-15 Regeneron Pharmaceuticals, Inc. IL2 agonists and methods of use thereof
US12319724B2 (en) 2019-12-20 2025-06-03 Regeneron Pharmaceuticals, Inc. IL2 agonists and methods of use thereof
US12215131B2 (en) 2019-12-20 2025-02-04 Regeneron Pharmaceuticals, Inc. IgG Fc-IL2-Rα-IL2 fusions and methods of use thereof
US12091440B2 (en) 2019-12-20 2024-09-17 Regeneron Pharmaceuticals, Inc. IL2 and peptide-MHC complex fusion proteins and methods of use thereof
US11491205B2 (en) 2020-01-14 2022-11-08 Synthekine, Inc. Biased IL2 muteins methods and compositions
US11897930B2 (en) 2020-04-28 2024-02-13 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
US12303567B2 (en) 2020-05-13 2025-05-20 Bonum Therapeutics, Inc. Compositions of protein complexes and methods of use thereof
US11642417B2 (en) 2020-05-13 2023-05-09 Bonum Therapeutics, Inc. Compositions of protein complexes and methods of use thereof

Also Published As

Publication number Publication date
RU2018147413A3 (enExample) 2020-07-21
JP7461741B2 (ja) 2024-04-04
RU2769282C2 (ru) 2022-03-30
IL263834A (en) 2019-01-31
JP2024167230A (ja) 2024-12-03
SG11201810509PA (en) 2018-12-28
CN109475602B (zh) 2023-05-16
US20240343810A1 (en) 2024-10-17
RU2018147413A (ru) 2020-07-21
JP7261379B2 (ja) 2023-04-20
TW201811820A (zh) 2018-04-01
CN116903741A (zh) 2023-10-20
US20210380699A1 (en) 2021-12-09
JP2022166172A (ja) 2022-11-01
TW201803904A (zh) 2018-02-01
CN109475603A (zh) 2019-03-15
RU2756236C2 (ru) 2021-09-28
TWI640536B (zh) 2018-11-11
WO2017220988A9 (en) 2018-02-15
TWI784957B (zh) 2022-12-01
EP3471753A1 (en) 2019-04-24
NZ789594A (en) 2025-07-25
JP2022180438A (ja) 2022-12-06
CN109475602A (zh) 2019-03-15
US20240360218A1 (en) 2024-10-31
CA3026474A1 (en) 2017-12-28
IL263834B1 (en) 2023-09-01
TW201900680A (zh) 2019-01-01
KR102379464B1 (ko) 2022-03-29
IL263834B2 (en) 2024-01-01
JP2019528083A (ja) 2019-10-10
MX2018016364A (es) 2019-11-28
WO2017220990A1 (en) 2017-12-28
US12209128B2 (en) 2025-01-28
TW201803905A (zh) 2018-02-01
WO2017220989A8 (en) 2018-12-27
KR20190032355A (ko) 2019-03-27
US20230312720A1 (en) 2023-10-05
NZ748710A (en) 2025-07-25
BR112018076260A2 (pt) 2019-03-26
JP2020511932A (ja) 2020-04-23
RU2018147423A (ru) 2020-07-21
KR20190030208A (ko) 2019-03-21
EP3471754A1 (en) 2019-04-24
ZA201900353B (en) 2021-09-29
CN109475603B (zh) 2023-06-13
TWI793162B (zh) 2023-02-21
WO2017220990A9 (en) 2018-03-01
CA3026477A1 (en) 2017-12-28
BR112018076281A2 (pt) 2019-03-26
JP7595618B2 (ja) 2024-12-06
WO2017220988A1 (en) 2017-12-28
AU2017281830A1 (en) 2018-12-13
AU2017281830B2 (en) 2023-04-06
RU2018147423A3 (enExample) 2020-10-16
KR102531889B1 (ko) 2023-05-17

Similar Documents

Publication Publication Date Title
US20240360218A1 (en) Anti-pd-l1 and il-2 cytokines
US20230192847A1 (en) Tigit antibodies, encoding nucleic acids and methods of using said antibodies in vivo
US11965026B2 (en) Anti-PD-L1 and IL-2 cytokines
WO2018115859A1 (en) Multispecific antibody with combination therapy for immuno-oncology
JP7290568B2 (ja) 癌免疫療法のための併用療法での多重特異性抗体
HK40005923A (en) Anti-pd-l1 and il-2 cytokines

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17734405

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3026474

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2019518159

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018076281

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20197001344

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017734405

Country of ref document: EP

Effective date: 20190121

ENP Entry into the national phase

Ref document number: 112018076281

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20181217